# Investigating Host and Environmental Influences of *Fusarium solani* Using a Novel Monoclonal Antibody

Submitted by

### Marwan Yaseen Abdulmajeed Al-Maqtoofi

To the University of Exeter as a Thesis for The Degree of Doctor of Philosophy in Biological Sciences in

### May 2016

This thesis is available for library use on the understanding that it is copyright material and that no quotation from this thesis may be published without proper acknowledgement.

I certify that all the material in this thesis which is not my own work has been identified and that no material has been previously submitted and approved for the award of a degree by this or any other University.

> Marwan Y. A. Al-Maqtoofi May 2016

### Abstract

Human fungal infections among severely immunocompromised individuals have increased dramatically over the last 30 years and that coincidence with an expanding patient numbers of bone marrow and solid organ transplantation and those receiving aggressive cytotoxic chemotherapy for neoplastic diseases or immunosuppressive drugs. In recent years, many of opportunistic fungi have emerged as serious human pathogens and causing life-threatening infections of humans such as Fusarium species. Due to lack of a highly accurate diagnostic test for tracking the pathogenic *Fusarium* species, fusariosis is frequently misdiagnosed as aspergillosis. Delays in identification and differentiation of Fusarium spp. from other causative agents of hyalohyphomycetes associated with high morbidity and mortality rate among immunocompromised patients. This research aimed to develop a highly specific monoclonal antibody (mAb) using hybridoma technology to produce a highly genus-specific murine mAb ED7 that could be used for tracking and early detecting circulating Fusarium species antigens from other opportunistic pathogens. At present, a very little is known about the pathogenicity and interaction of human pathogenic F. solani and cells of the innate immune system like alveolar macrophages (AMØ), the residential innate immune cells of alveoli. For this reason, F. solani was genetically transformed with GFP gene and a model of immunoassay was developed to investigate the interactions of F. solani with AMØ that would allow studying the fungal pathogenicity, visualising and quantification of the pathogen during the process of macrophage phagocytosis. In addition, this model can be used to evaluate the effect of a mAb on fungal uptake by AMØ. Habitates providing direct human

i

exposure to infectious propargules are largely unknown, but there is growing evidence that plumbing systems are sources of human pathogenic strains in the *F. solani* and *F. oxysporum* species complexes, the most common groups infecting humans. Using mAb ED7 specific to the *Fusarium* species, this work demonstrates how the mAb can be used as a powerful immunodiagnostic tool for accurately tracking the *Fusarium* species antigens in sink drain biofilms and water system samples containing mixed populations of human opportunistic filamentous and yeasts pathogenic fungi across a University campus and a tertiary care hospital. Specificity of the ELISA was confirmed by sequencing of the internally transcribed spacer 1 (ITS1)-5.8S-ITS2 rRNA-encoding regions of culturable yeasts and moulds that were recovered using mycological culture, while translation elongation factor (TEF)-1 $\alpha$  analysis of *Fusarium* isolates included FSSC 1-a, FOSC 33 and FDSC ET-gr, the most common clinical pathotypes in each group. The mAb ED7 is, therefore, suitable to be carried forward for use in diagnostic assays, such as the lateral flow device.

## **Table of Contents**

Abstract	i
Table of Contents	iii
List of Tables	viii
List of Figures	ix
Abbreviations	XV
Acknowledgment	xvii

# **Chapter 1. General Introduction**

1.0 Overview	1
1.1 Kingdom Fungi	2
1.1.1 Phylum Ascomycota	6
1.1.1.1 The fungus <i>Fusarium</i>	8
1.1.1.2 Classification of the genus Fusarium	9
1.2 Etiology and Pathogenesis	10
1.3 The Human Immune System	15
1.3.1 The innate immune system and fungal infection	15
1.3.2 The adaptive immune system and fungal infection	17
1.4 Antifungal Treatment	18
1.5 Diagnosis of invasive fungal infections	21
1.5.1 Non-Cultural Based Methods	24
1.5.1.1 Molecular Diagnosis	24
1.5.1.2 Antigen Detection Using Monoclonal Antibodies	25
1.6 Focus of This PhD	27

# Chapter 2. Production and Characterization of the Fusarium-Specific

### mAb ED7

2.1 Introduction	29
2.1 Introduction	29

2.1.1 Fusarium as a Plant Pathogen	29
2.1.2 Fusarium as Agents of Human Infectious Diseases	30
2.1.3 Diagnosis of <i>Fusarium</i> infections	32
2.1.3.1 Morphological Characteristics	32
2.1.3.2 Nucleic Acid-based Techniques	33
2.1.3.3 Serological Assays	34
2.1.3.3.1 Detection of 1,3- $\beta$ -D-Glucan and Galactomannan	34
2.1.3.3.2 Polyclonal and Monoclonal Antibodies	35
2.1.4 Objective of This Chapter	36
2.2 Materials and Methods	37
2.2.1 Ethics Statement	37
2.2.2 Fungal Cultures and Media	37
2.2.3 Preparation of Immunogen and Immunisation Regime	40
2.2.4 Production and Screening of Hybridomas and Determination of Antibody	
Specificity	41
2.2.5 Enzyme-Linked Immunosorbent Assay	43
2.2.6 Determination of Ig Subclass and Sub-cloning Procedure	44
2.2.7 Long-term Storage of Hybridoma Cells	44
2.2.8 Antigen Characterization	45
2.2.8.1 Gel Electrophoresis and Western Blotting	45
2.2.8.2 Characterization of Antigen by Enzymatic and Chemical Modifications and	
by Heating	45
2.2.8.3 Immunofluorescence and Immunogold Electron Microscopy	46
2.2.9 Spore Agglutination Assay	48
2.3 Results	49
2.3.1 Production of Hybridoma Cell Lines, Isotyping of monoclonal Antibody and	
Specificity	49
2.3.2 Western Blotting and Antigen Characterization	51

2.3.3 Immunofluorescence and Immunogold Electron Microscopy	55
2.3.4 Spore Agglutination Assays	57
2.4 Discussion	62

# Chapter 3. Alveolar Macrophage Phagocytosis and Killing of *F. solani*

Expressing Green Fluorescent Protein (GFP)	
3.1 Introduction	67
3.1.1 Immunity to Fungal Infections	68
3.1.2 GFP Transformation	70
3.1.3 Aims and objectives	71
3.2 Materials and Methods	74
3.2.1 Fungal Transformation with GFP	74
3.2.1.1 Protoplast preparation	74
3.2.1.2 Fungal Transformation	75
3.2.1.3 Determination of GFP protein expression by Enzyme-Linked	
Immunosorbent Assay	77
3.2.2 Morphological studies	77
3.2.2.1 Hyphal Growth and Spore Production	77
3.2.2.2 Quantification of Hyphal Biomass, Antigen Production and Spore	
Agglutination with mAb ED7	78
3.2.3 Live Cell Imaging of Spore Agglutination	78
3.2.4 Murine Alveolar Macrophage cell line MH-S	79
3.2.4.1 Details and Culture of Mouse Alveolar Macrophages	79
3.2.4.2 Quantification of Phagocytic Percentage and Phagocytic Index of Engu	ılfed
Spores	80
3.2.5 Live Cell Imaging of Spore Phagocytosis	82
3.2.6 Statistical analysis	82
3.3 Results	84

	97
3.3.7 Phagocytic Percentage and Phagocytic Index	97
3.3.6 Live Cell Imaging of Spore Phagocytosis	95
3.3.5 Live Cell Imaging of Spore Agglutination	93
3.3.4 Antigen Production, Biomass Accumulation and Spore Agglutination	90
3.3.3 Phenotypic Analysis of FS-GFP Transformant and Wild-type Strain	87
3.3.2 Detection of GFP Expression in FS-GFP Transformants by Using ELISA	86
3.3.1 Transformation of <i>F. solani</i> (CBS224.34) with GFP	84

# Chapter 4. Tracking Human Pathogenic *Fusarium* species in Sink Drain

# Biofilms by Using mAb ED7

4.1 Introduction	106
4.1.2 Environmental Sources of Human Pathogenic Fusarium Species	107
4.1.3 <i>Fusarium</i> Biofilms	108
4.1.4 Objective of Chapter 4	109
4.2 Materials and Methods	111
4.2.1 Study Location	111
4.2.2 Collection of Biofilm Swabs and Water Samples	111
4.2.3 Immunodetection of Fusarium Species in Sink Swabs and Mixed and Axer	nic
Cultures by ELISA	115
4.2.4 Fungal DNA Extraction	115
4.2.4.1 Identification of Fungi by Analysis of the ITS Regions of the rRNA-enco	ding
Gene Unit	116
4.2.4.2 Nucleotide Sequence Accession Numbers	117
4.2.4.3 Identification of Fusarium Species Complexes by Using Translation	
Elongation Factor-1α PCR	117
4.2.5 Phylogenetic Analysis	118
4.3 Results	120

4.3.1 Immunodetection of Fusarium Species In Sink Swabs	120
4.3.2 Identification of Fungi by Analysis of the ITS Regions of the rRNA-Enc	oding
Gene Unit and by Translation Elongation Factor-1 $\alpha$ PCR	121
4.3.3 Frequencies and Distributions of Fusarium Species Complexes	122
4.4. Discussion	135
Chapter 5. General Discussion	
5.1 Epidemiology of fungal infections	139
5.2 Diagnosis and Treatment of Fusarium Infections	141
BIBLIOGRAPHY	150
APPENDIX 1: Agglutination Data	210
APPENDIX 2: Phylogeny Trees	214
APPENDIX 3: ITS Sequences	221
APPENDIX 4: TEF-1α Sequences	298
APPENDIX 5: Published Article	344

### List of Tables

Table 2.1.	Details of fungi	used in mAb ED7	specificity tests	
------------	------------------	-----------------	-------------------	--

**Table 2.2** Agglutination trend of *Fusarium species* microconidia suspended in mAbED7 TCS and 10% TCM at 555 nm.61

Table 4.1Locations and identities of sink swabs and water samples andresults of ELISA tests and fungal identification based on ITS sequencing. The ITSsequences corresponding to each isolate are shown in Appendix 3124

#### List of Figures

**Figure 2.3.** Western immunoblot with ED7 using culture fluid from 2-d-old PDB cultures of *F. solani* (CBS224.34) (Lane 1) and *F. oxysporum* f.sp. *lycopersici* (CBS167.30) (Lane 2). Wells were loaded with 1.6  $\mu$ g of protein. M<sub>r</sub> denotes molecular weight in kDa. Note the major extracellular antigen with a molecular weight of ~200 kDa.........52

**Figure 2.4.** Characterization of antigens bound by mAb ED7. Absorbance values from ELISA tests with ED7 using surface washings containing water-soluble antigens immobilized to the wells of microtitre plates and treated with (A): trypsin, (B): pronase or PBS only (control) at 4°C and 37°C, and (C): Stability of the water-soluble ED7 antigen following heating of surface washings at 100°C over a 70 min period. Treated antigen was subsequently immobilized to the wells of microtitre plates and assayed by

ELISA. Bars are the means of three biological replicates  $\pm$  SE and bars with the same letter are not significantly different at p < 0.001 (ANOVA and Tukey-Kramer test). .....53

**Figure 2.7.** Immunogold labelling of sections of conidia and hyphae of *F. solani* (CBS224.34). (A) Transverse section of conidium incubated with ED7 and anti-mouse immunoglobulin 20 nm gold particles, showing antigen in the cell wall in an extracellular fimbrial matrix surrounding the spore (Scale bar = 250 nm); (B) Longitudinal section of hypha incubated with ED7 and anti-mouse immunoglobulin 20 nm gold particles, showing antigen in the cell wall and in an extracellular matrix surrounding the cell (scale bar = 100 nm); (C) Transverse section of a conidium incubated with TCM (negative control) and anti-mouse immunoglobulin 20 nm gold particles, showing a lack of staining by the secondary gold conjugate. Scale bar = 180 nm.

**Figure 2.9.** Agglutination of *Fusarium* species microconidia. (**A**) *F. solani* (CBS224.34) and (**B**) *F. dimerum* var. *dimerum* (CBS108944), spores suspended at  $10^6$  spores/ml in ED7 TCS and 10% TCM. Each point is the mean of 3 replicates ± S.E. Note rapid

Figure 3.1. Schema of the vector hygro-GFP construction. (Sesma & Osbourn, 2004)

**Figure 3.4.** Green fluorescent protein expression in a stable FS-GFP transformant, following single spore isolation and several rounds of sub-culturing onto PDA without hygromycin selection. (**A**) Brightfield image of ungerminated and germinated spore with germ tube. (**B**) The same image as (**A**), but examined under epifluorescence. (**C**) Brightfield image of spores. (**D**) The same image as (**C**), but examined under epifluorescence. (**E**) Brightfield image of control wild-type *F. solani* (CBS224.34) spores and germlings. (**F**) The same image as (**E**), but examined under epifluorescence. Note the lack of fluorescence of wild-type propagules. The magnification for panel **A** and **B** is x60 and x100 for the rest panels. Scale bars = 10  $\mu$ m.

**Figure 3.5.** Absorbance values from ELISA tests of a stable fluorescent FS-GFP transformant and the wild-type strain (CBS224.34). Each bar is the mean of 3 replicate samples  $\pm$  S.E. The level of significance indicates: \*\*\* < 0.001. Scale bars = 20  $\mu$ m..86

**Figure 3.11.** Phagocytosis of FS-GFP microconidia by AMØ at 2h, 12h, and 24 h under agglutinating (mAb ED7) or non-agglutinating (10%TCM- $\Delta$ FCS only) conditions. (**A**) Mean number of engulfed FS-GFP spores per AMØ, and (**B**) Numbers of AMØs containing (0, 1, 2, 3, 4 or >4) spores at each time point. Each bar is the mean of three replicates ± S.E. The levels of significance indicate: NS = non-significant, \* < 0.05. ...96

**Figure 4.1.** Biofilm sampling protocol and preparation of axenic cultures of recovered fungi. (**A** - **C**) Recovery of biofilms from sink drain using a cotton-tipped swab and immersion of biofilm-coated tip in PBS. (**D**) Vigorous vortexing of biofilm debris, (**E**) pelleted debris and (**F**) supernatant containing soluble antigens following centrifugation to test by (**G**) ELISA using mAb ED7 and (**H**) debris culturing on PDA supplemented with Rifampicin. (**I**) Typical mycological culture is showing different morphologies of culturable fungi on mixed culture plates. (**J**) Fungi were separated on the basis of gross morphologies and were sub-cultured until axenic cultures were obtained.

**Figure 4.2.** Schematic diagram showing diagnostic work-flow for identification of *Fusarium* species and unrelated yeasts and moulds recovered from sink drain biofilms.

Figure 4.3. PCR cycling parameters for ITS region amplification......116

Figure 4.4. PCR cycling parameters for TEF gene amplification......118

**Figure 5.4.** Phylogram of the recovered fungal isolates from sink drains and water system based on ITS compare with reference isolates from NCBI. The trees are divided based on location of swab samples (**A** and **B**): University, (**C**): ICU, (**D**): ITU, (**E**): Ophthalmology Unit, (**F**): Haematology Unit and (**G**): Oncology Unit.

mAb	Monoclonal Antibody
ITS	Internal Transcribed Spacer
rRNA	ribosomal Ribonucleic Acid
rDNA	ribosomal Deoxyribonucleic Acid
GM	Galactomannan
AIDS	Acquired Immune Deficiency Syndrome
PAMPs	Pathogen Associated Molecular Patterns
PRRs	Pattern Recognition Receptors
MØ	Macrophage
TLRs	Toll-like receptors
ELISA	Enzyme-Linked Immunosorbent Assay
PCR	Polymerase Chain Reaction
TEF-1α	Translation Elongation Factor-1α
BDG	1,3-β-D-Glucan
PDA	Potato Dextrose Agar
PDB	Potato Dextrose Broth
SDB	Sabouraud Dextrose Broth
MQ-H <sub>2</sub> O	Milli-Q H <sub>2</sub> O
SMQ-H <sub>2</sub> O	Sterile Milli-Q- H <sub>2</sub> O
PBS	Phosphate Buffered Saline
BSA	Bovine Serum Albumin
TCS	Tissue Culture Supernatant
ТМВ	TetraMethylBenzidine
ТСМ	Tissue Culture Medium
FBS	Fetal Bovine Serum
DBSA	Phosphate Buffered Saline containing
	Bovine Serum Albumin
AMØ	Alveolar Macrophage

# **Abbreviations**

TNF	Tumour Necrosis Factor
IL	Interleukins
MET	Macrophage Extracellular Traps
GFP	Green Fluorescent Protein
ES-GEP	Fusarium solani-Green Fluorescent
	Protein
ΔFBS	Heat-inactivated Fetal Bovine Serum
P%	Phagocytosis Percentage
Pi	Phagocytosis Index
IFI	Invasive Fungal Infections

### Acknowledgment

I am grateful for the support, guidance, enthusiasm and most of all patience of my Supervisor, Chris Thornton, to whom I am indebted. Without him, it would not have been possible. Thank you, Chris, very much.

I gratefully acknowledge Iraqi Cultural Attaché in London and Ministry of High Education and Scientific Research (MOHESR – Baghdad) and the University of Basrah, who provided the required supports for this project. I would be grateful thank to George Littlejohn, Pete Splat at bio-imaging Centre and to Tom Richard for bioinformatics and sequencing projects. Special thank for all members of the third-floor labs and office in Exeter, Past and present, who made the long days in the lab were much more enjoyable. I would particularly like to thank those who have given me advice and support Kate, Lauren, Mick Kershaw, Miriam, Magdalen and the members of our research group, in particular, Michael, Genna, and Odette.

I am truly indebted and thankful to my wife Alaa who was a great support for me when I was in this scholarship at Exeter University as well to my three kids lovely Aseel, Ahmed and Sara for their endless love and support during this study. I owe deep thanks to my dearest friends Luis. V. Lopez-Llorca and David Mwongera for endless back up through good and hard times. At the end, I cannot express my thanks or even love to my Mum whom I will not see her forever and Dad.

xvii

### Chapter 1. General Introduction

### 1.0 Overview

The human disease invasive fusariosis, caused by species in the fungal genus *Fusarium*, has emerged as a serious life-threatening disease with high rates of mortality and morbidity in immunocompromised patients. Specific and sensitive diagnostic tests for this infectious fungal pathogen are currently lacking, and early detection of *Fusarium* infections is vital for the prompt and appropriate management of disease (Jain *et al.*, 2011; Thornton, 2011; van Diepeningen *et al.*, 2015). Very little is known about the interaction of emerging human pathogenic fungi such as *Fusarium* and the immune system (Nucci & Anaissie, 2007). Furthermore, the response of *Fusarium* to antifungal drugs is poorly defined (Al-Hatmi *et al.*, 2015; Azor *et al.*, 2009). Arguably, one of the main reasons for this lack of knowledge is the insufficiency of techniques that allow accurate detection of the fungus *in vivo* and for tracking the fungus in epidemiological and immune cell interaction studies (Muhammed *et al.*, 2011).

This chapter will introduce the Kingdom Fungi, and will discuss the importance of *Fusarium* species as agents of disease in crops, animals and humans. The pivotal role of innate and adaptive immune system also will be highlighted, as will the immune response to fungal infections. This overview will encompass diagnosis of the *Fusarium* genus using conventional methods such as mycological culture and direct microscopic examination, in addition to non-cultural-base methods including nucleic acid-based techniques and antigen detection using mAbs. The concept of water-borne fungal disease and nosocomial infections, fungal dispersal, and the potential role of biofilms as

a source of infectious propagules in domestic and hospital settings will also be discussed.

### 1.1 Kingdom Fungi

Fungi are heterotrophic eukaryotic microorganisms that occur ubiquitously in almost all environments encompassing terrestrial, aquatic, polar, temperate and tropical ecosystems (Moore et al., 2011; Poole et al., 2013; Timling et al., 2014) They constitute a single kingdom, Kingdom Fungi, comprising seven phyla, Chytridiomycota, Blastocladiomycota, Glomeromycota, Microsporidia, Zygomycota, Ascomycota and Basidiomycota (Figure 1.1) (Berbee, 2001; Bonfante et al., 1996; Das et al., 2007; Mohanta & Bae, 2015; Moore et al., 2011; Pöggeler & Wöstemeyer, 2011; Rossman, 2008). Since fungi can produce a broad range of enzymes such as  $\alpha$ -amylase, cellulase, lipase, protease, and xylanase (Green & Beezhold, 2011) they are the main decomposers and recyclers of organic substrates in terrestrial ecosystems, with saprotrophism (or saprotrophic) enabling colonisation and utilisation of organic matter for nutrition. Since fungi are unable to fix carbon, they obtain nutrients from different organic sources to provide the energy required for growth and reproduction and so are called heterotrophic organisms. Fungi produce extracellular enzymes to degrade complex organic compounds into simpler metabolisable units such as glucose or amino acids and absorb these into the cell through the cell wall and plasma membrane. Most fungi have a saprotrophic phase in their life cycles, obtaining their nutrients from decaying organic matter of plants or animals (Jung et al., 2013). Pathogenic fungi are also able to derive

nutrients from parasitized hosts either biotrophically or via necrotrophism (Lowe & Howlett, 2012).



**Figure 1.1.** Phylogeny tree of the Kingdom Fungi. Strain names are given only when more than one organism in that species appeared in our dataset. Blocks coloured in red, blue, green, yellow and purple correspond to the Ascomycota, Basidiomycota, Chytridiomycota, Mucoromycotina and Microsporidia, respectively. The majority of fungi are related to the Ascomycota and Basidiomycota are distinguished by alternate red and blue colours, respectively. (Wang *et al.*, 2009).

The structure and composition of the fungal cell wall is a defining characteristic of these eukaryotes and may differ in architecture and dynamic function. The cell wall plays a vital role in in several biological processes including the fungal cell morphogenesis, growth, cell-cell interaction, and it provides a protective barrier from environmental conditions as it acts as a sensor and response to surrounding environment change such as osmotic pressure (Adams, 2004; Klis, 2001). For the pathogenic fungi, the cell wall components involve in virulence and pathogenicity through mediating fungal cell adhesion, colonization and biofilm developing (Bowman & Free, 2006; Free, 2013). The fungal cell wall is complex composed alycoproteins embedded а structure of within a polysaccharide matrix including of chitin and glucan, and there is evidence of extensive cross-linking between these components together to generate a three-dimensional structure with the cell membrane that contains a fungal unique lipid, ergosterol (Figure 1.2) (Bowman & Free, 2006; Latgé, 2010; Masuoka, 2004; Parks & Casey, 1995; Pasanen et. al., 1999). For this reason carbohydrates is the first component to contact host tissue (Hall et al., 2013; Masuoka, 2004). The inner layer of cell wall consists of chitin which is synthesized by chitin synthases, and glucan which is a homopolymer of glucose that include  $\beta$ -1,3-glucan, mixed  $\beta$ -1,3- with  $\beta$ -1,4-,  $\beta$ -1,6-, and  $\alpha$ -1,3-glucan. The glucan-chitin complex is covalently bound to other polysaccharides, and that varies in the pathogenic fungi. For example, Aspergillus fumigatus polysaccharides are composed of galactomannan and  $\beta$ -1,3 and  $\beta$ -1,4-glucan, whereas in *Candida albicans*  $\beta$ -1,6-glucan is the main contain (Aimanianda) et al., 2009; Fontaine et al., 2000). Glycoproteins including galactomannan and/or mannan are the main composition of the outer layer of the cell wall. Once the glucan braches, chitin, and glycoproteins are released into the cell

wall space, the components covalently cross-linked to form a rigid cell wall (Barreto-Bergter & Figueiredo, 2014; Free, 2013; Latgé, 2010; Masuoka, 2004)



**Figure 1.2.** Fungal cell wall architecture. Transmission electron micrographs of the *Candida albicans* cell walls are shown on the left. The right illustrates the structure of the *C. albicans* cell wall. (Brown *et. al.,* 2014).

Fungi are a major source of beneficial bioactive compounds used in medicine and agriculture, such as antibiotics (Bérdy, 2005) and plant-growth-promoting compounds (Naznin *et al.*, 2013), but also produce highly toxic secondary metabolites and allergens deleterious to human health (Brase *et al.*, 2009; Desjardins & Proctor, 2007). As opportunists, fungi can cause serious lifethreating infections both in immunocompetent and immunocompromised individuals, particularly those with haematological malignancies or bone marrow tansplants (Perfect, 2012).

In 2001, it was estimated that one and a half million species of fungi exist on the planet (Hawksworth, 2001). However, more recent molecular studies using

analysis of the ITS rRNA region suggests that more than 5 million fungal species exist (Blackwell, 2011; O'Brien *et al.*, 2005).

The majority of fungal species that have been discovered belong to the phyla Ascomycota and Basidiomycota, and so they are combined into a separate fungal sub-kingdom called Dikarya (Hibbett *et al.*, 2007). Pathogenic fungi are often found in the phyla Basidiomycota, Ascomycota, and Zygomycota (Galagan *et al.*, 2005).

The Basidiomycota includes important human pathogens such as the yeast *Cryptococcus* spp. (causative agent of the disseminated human disease cryptococcosis), *Trichosporon* spp. (disseminated trichosporonosis) and *Malassezia* spp. that causes superficial skin diseases (Anaissie *et al.*, 2009; Gaitanis *et al.*, 2012). Species of *Rhizopus*, *Mucor* and *Lichtheimia* are the main pathogenic agents of mucormycosis (Ribes *et al.*, 2000; Skiada *et al.*, 2011).

### 1.1.1 Phylum Ascomycota

Ascomycota is the largest fungal phylum and contains, at present, 64,000 species (Weete *et al.*, 2010). The main characteristic feature of this phylum is the formation of a sac-like structure (ascus) containing ascospores (Carlile *et al.*, 2001; Webster & Weber, 2007). Many ascomycetes reproduce asexually by producing copious airborne conidia or spores generated from mycelia. Alternatively, they can reproduce sexually, indicated by a teleomorphic phase (Hogg, 2005). For example, *Nectria haematococca* is the teleomorph state of *Fusarium solani* (the anamorph or asexual stage).

Ascomycetes include filamentous (hyphal)-organisms and yeasts. Unlike zygomycetes, ascomycete hyphae are septate with cross walls called septa. These fungi are ubiquitous and associated with food spoilage and are the main producers of mycotoxins. Examples include the filamentous fungi *Aspergillus* and *Fusarium* species (Pitt & Hocking, 2009). Many ascomycetes produce carcinogenic mycotoxins, such as aflatoxins and trichothecenes that can cause serious harm to animals and humans (Nelson *et al.*, 1993; Yazar & Omurtag, 2008; Yli-Mattila, 2010). Nevertheless, ascomycetes can be beneficial, and are amenable biotechnologically for the production of antibiotics such as penicillin, immunomodulatory compounds such as cyclosporins and edible mycoproteins. However, many ascomycete species are recognizable as aggressive plant pathogens, causing destructive crop diseases, such as Panama disease of banana caused by *F. oxysporum* f.sp. *cubense* race 4 (Dean *et al.*, 2005; De Ascensao & Dubery, 2000).

The clinical importance of opportunistic ascomycete fungi, such as *Aspergillus* (the cause of invasive pulmonary aspergillosis), *Fusarium* (fusariosis), and *Candida* (candidiasis) is increasing amongst the ever expanding populations of immunocompromised patients such as those with neutropenia, haematological malignancies and recipients of bone marrow transplants. Opportunistic ascomycetes are emerging as the most significant source of mortality and morbidity in these high-risk patient groups (Hanson, 2008; Kauffman *et al.*, 2011; Moore *et al.*, 2011).

### 1.1.1.1 The fungus *Fusarium*

The genus *Fusarium* is one of the most ubiquitous groups of filamentous fungi and contains several economically important plant pathogens and producers of mycotoxins such as fumonisins and trichothecenes. This heterogeneous genus is also an important producer of bioactive metabolites, including antibiotics and anti-cancer agents (Baker & Tatum, 1989; Chakravarthi *et al.*, 2008; Gerber & Ammar, 1979; Mohamed, 2012; Qureshi *et al.*, 2003; Tayung *et al.*, 2011).

A saprotroph and general opportunist, it is increasingly recognised as a serious human pathogen (Leslie & Summerell, 2006). This genus has been found in virtually all ecosystems on the planet and more than 1000 species of the genus have been described (Rios & Ortega, 2012; Summerell *et al.*, 2003).

*Fusarium* was initially described based on the presence of fusiform spores in 1809 by Link and validated by Fries in 1821 (Booth, 1971). The anamorphic (asexual) stage of *Fusarium* species is dominant and often produces both microconidia and macroconidia. The microconidia are small in size and oval to ovoid in shape and grow from the aerial mycelium on phialides. The macroconidia are distinctive, large, and septate, with curved to straight appearances, and are initiated from cushion-like structures called sporodochia (Leslie & Summerell, 2006; Toussoun & Nelson, 1975) as shown in **Figure 1.3**.



**Figure 1.3.** Gross morphology of *F. solani* (CBS224.34) in axenic culture on potato dextrose agar (A), with mycelia (B), macroconidia (C) and microconidia (D). Scales bars =  $20 \mu m$ . Images of Marwan Al-Maqtoofi.

### 1.1.1.2 Classification of the genus Fusarium

The first *Fusarium* taxonomical system was established in 1935 by Wollenweber and Reinking and in the 1940s by Snyder and Hansen (Nelson, 1975; Nelson, 1991). Since then, many species have been added or removed from the *Fusarium* genus due to morphological similarity (Rossman & Palm-Hernández, 2008). Plant pathogenic species within morphological groupings were further divided based on host specificity. As a consequence, varieties (var.) and formae speciales (f. sp.) are used to describe host specificities of *Fusarium* species (Agrios, 2005; Ma *et al.*,2010). For example, *F. oxysporum* f.

sp. *lycopersici* and *F. solani* f. sp. *pisi* are narrow in host infection, infecting the only tomato and pea plants, respectively (Lievens *et al.*, 2009; Namiki *et al.*, 1994; Suga *et al.*, 2002), while *F. graminearum* or *F. verticillioides* are selective pathogens for cereal crops (Shim *et al.*, 2006). However, some species, such as *F. oxysporum*, infect a broad range of hosts. As such, *F. oxysporum* is currently ranked as the fifth most important plant pathogen (Dean *et al.*, 2012; Ma *et al.*, 2010).

The genus Fusarium is currently classified as follows:

Phylum: Ascomycota

Subphylum: Pezizomycotina

Class: Sordariomycetes

Sub-class: Hypocreomycetidae

Order: Hypocreales

Family: Nectriaceae (Lumbsch & Huhndorf, 2007; Rossman et al., 2013).

Genus: Fusarium

### **1.2 Etiology and Pathogenesis**

Recently, the incidence of fungal infections has increased dramatically concomitant with the ever-expanding population of immunocompromised humans. This population is highly susceptible to fungal infections due to impaired host immune responses. Many health factors have been associated with suppression of host immune defence, including AIDS, malignant diseases, especially patients those receiving toxic chemotherapy agents like corticosteroids and intensive broad-spectrum antibiotic therapy, and solid organ transplantation (SOT) and bone marrow transplantation (BMT) (Low & Rotstein,

2011; Sganga, 2011; Silva, 2010). In the US between 1980 and 1997, the death rate due to invasive fungal infections (IFI) increased 320%. The most common fungal pathogens causing serious nosocomial life-threatening infections are Candida and Aspergillus species (Anaissie, 1992; Lockhart et al., 2009; Low & Rotstein, 2011; McNeil et al., 2001; Silva, 2010; Walsh & Groll, 1999). Significant increases in IFIhave also been reported with emerging pathogens, including hyaline septated filamentous fungi, such as Fusarium, Acremonium, Scedosporium, Paecilomyces, and Trichoderma. In addition, yeasts such as Trichosporon, Rhodotorula, and Geotrichum, the mucormycetes Rhizopus and *Mucor* species and dematiaceous fungi, including *Pseudallescheria*, *Bipolaris*, Exophiala, Phialophoraand Cladophialophora, have all been reported as opportunist pathogens of humans (Pfaller & Diekema, 2004; Ponton et al., 2000; Walsh et al., 2004; Walsh & Groll, 1999). The mortality rate of hematologic malignancy patients with invasive mould infections is far greater than that associated with yeasts infections with 64% mortality for mucormycosis, 53% for fusariosis, 42% for aspergillosis and 33% for candidiasis (Araujo et al., 2010; Pagano et al., 2006).

Fusariosis is the second most common invasive fungal infection among highrisk patients after *Aspergillus* (Boutati & Anaissie, 1997; Nucci *et al.*, 2004; Stanzani *et al.*, 2007; Walsh & Groll, 1999) and can be cutaneous or disseminated. These infections can occur in both immunocompromised and healthy individuals. In severely immunodeficient patients, invasive infection is more persistent (Jain *et al.*, 2011; Nucci & Anaissie, 2007). Because *Fusarium* is unresponsive to standard antifungal therapy, the incidence of the invasive fusariosis significantly increases with intensive use of cytotoxic agents and immunosuppressive drugs (Nucci *et al.*, 2014; Ponton *et al.*, 2000). Some *Fusarium* species comprise complexes of strains that vary in virulence towards humans. *F. solani*, for example, comprises the *F. solani* species complex (FSSC) (Zhang *et al.*, 2006). The two most virulent species complexes involved in disseminated fusariosis are FSSC, followed by the *F. oxysporum* species complex (FOSC) (Campbell *et al.*, 2013; Mayayo *et al.*, 1999; Moore *et al.*, 2011; Diepeningen *et al.*, 2014). The FSSC is also well known as a complex containing economically important crop pathogens. This species complex is one of the most common causes of fungal keratitis in immunocompetent people. Patients with hematologic malignancies receiving cytotoxic chemotherapy, SOT and stem cell transplant recipients, and patients with extensive burns are at high risk for invasive fusariosis associated with FSSC (Zhang *et al.*, 2006).

Pathogenic fungi can make biofilms in environment and even host tissues by proliferating and expanding extensive living forms of hyphae and conidia in an extracellular matrix (ECM) allowing adhesion to surfaces for penetration (Pierce *et al.*, 2008). Accordingly, this ability has identified as a serious clinical issue (Ramage *et al.*, 2012). Many of medically important fungi such *Candida* (Deorukhkar *et al.*, 2014; Ramage *et al.*, 2012), *Aspergillus* (Kaur & Singh, 2014) and *Fusarium* (Imamura *et al.*, 2008; Mukherjee *et al.*, 2012) that produce biofilms tend to display high resistance to host immunity response and antifungal agents. Recent studies have suggested that biofilm formation is one of the most important pathogenicity virulence factors in invasive mycoses, and associated with high mortality rates (Rajendran *et al.*, 2016; Tumbarello *et al.*, 2007). Since a biofilm is a surface-associated fungal community, a typical fungal biofilm development involves in four sequential steps including the cell

adhesion to a surface, cells colony formation, maturation into a threedimensional structure, and dispersion of cells (Ramage *et al.*, 2009), as shown in a model of filamentous (**Figure 1.4**) (Ramage *et al.*, 2011) and in yeasts (Chandra *et al.*, 2001) (**Figure 1.5**). Since *Fusarium* keratitis outbreat during 2005/6 in the US, *Fusarium* biofilm formation on soft contact lenses has been studied (Imamura *et al.*, 2008; Mukherjee *et al.*, 2012). Glycoprotein with mannose residues in the extracellular fibrillar matrix located on the outer cell wall layer of the *Fusarium* spore is thought to be a start point of adhesion and biofilm developing (Kwon & Epstein, 1997; Kwon & Epstein, 1993; Pan *et al.*, 2011; Gauthier & Keller, 2013; Kwon & Epstein, 1997). At present, little is known about *Fusarium* biofilm formation and its role in survival and pathogenicity of the fungus during invasive infections (Peigian *et al.*, 2014).



**Figure 1.4.** Aspergillus fumigatus biofilm development. The different phases of biofilm development are represented schematically, from initial adhesion of conidia, germling formation (8 h), a monolayer of intertwined hyphae (12 h) and mature 3D filamentous biomass (c. 200  $\mu$ m) encased within exopolymeric sub- stance (24 h). (Ramage *et al.*, 2011).



**Figure 1.5.** Schematic representation of biofilm development in *C. albicans.* (**a** and **b**) Biofilm grown on polymethylmethacrylate (PMA) strips. (**c** and **d**) Biofilm grown on silicone elastomer (SE) disks. Panels (**a**) and (**c**) represent the substrate seen from the top, while panels c and d show the view from the sides of the PMA strip and SE disk, respectively. ECM, extracellular material. (Chandra *et al.*, 2001).

### 1.3 The Human Immune System

The human immune system is comprised of a complex network of immune cells and soluble chemical components that interact effectively to prevent access and defend against fungal invasion. The innate and adaptive immune systems are a vital part of the immune responses towards infectious diseases (Romani, 2004). The innate immune system is the first line of protection (Brown, 2011; Figueiredo *et al.*, 2011). It is non-specific, mounting a rapid response to potential pathogens, and it lacks immunological memory. The main components of the innate immunity are a physical barrier, such as the skin, epithelium, and mucus that is produced in the airways and gastrointestinal tract (Romani, 2004; Romani, 2011). In addition, soluble components such as cytokines, complement, antimicrobial compounds and inflammatory mediators interact to deliver immunity (Abbas et al., 2007) alongside innate phagocytic cells such macrophages and neutrophils, natural killer cells, and dendritic cells (Folds, 2008).

The adaptive immune system can be activated once fungal propagules breach the innate immune system. The adaptive immune system provides a specific response and can generate immunological memory for life-long-acquired immunity. Both immune systems cooperate effectively to eliminate infectious pathogens (Williams *et al.*, 2012).

### **1.3.1** The innate immune system and fungal infection

The innate immune system provides an initial line of defence against potential pathogens by recognising PAMPs, foreign antigens, such as carbohydrates and

#### Chapter 1

proteins, unique to pathogens and which evoke a host immune response following recognition by PRRs. Innate immunity to fungi consists of physical barriers, serum factors including complement, cytokines, and natural immunoglobulins, and phagocytic cells (Carvalho *et al.*, 2010). These components work efficiently to prevent and control fungal dissemination and halt potential infections. The innate immune response lacks immunological memory and is non-specific, but is rapid. Each part of the innate immune system has an essential role against fungal invasion either directly or indirectly within a complex network of signalling.

The first line of protection is the physical barrier of the skin and the mucosal layer at potential portals of entry for fungi. Therefore, individuals with severe burns are at a high risk of fungal infections (Church et al., 2006), Epithelial tissues participate against microbial invasion via releasing antimicrobial compounds that either inhibit or kill microbial cells whilst also activating cellular innate immunity. Cellular innate immunity comprises phagocytic and antigenpresenting cells including sentinel  $M\emptyset$ , circulating polymorphonuclear neutrophils (PMN), natural killer cells (NK), and dendritic cells (DC). Innate immune cells aid in the clearance of infectious agents via phagocytosis and have antigen-presenting functions in the lymphoid organs that stimulate the adaptive immune response. Unlike human cells, fungi have a distinct cell wall that contains chitin, glucans, mannans and glycoproteins (Bowman & Free, 2006). Innate immune cells have specific surface receptors, such as the β-glucan receptor Dectin-1, mannose receptors, and TLRs, for fungal cell wall components and can discriminate between infectious cells and human cells (Folds, 2008; Shoham & Levitz, 2005). Despite this, some pathogenic fungi,
such as *Cryptococcus*, have developed mechanisms to avoid the innate immune system (Voelz & May, 2010). For example; phagocytosed *Cryptococcus* can be multiple inside macrophages and then escape either by a novel non-lytic mechanism (Johnston & May, 2010) or lysis host cells (Alvarez & Casadevall, 2006).

# **1.3.2 The adaptive immune system and fungal infection**

The adaptive immune system differs in some aspects to the innate immune system, not least in that it has immunological memory. Humoral immunity and cell-mediated immunity are the main arms of the adaptive immune system with adaptive cellular immunity consisting of T and B-lymphocytes. Humoral immunity refers to antibodies produced by B-cells. These antibodies can be either non-specific or specific for a certain pathogen, binding to conserved or pathogen-specific epitopes (antigenic determinants) on immunoreactive antigens. Antibodies participate in fungal elimination via a range of mechanisms, including preventing spore adhesion, neutralising extracellular enzymes, inhibiting yeast-hyphal morphological transitions, preventing spore germination, agglutinating and opsonizing fungal spores, and facilitating phagocytosis. There are different classes of antibodies or immunoglobulins (Ig). Ig classes that circulate in the bloodstream include Ig class M (IgM) and IgG. Others, including IgA and IgE, are located within mucous membranes (Romani, 2002). In response to the fungal invasion, T-helper cells (Th) and cytotoxic T-cells (CTLs) differentiate from a common lymphoid progenitor cell. Th cells produce cytokines and interferon-y (IFN-y) to activate macrophages to kill phagocytosed pathogens. CTLs play critical roles in the elimination of

pathogens by killing infected host cells (Abbas *et al.*, 2007; Blanco & Garcia, 2008).

# **1.4 Antifungal Treatment**

Unlike antibacterial antibiotics, the therapeutic options for managing fungal infections using antifungal compounds are limited, particularly with the dramatic increase in immunocompromised population and diversity of emerging human pathogenic fungi (Kanafani & Perfect, 2008; Richardson & Warnock, 2003). This limitation is associated with a poor prognosis (Ashley, et. al., 2006). The reason behind that is because fungal pathogens were not recognized as serious life threatening agents (Anaissie & Bodey, 1989). Furthermore, fungi and human beings are eukaryotes microorganisms and therefore have closely related to cellular machinery, structure and function. This necessities robust development of antifungal agents with little or minimal to mammalian host cells (Dixon & Walsh, 1996; Masuoka, 2004). Currently, three main classes of antifungal drugs including polyenes, the azoles and the echinocandins have been developed for treatment of fungal infections (Lattif & Swindell, 2010). In addition, there is a miscellaneous group of compounds, such as flucytosine and griseofulvin are also utilised (Richardson & Warnock, 2003). The pharmaceutical form of antifungal are mainly administered orally, intravenous and eye drops (Arthur et. al., 2004; Kawamura et. al., 2000).

Antifungal agents target only unique fungal cell structure and processes that involve synthesis of cell wall components such as chitin,  $\beta$ -glucans, ergosterol in addition to disrupting the in cell membrane. This selectively kills the fungal

cells without affecting the mammalian cells (Figure 1.6) (Free, 2013; Ghannoum & Rice, 1999; Kathiravan *et al.*, 2012).



Figure 1. 6. Sites of action of antifungals. (Gubbins & Anaissie, 2009).

Azoles compounds such voriconazole and psoaconazole interfere with the synthesis of ergosterol in the fungal cell membrane through inhibiting the cytochrome P450 enzyme, lanosterol demethylase in fungi (Kanafani & Perfect, 2008). Amphotericin B deoxycholate and its lipid-form belong to polyenes antifungal group and act with ergosterol by making holes in the fungal membrane allowing leakage of essential cytoplasmic materials, such as

potassium, leading to cell death (Ghannoum & Rice, 1999; Kanafani & Perfect, 2008). The echinocandins have a unique mechanism of action, inhibiting  $\beta$ -(1,3)-D-glucan synthase an essential component of the fungal cell wall (Sucher *et. al.*, 2009). In comparison to the azoles and polyenes, the echinocandin group including caspofungin , micafungin and anidulafungin are not widely used for therapy of invasive mycoses due to their large molecular weight and therefore poor absorption through the digestive tract (Lattif & Swindell, 2010).

Pathogenic fungi have developed mechanisms to resist antifungal compounds thereby reducing drug efficiency. The main strategies employed to reduce efficiency of the antifungal compounds by pathogenic fungi include reduction of drug accumulation in the fungal cell, reduction of the target affinity for the drug and changes to the metabolism. (Pemán *et al.*, 2009; Terra *et al.*, 2014).

Managing fusariosis is a serious challenge since most of pathogenic *Fusarium* species are resistant to most antifungal agents thereby limiting treatment options for invasive infections (Azor *et. al.*, 2007; Muhammed *et. al.*, 2011; Mukherjee *et. al.*, 2012; Nucci *et. al.*, 2013). There is no clear and optimum treatment strategy for *Fusarium* infections (Blyth *et al.*, 2014; Carneiro *et al.*, 2011; Liu *et al.*, 2014; Muhammed *et al.*, 2011; Nucci & Anaissie, 2007). Therefore, treatment of immunocom-promised patients with disseminated fusariosis is difficult and is compounded by the wide variation of *Fusarium* species complex that leads to variability in response to the antifungal agents (Stanzani *et al.*, 2007). That may explain the low survival rate of persistent neutropenic and transplant recipient patients (Nucci *et al.*, 2014). However,

some studies showed that Amphotericin B (AMB) was the best active antifungal agent with minimal inhibitory concentration (MIC) no lower than 2 µg/ml (Azor et al., 2007). In contrast, terbinafine (TBF) was the most active drug for treating fusariosis at MIC of 0.60 µg/ml compared to the other rest azole drugs such as ravuconazole (RVC), albaconazole (ABC), itraconazole (ITC), and ketoconazole (KTC), fluconazole (FLC), flucytosine (5-FC) (Azor et al., 2009) which had relatively high MIC ranging from 4.24 to 32 µg/ml). Treatment immunocompromised patients with high intravenous doses of amphotericin B or the lipid formulations is recommended as a first choice therapy for invasive fusariosis (Wheat et. al., 2002) with voriconazole and posaconazole as an alternative therapies (Muhammed et. al., 2011). Granulocyte colonies stimulating factor (G-CSF) or granulocyte-macrophage colony stimulating factor (GM-CSF) are also tools for managing fusariosis (Jain et. al., 2011). In conclusion, evidence available indicates there no single effective strategy for treating invasive fusariosis with response to antifungals such azole varying widely (Gubbins & Anaissie, 2009).

# 1.5 Diagnosis of invasive fungal infections

In comparison with other infectious diseases, the diagnosis of fungal infections (mycosis) is still underscored by the management of the disease. It is a major problematic health issue, especially in the absence of a clear understanding of the epidemiology of fungal infections. The need for accurate and sensitive diagnostic approaches for invasive mycosis is becoming more important, particularly with the dramatic increase in severely immunocompromised patients and the rise in nosocomial infections. Early diagnosis allows timely treatment

with appropriate antifungal drugs and successful management of the fungal disease. Establishing a sensitive and rapid diagnostic test for fungal infections is complicated. Traditional methods of diagnosis that are used include direct microscopy, mycological culture, histopathology, clinical symptoms, radiology and serological tests. The direct microscopic examination is the primary method used to identify fungal propagules in clinical samples visually. Definitive diagnosis of disseminated mycosis requires the recovery and identification of fungal pathogens from samples such as skin, sinuses, lung, and body fluids (in particular blood) using culture and microscopy (Nucci & Anaissie, 2009). Selective stains are used to detect fungal elements. For example, calcofluor white and India ink are used to visualise fungal cells with fluorescence or contrast microscopy (Stevens, 2002).

Identification of fungal pathogens at the species level is often needed for appropriate antifungal treatment. Direct microscopical examination is cheap and widely available but is not able to identify pathogenic fungi at a species level. Furthermore, it requires expertise in medical mycology to discriminate different morphological features of infectious agents (Alexander & Pfaller, 2006; Steinbach *et al.*, 2003). A notable example is the invasive hyaline fungal pathogens (causative agents of hyalohyphomycosis). This group of organisms, which includes *Aspergillus*, *Fusarium*, *Scedosporium*, *Penicillium* and *Acremonium* all have hyaline septate hyphae with narrow-angle branching (Arvanitis *et al.*, 2014; Tortorano *et al.*, 2014; Nguyen *et al.*, 2012; Nucci & Anaissie, 2009). Moreover, some pathogenic fungi, such *Acremonium* spp., grow slowly and require around 14 days (Park *et al.*, 2011).

#### Chapter 1

Clinical manifestations of deep mycosis are non-specific, and variable, depending on infection site and patient status. For example, severely immunocompromised hosts more frequently undergo fever, chest pain, skin lesions, pulmonary infiltration and other clinical features. A broad range of fungal pathogens, such as *Fusarium, Curvularia, Bipolaris, Exserohilum, Alternaria, Aspergillus* species and *Pseudallescheria boydii* can all mimic the same clinical signs (Guarner & Brandt, 2011; Park *et al.*, 2011; Pauw & Meis, 2005). Radiological findings, including X-ray and computed tomography (CT) scans, are similarly non-specific, but can indicate invasive fungal infection. Therefore, a combination of diagnostic approaches is indispensable to prevent misdiagnosis (Alexander & Pfaller, 2006; Barnes, 2008; Oh *et al.*, 2000; Richardson & Warnock, 2003).

The fungal cell wall has a wide variety of antigenic structures that can stimulate the adaptive immune system. In this case, activated B-cells produce antibodies that aid in opsonization and clearance of propagules by phagocytic cells. Fungal-specific serum antibody titers tend to be elevated during fungal infections in patients that can mount a B cell response and so can be used in some instances to detect circulating antigens released during disseminated disease (Blanco & Garcia, 2008; Shoham & Levitz, 2005). However, in patients with impaired immune responses, it is not possible to generate detectable antibody titers against systemic fungal infections (Stevens, 2010).

Conversely, serodiagnostic tests using polyclonal or monoclonal antibodies, generated against fungal antigens in rabbits or mice, have been developed and used to track infections using crude antigen extracts or recombinant proteins

(Brandt & Warnock, 2003). Serodiagnostic tests are rapid and are achieved using immunoassays such as ELISA or immunodiffusion (ID) (Morrison & Warnock, 2007). Because polyclonal antibodies are not specific to a given genus or species (Badiee & Hashemizadeh, 2014), serological assays are less likely to be able to discriminate between the many different fungal pathogens (Ahmad *et al.*, 2010; Alexander, 2002; Limper, 2010). For this reason, highly specific monoclonal antibodies generated using hybridoma technology are needed for accurate serological diagnosis. With the broad variety of emerging opportunistic fungal pathogens, conventional diagnostic methods are considered time-consuming, inaccurate, and/or not sensitive enough. This leads to an increased chance of misidentification and mistreatment (Alexander & Pfaller, 2006; Arvanitis *et al.*, 2014).

#### 1.5.1 Non-Cultural Based Methods

Non-culture based methods have been developed to improve the accuracy and speed of diagnosis of invasive fungal infections. These methods include molecular (nucleic acid-based) detection methods and fungal antigen detection using mAbs (Alexander & Pfaller, 2006; Kozel & Wickes, 2014).

### 1.5.1.1 Molecular Diagnosis

The increasing incidence of emerging pathogenic fungi has necessitated the development of more accurate and rapid techniques for fungal diagnosis. DNA sequence-based approaches are considered the pivotal methods in the fungal identification, with a turn-around time of about 24 h (Balajee *et al.*,

2009). Molecular diagnostic techniques are culture-independent methods that do not require morphological features of living cells or colonies for identification. Most of the molecular based tools are based on the use of PCR. This technique amplifies and analyses constant genetic markers of fungal cells that provide rich data for fungal identification (Kozel & Wickes, 2014).

PCR-based techniques are increasingly being used as a rapid tool for detection and amplification of marker genes specific to each fungal species, such as TEF-1 $\alpha$  for *Fusarium* species,  $\beta$ -tubulin for *Aspergillus*, endo-polygalacturonase for *Alternaria*, and calmodulin for *P. boydii* (Romanelli *et al.*, 2014). Several regions of the fungal genome have been evaluated as potential targets for detection, such as the ITS region of the nuclear ribosomal DNA (rDNA) (Richardson & Warnock, 2003). However, getting sufficient DNA yield from clinical samples is not always feasible (Guarner & Brandt, 2011). Furthermore, it has been shown that PCR-based techniques cannot completely replace culture-based methods due to their variable sensitivities and the possibility of contamination in the diagnostic laboratory (Alexander & Pfaller, 2006).

## **1.5.1.2 Antigen Detection Using Monoclonal Antibodies**

Hybridoma technology enables the produce of highly specific mAbs against a specific antigen *in vitro*, and can make a significant contribution to the improved accuracy and speed of diagnosis for fungal pathogens. This technology was first described by Georges Köhler and Cesar Milstein in 1975 (Köhler & Milstein, 1975) and allows the identification of B-cells secreting antibodies of predefined specificity. Antibody-producing B-cells cannot survive

*in vitro* unless they are first fused with a myeloma cell, to produce a hybridoma cell. These immortalised B-cells cell lines can then be grown in culture and their antibodies harvested for use in immunodiagnostics (Abbas *et al.,* 2007).

MAbs can identify fungi at the genus (Thornton *et al.*, 2002) and species levels (Thornton *et al.*, 1993). Highly specific mAbs have been developed to identify pathogenic fungi in soil and plants (Dewey & Thornton, 1995; Dewey *et al.*, 1997; Thornton *et al.*, 1993; Thornton, 2008a; Thornton *et al.*, 2002; Thornton & Talbot, 2006; Thornton *et al.*, 2004). For medical purposes, specific mAbs have been developed for the early diagnosis of mycoses, particularly invasive infections (Thornton, 2009a; Thornton, 2008b). Successful diagnosis of human pathogenic fungi using mAbs developed previously against plant pathogens have also been reported (Thornton, 2009b; Thornton, 2008b; Thornton & Wills, 2013).

Many mAbs have been developed for accurate, sensitive and rapid detection of opportunistic fungal pathogens. Specifically, mAbs for *Aspergillus* (Thornton, 2008), *P. boydii* (Thornton, 2009), *Scedosporium prolificans* (Thornton *et al.*, 2015), and *Trichosporon asahii* (Davies & Thornton, 2014a) have all been developed. In medical mycology, the availability and accuracy of new diagnostic tests have a significant impact on the management of fungal infections and reduction of mortality levels.

### 1.6 Focus of This PhD

The ever expanding population of patients with compromised immune systems is at risk of disseminated infections associated with opportunistic fungal pathogens (Crabol *et al.*, 2014; Kriengkauykiat *et al.*, 2011). The most common disseminated fungal infections are caused by species of *Candida* and *Aspergillus*, with considerable rates of morbidity and mortality (Nucci & Marr, 2005). However, some opportunistic fungi such as *Fusarium* and *Scedosporium*, *Rhizopus*, *Mucor*, *Trichosporon*, *Rhodotorula*, *Paecilomyces* and *Exophiala* have emerged as significant causes of life-threatening infections in humans, but relatively little is known about their pathobiologies (Anaissie *et al.*, 1989; Boutati & Anaissie, 1997; Kauffman, 2004; Nucci *et al.*, 2002; Pfaller & Diekema, 2004).

Furthermore, these fungi are typically less susceptible to antifungal agents currently used in the clinical setting (Srinivasan *et al.*, 2014). Early diagnosis of these organisms is critical, but rapid and accurate detection remains a serious challenge (Barnes, 2008; Low & Rotstein, 2011).

The aim of this work was to develop and characterise highly *Fusarium*-specific mAb that can be used to detect this important emerging human pathogen and as a tool to study its epidemiology and interaction with cells of the innate immune system.

The specific aims of these investigations were:

**1.** To characterize a *Fusarium*-specific mAb (mAb ED7) by investigating the chemical nature and cellular localization of its target antigen (**Chapter 2**);

**2.** To use mAb ED7 to study the interaction of *Fusarium* spores with cells of innate immunity (**Chapter 3**);

**3.** To use mAb ED7 to identify sources of the pathogen for nosocomial and community-acquired infections (**Chapter 4**).

# Chapter 2. Production and Characterization of the *Fusarium*-Specific mAb ED7

# 2.1 Introduction

#### 2.1.1 *Fusarium* as a Plant Pathogen

Fusarium species are major plant pathogens causing a range of diseases in a large number of economically important crops with yield losses of up to 100% (Burgess, Knight, Tesoriero, & Phan, 2008; Leslie & Summerell, 2006). The genus causes diseases of cereals (Abbas et al., 1998; Francis & Burgess, 1977; Moretti, 2009), fruits (Jiménez et al., 1993; Zhang et al., 1999), and vegetables (Naef & Défago, 2006; Roy, 1997), with species listed in the top 10 fungal plant pathogens according to economic importance including F. graminearum (fourth) and F. oxysporum (fifth) (Dean et al., 2012). The best known Fusarium disease in plants is Fusarium Head Blight (FHB), a disease affecting cereal crops, rice and wheat. FHB is caused by *F. oxysporum* (Nganje et al., 2004), F. graminearum (Goswami & Kistler, 2004), F. avenaceum (Yli-Mattila, 2010), F. culmorum, F. pseudograminearum (Balmas et al., 2015) and F. proliferatum (O'Donnell et al., 2010). Other Fusarium diseases include sudden death syndrome (SDS), Fusarium wilt, root, stem and seed rots and cankers of many fruits and vegetables including tomato, potato, cotton, cabbage, cucumbers, melons, date palms, peas, and soybeans (Ahmet, 2011; Ajilogba & Babalola, 2013; Gupta et al., 2009; Moretti et al., 2002; Vicente et al., 2014; Pilotti et al., 2002; Schroers et al., 2009). A number of Fusarium species, for example, F. solani and F. oxysporum, are capable of infecting both plants and humans (Moore *et al.*, 2011).

#### 2.1.2 *Fusarium* as Agents of Human Infectious Diseases

The most frequently cited fungal pathogens of humans include *Candida*, *Cryptococcus*, *Aspergillus*, *Fusarium*, *Scedosporium*, *Rhizopus* and *Mucor* (Araujo *et al.*, 2010; Esnakula *et al.*, 2013; Pontón *et al.*, 2000). Invasive infections caused by *Fusarium* species (known as fusariosis) mainly occur in immunocompromised humans and, in certain settings, have emerged as the second most common opportunistic pathogen after *Aspergillus* (Boutati & Anaissie, 1997; Nucci *et al.*, 2004; Walsh & Groll, 1999), causing localised and disseminated infections in humans (Nelson *et al.*, 1994; Nucci & Anaissie, 2007).

The first case of disseminated infection due to *F. solani* was reported in an immuno-compromised child in 1973 (Cho *et al.*, 1973). Since then, *F. solani* has been recognised as a serious opportunistic pathogen of humans (Mayayo *et al.*, 1999; Schmidig, 2012; Stanzani *et al.*, 2007). The dramatic increase in fusariosis during the last three decades coincides with the ever expanding populations of severely immune deficient individuals, including those with acquired immune deficiency syndrome (AIDS), BMT and SOT recipients, and those who receiving cytotoxic agents such as immunosuppressive drugs, intensive broad-spectrum antibiotics, radiotherapy and chemotherapy (Dignani & Anaissie, 2004; Muhammed *et al.*, 2011; Schmidig, 2012). Mortality and morbidity rates for disseminated fusariosis are estimated to be between 50-75% (Jensen *et al.*, 2004; Krcmery *et al.*, 1997). However, recent studies have suggested that this could even be as high as 100% (Nucci & Anaissie, 2007). The increasing incidence of invasive fusariosis and high mortality rates are likely due to *Fusarium* virulence factors, the production of mycotoxins and

lytic enzymes, and spore adhesion and biofilm formation. In addition, *Fusarium* is resistant to almost all currently available antifungal drugs (Azor *et al.*, 2007; Nelson *et al.*, 1994; Nucci & Anaissie, 2007; Pujol *et al.*, 1997; Tortorano *et al.*, 2014).

Many other clinically relevant *Fusarium* species include *F. oxysporum*, *F. verticillioidis*, *F. moniliforme*, *F. dimerum*, *F. proliferatum*, *F. chlamidosporum*, *F. sacchari*, *F. nygamai*, *F. napiforme*, *F. antophilum*, and *F. vasinfectum* (Dignani & Anaissie, 2004; Nucci & Anaissie, 2007; Wang *et al.*, 2011). The FSSC group is the most frequent and virulent group involved in invasive infections (Mayayo *et al.*, 1999; O'Donnell *et al.*, 2010; Diepeningen *et al.*, 2014), followed by *F. chlamydosporum* species complex (FCSC), *F. incarnatum/equiseti* species complex (FIESC), FOSC and *F. dimerum* species complex (FDSC) (Balajee *et al.*, 2009; Diepeningen *et al.*, 2014).

*Fusarium* infections may occur at various sites of the human body, manifesting as superficial, subcutaneous or deep infections. *Fusarium* infections can be localized on the skin (dermatophytosis), cornea (keratitis) (Chang *et al.*, 2006; Cuero, 1980; Gungel *et al.*, 2011; Sekeroglu *et al.*, 2012; Verma & Tuft, 2002), or nails (onychomycosis) (Brasch & Köppl, 2009; Brasch & Shimanovich, 2012; Girmenia *et al.*, 1992). Compared to immunocompetent hosts, infections in immunocompromised patients are typically disseminated, due to the lack of an innate immune response (Bachmeyer, 2007; Bushelman *et al.*, 1995; Cooke *et al.*, 2009; Perez *et al.*, 2007; Yera *et al.*, 2003; Ammari et.al., 1993; Ascioglu *et al.*, 2002; Lucca, 2007; Nucci *et al.*, 2004; Nucci & Anaissie, 2002, 2007; Tortorano *et al.*, 2014; Venditti *et al.*, 1988). Broken skin and the

respiratory tract are the primary portals of entry for *Fusarium* propagules (Legrand *et al.*, 1991; Muhammed *et al.*, 2011; Nucci & Anaissie, 2007). Additionally, *Fusarium* can also cause allergic symptoms during the aerosolization of spores in dusty indoor environments (Noble *et al.*, 1997).

# 2.1.3 Diagnosis of *Fusarium* infections

## 2.1.3.1 Morphological Characteristics

As with all other human fungal pathogens, identification of Fusarium infection depends on the identification of characteristic morphologic features of cultured samples and microscopic examination of clinical samples from sterile sites or biopsy (Esnakula et al., 2013; Marcio Nucci et al., 2004; Marcio Nucci & Anaissie, 2007). However, the morphological appearance of *Fusarium* is highly variable (O'Donnell et al., 1998; Summerell et al., 2003; Diepeningen et al., 2015), and its polyphyletic taxonomy makes it one of the most challenging groups of fungi to categorise (Leslie & Summerell, 2006). Identification of Fusarium species using direct microscopical examination can lead to misdiagnosis due to similarities in morphology with other fungal pathogens. Acute-branching septate hyaline hyphae with or without sporulation are characteristics shared between Fusarium and other hyalohyphomycetes fungi, including Aspergillus, Scopulariopsis and Acremonium (Jain et al., 2011; Nucci & Anaissie, 2007; Tortorano et al., 2014). Identification based on morphological features requires the preparation of axenic cultures which is time-consuming and delays diagnosis (Dignani & Anaissie, 2004; Muhammed et al., 2011b). Notwithstanding this, mycological culture remains the gold standard test for

fungal detection in clinical laboratories (McClenny, 2005) despite its poor sensitivity compared to other diagnostic procedures.

#### 2.1.3.2 Nucleic Acid-based Techniques

Diagnostic techniques that detect nucleic acids have been used to identify IFlat early stages of clinical manifestations. The need for accurate identification of Fusarium at the species level requires construction of an accurate phylogeneticbased classification (O'Donnell, 1996; O'Donnell, 2000). To this end extensive taxonomical studies have been undertaken to identify DNA sequences specific to Fusarium species or species complexes (Leslie & Summerell, 2006). Barcoding based on the rDNA ITS region has been used to differentiate closely related species and to identify inter- and intraspecific variation (Bryan et al., 1995; O'Donnell, 1996; Seifert, 2009). This technique has enabled accurate discrimination of the most common pathogenic fungi involved in invasive mycoses at the species level (Spiess et al., 2007). However, in this setting, the use of ITS sequencing for Fusarium species identification is inadequate, as it does not reveal sufficient information for discriminating Fusarium species complex, such as FSSC and FOSC (Balajee et al., 2009; Geiser et al., 2004; O'Donnell et al., 2010; O'Donnell & Cigelnik, 1997). For this reason, Fusarium protein-encoding genes have been sequenced to identify marker genes for diagnosis, including the TEF-1α gene (Geiser *et al.*, 2004; Harrow *et al.*, 2010; Kristensen et al., 2005; Yli-Mattila et al., 2002), the β-tubulin gene (Mach et al., 2004; Seifert & Lévesque, 2004; Yli-Mattila et al., 2004), and two genes encoding the largest and second largest subunits of RNA polymerase (RPB1 and RPB2, respectively) (Boonyuen et al., 2011; O'Donnell et al., 2010) and

calmodulin (Mulè *et al.*, 2004). The TEF-1 $\alpha$  gene has been validated as a more informative gene compared to the other encoding genes sequenced. TEF-1 $\alpha$  can be used for the identification and phylogenetic analysis of the *Fusarium* genus (O'Donnell *et al.*, 1998), but the use of molecular-based techniques for detection of *Fusarium* infections is used alongside other tests for clinical diagnosis (Tortorano *et al.*, 2014).

## 2.1.3.3 Serological Assays

The chemical composition of the fungal cell wall is unique and presents opportunities for the development of diagnostic test based on detection of characteristic signature molecules. While the chemical components of the fungal cell wall are similar at the level of the phylum, the antigenic composition at genus and species levels can vary considerably allowing the identification of genus and species-specific biomarkers for diagnostic test development (Free, 2013). During disseminated infections, antigens are shed into the bloodstream and bronchoalveolar lavage fluid (BAL) (Kozel & Wickes, 2014).

#### 2.1.3.3.1 Detection of 1,3-β-D-Glucan and Galactomannan

Detection of the fungal cell wall components BDG and GM form are the main serological tests commercially available and used widely in clinical settings for invasive fungal pathogens (Kozel & Wickes, 2014). However, the BDG test is not specific and is an insufficient tool for the diagnosis of fusariosis, as *Fusarium* species often cross-react with other species like *Aspergillus*, *Candida*, *Acremonium* and *Trichosporon*. (Esnakula *et al.*, 2013; Ostrosky-Zeichner

*et al.*, 2005; Yoshida *et al.*, 1997). In 1992, Stynes described the development of a unique mAb (EB-A2) that strongly reacts the tetra  $(1\rightarrow 5)$ -  $\beta$ -Dgalactofurano-side, a specific glycoprotein epitope of *Aspergillus* GM (Stynen *et al.*, 1992). Ever since the GM test has become a medically important application for the early diagnosis of invasive *Aspergillus* infections, and it is commercially available as an ELISA kit (Kappe & Schulzeberge, 1993; Latge *et al.*, 1994; Leeflang *et al.*, 2008; Tanriover *et al.*, 2008; Verweij *et a*., 2006). The GM test cross-reacts with several other invasive pathogenic fungi, including *Penicillium*, *Fusarium*, *Alternaria*, *Histoplasma*, *Trichothecium*, *Geotrichum*, *Cladosporium* and *Acremonium* (Aquino *et al.*, 2007; Giacchino *et al.*, 2006; Huang *et al.*, 2007; Kappe & Schulzeberge, 1993; Mikulska *et al.*, 2012; Swanink et al., 1997; Tortorano *et al.*, 2012; Wheat *et al.*, 2007). Therefore, serological tests have been of limited benefit for the diagnosis of fusariosis (Muhammed *et al.*, 2011).

# 2.1.3.3.2 Polyclonal and Monoclonal Antibodies

For this reason, diagnosis of invasive mycoses based on cell wall composition using a polyclonal antibody is a routin approach employed in clinical laboratories (Brandt & Warnock, 2003). MAbs are an attractive diagnostic tool for systemic fungal infections and have exclusive specificity for detecting the smallest and unique fungal surface epitopes. This technology saves time and is sensitive for a definitive diagnosis of fungal infections at a genus or species level, and can guide appropriate antifungal therapy usage. Furthermore, antigen tests do not require any immune response. They rely only on the tracking of a fungal cell, or even cell wall debris in the blood stream or other body fluids at any detectable level.

# 2.1.4 Objective of This Chapter

To date, no studies have been undertaken to develop a diagnostic antibody that can detect human pathogenic strains of *Fusarium*. The purpose of the work presented in this chapter was to generate mAbs specific to a constitutively expressed extracellular antigen from *F. solani* that might be appropriate for tracking human pathogenic strains and to investigate their interaction with cells of the immune system (**Chapter 3**) and during epidemiological studies (**Chapter 4**). This work takes advantage of hybridoma technology, using approaches already successfully exploited in this laboratory for the development of murine mAbs for the detection of invasive fungal infections, including aspergillosis (Thornton, 2010; Thornton, 2008) and scedosporiosis (Thornton, 2009).

# **2.2 Materials and Methods**

## 2.2.1 Ethics Statement

All animal work described in this study was conducted under a UK Home Office Project License, and was reviewed by the institution's Animal Welfare Ethical Review Board (AWERB) for approval. The work was carried out in accordance with The Animals (Scientific Procedures) Act 1986 Directive 2010/63/EU, and followed all the Codes of Practice which reinforce this law, including all elements of housing, care, and euthanasia of the animals.

# 2.2.2 Fungal Cultures and Media

Details of the fungi used in this study are in **Table 2.1** All fungi were grown and maintained on PDA or in PDB (PDB; Difco, 254920) 2.4% containing 2% (w/v) agar). For liquid cultures, fungal spores at a concentration of 1 x  $10^3$  ml<sup>-1</sup>, or 3 x 5 mm agar plugs taken from the leading edge of PDA cultures, were inoculated into 250 ml conical flasks containing 100 ml of PDB, or in SDB (SDB; Oxoid; CM0147) (3%). All media was autoclaved at 121°C for 15 min prior to use. Fungi were grown on slopes or on Petri dishes under a 16-h fluorescent light regimen at 27°C.

# Table 2.1. Details of fungi used in mAb ED7 specificity tests.

Organism	Isolate no.	Source <sup>a</sup>
Aspergillus cervinus	537.65	CBS
Aspergillus ficuum	555.65	CBS
Aspergillus flavus	91856iii	IMI
Aspergillus fumigatus	AF293	SK
Aspergillus nidulans	A4	FGSC
Aspergillus niger	102.4	CBS
Aspergillus oryzae	672.92	CBS
Aspergillus restrictus	116.5	CBS
Aspergillus terreus var. terreus	601.65	CBS
Botrytis cinerea	R2	CRT
Byssochlamys nivea	153.59	CBS
Candida glabrata	4692	CBS
Candida krusei	5590	CBS
Candida parapsilosis	8836	CBS
Candida tropicalis	1920	CBS
Cryptococcus neoformans (Serotype D)	5728	CBS
Cunninghamella elegans	151.8	CBS
Filobasidiella bacillispora	10865	CBS
Filobasidiella neoformans	10490	CBS
Filobasidiella neoformans	10496	CBS
Fusarium acutatum	402.97	CBS
Fusarium anthophilum	222.76	CBS
Fusarium avenaceum	386.62	CBS
Fusarium cerealis	134.8	CBS
Fusarium chlamydosporium var. chlamydosporium	491.77	CBS
Fusarium culmorum	256.51	CBS
Fusarium dimerum var. dimerum	108944	CBS
Fusarium incarnatum	678.77	CBS
Fusarium nygamai	140.95	CBS
Fusarium oxysporum f.sp. cucurbitacearum	254.52	CBS
Fusarium oxysporum f.sp. lycopersici	167.3	CBS
Fusarium oxysporum f.sp. marmaris	420.8	CBS
Fusarium oxysporum f.sp. radicis-lycopersici	872.95	CBS

Fusarium oxysporum f.sp. vasinfectum	409.9	CBS
Fusarium proliferatum var. proliferatum	181.3	CBS
Fusarium sacchari	183.32	CBS
Fusarium solani	224.34	CBS
Fusarium solani	109696	CBS
Fusarium solani	188.34	CBS
Fusarium solani	115659	CBS
Fusarium solani	117608	CBS
Fusarium solani	119223	CBS
Fusarium solani var. petroliphilum	102256	CBS
Fusarium verticillioides	102699	CBS
Geotrichum candidum	115.23	CBS
Haematonectria haematococca	114067	CBS
Haematonectria haematococca	119603	CBS
Haematonectria haematococca	130692	CBS
Lichtheimia corymbifera	T14A (FJ713070)	CBS
Magnusiomyces capitatus	207.83	CBS
Mucor circinellioides f.sp. circinellioides	E2A (FJ713065)	CRT
Neosartorya fischeri var. fischeri	687.71	CBS
Paecilomyces variotii	339.51	CBS
Penicillium cyclopium	123.14	CBS
Penicillium islandicum	338.48	CBS
Penicillium spinulosum	346.61	CBS
Pichia norvegensis	6564	CBS
Pseudallescheria boydii	835.96	CBS
Pythium insidiosum	673.85	CBS
Rhizomucor miehei	MG4(2) (FJ713069)	CRT
Rhizopus stolonifera	389.95	CBS
Rhodosporidium toruloides	6016	CBS
Rhodotorula mucilaginosa	326	CBS
Scedosporium apiospermum	117407	CBS
Scedosporium aurantiacum	121926	CBS
Scedosporium aurantiacum	118934	CBS
Scedosporium prolificans	102176	CBS
Sporidiobolus salmonicolor	6781	CBS
Trichoderma hamatum	GD12 (AY247559)	CRT

Trichosporon asahii var. asahii	8973	CBS
Trichosporon asahii var. asahii	5286	CBS
Trichosporon asahii var. asahii	7632	CBS
Trichosporon asahii var. asahii	5599	CBS
Trichosporon asteroids	6183	CBS
Trichosporon asteroids	7623	CBS
Trichosporon asteroids	2481	CBS
Trichosporon asteroids	7624	CBS
Trichosporon cutaneum	2466	CBS
Trichosporon inkin	7630	CBS
Trichosporon inkin	7655	CBS
Trichosporon loubieri	7065	CBS
Trichosporon ovoides	7556	CBS
Trichosporon mycotoxinovorans	9756	CBS
Wickerhamomyces anomalus	5759	CBS

**a** CBS = Centraalbureau voor Schimmelcultures, PO Box 85167, 3508 AD Utrecht, The Netherlands; CRT = C.R. Thornton; IMI = International Mycological Institute, Egham, England; SV = S. Krappman, Institute of Microbiology and Genetics, Department of Molecular Microbiology and Genetics, Georg-August-University, Gottingen, Germany.

### 2.2.3 Preparation of Immunogen and Immunisation Regime

BALB/c mice were immunised with soluble antigens prepared from lyophilized mycelium of a human pathogenic strain of FSSC 1-a (CBS strain 224.34). Conidia were suspended in water after 10-day old PDA slant cultures were flooded with 5 ml MQ-H<sub>2</sub>O and gently agitated with an inoculation loop. Conidial suspensions were then filtered through Miracloth to remove mycelium and transferred to 1.5 ml micro-centrifuge tubes. The conidia were washed three times with MQ-H<sub>2</sub>O by repeated vortexing and centrifugation at 14,462 *g* for 5 min and finally suspended in MQ-H<sub>2</sub>O to give a concentration of  $10^6$  spores

ml<sup>-1</sup> solution. Flasks containing 100 ml of sterilised PDB were inoculated with 200  $\mu$ l of the conidial suspension and incubated with shaking (75 rpm) for 48 h at 26°C. Hyphal biomass was collected on Miracloth, snap frozen in liquid N<sub>2</sub>, and lyophilized. Culture filtrates were retained for gel electrophoresis and Western blotting studies and stored at –20°C until required. One mg of lyophilized biomass was suspended in 1 ml PBS (0.8% NaCl; 0.02% KCl; 0.115% Na<sub>2</sub>HPO<sub>4</sub>; 0.02% KH<sub>2</sub>PO<sub>4</sub>; pH7.2) and the resultant suspension centrifuged for 5 min at 14,462 *g*. The supernatant, containing solubilized antigens, was used as the immunogen and as a source of antigens for hybridoma screening assays. For immunisation, 6-wk-old BALB/c female white mice were given four intraperitoneal injections (300  $\mu$ l per injection) of antigen extract containing 2.3 mg protein ml<sup>-1</sup> PBS at 2-wk intervals and a single booster injection five days before fusion.

# 2.2.4 Production and Screening of Hybridomas and Determination of Antibody Specificity

Hybridoma cells were produced by the method described by Thornton (2001). The myeloma cell line SP2/0-Ag14, in the exponential phase of growth, was prepared at a concentration of  $10^7$  cells ml<sup>-1</sup> by enumeration using a haemocytometer. The mouse selected for hybridoma production was euthanised and then doused with 70% (v/v) ethanol. The spleen was removed aseptically and placed in a 30-ml Universal tube containing 10 ml warm 20% TCM. Following this, the spleen was placed in a 9-cm Petri dish containing 15 ml of fresh 20% TCM and the splenocytes released by teasing the tissues with sterile hypodermic needles. The splenocytes were transferred to a sterile

50-ml Falcon tube and, alongside the myeloma cells, were centrifugation at 250 g for 5 min. The supernatants were discarded and the cells were re-suspended in 2.5 ml of RPMI serum-free medium. The two suspensions were combined, mixed, and centrifugation in a sterile round-bottomed 10-ml tube at 250 g for 5 min. Next, the supernatant was aspirated and 0.3 ml of 33% (w/v) PEG solution was added allowing exposure of the cells for 7 min including 1 min centrifugation at 500 g. The PEG was gently removed and then the pellet was slowly re-suspended by adding 5 ml of serum-free medium. The fusion products were diluted into 95 ml of selective medium consisting of 10% TCM with hypoxanthine, aminopterin and thymidine (HAT; Sigma, H0262) supplement and 100 µl volumes of the cell suspension transferred to the wells of 96-well culture plates for incubation at 37°C and 5% CO<sub>2</sub>. After 7 days, the cells were fed with 10% TCM supplemented with hypoxanthine and thymidine (HT; Sigma, H0137) and wells containing hybridomas identified subsequently. The cell supernatants were screened by ELISA against of F. solani (CBS224.34) antigens immobilized to the wells of Maxisorp microtitre plates (442404; Nunc) (50 µl per well). Selected cell lines were sub-cloned, growing in non-selective 10% TCM, and then preserved by freezing in  $LN_2$ .

For antibody specificity tests, fungi were grown on replicate agar slopes and surface washings containing water-soluble antigens prepared as described in Thornton (2001). Protein concentrations, determined spectrophotometrically at 280 nm (Nanodrop, Agilent Technologies Limited, Berkshire, UK), were adjusted to 60 µg ml<sup>-1</sup> buffer. Fifty µl volumes were then used to coat the wells of microtitre plates. After incubating overnight at 4°C, wells were washed four times with PBST (PBS containing Tween-20, 0.05% (v/v)), once each with PBS

and MQ-H<sub>2</sub>O and then air-dried at 23°C in a laminar flow hood. The plates were stored in sealed plastic bags at 4°C in preparation for the screening of hybridoma supernatants by ELISA as described below.

# 2.2.5 Enzyme-Linked Immunosorbent Assay

Wells containing immobilized antigens were blocked for 10 min with 100 µl of blocking solution 1% (wt/vol) BSA (Sigma A-7030) in PBS and incubated successively with hybridoma tissue culture supernatant (TCS) for 1 h, followed with goat anti-mouse polyvalent (Ig classes IgG, IgA, and IgM) peroxidase conjugate (A0412; Sigma Chemical Company, Poole, United Kingdom) diluted 1 in 1000 in PBST for a further hour. Bound antibody was visualised by incubating wells with TMB (T2885; Sigma) substrate solution (Thornton, 2001) for 30 min. The reactions were stopped by the addition of 3 M H<sub>2</sub>SO<sub>4</sub> and absorbance values were determined at 450 nm with an MRX automated microplate reader (Dynex Technologies, Billingshurst, UK). Wells were given four 5-min rinses with PBST between incubations and a final rinse with PBS before addition of the substrate solution. Working volumes were 50 µl per well and control wells were incubated with TCM containing 10% (v/v) FBS. All incubation steps were performed at 23°C in sealed plastic bags. The threshold for detection of the antigen in ELISA was determined from control means (2 x TCM absorbance values) (Sutula et al., 1986). These values were consistently in the range (0.05 - 0.10). Consequently, absorbance values > 0.100 were considered as positive for the detection of antigen.

#### 2.2.6 Determination of Ig Subclass and Sub-cloning Procedure

The Ig class of mAbs was determined by using antigen-mediated ELISA. Wells of microtitre plates coated with *F. solani* (CBS224.34) water-soluble antigens from surface washings were incubated successively with ED7 TCS for 1 h, followed with goat anti-mouse IgG<sub>1</sub>, IgG<sub>2a</sub>, IgG<sub>2b</sub>, IgG<sub>3</sub>, IgM, or IgA-specific antiserum (ISO-2; Sigma) diluted 1 in 3000 in PBST for 30 min and rabbit anti-goat peroxidase conjugate diluted 1 in 1000 (A-5420; Sigma) for a further 30 min. Bound antibody was visualised with TMB substrate as described above. Hybridoma cells lines were subcloned three times by limiting dilution according to the method described in Thornton (2001).

### 2.2.7 Long-term Storage of Hybridoma Cells

Hybridoma cells were frozen for long-term storage in liquid nitrogen (LN<sub>2</sub>). Culture plates containing 20 ml 10% TCM were seeded with 5 ml of cell suspension and incubated for 24 h at 37°C and 5% CO<sub>2</sub>. Suspended cells were transferred to 15-ml sterile Falcon tubes (Sarstedt, 62.547.254). The contents were pelleted at 2000 rpm for 5 min in a centrifuge (HERMLE 2323K) and the supernatant removed by aspiration. The cell pellet was gently re-suspended in 600  $\mu$ l of freezing medium (92:8 (vol/vol) FBS: dimethyl sulphoxide (DMSO; Sigma HYBRI-MAX, D-2650). Cell suspensions were transferred at 150  $\mu$ l volumes into separate cryovials. The vials were frozen overnight in a -80°C freezer, before long-term storage in a Dewar (Tylor-Wharton, XT-20) containing LN<sub>2</sub>.

#### 2.2.8 Antigen Characterization

# 2.2.8.1 Gel Electrophoresis and Western Blotting

For sodium-dodecyl-sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), culture filtrates from 2-d-old PDB shake cultures of F. solani (CBS224.34) and F. oxysporum f.sp. lycopersici (CBS167.30), prepared as described, were diluted in Laemmli buffer (Laemmli, 1970) and were denatured by heating at 95°C for 10 min. Antigens were separated in 4-20% (w/v) polyacrylamide gradient gels (161-1159; Bio-Rad) for 1.5 h at 23°C (165V) under denaturing conditions, and pre-stained broad range markers (161-0318; Bio-Rad) were used for molecular weight determinations. For Westerns, separated antigens were transferred electrophoretically to a PVDF membrane (162-0175; Bio-Rad). The membranes were blocked for 16 h at 4°C with PBSA (PSB + 1% (w/v) BSA) and incubated with ED7 TCS diluted 1 in 2 with PBSA (PBS + 0.5% (w/v) BSA) for 2 h at 23°C. After washing three times with PBS, membranes were incubated for 1 h with goat anti-mouse IgM (u - chain specific) alkaline phosphatase conjugate (A-9688; Sigma), diluted 1 in 15,000 in PBSA. After the membranes were washed twice with PBS and once with PBST, the bound antibodies were visualised by incubation in BCIP/NBT substrate solution. Reactions were stopped by immersion in MQ-H<sub>2</sub>O and air-dried between sheets of Whatman filter paper.

# 2.2.8.2 Characterization of Antigen by Enzymatic and Chemical Modifications and by Heating

Water-soluble antigens from surface washings of slopes of *F. solani* (CBS224.34) were prepared as described. Heat stability studies were

conducted by placing tubes of solubilized antigen in a boiling water bath. At 10 min intervals, samples were removed, centrifuged at 14,462 *g* for 5 min, and antigens immobilized to the wells of microtitre plates for assay by ELISA as described. For periodate oxidation, microtitre wells containing immobilized antigens from surface washings of the fungus were incubated with 50 µl of sodium *meta*-periodate solution (20 mM NaIO<sub>4</sub> in 50 mM sodium acetate buffer [pH4.5]) or acetate buffer only (control) at 4°C in sealed plastic bags, for time course (0, 5, 10 15, 20 hrs). Plates were given four 3-min PBS washes before processing by ELISA as described. For protease digestions, microtitre wells containing immobilized antigen were incubated with 50 µl of pronase (protease XIV; 0.9 mg ml<sup>-1</sup> in PBS) or trypsin (1 mg ml<sup>-1</sup> in MQ-H<sub>2</sub>O) solution or MQ-H<sub>2</sub>O or PBS only controls respectively for 4 h at 37°C or 4°C. Plates were given four 3-min rinses with PBS and then assayed by ELISA with ED7 TCS as described.

#### 2.2.8.3 Immunofluorescence and Immunogold Electron Microscopy

For immunofluorescence (IF), sterilised slides were coated with a washed spore suspensions of *F. solani* (CBS224.34) containing 1% (w/v) glucose solution and incubated at 27°C for 16 h to allow spore germination and formation of germ tubes. After air-drying, the cells were fixed to the slides as described in (Thornton, 2001) and incubated with ED7 TCS or TCM only (negative control) for 1 h, followed by three 5 min PBS washes. Slides were then incubated with goat anti-mouse polyvalent fluorescein isothiocyanate (FITC) conjugate (diluted 1 in 40 in PBS) (F1010; Sigma) for 30 min. Slides were given three 5 min washes with PBS and mounted in PBS-glycerol mounting medium (F4680; Sigma) beforeoverlaying with coverslips. All incubation steps were performed

at 23°C in a humid environment to prevent evaporation and slides were stored in the dark, at 4°C, prior to examination using an epifluorescence microscope (Olympus IX81) fitted with 495 nm (excitation) and 518 nm (emission) filters for FITC. For immunogold electron microscopy (IEM) the method described in (Thornton & Talbot, 2006) was used. Spores and hyphae of F. solani were prepared by incubating washed conidia in 1% (w/v) glucose solution at 27°C for 16 h to allow spore germination and formation of germ tubes. Cells were embedded in LR White resin (Agar Scientific Ltd.) and ultra-thin sections prepared for immunolabeling. Sections immobilized to nickel grids were blocked by immersion in PBST containing 1% (w/v) BSA (PBST-BSA) which had been sterile filtered through a 0.2 µm filter. The grids were washed three times (3 min each) in sterile filtered PBST and then incubated in ED7 TCS or TCM only (negative control) for 1 h. After four washes (3 min each) with sterile filtered PBST, the grids were incubated for a further hour in PBST-BSA containing a 1:20 dilution of goat anti-mouse 20 nm gold conjugate (EM GAF20; BBI Solutions). The grids were washed four times (3 min each) in sterile filtered PBST and then placed on Whatman filter paper to dry. Dried grids were then incubated for 20 min in 2% (w/v) uranyl acetate solution followed by 2% (w/v) lead citrate solution for 4 min. Working volumes were 100 µl and incubation, and washing steps were carried out at 23°C. Immunostained samples were examined using a Jeol JEM 1400 transmission electron microscope fitted with a Gatan ES 100W CCD camera.

# 2.2.9 Spore Agglutination Assay

Preliminary investigations showed that mAb ED7 was able to agglutinate spores of *Fusarium*. To study this phenomenon further, a light absorbance assay was developed to enable quantification of the agglutination process. To investigate the wavelength at which spores of *Fusarium* spores absorb light, washed spores of *F. solani* (CBS224.34) were re-suspended at a final concentration of 10<sup>6</sup> ml<sup>-1</sup> in plastic cuvettes (Greiner Bio-one 613101) using either mAb ED7 TCS or 10% TCM only. Absorbance of spore suspensions was determined across a range of wavelengths from 290 nm to 610 nm, using a Janeway 7300 spectrophotometer (Bibby Scientific Limited, UK). The maximum absorbance of light for spores suspended in TCM (non-agglutinating condition) was found to be 555 nm, and so this wavelength was used for all subsequent *Fusarium* spore agglutination assays. The light absorbance of spore suspensions was recorded every 5 min, following suspension in TCM or in mAb ED7 TCS (agglutinating conditions) up to 110 to 300 min depends on agglutination status compare with the control isolate *F. solani* (CBS224.34).

# 2.3 Results

# 2.3.1 Production of Hybridoma Cell Lines, Isotyping of monoclonal Antibody and Specificity

A single fusion was performed, and 389 hybridoma cell lines were screened for specificity against a range of clinically relevant yeasts and moulds (**Table 2.1**). The aim was to identify cell lines secreting mAbs specific to *Fusarium* that could be used to track the fungus in environmental samples containing mixed species of human pathogenic fungi. To this end, a single cell line, ED7, was identified that produced mAb belonging to the immunoglobulin class M (IgM), which was genus-specific, reacting in ELISA tests with antigens from *Fusarium* species and with the *F. solani* teleomorph *Haematonectria haematococca* only (**Figure 2.1 A and B**). It did not cross-react with antigens from a wide range of unrelated mould and yeast species (**Figure 2.1 A**).



**Figure 2.1.** Specificity of mAb ED7 determined by ELISA tests of surface washings containing water-soluble antigens from *Fusarium* species and related and unrelated yeasts and moulds. (**A**) ELISA absorbance values at 450 nm for antigens from *F. solani* and unrelated yeasts and moulds and (**B**) for antigens from the *F. solani* teleomorph *Haematonectria haematococca* and related *Fusarium* species. Wells were coated with 60 µg protein ml<sup>-1</sup> buffer. Bars are the means of three biological replicates ± standard errors and the threshold absorbance value for detection of antigen in ELISA is ≥ 0.100 (indicated by lines on graphs). Numbers in parentheses after species names denote strain numbers with further details of strains provided in Table 2.1.

# 2.3.2 Western Blotting and Antigen Characterization

Gel electrophoresis and Western blotting studies showed that ED7 binds to a major antigen with a molecular weight of ~200 kDa which is secreted extracellularly by both *F. solani* and *F. oxysporum* (Figure 2.2). *F. solani* antigens were subjected to enzymatic (Figure 2.3 A and B), heat (Figure 2.3 C) and chemical (Figure 2.4) modifications to characterize the epitope bound by ED7. The lack of reduction in ED7 binding following digestion of immobilized antigen with trypsin (Figure 2.3 A) and pronase (Figure 2.3 B) shows that it does not bind to a protein epitope. There was no significant decrease in ED7 binding over 70 min of heating, demonstrating that its epitope is heat stable (Figure 2.3 C). Reductions in mAb binding following chemical digestion of an antigen with periodate oxidation show that its epitope is carbohydrate and contains vicinal hydroxyl groups (Figure 2.4).



**Figure 2. 2.** Western immunoblot with ED7 using culture fluid from 2-d-old PDB cultures of *F. solani* (CBS224.34) (Lane 1) and *F. oxysporum* f.sp. *lycopersici* (CBS167.30) (Lane 2). Wells were loaded with 1.6  $\mu$ g of protein. M<sub>r</sub> denotes molecular weight in kDa. Note the major extracellular antigen with a molecular weight of ~200 kDa.


**Figure 2. 3.** Characterization of antigens bound by mAb ED7. Absorbance values from ELISA tests with ED7 using surface washings containing water-soluble antigens immobilized to the wells of microtitre plates and treated with (**A**): trypsin, (**B**): pronase or PBS only (control) at 4°C and 37°C, and (**C**): Stability of the water-soluble ED7 antigen following heating of surface washings at 100 °C over a 70 min period. Treated antigen was subsequently immobilized to the wells of microtitre plates and assayed by ELISA. Bars are the means of three biological replicates ± SE and bars with the same letter are not significantly different at *p* < 0.001 (ANOVA and Tukey-Kramer test).



**Figure 2. 4.** Absorbance values from ELISA tests with ED7 using surface washings containing water-soluble antigens immobilized to the wells of microtitre plates and treated with periodate (open circles) or with acetate only control (closed circles) at  $4^{\circ}$ C over a 20 h period. Each point is the mean of three biological replicates ± SE.

#### 2.3.3 Immunofluorescence and Immunogold Electron Microscopy

Immuno-localisation studies using IF showed that the ED7 antigen was present on the surface of spores and hyphae (**Figure 2.5 A to D**), while IEM showed that the antigen was present in the spore and hyphal cell wall in an extracellular matrix surrounding both (**Figure 2.6 A to C**).



**Figure 2. 5.** Photomicrographs of *F. solani* (CBS224.34) cells, immunostained with mAb ED (**A**, **B**) or TCM only (**C**, **D**) and anti-mouse polyvalent Ig fluorescein isothiocyanate. (A) Bright field image of germinated conidium with hypha; (**B**) Same field of view as panel A but examined under epifluorescence. Note the intense staining of the hyphal and conidium cell wall. (**C**) Bright field image of germinated conidium with hypha. (**D**) Same field of view as panel (**C**) but examined under epifluorescence. Scale bar = 8  $\mu$ m.



**Figure 2. 6.** Immunogold labelling of sections of conidia and hyphae of *F. solani* (CBS224.34). (**A**) Transverse section of conidium incubated with ED7 and anti-mouse immunoglobulin 20 nm gold particles, showing antigen in the cell wall in an extracellular fibrial matrix surrounding the spore (Scale bar = 250 nm); (**B**) Longitudinal section of hypha incubated with ED7 and anti-mouse immunoglobulin 20 nm gold particles, showing antigen in the cell wall and in an extracellular matrix surrounding the cell (scale bar = 100 nm); (**C**) Transverse section of a conidium incubated with TCM (negative control) and anti-mouse immunoglobulin 20 nm gold particles, showing a lack of staining by the secondary gold conjugate. Scale bar = 180 nm.

#### 2.3.4 Spore Agglutination Assays

A peak in light absorbance (absorbance value of 0.20) with *F. solani* (CBS224.34) microconidia suspended in 10% TCM was found at 555 nm, while the lowest absorbance (absorbance value of 0.048) was recorded at 340 nm (**Figure 2.7**). Using the wavelength of 555 nm, agglutination of *Fusarium* spores with mAb ED7 was investigated. The result shows that the microconidia of *Fusarium* species suspended in mAb ED7 have two agglutinations and not agglutination trends behaviour as shown in **Table 2.2** and **Appendix 1**. Spores of *F. solani* (CBS224.34) and *F. dimerum* var. *dimerum* (CBS108944) were represented the agglutination trend in mAb ED7 with rapid decreases in absorbance values when compared to the TCM only control (**Figure 2.8** and **Appendix 1**). In contrast, spores of *F. equiseti* (CBS185.34) and *F. solani* (CBS119.223) were represented not agglutinated species by mAb ED7 (**Figure 2.9** and **Appendix 1**).



**Figure 2. 7.** Absorbance of light at different wavelengths by non-agglutinated *F. solani* (CBS224.34) microconidia suspended in 10% TCM at  $10^6$  spore ml<sup>-1</sup>. Each point is the mean of 3 replicates ± S.E. Note peak absorbance of spores at 555nm. This wavelength was therefore chosen for subsequent agglutination assays with mAb ED7 and different species, formae speciales and varieties of *Fusarium*.



**Figure 2. 8.** Agglutination of *Fusarium* species microconidia. (**A**) *F. solani* (CBS224.34) and (**B**) *F. dimerum* var. *dimerum* (CBS108944), spores suspended at  $10^6$  spores/ml in ED7 TCS and 10% TCM. Each point is the mean of 3 replicates ± S.E. Note rapid decrease in absorbance of light at 555 nm due to agglutination of spores by mAb ED7.



**Figure 2. 9.** Agglutination of *Fusarium* species microconidia. (**A**) *F. equiseti* (CBS185.34) and (**B**) *F. solani* (CBS119.223) spores in ED7 TCS and 10%TCM. Each point is the mean of 3 replicates  $\pm$  S.E. Note lack of agglutination of spores of this fungus by mAb ED7.

**Table 2.2.** Agglutination trend of *Fusarium species* microconidia suspendedin mAb ED7 TCS and 10% TCM at 555 nm.

Agglutinated isolate	Weakly agglutinated	Not agglutinated
	isolate	isolate
F. solani (CBS224.34)	F. proliferatum var. proliferatum (CBS181.30)	F. chlamydosporium
		var. chlamydosporium
		(CBS491.77)
F. dimerum var. dimerum	<i>F. nygami</i> (CBS140.93)	F. equiseti
(CBS108944)		(CBS185.34)
	F. oxysporum f.sp.	
F. sacchari (CBS183.32)	radicis-lycopersici	F. solani (CBS119.223)
	(CBS872.95)	
F. verticilliodes (CBS102.699)	<i>F. oxysporum</i> f.sp. <i>lycopersici</i> (CBS167.30)	F. oxysporum f.sp.
		cucurbitacearum
		(CBS254.52)
F. oxysporum var. vasinfectum	_	F. incarnatum
(CBS409.96)		(CBS678.77)
F. solani var. petroliphilum	-	F. solani (CBS115.659)
(CBS102256)		
F. anthophilum (CBS222.76)	-	-
F. solani (CBS188.34)	-	-
<i>F. solani</i> (CBS117.608)	-	-
F. solani (CBS109.696)	-	-

#### 2.4 Discussion

Monoclonal antibodies are highly specific and can be generated and massproduced using hybridoma technology. This characteristic feature makes them ideal for several applications, including disease diagnosis, as therapeutic agents and as reagents for a variety of scientific research applications (Li *et al.,* 2010; Modjtahedi et al., 2012; Morgan & Levinsky, 1985).

While mAbs have been developed for detecting and differentiating plant pathogenic *Fusarium* species (Arie *et al.*, 1995, 1991; Banks *et al.*, 1996; Hayashi *et al.*, 1998; Hu *et al.*, 2012, 2013; Wong *et al.*, 1988), few attempts have been made to develop mAbs for the detection of human pathogenic species. Nevertheless, Jensen et al. (2011) recently reported the development of *Fusarium*-specific mAbs for immunohistochemical diagnosis of fusariosis.

The IgM mAbs, which recognise 51 and 63 kDa antigens, reacted strongly with fungal elements in both experimentally infected animals and biopsy samples from patients with fusariosis. The aim of this study was to use hybridoma technology to develop *Fusarium*-specific mAbs for use in tracking human pathogenic species during interactions with cells of the immune system (**Chapter 3**) and during environmental studies (**Chapter 4**). Here, Hybridoma technology was used to generate a mAb against immunogenic antigens from surface washings prepared from *F. solani*, which is one of the most frequent etiologic agents of systemic fusariosis infections in humans.

There were two specific aims required to fulfil this objective. The first was the development of a mAb specific to the genus *Fusarium*. It was important that this mAb lacked cross-reactivity with other related and unrelated pathogenic filamentous fungi and yeasts involved in disseminated mycosis, such as *Aspergillus* (Thornton, 2010a), *Candida* (Marcio Nucci & Marr, 2005), *Scedosporium* (Thornton et al., 2015), *P. boydii* (Thornton, 2009), *Trichosporon* (Davies & Thornton, 2014b), *Rhizopus, Mucor, and Rhizomucor* (Kauffman, 2004).

Because immunogenic antigens such polysaccharides and proteins can be secreted in blood and other body fluids during invasive infections (Thornton, 2008), the second specific aim was to produce a mAb against an extracellular antigen and to investigate its suitability as a diagnostic target for pathogen detection. Using hybridoma technology, murine mAb ED7 was raised against surface antigens from a human pathogenic strain of *F. solani* (strain CBS 224.34).

Using ELISA tests, it was shown that mAb ED7 is genus-specific, reacting with a wide range of species within the genus including the most frequent causes of human fusariosis *F. solani* and *F. oxysporum*. Importantly, it does not crossreact with unrelated opportunistic fungal pathogens, including yeasts and moulds in the genera *Aspergillus* (Thornton & Wills, 2015), *Candida*, *Geotrichum*, *Rhodotorula* and *Trichosporon* (Davies & Thornton, 2014; Miceli *et al.*, 2011), *Cyphellophora* and *Phialophora* (Feng *et al.*, 2014), *Exophiala* (Zeng *et al.*, 2007), *Trichoderma* (Sandoval-Denis *et al.*, 2014), *Engyodontium* (Macêdo *et al.*, 2007; Thamke *et al.*, 2015) and *Mucor* (Petrikkos *et al.*, 2012).

The genus specificity of mAb ED7 and the identification of its target antigen (through heat, chemical and enzymatic modification) as a heat-stable carbohydrate makes it an ideal partnership for tracking pathogenic strains of *Fusarium* in humans and the natural environment. Heat-stable carbohydrate antigens have been used successfully as diagnostic targets for mAb-based detection during human and animal infection (Wiederhold *et al.*, 2013; Rolle *et al.*, 2016) and in environmental monitoring studies (Thornton, 2009; Sharpe *et al.*, 2016).

Immunofluorescence and immunogold electron microscopy showed that the antigen bound by the mAb ED7 is located in the outer cell wall of hyphae and spores in a microfibrillar matrix that surrounds microconidia. The extracellular microfibrillar matrix of F. solani spores was first reported in 1975 (Tewari & Skoropad, 1975). It was the first immunological study conducted to investigate a matrix-associated antigen in *Fusarium* species. A putative 90 kDa glycoprotein is thought to be associated with the adhesive properties of macroconidia of the plant pathogen Haematonectria haematococca (the teleomorph stage of F. solani) (Kwon & Epstein, 1993), but adhesion negative strains (Att) of the fungus also produce the 90 kDa antigen. Furthermore, Att strains produce a conidial tip mucilage, suggesting that the 90 kDa glycoprotein is not the only molecule involved in adhesion (Schuerger & Mitchell, 1993). In a subsequent study, Hayashi and co-workers (Hayashi et al., 1998) showed that a mAb (API9-2), raised against a F. oxysporum hyphal antigen, can recognise the antigenic carbohydrate, mannan, with a molecular weight of ~55 kDa. From the characterization work conducted here, I have shown that the antigen bound by mAb ED7 is an immunodominant, heat-stable, carbohydrate. Western blotting

studies demonstrated that the antigen is extracellular and has a molecular weight of ~200 kDa, indicating that the antigen recognised by mAb ED7 may be a novel high molecular weight antigenic structure. Agglutination by the mAb shows that it binds to a previously uncharacterized component on the spore surface and may be associated with the spore agglutination process described previously.

Previous studies have investigated the process of spore adhesion and agglutination prior to germination. The process of spore adhesion occurs naturally prior to spore germination in *F. solani* and is thought to be essential to successful plant infection by the fungus. It has been shown that ungerminated conidia agglutinate during attachment to host roots, before spore mucilage is produced and prior to spore germination. Consequently, adhesion and agglutination allow the macroconidia to come into contact with the host root after which germination and infection occur (Schuerger & Mitchell, 1993). A similar process is believed to occur in *H. haematococca*. Host nutrients stimulate spores to become adhesion competent, allowing macroconidia to adhere and agglutinate at their apices during host tissue attachment (Epstein & Nicholson, 2006; Jones & Epstein, 1990).

The process of mAb ED7 agglutination was investigated with a strain of *F. solani* whose spore production is dominated by microconidia. The agglutinating activity of mAb ED7 was not universal, with certain *Fusarium* species, and even strains of *F. solani*, failing to agglutinate with the antibody. This is consistent with previous studies that have shown that strains of *F. solani* 

differ in spore adhesion and agglutination properties (Epstein & Nicholson, 2006).

Similar to other fungal pathogens (Tucker & Talbot, 2001), the initial stages of *Fusarium* infection include spore adhesion, germination, and hyphal network establishment, followed by penetration of the host cells (Stephens *et al.*, 2008). The lack of spore adhesion by mAb ED7 in certain isolates of the fungus warrants further investigations of the spatio-temporal expression of the antigen in agglutinating and non-agglutinating strains of the pathogen.

#### Summary of Key Findings:

- 1. A single B-cell line, ED7, produces mAb belonging to the IgM class, which is genus-specific, *Fusarium*-specific, reacting with antigens from *Fusarium* species and it does not cross-react with antigens from a wide range of unrelated mould and yeast species.
- 2. The mAb ED7 binds to an antigen with a molecular weight of ~200 kDa. The antigen epitope is a carbohydrate contains vicinal hydroxyl groups, not protein and a heat.
- **3.** The ED7 antigen is located in an extracellular microfibrillar matrix in the outer cell wall surrounding both the of hyphae and spores.
- **4.** The *Fusarium* species microconidia suspended in mAb ED7 have two agglutinations and non-agglutination trends at wavelength of 555 nm.

### Chapter 3. Alveolar Macrophage Phagocytosis and Killing of *F. solani* Expressing Green Fluorescent Protein (GFP)

#### **3.1 Introduction**

*Fusarium* species are emerging as lethal human pathogens and constitute an important cause of morbidity and mortality, particularly in severely immunocompromised patients. The number of systemic *Fusarium* infections in humans has increased since the mid-1970s (Cho *et al.*, 1973). This upward trend has coincided with an expanding population of immune impaired patients, including neutropenic patients with haematological malignancies, recipients of haematopoietic stem cell transplants (HSCTs) or SOTs, patients with diabetes, AIDS patients, and those having toxic chemotherapy or radiotherapy treatments (Dignani & Anaissie, 2004; Guarro *et al.*, 2000; O'Donnell *et al.*, 2007; Walsh *et al.*, 2004; Zhang *et al.*, 2006). *F. solani* is the most frequently reported species, involved in approximately 50% of fusariosis cases, and followed by *F. oxysporum* and *F. verticillioid*es (Jain et al., 2011; Marcio Nucci & Anaissie, 2007).

*Fusarium* infections can be superficial, local or disseminated (Marcio Nucci & Anaissie, 2002). In addition to producing allergens and many types of mycotoxins (that cause respiratory infections and organ damage) (Li *et al.*, 2011), deaths due to invasive fusariosis are being increasingly reported due, in part, to inherent resistance to many of the antifungal drugs that are currently available for clinical treatment (Azor *et al.*, 2007; Tortorano *et al.*, 2014).

Diagnosis of disseminated fusariosis is also a big challenge. Morphological identification using traditional microscopic and cultural base methods can lead to misdiagnosis, especially in the absence of macroconidia that are characteristic of some *Fusarium* species. These methods are time-consuming and required extensive knowledge of mycology (Alexander & Pfaller, 2006). Additionally, recent studies have shown serodiagnostic tests, such as GM and BDG tests, are not especially effective for diagnosing *Fusarium* infections (Esnakula *et al.*, 2013).

#### 3.1.1 Immunity to Fungal Infections

The skin is the first physical barrier of the innate immune system and is critical in isolating the sterile internal tissues from the external environment. This physical barrier prevents fungal invasion and provides an initial immunity to fungi such as *Fusarium*. Fungal propagules have to adhere and penetrate epithelial tissue under the skin or mucous membranes, to develop into deep-seated infections and that can lead to tissue damage (Williams *et al.*, 2012). As a result of tissue damage, broad-spectrum antimicrobial peptides (AMPs), such as defensins, cathelicidins and collectins, are secreted by epithelial cells to eliminate fungal infections. AMPs play an integral role in host defence by destroying fungal cells directly through binding to the cell membrane or cell wall carbohydrates, or indirectly via activation and recruitment of innate immune phagocytic cells (Kolar *et al.*, 2013; McDermott, 2009). Cellular innate immunity includes residential macrophages and circulated neutrophils. These cells are involved in the innate immune host defence and are considered a core immune response to fungal invasions (Bain *et al.*, 2014; Grazziutti *et al.*, 2005). PRRs on

phagocytic cells are able to recognise effectively a variety of polysaccharide antigens found on the fungal cell wall. These antigens are known as PAMPs. Common examples include  $\beta$ -glucan and mannan (Figueiredo *et al.*, 2011; McCann *et al.*, 2005). After antigen recognition, AMØ are associated with the clearance of *Fusarium* propagules via phagocytosis (Brakhage *et al.*, 2010; Roilides *et al.*, 2006; Walsh & Groll, 1999). Macrophages and neutrophils can damage *Fusarium* hyphae by producing Interferon gamma (IFN $\gamma$ ), granulocytecolony stimulating factor (G-CSF) and granulocyte-macrophage-colonystimulating factor (GM-CSF) (Gaviria *et al.*, 1999).

TLRs expressed on the surface of phagocytic cells bind to β-glucan and mannose, and play a crucial role in the recognition of Fusarium cell wall components. These receptors mediate the phagocytosis process and stimulate the adaptive immune response (Gordon & Read, 2002; Guo et al., 2008; Jin et al., 2007; Shoham & Levitz, 2005; Tarabishy et al., 2008). Furthermore, these receptors cooperate in a complex network to activate the production of cytokines and chemokines, including tumour necrosis factor (TNF), interleukins (IL-1 $\alpha$ , IL-1 $\beta$ , IL-6) and macrophage inflammatory proteins (MIP-2 and 1) to attract other innate phagocytic cells to the site of invasion (Abbas et al., 2007). Recent studies have shown a novel way of neutrophil-mediated killing of pathogenic bacteria, via the release of extracellular networks (NETs) (Brinkmann et al., 2004). Since then, subsequent studies have revealed the effector role of NETs in trapping pathogenic fungi and eliminating infections, such as Aspergillus fumigatus (Bruns et al., 2010), and Candida albicans (Branzk et al., 2014) infections. This unique phenomenon has also been reported in macrophages as an initial process for host defence, resulting in

microorganism clearance and destruction via the release of macrophage extracellular traps (METs). MET formation is induced by microbial cell invasion, such as by *Mannheimia haemolytica* (Aulik *et al.*, 2012; Hellenbrand *et al.*, 2013) and *Candida albicans* (Liu *et al.*, 2014). The MET is a structure of nuclear DNA fibres supported with active proteins. This trap has fungistatic and fungicidal affectivity to prevents fungal dissemination, and may recruit other phagocytic cells to the infection site (Aulik *et al.*, 2012, Guimarães-Costa *et al.*, 2012, Brakhage *et al.*, 2010).

In healthy individuals, innate immune responses can detect and clear most fungal invaders within a short time (Blanco & Garcia, 2008). However, disseminated *Fusarium* infections often occur in immunocompromised patients and these patients have defective or completely lack an innate immune response, often due to having immunosuppressive therapy (Abbas *et al.*, 2007; Jain *et al.*, 2011; Nucci & Anaissie, 2007; Roilides *et al.*, 2006).

#### 3.1.2 GFP Transformation

GFP isolated from the luminescent jellyfish, *Aequorea victoria*, absorbs blue light, and then re-emits it as green fluorescence. This characteristic feature has been used to monitor microbial cells via gene expression, without affecting natural microbial behaviour (Chalfie *et al.*, 1994). This technique has also been used as a reporter for macromolecular localization in bacterial cells (Margolin, 2000). Furthermore, a synthetic GFP method has been successfully used as a reporter gene expression tool, for transformant cell isolation and cellular gene expression quantification. This has allowed the study of host-fungal pathogen

interactions and the assessment fungal or yeast biomass (Cormack *et al.*, 1997; Lorang *et al.*, 2001). In addition, GFP techniques have been used for yeast cell quantitative analysis (Barelle *et al.*, 2004) and have been applied to many filamentous fungi for monitoring growth, behaviour in different environments, and to study fungal pathogenicity and assess antifungal activity (Bae & Knudsen, 2000; Knudsen & Dandurand, 2014; Spellig *et al.*, 1996).

Studies have shown the application of GFP techniques to quantitatively investigate fungi and follow the plant infection processes of a number of *Fusarium* plant pathogens, including *F. oxysporum* (Inoue *et al.*, 2002; Lagopodi *et al.*, 2002; Zhang *et al.*, 2013), *F. equiseti* (Maciá-Vicente *et al.*, 2009), *F. graminearum* (Skadsen & Hohn, 2004) and *F. verticillioides* (Oren *et al.*, 2003). Additionally, transformation with GFP is considered to be an appropriate tool for studying the phagocytic cell response of the cellular innate immune system against fungal pathogen invasion *in vitro*. Expression of GFP facilitates fungal propagule visualisation, allowing the assessment of the efficiency of pathogenic fungal cell internalisation and clearance. This method has been used for both *Aspergillus* (WasyInka & Moore, 2002) and *Candida* (Katragkou *et al.*, 2010) species. To the best of my knowledge, no studies have been undertaken to transform *F. solani* with GFP or to use it to track *F. solani* during phagocytosis by AMØ.

#### 3.1.3 Aims and objectives

Presently, very little is known about the cellular innate immune response to human pathogenic *Fusarium* species, particularly *F. solani*. AMØs and the

phagocytic processes of engulfment and destruction are important topics that are under-studied (Gaviria et al., 1999a; Schäfer et al., 2014). Recognition of PAMPs present in the pathogen cell wall, via PRRs on the phagocytic cell membrane, is the initial step for engulfment and pathogen clearance (Brown, 2011; Luigina Romani, 2011). Some studies have been conducted to identify immunodominant epitopes on surface antigens of pathogenic fungi and to follow antigen production during the activation of the phagocytic cells of the innate immune system (Figueiredo et al., 2011; Karthikeyan et al., 2011; Tarabishy et al., 2008). Identification of the molecular form of the antigenic structures of the fungal spore cell wall is incompletely defined. Knowledge of these immunodominant molecules is required to understand their role in inducing proinflammatory cytokine and chemokine responses through host cell receptor binding. Identification and characterization of fungal cell wall antigenic epitopes that evoke immune response might lead to their use as vaccines to immunise human patients against fungal infections (Levitz et al., 2014). They may also drive novel therapeutic approaches to prevent or control opportunistic fungal infections, such as F. solani.

The overall aim of the work in this chapter was to investigate the innate immune response to *F. solani* spores by studying phagocytosis of conidia by mouse AMØs. No studies examining the phagocytic clearance of *F. solani* by AMØs have been conducted and there is an apparent need to evaluate innate immune cell responses to this emerging opportunistic pathogen since it is the most frequent *Fusarium* species causing life-threating disease among immunocompromised patients. To achieve this aim, the following objectives were identified:

1.Generation of a *F. solani* strain expressing GFP to enable the interaction of spores with AMØ to be visualised; To develop a live-cell imaging system, to allow the phagocytosis of *F. solani* spores by AMØ to be investigated in real-time; To determine the effect of spore agglutination by mAb ED7 in the phagocytic process.Current techniques to quantify fungal biomass, based on measurements of metabolic activity (Wallander *et al.*, 2013), do not allow for discrimination between the metabolic activities of the fungus and of the engulfing phagocytes. Consequently, fungus-specific techniques need to be developed to monitor the effects of phagocytosis on fungal proliferation. Here, a murine AMØ method was developed that allows the monitoring and quantification of *F. solani* germination and hyphal development during phagocytosis in the presence and absence or the spore-agglutinating mAb ED7. This novel approach allowed the quantitative determination of phagocytosis of the fungus under these conditions.

#### **3.2 Materials and Methods**

#### 3.2.1 Fungal Transformation with GFP

#### 3.2.1.1 Protoplast preparation

*F. solani* (CBS224.34) conidia were harvested from 7-day old PDA plates after flooding with 5 ml SMQ-H<sub>2</sub>O, conidia suspension was filtered through Miracloth then washed three times with SMQ-H<sub>2</sub>O. Washed conidia were suspended in 20 ml of PDB media and incubated in Petri dishes at a concentration of 10<sup>6</sup> spore ml<sup>-1</sup>. Plates were incubated at for 48 h at 27°C, the mycelium collected by filtering through sterile Miracloth (Calbiochem), rinsed with SMQ-H<sub>2</sub>O and dried with paper towel.

Fungal protoplasts were prepared by re-suspending 0.3 g of fresh and washed mycelium in filter-sterilized enzyme solution (1.2 mg chitinase (Sigma), 7 mg lyticase (Sigma), 44 mg cellulase (Sigma), in 2.4 ml of mannitol osmoticum (5 ml 1M CaCl<sub>2</sub>, 9.11 g mannitol, 1.06 g MES [2-(N- Morpholino) ethanesulfonic acid hydrate], 95 ml dH<sub>2</sub>O, pH adjusted to 5.5 with KOH) in a 15-ml Falcon tube (Becton Dickinson). The suspensions were mixed by shaking at 225 rpm for 25 min on a flat-bed shaker (New Brunswick Scientific, USA) at RT. Protoplast suspensions were filtered through sterile Miracloth, washed with 5 ml of sterile osmotic buffer, and then centrifuged at 3,044 *g* for 5 min at 4°C. The protoplast pellets were washed twice by centrifugation and re-suspension and were finally suspended in 300  $\mu$ l of sterile osmoticum. The protoplast numbers were determined by using a haemocytometer.

#### 3.2.1.2 Fungal Transformation

For F. solani (CBS224.34) protoplast transformation, 300 µl of washed protoplasts, at a concentration  $10^7$  ml<sup>-1</sup>, were mixed with 6 µg of the DNA plasmid that containing a modified hygromycin resistance gene under the control of the Aspergillus nidulans TRPC promoter together with the SGFP gene under the control of the Pyrenophora tritici-repentis TOXA gene promoter was isolated from pCT74 (was provided kindly by N. Talbot group – Bioscience, the University of Exeter, UK) previously suspended in 34 µl of SMQ (Figure 3.1). As a negative control, the same concentration of protoplasts was re-suspended in osmotic buffer only. Both suspensions were incubated on ice for 20 min, and then each tube was treated with 130 µl of polyethylene glycol solution (40% PEG 8000 in osmoticum). Next, the tubes were mixed gently by inversion, followed by incubation for 30 min at RT. The treated protoplasts were mixed gently with cell wall regeneration medium containing molten PDA (42°C) and 2.2 µg/ml of hygromycin B (Caliobiochem) as a selective agent, and 0.8% (w/v) sucrose), poured into five Petri dishes, and then incubated for 24 h at 26°C in the dark. Putative Fusarium transformants were selected by adding a thin overlay of molten PDA, containing hygromycin B at the same concentration 2.2 µg/ml, on the top of the plates. Single spore isolates of putative transformants were produced on PDA-hygromycin plates and transferred to PDA slopes for long-term storage. Expression of the GFP protein in putative transformants (hereafter referred to as FS-GFP transformants) was determined by examining tissue sections under epifluorescence by using an Olympus microscope (IX81, Visitron System, GmbH), fitted with a 365 nm UV excitation filter and a GFP absorption filter. Bright-field and fluorescence images

were captured using a Photometrics Cool SNAP HQ2 camera (Roper Scientific,

Germany).



**Figure 3.1.** Schema of the vector hygro-GFP construction. (Sesma & Osbourn, 2004)

## 3.2.1.3 Determination of GFP protein expression by Enzyme-Linked Immunosorbent Assay

Expression of the GFP protein in fluorescent-positive FS-GFP transformants was further established by confirmatory ELISA, using the ELISA protocol essentially as described previously (**Section 2.2.5**). Wells were blocked for 10 min with 100 µl of blocking solution (1% (w/v) Bovine Serum Albumin (BSA; Sigma, A-7030) in PBS, and then incubated for 1 h with 50 µl of the anti-GFP mAb class IgG (Ref-11814460001; Roche, Germany) diluted 1:1 at a final concentration 0.02 mg/ml in PBS with Tween 20 (PBST; PBS containing 0.05% (v/v) Tween-20 (polyoxyethylene-sorbitan monolaurate) Sigma; P7949)). The goat anti-mouse polyvalent (Ig classes IgG, IgA, and IgM) peroxidase conjugate (A-0412; Sigma Chemical Company, Poole, United Kingdom) was used as secondary antibody. Control wells were incubated with PBST only.

#### 3.2.2 Morphological studies

#### 3.2.2.1 Hyphal Growth and Spore Production

The hyphal growth of wild-type *F. solani* (FS) and FS-GFP transformants was determined by inoculating replicate PDA plates centrally with 5-mm agar plugs of inoculum taken from the leading edge of 5-day old fungal cultures. Plates were incubated at 27°C, and colony diameters were measured every 4 days for 12 days. For spore counts, wild-type and GFP transformants plate cultures were flooded with 5 ml SMQ  $H_2O$  and spore concentration determined by using haemocytometer at dilution factor 1:500 after 1, 4, 8 and 12 days.

### 3.2.2.2 Quantification of Hyphal Biomass, Antigen Production and Spore Agglutination with mAb ED7

Hyphal biomass and antigen production were quantified on the abundance of fungal propagules for the wild type, *F. solani* (CBS224.34), and FS-GFP transformants isolate. Longer-term (21 days) growth experiments were constituted by inoculating three replicates of 250 ml flasks containing 100 ml PDB with 1 X 10<sup>3</sup> spore ml<sup>-1</sup> of the isolate. Flasks were incubated with shaking (New Brunswick Scientific, USA) at 125 rpm for 21 days at 27°C. Culture filtrates and hyphal biomass were collected every 3 days by straining the contents of the flasks through a sterile Miracloth and transferred into fresh Falcon tubes. The dry weights of hyphal biomass were determined in milligramme (mg) using scale (Mettler Toledo AB54-5/Facts, Switzerland) after drying at 70°C for 16 h. Culture filtrates containing soluble antigens were stored at -20°C until used to perform soluble antigens production using ELISA as described in (**Section 2.2.5**). For testing spore agglutination, the protocol followed was previously described in (**Section 2.2.9**).

#### 3.2.3 Live Cell Imaging of Spore Agglutination

*F. solani* spores were harvested and washed as described previously. One hundred-µl of either mAb ED7 (spore agglutinating) TCS, were mixed with 6 µl of washed spore suspension at a concentration of 10<sup>6</sup> spore ml<sup>-1</sup>. Control samples received 10% TCM only. The agglutination process was captured with an Olympus microscope (IX81, Visitron System, GmbH) and images were recorded every 10 sec for 35 min using a Photometrics CoolSNAP HQ2 camera (Roper Scientific, Germany). Image sequences were combined using the Metamorph software package (MDS Analytical Technologies, Winnersh, UK). Both agglutinated and unagglutinated spores were counted manually in 5 independent fields of view with three replicates for each mAb ED7 and TCM the control, and the percentage of non-agglutinated spores (S%) were plotted as bar charts after 30 mins using this formula:

S% = (Number of Single Spores / Total Number of Spore) X 100

#### 3.2.4 Murine Alveolar Macrophage cell line MH-S

#### 3.2.4.1 Details and Culture of Mouse Alveolar Macrophages

The mouse AMØ cell line MH-S (ATCC CRL-2019) used in this study was developed from mouse lung tissues (Mbawuike & Herscowitz, 1989). The AMØ cell line was derived by SV40 transformation of an adherent cell-enriched population of mouse AMØ and retains properties of AMØ including phagocytosis and typical macrophage morphology. The cell line is esterase positive and peroxidase negative, Fc receptor positive, expresses the complement receptor CD11b (Mac-1), Class II antigens (I-A) and T antigen, and produces the pro-inflammatory cytokine interleukin-1.

The AMØ cell line was cultured for 48 h in 25 cm<sup>2</sup> tissue culture flasks, containing 10 ml of MH-S tissue culture medium (MH-S TCM; RPMI-1640 medium, 10%(v/v) heat-inactivated fetal bovine serum ( $\Delta$ FBS; Biosera), 2 mM L-glutamine, 0.05 mM 2-mercaptoethanol, and the antibiotics penicillium and streptomycin, which was prepared by dissolving 0.3 g penicillin-G (Duchefa Biochemie, P0142) and 0.5 g streptomycin sulphate (Melford, S0148) in 5 ml

MQ-H<sub>2</sub>O, followed by filter sterilization through a 0.2  $\mu$ m filter disc. The cells were incubated in a CO<sub>2</sub> incubator (San

### 3.2.4.2 Quantification of Phagocytic Percentage and Phagocytic Index of Engulfed Spores

Spores of FS-GFP transformants were harvested from 5-day old PDA Petri-dish cultures by flooding the plates with 5 ml of sterile SMQ-H<sub>2</sub>O and stroking the surface with a sterile L-shaped spreader. Next, suspensions were filtered through sterile Miracloth (Calbiochem) to remove fragments of mycelium, and the spores were pelleted by centrifugation at 14,489 *g* for 5 min. Spores were washed twice with sterile SMQ-H<sub>2</sub>O and re-suspended in 1 ml of MHS TCM.

AMØ cell concentration was determined with a hemocytometer. Cells were diluted to 5 x 10<sup>5</sup> ml<sup>-1</sup> in MH-S TCM- $\Delta$ FBS and inoculated into 8-well culture  $\mu$ -Slides (ibidi, 80826, Germany) for use in microscopy. Slide cultures were incubated for 24 h at 37°C and 5% CO<sub>2</sub>. Cells received fresh 10% MH-S TCM- $\Delta$ FBS containing washed FS-GFP transformant spores at a final concentration of 10<sup>6</sup> spore ml<sup>-1</sup>. Inoculated slides were incubated for 2, 12 or 24 h, after which wells were washed 3 times with sterile, warmed PBS, to remove any unengulfed spores. Phagocytosis of FS-GFP transformant spores was quantified by counting 100 AMØ cells in each of five random fields of view (x100 magnification), using an inverted an Olympus epifluorescence microscope (IX81, Visitron System, GmbH), fitted with a 365 nm UV excitation filter and a 420 nm GFP absorption filter.

The phagocytosis percentage (P%) and phagocytosis index (Pi) were then determined for each treatment, according to the following formula, where: P% is the percentage of cells containing spores, calculated according to the formula:

 $P\% = [(B+C+D+E+F) / (A+B+C+D+E+F)] \times 100$ , where:

A: is the number of cells with no spores.

B: is the number of cells with 1 spore.

C: is the number of cells with 2 spores.

D: is the number of cells with 3 spores.

E: is the number of cells with 4 spores.

F: is the number of cells with >5 spores.

Pi is the average number of phagocytosed spores per macrophage, calculated according to the formula:

Pi = (B+2C+3D+4E+5F) / (B+C+D+E+F), where:

A: is the number of cells with no spores.

- B: is the number of cells with 1 spore.
- C: is the number of cells with 2 spores.

D: is the number of cells with 3 spores.

- E: is the number of cells with 4 spores.
- F: is the number of cells with >5 spores.

Spores that remained attached to AMØ cells after 3x PBS washes, but had been 50% ingested, were considered to have been phagocytosed (Gill-Lamaignere *et al.*, 2002).

#### 3.2.5 Live Cell Imaging of Spore Phagocytosis

A model for live cell imaging of FS-GFP spore phagocytosis by AMØ and evaluation of P% and Pi following agglutination with mAb ED7 was established using 8-well culture µ-Slides (ibidi, 80826, Germany) as shown in Figure 3.2. The slides were modified by creating cross channels between well numbers 1 and 2 and 3 and 4 using a heated 1.25 mm syringe needle. This allowed media connectivity between the wells. Wells number 1 and 3 were inoculated with fresh cultures of AMØ cells in MH-S TCM-ΔFBS at a concentration of 10<sup>4</sup> cells ml<sup>-1</sup>. Washed spores of the FS-GFP transformant were re-suspended in MH-S TCM- $\Delta$ FBS, and the concentration was adjusted to 10<sup>4</sup> spore ml<sup>-1</sup> prior to phagocyte challenge. A confocal microscope (Zeiss LSM 510 META), fitted with an environmental chamber heated to 37°C and 5% CO<sub>2</sub> and 488 nm excitation/ emission filters, was used for live cell imaging of spore phagocytosis. MH-S TCM-∆FBS bathing the AMØ cells in wells 1 and 3 was aspirated and replaced with the MH-S TCM spore suspension. Well numbers 2 and 4 were then filled with mAb ED7 TCS or TCM-∆FBS only, respectively. Images of spore agglutination and phagocytosis by the AMØ cells were then captured every 60 sec, for a total of 8 h, with DIC optics (Plan-Apochromat 63x/1.40 Oil DIC M27), and 488 nm laser excitation.

#### 3.2.6 Statistical analysis

The data was analysed using the statistical programme Minitab (Minitab Express, Minitab®, Coventry, UK). Statistical differences between treatments and controls were established by t-test or means of one-way analysis of variance (ANOVA). Post hoc Tukey-Kramer analysis was then performed to

distinguish which groups were significantly different from one another. Results of the test had levels of significance indicate: NS = non-significant, and significant when *p*-values were \* < 0.05, \*\* < 0.01, \*\*\* < 0.001.



**Figure 3.2.** Schematic diagram showing the experimental system developed for real-time imaging of phagocytosis of FS-GFP spores during agglutination with the Fusarium-specific mAb ED7. Adherent AMØ cells in wells 1 and 3 were challenged with FS-GFP spores, while ED TCS or TCM- $\Delta$ FBS only was placed in wells 2 and 4 respectively. Antibody permeating through the cross channel into well 1 allowed the effect of spore agglutination on AMØ phagocytosis to be quantified by calculating P% and Pi of fluorescent spores.

#### 3.3 Results

#### 3.3.1 Transformation of F. solani (CBS224.34) with GFP

*F. solani* (CBS224.34) produced a typical spherical protoplast as shown in **Figure 3.3**. Putative FS-GFP transformants appeared as white colonies under hygromycin selection, compared to no growth of wild-type control protoplasts. Under epifluorescence, putative FS-GFP transformants had green fluorescent spores and hyphae (**Figure 3.4 A to D**), when compared to the untransformed wild-type strain, which showed no fluorescence (**Figure 3.4 E and F**). Stable FS-GFP transformants were obtained following single spore isolation and repeated sub-culturing onto PDA without hygromycin.



**Figure 3.3.** Selection of hygromycin-resistant FS-GFP strains following the transformation of *F. solani* protoplasts. Typical *F. solani* protoplast. Scale bars =  $10 \mu m$ .



**Figure 3.4.** Green fluorescent protein expression in a stable FS-GFP transformant, following single spore isolation and several rounds of sub-culturing onto PDA without hygromycin selection. (**A**) Brightfield image of ungerminated and germinated spore with germ tube. (**B**) The same image as (**A**), but examined under epifluorescence. (**C**) Brightfield image of spores. (**D**) The same image as (**C**), but examined under epifluorescence. (**E**) Brightfield image of control wild-type *F. solani* (CBS224.34) spores and germlings. (**F**) The same image as (**E**), but examined under epifluorescence. Note the lack of fluorescence of wild-type propagules. The magnification for panel **A** and **B** is x60 and x100 for the rest panels. Scale bars = 10  $\mu$ m.

# 3.3.2 Detection of GFP Expression in FS-GFP Transformants by Using ELISA

Expression of GFP in fluorescent FS-GFP transformants was confirmed by ELISA tests using anti-GFP antiserum. The ELISA absorbance values at 450 nm of antigens extracted from cultures of the FS-GFP strain compare with the wild-type are shown in (**Figure 3.5**). The absorbance value for the transformants (A<sub>450</sub> 1.87) is significantly greater than the control strain (A<sub>450</sub> 0.183) when analysed using the Student's t-test (p <0.01). The ELISA therefore confirms GFP expression in this fluorescent FS-GFP transformants.



**Figure 3.5.** Absorbance values from ELISA tests of a stable fluorescent FS-GFP transformant and the wild-type strain (CBS224.34). Each bar is the mean of 3 replicate samples  $\pm$  S.E. The level of significance indicates: \*\*\* < 0.001. Scale bars = 20  $\mu$ m.

# 3.3.3 Phenotypic Analysis of FS-GFP Transformant and Wild-type Strain

Linear growth of the FS-GFP transformant and *F. solani* (CBS224.34) was determined by measuring colony diameters over a 12-day period (**Figure 3.6**). Three replicate culture plates for both strains were scanned daily with an Epson Perfection V750 Pro scanner. The results showed that colony diameters were similar for both strains with no significant differences over the experimental period (p > 0.05) (**Figure 3.7 A**). The FS-GFP transformant had a significantly reduced spore concentration compared to the wild-type strain when grown under the same conditions (**Figure 3.7 B**).



**Figure 3.6.** Colony morphologies of wild-type *F. solani* (CBS224.34) and the stable FS-GFP transformant when grown on PDA over a 12-day period. The two strains have similar morphologies, showing that transformation with GFP has had no discernible effect on gross morphology.


**Figure 3.7.** Time course of wild-type *F. solani* (CSB224.34) and putative GFP strain over 12 days growth on PDA. (**A**) colony diameters (mm), the chart shows the similarity in linear growth of both the wild-type and FS-GFP strain. (**B**) spore production, note a decrease in spore production by the FS-GFP strain. Each point is the mean of 3 replicates  $\pm$  S.E. The levels of significance indicate: NS= non-significant, \* < 0.05, \*\*\* < 0.001.

## 3.3.4 Antigen Production, Biomass Accumulation and Spore Agglutination

Antigen production (determine by ELISA) by the FS-GFP transformant did not differ significantly to the wild-type strain during the 21 days sampling period (p > 0.05) (**Figure 3.8 A**). However, biomass accumulation of the FS-GFP transformant was significantly reduced in PDB cultures compared to the wild-type strain *F. solani* (CBS224.34) at (p < 0.05) (**Figure 3.8 B**). MAb ED7 strongly agglutinated spores from both the wild-type *F. solani* strain (CBS224.34) (**Figure 3.9 A**) and the FS-GFP transformant (**Figure 3.9 B**), compared to the TCM control. This shows that transformation of the fungus with GFP had not altered the agglutination properties of its spores.



**Figure 3.8.** (**A**) Antigen production by the wild-type strain and FS-GFP transformant determined by ELISA over the same time period. (**B**) Biomass accumulation of *F. solani* (CBS224.34) and the FS-GFP transformant during 21 days growth in PDB. Each point is the mean of 3 replicates  $\pm$  S.E.



**Figure 3.9.** Agglutination of wild-type *F. solani* (CBS 224.34) spores (**A**) and spores of the FS-GFP transformant (**B**) by mAb ED7. Note the rapid decline in absorbance for both strains in the presence of the antibody, but the lack of agglutination by in TCM only. Each point is the mean of 3 replicates  $\pm$  S.E.

## 3.3.5 Live Cell Imaging of Spore Agglutination

Live cell imaging showed that *F. solani* (CBS224.34) spores agglutinated within 5 min of re-suspension in mAb ED7 (**Figure 3.10 A**). Agglutination was not exhibited in TCM (**Figure 3.10 B**). Movies demonstrating the agglutination phenomenon over 30 min are archived at 35 mins. Single spores were quantified manually using Patina software version 1.0.1 (Atek, Inc., Patina App.com) (**Figure 3.10 C**).



**Figure 3.10.** Agglutination of *F. solani* (CBS224.34) spores in TCS of mAb ED7 (**A**) and TCM only (**B**) over a 30 min sampling period. Note agglutination with mAb ED7, but the lack of agglutination with TCM. Scale bars = 10  $\mu$ m. (**C**) Quantification of the agglutination process. The percentage of non-agglutinated spores were calculated from 7 fields of view at each time point, three biological replicates for each treatment. The number of single spores was significantly decreased in the ED7 mAb treatment. The level of significance indicate: \*\* < 0.01.

### 3.3.6 Live Cell Imaging of Spore Phagocytosis

Phagocytosis of FS-GFP spores by AMØs was quantified by determining the P% and Pi. The experiments were conducted with the fluorescently-labelled strain to facilitate spore counting and to allow live cell imaging of the phagocytic process. There was an increase over time in the mean number of engulfed spores per AMØ, both with mAb ED7-treated (agglutinated) and with control TCM-treated (non-agglutinated) spores (**Figure 3.11 A**). There was a significant reduction in the mean number of spores per AMØ at 2 h under agglutinating conditions compared to TCM only and no significant differences in the treatments thereafter. This shows that spore agglutination delayed the phagocytic process. This finding was corroborated by the significantly greater number of AMØs at 2 h, in the ED7 treatment compared to the control, which contained no spores (**Figure 3.11 B**). Thereafter, there were no significant differences in treatments.



**Figure 3.11.** Phagocytosis of FS-GFP microconidia by AMØ at 2h, 12h, and 24 h under agglutinating (mAb ED7) or non-agglutinating (10%TCM- $\Delta$ FCS only) conditions. (**A**) Mean number of engulfed FS-GFP spores per AMØ, and (**B**) Numbers of AMØs containing (0, 1, 2, 3, 4 or >4) spores at each time point. Each bar is the mean of three replicates ± S.E. The levels of significance indicate: NS = non-significant, \* < 0.05.

### **3.3.7 Phagocytic Percentage and Phagocytic Index**

The P% and the Pi values for were not significantly different (p > 0.05) between the FS-GFP spores treated with mAb ED7 or with TCM only at 2, 12 and 24 h as shown in **Figure 3.12 A** and **Figure 3.12 B**. Phagocytic percentages increased over time under both conditions and while there was no significant increase in P% over time under non-agglutinating conditions (TCM only), there was a significant increase in P% between 2 h and 12 h under agglutinating conditions. This further illustrates the delay in phagocytosis due to spore agglutination by mAb ED7.



**Figure 3.12.** Phagocytic activity of FS-GFP microconidia by AMimes at 2h, 12h, and 24 h under agglutinating (mAb ED7) or non-agglutinating (10% TCM- $\Delta$ FCS only) conditions. (**A**) Phagocytic percentage (P%), and (**B**) Phagocytic index (Pi). Each bar is the mean of three biological replicates ± S.E. The levels of significance indicate: NS = non-significant (p > 0.05).

#### 3.4 Discussion

The fungal genus *Fusarium* contains opportunistic fungal pathogens that have emerged over recent decades as causative agents of life-threatening disease in humans (van Diepeningen *et al.*, 2015). *F. solani* is the most common and virulent species and is associated with high rates of mortality and morbidity in individuals with impaired immunity. Effector cells of innate immunity (macrophages and neutrophils) are a critical first-line of defence against infection by the fungus. In the absence of effective phagocytosis and clearance of infectious propagules, the fungus can disseminate, causing the frequently fatal invasive disease fusariosis. *Fusarium* infectious propagules (spores) enter the human body mainly through the respiratory tract, wounds, catheters, trauma sites and contaminated contact lenses (Mukherjee *et al.*, 2012; Marcio Nucci & Anaissie, 2007; Sanz *et al.*, 1993).

Phagocytic cells in the lungs AMØ typically phagocytose and destroy spores and, along with neutrophils, are highly efficient barrier preventing spore germination and dissemination from the lung tissues (Bain *et al.*, 2014). The mechanisms of AMØ recognition and destruction of mould spores have been investigated in detail in *Aspergillus fumigatus*, the cause of invasive pulmonary aspergillosis. Fungal recognition by AMØ is the first step of the innate immune response that leads to phagocytosis and intracellular intra-cellular degradation of inhaled conidia of *A. fumigatus* (Nicola *et al.*, 2008). The antigenic fungal cell wall components including  $\beta$ -glucans, chitin and mannose or galactomannan are the first point of contact and can be recognised as PAMPs by PRRs that present on the phagocytic cell surface (Chotirmall *et al.*, 2013). PRRs that include different recognition receptors such as TLR2 and TLR4, dectin-1 and 2, and mannose receptor (MR) are able to detect invading *Aspergillus* species (Gersuk *et al.*, 2006; Luther & Ebel, 2006; Park & Mehrad, 2009). The PRRs and PAMPs interaction induces generation of AMPs such as defensins and production of inflammatory cytokines such as interleukins group, TNF- $\alpha$  and IFN $\gamma$  that can play a key role in recognising fungal elements, recruiting other phagocytes and activating adaptive immune response resulting in increased fungal clearance via phagocytosis (Blanco & Garcia, 2008; Brieland *et al.*, 2001; Hegedüs & Marx, 2013; Luther & Ebel, 2006; Park & Mehrad, 2009; Phadke & Mehrad, 2005).

Following this interaction, AMØs engulf conidia in an actin-dependent manner within phagosome that fuse with lysosomes leading to the killing of conidia by oxidative such as and non-oxidative ways depends on phagolysosome acidification (Agapov *et al.*, 2009; Brakhage *et al.*, 2010; Ibrahim-Granet *et al.*, 2003; Nicola *et al.*, 2008). However, *Aspergillus* species have developed inhibitory mechanism against phagolysosome acidification effect resulting in conidia germinating, macrophage pierces and escape (Dagenais & Keller, 2009; Slesiona *et al.*, 2012).

Macrophages like other leukocytes produce METs like a network to further control *A. fumigatus* proliferation that forming of the nuclear DNA with antimicrobial molecules to surround and trap fungi (Aulik *et al.*, 2012; Bruns *et al.*, 2010). Despite an increasing knowledge of the mechanisms of innate immunity to other mould pathogens, our understanding of the interactions between phagocytic immune cells and spores of pathogenic *Fusarium* species remains limited.

To study the interactions between *F. solani* propagules and AMØ, the major phagocytes present in lung alveoli, a GFP-expressing isolate of *F. solani* was constructed. This allowed the process of spore phagocytosis to be more easily observed in live cell imaging investigations.

The use of the GFP-expression technique to study the interaction and phagocytosis process between macrophages and fungi has been reported in *Aspergillus fumigatus* (WasyInka & Moore, 2002) and *C. albicans* (Katragkou *et al.,* 2010). Also, this tool was used to investigate plant infections by pathogenic *Fusarium* species, including *F. oxysporum* (Lagopodi *et al.,* 2002), *F. equiseti* (Maciá-Vicente *et al.,* 2009), *F. graminearum* (Skadsen & Hohn, 2004), and *F. verticillioides* (Oren *et al.,* 2003).

To the best of my knowledge, this work has two novel aspects not previously undertaken by others: (1) *F. solani* was transformed with GFP to allow the phagocytosis process by AMØ to be studied in real-time. This work demonstrates that GFP is an excellent reporter system in *F. solani.* (2) An *in-vitro* system was developed to mimic *Fusarium*-innate immune cell interactions. These two developments enabled me to track internalization of FS-GFP spores by mouse AMØ using live-cell imaging for up to 8 hr, and (to assess the effect of spore agglutination by the *Fusarium*-specific mAb ED7 on the phagocytosis process.

In this study, a total of four hygromycin-B resistant colonies were recovered on selection plates for *F. solani* GFP transformation. In contrast to the wild-type strain, the putative transformants displayed GFP expression under epifluorescence. One of the four transformants (FS-GFP) was selected for the

phagocytosis studies. The GFP expression and hygromycin-B resistance of the selected transgenic isolate were stable after five generations on non-selective media, with the fluorescent protein expressed in both fungal hyphae and conidia. Previous studies have reported similar observations in *F. oxysporum* f. sp. *radicis-lycopersici* GFP transformants (Lagopodi *et al.*, 2002) and *F. equesiti* (Maciá-Vicente *et al.*, 2009). Apart from a decrease in spore and biomass production, compared to the wild-type strain, the FS-GFP transformant had a similar morphological appearance in axenic culture and had similar antigenic properties, both regarding extracellular antigen production and spore agglutination by mAb ED7. This gave confidence that the FS-GFP strain could be used to investigate phagocytosis of antigenic *F. solani* spores and also to determine how spore agglutination might affect the phagocytic process.

Opsonization and agglutination of micro-organisms by antibodies can have a profound effect on phagocytosis by complexing infectious propagules and increasing their accessibility to macrophages and neutrophils. Besides antibodies have a significant role in microbial toxin neutralization, they are able to coat and opsonize microbial cell surface leading to enabling efficient recognition by phagocytic cells, then promote and accelerate pathogen uptaking by efficiently (Casadevall & Pirofski, 2012; Lindow *et al.*, 2011; McCullough *et al.*, 1988; van Kessel *et al.*, 2014). Furthermore, antibodies can prevent fungal biofilm and cell adherence resulting in biomass agglutination and facilitating phagocytosis (Casadevall & Pirofski, 2007; Martinez & Casadevall, 2005; Mishra *et al.*, 2014).

Opsonized fungal cell with human serum antibody or a specifically targeted antibody can be recognised by mediated phagocytosis receptor such as Fc receptors (Fc-Rs) located on the phagocytic cell surface (Levitz, 2010; van Kessel *et al.*, 2014; Wellington *et al.*, 2003; Wellington *et al.*, 2007). Recent studies have shown that the shape and size of agglutinated microbial cells by antibodies have a critical impact on phagocytosis rate of macrophages cells (Litvack *et al.*, 2011). A large agglutinated biomass exceeds macrophage cells can inhibit and block engulfment (Champion & Mitragotri, 2006; Litvack *et al.*, 2011).

In this study, I investigated the effect of spore agglutination by using two measures of AMØ phagocytic efficiency, P% and Pi, under agglutinating and non-agglutinating conditions. P% is the percentage of cells containing spores, while Pi is the average number of phagocytosed spores per macrophage.

Using this technique, no significant overall variation was found in P% and Pi for agglutinated and non-agglutinated spores. However, the percentage of AMØ that did not engulf spores was higher after the spores were treated with mAb ED7 during the first two hours of challenge. This suggests that spore agglutination by mAb ED7 delays the process of phagocytosis. There are two possible explanations for this delay. The first is that the antibody blocks AMØ recognition of surface antigen that binds via cell surface receptors. The cell line used in this study, MH-S, employs the complement receptor CR3 (CD11b/CD18) also to recognize fungal  $\beta$ -D-glucan and mannan (Xia *et al.,* 1999). While the extracellular antigen bound by mAb ED7 has been shown to be an immunodominant high molecular weight glycoprotein (**see Section 2.3.2**,

**Chapter 2**), its full molecular identity and involvement in phagocyte recognition have yet to be determined. Notwithstanding this, it is feasible that ED7 blocks receptor binding to an immunodominant antigen on the spore surface is thereby delaying recognition and engulfment by the phagocyte. An alternative explanation for the delay in phagocytosis is physical impairment. The increase in fungal biomass due to spore agglutination may simply prevent efficient uptake by the AMØ. A combination of reduced recognition by cell surface receptors and physical impairment may also account for the delay. Currently, little is known about the cell wall components of *F. solani* involved in recognition and uptake by macrophages, which warrants further investigation.

The work conducted here shows that murine AMØs efficiently internalize FS-GFP conidia and germinated spores, even despite delays in phagocytosis due to spore agglutination Indeed, single AMØ were able to phagocytose up to 12 spores. However, it was observed that engulfed FS-GFP conidia were able to germinate and continued to grow within the AMØ, ultimately leading to their escape from the macrophages and host cell lysis. Attempts were made by neighbouring macrophages to engulf developing hyphae, but no apparent damage appeared to occur to hyphae, which continued to proliferate into a hyphal network. Similar observations of cell lysis and death of murine macrophages by hyphae have been reported in the related fungus *F.oxysporum* (Schäfer *et al.*, 2014) and the dimorphic yeast *Candida albicans* (Bain *et al.*, 2012). Further analysis of the time-lapse movies generated here revealed a very rapid expulsion of FS-GFP conidia from intact macrophages. Importantly, this phenomenon during *F. solani* phagocytosis was only observable because of the real-time imaging system employed here. While the process of

vomocytosis has been reported in the yeasts *Cryptococcus neoformans* (Alvarez & Casadevall, 2006; Ma *et al.*, 2006) and *C. albicans* (Bain *et al.*, 2012), this is the first time this phenomenon has been reported for a mould pathogen and might explain, in part, how *F. solani* is able to escape innate immune cell killing.

#### Summary of Key Findings:

- Transformation of *F. solani* (CBS224.34) with GFP marker is a convenient, fast, and effective approach for studying the cellular innate immunity–fungus interaction without using chemical stains. To the best of my knowledge, this work is novel.
- 2. The level of gfp expression in single-spore isolated transformant is high and stable for long term in the vegetative and reproductive forms of the fungus, including the mycelium and microconidia.
- **3.** The putative FS-GFP transformants colony has similar morphology, growth and antigenic characteristics to the wild-type isolate. However, there is a significantly reduction in spore production compare to the wild-type strain.
- 4. The developed *in-vitro* system to mimic *Fusarium*-innate immune cell interactions is simple, effective and can be used for visualization and live cell imaging of the phagocytosis process in real-time. To the best of my knowledge, this system is novel.
- **5.** The FS-GFP spore agglutination by *Fusarium*-specific mAb ED7 delays the phagocytic process by AMØs compare with the control 10% TCM.

# Chapter 4. Tracking Human Pathogenic *Fusarium* species in Sink Drain Biofilms by Using mAb ED7

#### 4.1 Introduction

Species in the fungal genus *Fusarium* are ubiquitous environmental moulds, and pathogens of both plants and animals (Thornton & Wills, 2015; Zhang et al., 2006). In immunocompromised humans, such as patients with haematological malignancies and HSCT and SOT recipients, Fusarium species are significant emerging pathogens, causing a frequently fatal disseminated disease known as fusariosis with an associated mortality rate of 50 - 100% (Boutati & Anaissie, 1997; Dignani & Anaissie, 2004; Girmenia et al., 2000; Jensen et al. 2004; Musa et al., 2000; Nucci & Anaissie, 2007; O'Donnell et al., 2008), and have appeared in some tertiary cancer centres as the second most common mould pathogen after Aspergillus (Boutati & Anaissie, 1997; Walsh & Groll, 1999). Regardless of immunocompetency, Fusarium species can cause localised nail infections (onychomycosis) (Arrese et al., 1996), bone and joint infections (Koehler et al., 2014), infections of burn wounds (Latenser, 2003), skin infections (Bodey et al., 2002; Gupta et al., 2000; Gurusidappa & Mamatha, 2011; Nucci & Anaissie, 2002), and are the most frequent cause of fungal keratitis (Jurkunas et al., 2009), leading to progressive corneal destruction and endophthalmitis, with loss of vision or even loss of the affected eye (Dursun et al., 2003; Edelstein et al., 2012).

A recent outbreak of fungal keratitis in the USA, Singapore and Hong Kong was associated with contact lens solution contaminated with multiple strains of *Fusarium* and which led to a visual loss in many patients and the need for corneal transplantation (Chang *et al.*, 2006). While such outbreaks are rare, disseminated *Fusarium* infections and keratomycosis have increased in frequency over the past decade (Koehler *et al.*, 2014) and an increasing body of evidence suggests that the main environmental sources of human pathogenic *Fusarium* species are contaminated water systems (Adams *et al.*, 2013; Anaissie *et al.*, 2001; Anaissie *et al.*, 2002; Doggett, 2000; Mehl & Epstein, 2008).

# 4.1.2 Environmental Sources of Human Pathogenic *Fusarium* Species

Increasing incidences of nosocomial fungal infections caused by *Candida, Aspergillus, Mucor, Rhizopus, Fusarium, Acremonium, Alternaria, Bipolaris* and *Curvularia* species have been reported (Fridkin & Jarvis, 1996; Scheel *et al.,* 2013), necessitating improved identification and monitoring of hospitals for potentially infectious propagules.

As with many fungal pathogens, *Fusarium* species have adapted to survive in a wide range of ecosystems, with the dispersal of spores into terrestrial and aquatic habitats (Short *et al.*, 2011) through air, soil, wind, rain, river water and sewage (Defra, 2011). Additionally, a number of studies have recovered pathogenic *Fusarium* species from plumbing fixtures and it is hypothesised that microbial biofilms on fixtures may serve as important reservoirs of infectious *Fusarium* propagules in hospitals and domestic environments (Anaissie *et al.*, 2001; Mehl & Epstein, 2008; Scheel *et al.*, 2013; Short *et al.*, 2011; Zhang *et al.*, 2006). The idea of water-borne infections has been suggested for other

opportunistic fungal pathogens such as *Aspergillus* (Anaissie *et al.,* 2002; Gangneux *et al.,* 2002), *Cladosporium* (Mesquita-Rocha *et al.,* 2013), *Exophiala* (Marcio Nucci *et al.,* 2002), *Candida* and Penicillium (Arvanitidou *et al.,* 1999).

Tracking environmental sources of pathogenic fungi is critical to the prevention and control of outbreaks of hospital infections (Anaissie et al., 2001). A number of pathogenic Fusarium species have been recovered from naturally-infested water samples, including F. anthophilum, F. acuminatum, F. chlamydosporum, F. culmorum, F. equiseti, F. verticillioides, F. oxysporum, F. dimerum, F. proliferatum, F. solani, F. sambucinum and F. sporotrichioides (Anaissie et al., 2001; Palmero et al., 2009; Sautour et al., 2012). However, the most frequent human pathogenic species recovered from water tanks, sink drains, shower heads and plumbing systems in hospitals and domestic residences belong to the FSSC, FOSC and FDSC (Anaissie et al., 2001; Arvanitidou et al., 1999; Hageskal et al., 2006; Mehl & Epstein, 2007; O'Donnell et al., 2007, 2009, 2010; Sautour et al., 2012; Schroers et al., 2009; Short et al., 2011; Steinberg et al., 2015; Zhang et al., 2006). Immuno-compromised individuals exposed to these water-borne species complexes are at increased risk of disseminated fusariosis (Anaissie et al., 2003; Carneiro et al., 2011; Garnica & Nucci, 2013; Nucci & Anaissie, 2007; O'Donnell et al., 2004).

#### 4.1.3 Fusarium Biofilms

*Fusarium* species complexes can form thick biofilms in plumbing systems in which the fungal spores and hyphae are proliferate and enmeshed in an extracellular matrix allowing adhesion to surfaces (Pierce *et al.,* 2008). The

formation of biofilms is thought to contribute to Fusarium antifungal resistance and pathogenicity (Mukherjee et al., 2012). Fungal spore adhesion to living cells or surfaces is a crucial step to the establishment of biofilms and the development infections (Ramage et al., 2009). Fusarium spores adhere to surfaces through interaction with an extracellular fibrillar matrix located on the outer layer of the spore cell wall. The process of adhesion starts within few minutes and construction a biofilm is completed within a few hours (Kwon & Epstein, 1997; Kwon & Epstein, 1993; Pan et al., 2011). The extracellular matrix typically consists of glycoprotein with mannose residues that act as an adhesive for spore attachment (Gauthier & Keller, 2013; Kwon & Epstein, 1997). Involvement of extracellular matrices in adhesion of other pathogenic fungi has also been reported for Aspergillus (Wasylnka & Moore, 2000; Yang et al., 2000), Penicillium (Srinoulprasert et al., 2009), Candida (Tournu & Van Dijck, 2011) and Rhizopus (Bouchara et al., 1996). At present, little is known about Fusarium biofilm formation and its role in survival and pathogenicity of the fungus (Peigian et al., 2014).

#### 4.1.4 Objective of Chapter 4

In Chapter 2 of this thesis, I described the development and characterization of the *Fusarium*-specific mAb, ED7, that binds to an abundant extracellular glycoprotein antigen present in a fibrillar matrix surrounding the spores and hyphae of *F. solani*. Furthermore, I showed that the antibody was able to agglutinate spores of *F. solani* and other pathogenic species. In this Chapter, I set out to determine whether mAb ED7 could be used to track the fungus in environmental samples by detecting the water-soluble diagnostic antigen in

swabs of communal and hospital sink drain biofilms. By using the mAb in an ELISA, I show that it can differentiate *Fusarium* species from other human pathogenic yeasts and moulds present in mixed fungal communities in sink drain biofilms. In doing so, I show that the ELISA represents a simple method for specific detection of *Fusarium* species in environmental reservoirs and for identifying water systems contaminated with the fungus.

The work described in this chapter and accompanying work in Chapter 2 forms the basis of a paper published in 2016 in the journal *Environmental Microbiology* (Al-Maqtoofi, M. and Thornton, C.R. [2016] Detection of human pathogenic *Fusarium* species in hospital and communal sink biofilms by using a highly specific mAb. *Environmental Microbiology*, in press. DOI:10.1111/1462-2920.13233) and which is presented at the rear of this thesis.

#### 4.2 Materials and Methods

#### 4.2.1 Study Location

A total of 65 drain and water samples were collected between March and December 2014 from communal sinks located on the University of Exeter Streatham Campus (Exeter, Devon, UK) and from sinks located at the Royal Devon & Exeter tertiary care hospital (Exeter, Devon, UK). At the start of the study, 33 sink drain samples from six locations on the University campus were collected. An additional 32 samples were then collected from five areas of the hospital, namely the Intensive care unit (ICU), Intensive Therapy Unit (ITU), Haematology Unit, Ophthalmology Unit and Oncology unit. Permission for sink sampling at the Royal Devon and Exeter Hospital was granted by the Director of Infection Prevention and Control.

#### 4.2.2 Collection of Biofilm Swabs and Water Samples

Sink drain biofilms were collected using sterile 15-cm cotton-tipped applicators (Technical Service Consultants Ltd., UK) as illustrated in **Figure 4.1** and **Figure 4.2**. The cotton tips were wetted with sterile PBS buffer, inserted into the drain pipes through the sink strainers and used to scour the interior surface of drain pipes for approximately 10 sec. Applicators with visible detritus were immersed into 1.5 ml microcentrifuge tubes containing 1 ml of sterile PBS buffer to dislodge biofilm debris (**Figure 4.1 A to C**). For sink water samples, 1 ml of tap water was collected in sterile microcentrifuge tubes. Sealed tubes were immediately transferred to the laboratory for processing by mycological culture and ELISA. Samples were vortexed vigorously for 1 min (**Figure 4.1 P to G**), centrifuged at 14,462 *g* for 10 min and supernatants (**Figure 4.1 F to G**)

transferred to clean tubes prior and stored at – 20 °C before processing by ELISA. For mycological culture pelleted biofilm debris (**Figure 4.1 H**) were re-suspended in 250 µl sterile PBS buffer, homogenized by vortex, and 200 µl of suspension spread on the surface of PDA containing 0.1 mg/ml of the broad-spectrum antibiotic Rifampicin (Cat. No. 195490, MB Biomedicals LLC, Germany) using a sterile L-shape spreader. The culture plates were incubated at 26 °C, fungal colonies were separated on the basis of gross morphological characteristics (**Figure 4.1 I**) and were sub-cultured on PDA until axenic cultures were generated (**Figure 4.1 J**). A reference code was allocated to each of the 225 strains recovered, and isolates were maintained as PDA slopes at room temperature before identification by ITS sequencing and TEF-1 $\alpha$  polymerase chain reaction.



**Figure 4.1.** Biofilm sampling protocol and preparation of axenic cultures of recovered fungi. (**A** - **C**) Recovery of biofilms from sink drain using a cotton-tipped swab and immersion of biofilm-coated tip in PBS. (**D**) Vigorous vortexing of biofilm debris, (**E**) pelleted debris and (**F**) supernatant containing soluble antigens following centrifugation to test by (**G**) ELISA using mAb ED7 and (**H**) debris culturing on PDA supplemented with Rifampicin. (**I**) Typical mycological culture is showing different morphologies of culturable fungi on mixed culture plates. (**J**) Fungi were separated on the basis of gross morphologies and were sub-cultured until axenic cultures were obtained.



**Figure 4.2.** Schematic diagram showing diagnostic work-flow for identification of *Fusarium* species and unrelated yeasts and moulds recovered from sink drain biofilms.

# 4.2.3 Immunodetection of *Fusarium* Species in Sink Swabs and Mixed and Axenic Cultures by ELISA

The ELISA described in Chapter 2 was used for detection of the ED7 diagnostic antigen in swab samples (**Table 4.1** and **Table 4.2**; Swab-ELISA) and mixed cultures and axenic cultures (**Table 4.1** and **Table 4.2**; Mixed culture-ELISA and Axenic culture-ELISA, respectively). Swab samples stored at -20°C were thawed and 50 µl samples transferred to the wells of microtitre plates for overnight antigen immobilization and assay by ED7 ELISA as described. Crude antigen extracts were prepared as surface washings from mixed cultures and axenic cultures and, following overnight antigen immobilization of 50 µl samples to the wells of microtitre plates.

#### 4.2.4 Fungal DNA Extraction

A rapid method for fungal DNA extraction was developed from the protocol used by Wand and co-workers (Wang *et al.*, 1993). For a collection of fungal biomass, axenic PDA slope cultures were flooded with 3 ml of sterile MQ-H<sub>2</sub>O and the surfaces stroked using sterile pipette tips. The washings containing spores and hyphal fragments were transferred to 1.5 ml micro-centrifuge tubes and tissues were pelleted by centrifugation at 14,462 *g* for 5 min. The supernatants were discarded, and 50 – 100 mg of biomass were transferred to clean microcentrifuge tubes to which were added 500 µl of 350 mM NaOH. The mixtures were vortexed for 30 sec, and 10 µl of suspension were diluted in 490 µl of 100 mM Tris-HCl, pH 8.0. All steps were performed at room temperature and the mixtures were stored at – 20°C before use.

# 4.2.4.1 Identification of Fungi by Analysis of the ITS Regions of the rRNA-encoding Gene Unit

Fungi were identified by sequencing of the ITS1-5.8S-ITS2 region of the rRNAencoding gene unit (White *et al.*, 1990) according to procedures described elsewhere (Thornton *et al.*, 2002), using the primers ITS1ext (5'-GTAACAAGGT TTCCGTAGGTG-3') and ITS4 ext (5'TTCTTTTCCTCCGCTTATTGATATGC-3'). PCR mixtures contained the following components: 1  $\mu$ I DNA template, 12.5  $\mu$ I of GoTaq® G2 Green Master Mix DNA polymerase (Promega, MF7112), 9.5  $\mu$ I of nuclease free water (Promega) and 1  $\mu$ I of each at 20 picomoles (pmoI). The PCR cycling parameters (**Figure 4.3**) were: an initial denaturation step for 5 min at 95°C; 35 cycles of 30 sec at 94°C (denaturation), 30 sec at the 55°C (annealing), 1.5 min at 72°C (extension), followed by a final 10 min extension step at 72°C (Thornton *et al.*, 2002). Species identity was predicted based on >95% sequence identity (E-value = 0.0) (Altschul *et al.*, 1997) of the ITS1-5.8S-ITS2 region of recovered species to species recorded in GenBank.



Figure 4.3. PCR cycling parameters for ITS region amplification.

#### **4.2.4.2 Nucleotide Sequence Accession Numbers**

Newly determined ITS sequences (**Appendix 3**) were submitted to GenBank and the ITS accession numbers KT876496 to KT876723 were obtained. Species designations of recovered fungi are shown in **Table 4.1**.

# 4.2.4.3 Identification of *Fusarium* Species Complexes by Using Translation Elongation Factor-1α PCR

*Fusarium* species were further identified to species complex level by using the forward primer tef-1 (5'-ATGGGTAAGGA(A/G)GACAAGAC-3') and reverse primer tef-2 (5'-GGA(G/A)GTACCAGT(G/C)ATCATGTT-3'), which amplify an ~700 bp region of TEF-1 $\alpha$ , the single-locus identification tool in *Fusarium* (Geiser *et al.*, 2004). PCR reactions were carried out in a total volume of 25 µl consisting of 1 µl DNA at a concentration of 30 - 75 ng µl<sup>-1</sup>, 12.5 µl of GoTaq® Green Master Mix DNA polymerase (Promega, MF7112), 9.5 µl of nuclease free water (Promega) and 1 µl of each primer at 20 pmol. The following cycling parameters (**Figure 4.4**) were used: an initial denaturation step at 95°C for 8 min; 35 cycles of 15 sec at 95°C (denaturation); 20 sec at 54°C (annealing), 1 min at 72°C (extension) followed by a final 5 min extension step at 72°C. Phylogenetic sub-groups of *Fusarium* species (**Table 4.3**) were determined by interrogation of the FUSARIUM-ID v. 1.0 database (isolate.fusariumdb.org) (O'Donnell *et al.*, 2010), with the newly acquired TEF-1 $\alpha$  sequences (**Appendix 4**).



Figure 4.4. PCR cycling parameters for TEF gene amplification.

#### 4.2.5 Phylogenetic Analysis

A total of 225 ITS sequences were compared with those deposited in the National Center for Biotechnology Information (NCBI) databases by using NCBI BLAST® (https://blast.ncbi.nlm.nih.gov). A combination of software were utilized for basic editing and analysis to establish the phylogeny tree (**Appendix 2**) including SeaView Version 4.5.4 (http://doua.prabi.fr/software/seaview) (Manolo Gouy, Laboratoire de Biométrie et Biologie Evolutive CNRS/ Université de Lyon "Licensed under the GNU General Public Licence."), FigTree Version 1.4.2 (http://tree.bio.ed.ac.uk/software/figtree/) (Andrew Rambaut Institute of Evolutionary Biology, University of Edinburgh), REFGENE bioinformatics tool (http://richardslab.exeter.ac.uk/refgen.html) and TREENAMER bioinformatics tool(http://richardslab.exeter.ac.uk/treenamer.html) as published by (Leonard *et al.*, 2009).

ITS sequences were blasted in NCBI, and at least 8 of the closest species based on high identity (Ident) percentage were selected and downloaded in FASTA format and saved as (Plain.txt) file by Microsoft word. The accession

number for NCBI isolates was extracted by loading the last file on REFGENE website, and data were saved as a (\*.csv) file and text file. A master file was established by adding ITSs and NCBI (accession numbers) DNA sequences data within one file by word office and finally saved as the (plain.txt) file format. For DNA sequences alignment, Master file was uploaded on MAFFT website (http://mafft.cbrc.jp/alignment/server/) (Katoh & Standley, 2013) and aligned DNA sequences were saved as FASTA format file on word Microsoft Office and then as a (plain.txt) format. Next, for extra basic edition and construction of phylogenetic trees the Master (plain.txt) files were exhibited by SeaView software, followed by serial of process to select one of the closest alignment to each ITS sequence and built pre-final phylogeny tree (PhyML) files and then were saved with (\*.mase) extension. Last files were displayed by FigTree programme and saved.

Following, NCBI isolate names were re-extracted from accession numbers to identify ITS data by TREENAMER website through uploading two files were generated previously (\*.csv) file and (PhyML) file as a result, Newick file saved on word Microsoft office and converted to (plain.txt) to be displayed on FigTree. For cosmetic editing of phylogeny tree, Inkscape v 0.91 software (https://inkscape.org/en/download/) (Free Software Foundation, Inc., 59 Temple Place, Suite 330, Boston, MA 02111-1307 USA) was used. ITS sequence did not match any of NCBI sequence was considered novel species.

#### 4.3 Results

### 4.3.1 Immunodetection of *Fusarium* Species In Sink Swabs

Monoclonal antibody ED7 was highly specific for the three human pathogenic species of Fusarium, F. solani, F. oxysporum and F. dimerum, which were culturable from 75% of the sink swabs (Table 4.1 and Table 4.2). ELISA tests of the saline sink swabs showed that 52% contained detectable levels of Fusarium antigen (Table 4.1 and Table 4.2), with ELISA absorbance values in the range  $\geq 0.100$  (the threshold value for antigen detection) and up to 1.500. In four hospital samples (samples S47, S48 and S49 from ophthalmology and sample S64 from oncology) Fusarium strains could not be recovered for identification by ITS sequencing despite detection of the diagnostic antigen in swab samples with absorbance values of 0.264, 0.530, 0.187 and 0.193 respectively (Table 4.1). This was likely due to the Fusarium isolates being outgrown in the mixed culture plates by faster growing or more abundant unrelated fungi. Importantly, ED7 was shown not to cross-react with unrelated fungi (axenic culture absorbance values of  $\leq 0.100$  in all cases) including the human pathogenic yeast or yeast-like fungi Candida, Exophiala, Meyerozyma, Rhodotorula, Trichosporon, the human pathogenic hyaline or dematiaceous moulds Aspergillus, Phialophora, Phoma, Trichoderma, and the human pathogenic mucormycete Mucor (Table 4.1). The remaining 93% of samples positive for Fusarium antigen, either at the swab stage or following periods of biological amplification in mixed or axenic cultures (Table 4.2), yielded strains of the three Fusarium species. In addition to drain swabs, water samples were collected from the taps of sinks in the hospital haematology and oncology units and the main water tanks feeding the ophthalmology unit. The ED7 diagnostic antigen could not be detected in any of the water samples directly. However, the oncology samples W57 and W60 contained *Fusarium* strains that belonged to FDSC ET-gr. and were detectable by ELISA at the mixed culture stage (**Table 4.3**). The sink biofilms corresponding to these water samples were also positive at the swab ELISA stage (**Table 4.1**).

## 4.3.2 Identification of Fungi by Analysis of the ITS Regions of the rRNA-Encoding Gene Unit and by Translation Elongation Factor-1 $\alpha$ PCR

There was 100% agreement between *Fusarium* genus identification by ELISA and species identification by ITS sequencing (**Table 4.1**). The species of *F. solani* and *F. oxysporum* recovered from sink swabs were subsequently shown by TEF-1 $\alpha$  PCR (**Table 4.3**) to belong to FSSC 1-a, 1-c, 2-a, 2-v, 5-d, 5-k, 9-a, 15-a, 20-d and FOSC 16, 33, 99, 111, 126, 134, 183 (**Table 4.3**). All of the recovered *F. dimerum* isolates belonged to the FDSC ET-gr (**Table 4.3**). ITS analysis of axenic cultures (**Table 4.1**) showed that a number of sink samples (e.g. S2, S6, S17, S19, S21, S24, S30, S38) contained mixtures of *Fusarium* species, while ITS and TEF-PCR analysis (**Table 4.1** and **Table 4.3**) showed that others contained mixtures of species complexes of the same species (e.g. S8, S9, S25, S28). Only two of the tap samples (oncology W57 and W60) contained *Fusarium* strains which were shown to belong to FDSC ET-gr.

### 4.3.3 Frequencies and Distributions of *Fusarium* Species Complexes

By combining the ITS and TEF-PCR data, the dominant species complex recovered from the University sink drain biofilms was shown to be FOSC (47.6%), followed by FSSC (11.2%) and then FDSC (7.4%) (**Figure 4.5 A**). At the RD&E hospital, FDSC (27.1%) was found the most frequent grouping, followed by FSSC (9.3%) and then by FOSC (3.3%) (**Figure 4.5 A**). Different species complexes dominated in the different hospital units tested (**Figure 4.5 B**).



**Figure 4.5.** Frequency of *F.* species complex recovered from sink drain biofilms based on ITS and TEF-PCR identification. (**A**) depends on collection area and (**B**) depends on RD&E hospital units. The total number of samples is 225. FOSC, *F. oxysporum* species complex; FDSC, *F. dimerum* species complex; FSSC, *F. solani* species complex.

**Table 4. 1.** Locations and identities of sink swabs and water samples andresults of ELISA tests and fungal identification based on ITS sequencing. TheITS sequences corresponding to each isolate are shown in Appendix 3.

Sink ID	Location (Source)ª	Swab ELISA abs (450nm) <sup>b</sup>	Mixed culture ELISA abs (450nm) <sup>b</sup>	Isolate No.	Axenic culture ELISA abs (450nm) <sup>b</sup>	Identification based on ITS sequencing <sup>c</sup>	GenBank Accession No.
A1	University (S1)	0.0763	0.0575	A1-1	1.3736	Fusarium oxysporum	KT876668
	University (S1)			A1-2	0.7646	Fusarium oxysporum	KT876662
	University (S1)			A1-3	0.0196	Penicillium crustosum	KT876719
	University (S1)			A1-4	0.0139	Penicillium expansum	KT876718
A2	University (S2)	0.5472	0.0045	A2-1	1.5723	Fusarium solani	KT876635
	University (S2)			A2-3	0.6554	Fusarium oxysporum	KT876690
	University (S2)			A2-5	1.1312	Fusarium solani	KT876631
A3	University (S3)	0.0053	0.0077	A3-1	0.0082	Trichosporon domesticum	KT876717
	University (S3)			A3-2	0.0162	Cadophora fastigiata	KT876615
	University (S3)			A3-3	0.0014	Cyphellophora oxyspora	KT876613
	University (S3)			A3-4	0.0093	Penicillium crustosum	KT876714
A4	University (S4)	0.0297	0.0049	A4-1	0.0105	Phoma herbarum	KT876697
	University (S4)			A4-2	0.0079	Penicillium echinulatum	KT876710
	University (S4)			A4-3	0.0029	Cytobasidium slooffiae	KT876704
	University (S4)			A4-6	0.0060	Trichoderma asperellum	KT876620
A5	University (S5)	0.0206	0.0039	A5-1	1.1815	Fusarium oxysporum	KT876692
	University (S5)			A5-2	0.0034	Penicillium crustosum	KT876715
	University (S5)			A5-5	0.0088	Aspergillus niger	KT876702
	University (S5)			A5-6	1.0630	Fusarium oxysporum	KT876667
	University (S5)			A5-7	0.0037	Rhodotorula mucilaginosa	KT876700
	University (S5)			A5-8	0.0088	Cyphellophora oxyspora	KT876614
A6	University (S6)	0.0251	0.0412	A6-1	1.1130	Fusarium oxysporum	KT876648
	University (S6)			A6-2	0.9410	Fusarium oxysporum	KT876678
	University (S6)			A6-3	0.6377	Fusarium oxysporum	KT876688
	University (S6)			A6-4	1.0020	Fusarium solani	KT876640
A7	University (S7)	0.1716	0.0082	A7-1	0.0098	Exophiala pisciphila	KT876618
	University (S7)			A7-2	0.0096	Penicillium brevicompactum	KT876695
	University (S7)			A7-3	1.0556	Fusarium oxysporum	KT876684
	University (S7)			A7-4	1.0077	Fusarium oxysporum	KT876671
A8	University (S8)	0.0431	0.0008	A8-1	1.1045	Fusarium oxysporum	KT876672
	University (S8)			A8-2	0.9707	Fusarium oxysporum	KT876654
	University (S8)			A8-3	0.0091	Trichoderma atroviride	KT876622
-----	------------------	--------	--------	--------	--------	------------------------------	----------
A9	University (S9)	0.3806	0.0052	A9-1	0.9087	Fusarium solani	KT876639
	University (S9)			A9-2	0.8849	Fusarium solani	KT876638
	University (S9)			A9-3	0.9004	Fusarium solani	KT876632
	University (S9)			A9-4	0.8093	Fusarium solani	KT876636
A10	University (S10)	0.0034	0.0028	A10-1	0.0188	Rhodotorula slooffiae	KT876705
	University (S10)			A10-2	0.0020	Exophiala pisciphila	KT876616
B1	University (S11)	0.0231	0.0005	B1-1	0.6064	Fusarium dimerum	KT876625
	University (S11)			B1-6	0.8138	Fusarium dimerum	KT876628
B2	University (S12)	0.0200	0.0020	B2-1	0.5678	Fusarium dimerum	KT876626
	University (S12)			B2-5	0.4827	Fusarium dimerum	KT876624
B3	University (S13)	0.0091	0.0023	B3-4	0.0026	Phoma herbarum	KT876696
B4	University (S14)	0.0163	0.0008	B4-1	0.6992	Fusarium dimerum	KT876627
B5	University (S15)	0.0132	0.0003	B5-1	0.8008	Fusarium oxysporum	KT876674
	University (S15)			B5-2	0.0048	Mucor circinelloides	KT876701
	University (S15)			B5-3	0.8851	Fusarium oxysporum	KT876677
B6	University (S16)	0.0229	0.0002	B6-1	0.8193	Fusarium oxysporum	KT876676
	University (S16)			B6-2	0.7582	Fusarium oxysporum	KT876661
B7	University (S17)	0.0395	0.0014	B7-1	0.8201	Fusarium oxysporum	KT876675
	University (S17)			B7-6	0.7758	Fusarium dimerum	KT876623
B8	University (S18)	0.0133	0.0011	B8-1	0.7347	Fusarium solani	KT876637
	University (S18)			B8-7	0.0095	Rhodosporidium babjevae	KT876706
B9	University (S19)	0.0212	0.0048	B9-1	0.0051	Meyerozyma guilliermondii	KT876707
	University (S19)			B9-2	0.8104	Fusarium oxysporum	KT876657
	University (S19)			B9-3	0.6302	Fusarium solani	KT876634
	University (S19)			B9-5	0.0017	Penicillium crustosum	KT876720
B10	University (S20)	0.5467	0.0394	B10-1	0.7467	Fusarium oxysporum	KT876680
	University (S20)			B10-2	0.7667	Fusarium oxysporum	KT876659
	University (S20)			B10-6	0.0071	Candida parapsilosis	KT876703
	University (S20)			B10-7	0.0251	Meyerozyma guilliermondii	KT876711
	University (S20)			B10-9	0.0031	Cystobasidium slooffiae	KT876712
	University (S20)			B10-12	0.0251	Trichosporon asteroides	KT876713
C1	University (S21)	0.0083	0.0269	C1-1	0.0044	Clavispora lusitaniae	KT876708
	University (S21)			C1-3	0.8875	Fusarium oxysporum	KT876682
	University (S21)			C1-4	0.8884	Fusarium dimerum	KT876629
	University (S21)			C1-7	0.0003	Exophiala pisciphila	KT876617
C2	University (S22)	0.2977	0.0047	C2-1	0.9443	Fusarium oxysporum	KT876658
	University (S22)			C2-4	0.9825	Fusarium oxysporum	KT876694
	University (S22)			C2-7	0.8677	Fusarium oxysporum	KT876687
C3	University (S23)	0.0808	0.0116	C3-1	0.9853	Fusarium oxysporum	KT876683
	University (S23)			C3-2	1.0160	Fusarium oxysporum	KT876693
	University (S23)			C3-4	0.7485	Fusarium oxysporum	KT876644
C4	University (S24)	0.1113	0.0202	C4-1	0.8930	Fusarium oxysporum	KT876670

	University (S24)			C4-2	0.0028	Candida intermedia	KT876709
	University (S24)			C4-5	0.9008	Fusarium dimerum	KT876630
C5	University (S25)	0.5741	0.0097	C5-1	0.9874	Fusarium oxysporum	KT876652
	University (S25)			C5-2	1.0996	Fusarium oxysporum	KT876656
	University (S25)			C5-3	1.1236	Fusarium oxysporum	KT876649
	University (S25)			C5-4	1.0355	Fusarium oxysporum	KT876669
	University (S25)			C5-5	1.0672	Fusarium oxysporum	KT876660
C6	University (S26)	0.0603	0.0348	C6-1	1.0135	Fusarium oxysporum	KT876665
	University (S26)			C6-2	0.9362	Fusarium oxysporum	KT876681
	University (S26)			C6-3	0.8898	Fusarium oxysporum	KT876673
	University (S26)			C6-4	1.0577	Fusarium oxysporum	KT876686
	University (S26)			C6-5	0.9445	Fusarium oxysporum	KT876646
C7	University (S27)	0.1279	0.0113	C7-1	0.9724	Fusarium oxysporum	KT876666
C8	University (S28)	0.0607	0.0035	C8-1	0.8694	Fusarium oxysporum	KT876685
	University (S28)			C8-2	0.9599	Fusarium oxysporum	KT876655
	University (S28)			C8-3	0.0031	Penicillium expansum	KT876716
	University (S28)			C8-4	0.0049	Phoma herbarum	KT876698
	University (S28)			C8-6	0.9003	Fusarium oxysporum	KT876679
C9	University (S29)	0.0310	0.0001	C9-1	1.0488	Fusarium oxysporum	KT876651
	University (S29)			C9-2	0.9254	Fusarium oxysporum	KT876645
	University (S29)			C9-3	0.9711	Fusarium oxysporum	KT876664
	University (S29)			C9-4	1.035	Fusarium oxysporum	KT876647
	University (S29)			C9-5	0.9604	Fusarium oxysporum	KT876663
C10	University (S30)	0.1002	0.0333	C10-1	0.9254	Fusarium oxysporum	KT876689
	University (S30)			C10-2	1.0198	Fusarium solani	KT876642
	University (S30)			C10-4	0.9007	Fusarium solani	KT876641
	University (S30)			C10-7	1.0697	Fusarium solani	KT876643
CRT-1	University (S31)	0.6175	0.1129	CRT1-1	0.4639	Fusarium oxysporum	KT876691
	University (S31)			CRT1-2	0.9086	Fusarium oxysporum	KT876650
	University (S31)			CRT1-3	0.7503	Fusarium oxysporum	KT876652
CRT-2	University (S32)	0.0303	0.0021	CRT2-1	0.0040	Trichoderma asperellum	KT876619
	University (S32)			CRT2-2	0.0417	Trichoderma asperellum	KT876621
CRT-3	University (S33)	0.0663	0.0028	CRT3-1	0.0256	Phoma herbarum	KT876699
R1	ICU (S34)	0.0285	0.3620	R1-1	1.5057	Fusarium solani	KT876550
	ICU (S34)			R1-2	1.5154	Fusarium solani	KT876551
	ICU (S34)			R1-3	1.5555	Fusarium solani	KT876549
R2	ICU (S35)	0.0071	0.0147	R2-4	0.0096	Clonostachys rosea	KT876552
	ICU (S35)			R2-5	0.0018	Clonostachys rosea	KT876553
	ICU (S35)			R2-6	0.0035	Clonostachys rosea	KT876554
R3	ICU (S36)	0.0391	0.045	R3-1	0.0006	l richoderma asperellum	KT876548
R5	ITU (S37)	0.7291	0.7724	R5-1	1.5606	Fusarium dimerum	KT876561
	ITU (S37)			R5-2	1.3481	Fusarium dimerum	KT876565
	ITU (S37)			R5-3	1.4990	Fusarium dimerum	KT876567
R6	ITU (S38)	1.2086	0.3691	R6-1	1.3388	Fusarium dimerum	KT876572
	ITU (S38)			R6-2	1.4734	Fusarium dimerum	KT876563
	ITU (S38)			R6-3	1.4312	Fusarium dimerum	KT876562
	ITU (S38)			R6-9	1.2648	Fusarium oxysporum	KT876557

R7	ITU (S39)	0.1121	0.8186	R7-1	1.3266	Fusarium dimerum	KT876570
	ITU (S39)			R7-2	1.2352	Fusarium dimerum	KT876564
R8	ITU (S40)	1.0157	0.3612	R8-1	1.2399	Fusarium dimerum	KT876568
	ITU (S40)			R8-2	1.1552	Fusarium dimerum	KT876566
	ITU (S40)			R8-3	1.1856	Fusarium dimerum	KT876558
R9	ITU (S41)	0.0391	0.0477	R9-3	0.0113	Exophiala phaeomuriformis	KT876555
R10	ITU (S42)	0.0549	0.0097	R10-2	0.0072	Cadophora fastigiata	KT876556
	ITU (S42)			R10-6	0.0124	Coniochaeta fasciculata	KT876721
X2	ITU (S43)	0.0630	1.5751	X2-2	1.1492	Fusarium dimerum	KT876571
	ITU (S43)			X2-4	1.2505	Fusarium dimerum	KT876560
	ITU (S43)			X2-5	1.1397	Fusarium dimerum	KT876569
	ITU (S43)			X2-6	1.1716	Fusarium dimerum	KT876559
Х3	Ophthalmology Unit (S44)	1.0313	1.5035	X3-1	1.1353	Fusarium dimerum	KT876509
	Ophthalmology Unit (S44)			X3-2	0.0224	Candida parapsilosis	KT876498
	Ophthalmology Unit (S44)			X3-3	1.1856	Fusarium dimerum	KT876512
X4	Ophthalmology Unit (S45)	1.4582	1.4049	X4-1	1.1322	Fusarium dimerum	KT876511
	Ophthalmology Unit (S45)			X4-2	1.1523	Fusarium dimerum	KT876500
	Ophthalmology Unit (S45)			X4-3	0.0622	Candida parapsilosis	KT876508
	Ophthalmology Unit (S45)			X4-4	0.1245	Gloeotinia temulenta	KT876515
X5	Ophthalmology Unit (S46)	0.3325	1.4466	X5-2	1.0654	Fusarium dime rum	KT876510
	Ophthalmology Unit (S46)			X5-3	0.0599	Rhodotorula mucilaginosa	KT876501
	Ophthalmology Unit (S46)			X5-4	1.0862	Fusarium dimerum	KT876513
X6	Ophthalmology Unit (S47)	0.2640	1.3729	X6-1	0.0616	Candida paraphilia's	KT876499
	Ophthalmology Unit (S47)			X6-2	0.063	Engyodontium album	KT876522
	Ophthalmology Unit (S47)			X6-3	0.0603	Engyodontium album	KT876521
	Ophthalmology Unit (S47)			X6-4	0.0657	Exophiala phaeomuriformis	KT876504
X8	Ophthalmology Unit (S48)	0.5299	0.0223	X8-2	0.0118	Cladosporium macrocarpum	KT876506
	Ophthalmology Unit (S48)			X8-3	0.0985	Gloeotinia temulenta	KT876514
	Ophthalmology Unit (S48)			X8-4	0.0662	Engyodontium album	KT876523
X9	Ophthalmology Unit (S49)	0.1872	0.0061	X9-1	0.0686	Engyodontium album	KT876520
	Ophthalmology Unit (S49)			X9-2	0.0611	Candida parapsilosis	KT876496
	Ophthalmology Unit (S49)			X9-3	0.0641	Candida parapsilosis	KT876497
	Ophthalmology Unit (S49)			X9-4	0.0677	Exophiala dermatitidis	KT876503
	Ophthalmology Unit (S49)			X9-5	0.0705	Engyodontium album	KT876519

	Ophthalmology Unit (S49)			X9-7	0.0660	Exophiala pisciphila	KT876502
X10	Ophthalmology Unit (T1)	0.0132	0.0159	X10-1	0.0868	Cladosporium sphaerospermum	KT876507
	Ophthalmology Unit (T1)			X10-3	0.0130	Engyodontium album	KT876518
E1	Ophthalmology Unit (T2)	0.0117	0.0883	W1-1	0.0114	Paraconiothyrium fuckelii	KT876505
	Ophthalmology Unit (T2)			W1-2	0.0139	Engyodontium album	KT876517
	Ophthalmology Unit (T2)			W1-3	0.0108	Engyodontium album	KT876516
K1	Haematology Unit (S50)	0.2694	0.0093	K1-1	0.0172	Trichoderma asperellum	KT876534
K2	Haematology Unit (S51)	0.7466	1.1746	K2-1	0.0144	Trichoderma viride	KT876533
	Haematology Unit (S51)			K2-3	1.1385	Fusarium solani	KT876543
	Haematology Unit (S51)			K2-4	1.2487	Fusarium solani	KT876542
K6	Haematology Unit (S52)	1.0621	1.3090	K6-1	1.1544	Fusarium oxysporum	KT876541
	Haematology Unit (S52)			K6-4	0.0071	Candida parapsilosis	KT876524
K8	Haematology Unit (S53)	1.0120	1.2628	K8-1	1.2376	Fusarium solani	KT876722
	Haematology Unit (S53)			K8-2	1.2983	Fusarium solani	KT876723
	Haematology Unit (S53)			K8-6	0.0084	Cadophora fastigiata	KT876531
	Haematology Unit (S53)			K8-7	0.0051	Trichoderma asperellum	KT876535
K9	Haematology Unit (S54)	0.9843	1.2903	K9-1	0.0046	Candida parapsilosis	KT876525
	Haematology Unit (S54)			K9-2	0.0090	Rhodotorula dairenensis	KT876526
	Haematology Unit (S54)			K9-4	0.0073	Cadophora fastigiata	KT876532
	Haematology Unit (S54)			K9-5	1.1652	Fusarium solani	KT876547
	Haematology Unit (S54)			K9-6	1.0316	Fusarium solani	KT876545
K10	Haematology Unit (S55)	0.8638	1.0753	K10-1	1.0684	Fusarium solani	KT876546
	Haematology Unit (S55)			K10-2	1.0386	Fusarium solani	KT876544
	Haematology Unit (W50)	0.0082	0.0451	G1-2	0.0097	Exophiala pisciphila	KT876529
G2	Haematology Unit (W51)	0.0581	0.0553	G2-1	0.0104	Engyodontium album	KT876540
	Haematology Unit (W51)			G2-3	0.0062	Exophiala pisciphila	KT876530
G7	Haematology Unit (W52)	0.0125	0.0118	G6-2	0.0161	Exophiala castellanii	KT876528
G8	Haematology Unit (W53)	0.0075	0.0219	G8-1	0.0065	Engyodontium album	KT876538
G9	Haematology Unit (W54)	0.0002	0.0164	G9-2	0.0005	Gloeotinia temulenta	KT876537
G10	Haematology Unit (W55)	0.0021	0.0182	G10-1	0.0051	Engyodontium album	KT876539

H1	Oncology Unit (S56)	0.4822	1.2287	H1-1	0.9022	Fusarium dimerum	KT876595
	Oncology Unit (S56)			H1-3	0.0151	Pichia kudriavzevii	KT876578
H2	Oncology Unit (S57)	1.0579	1.1650	H2-1	0.9312	Fusarium dimerum	KT876590
	Oncology Unit (S57)			H2-5	0.0061	Magnusiomyces capitatus	KT876611
H3	Oncology Unit (S58)	1.0938	1.2091	H3-1	0.8909	Fusarium oxysporum	KT876584
	Oncology Unit (S58)			H3-4	0.0075	Candida palmioleophila	KT876573
	Oncology Unit (S58)			H3-5	0.0140	Rhodotorula glutinis	KT876598
H4	Oncology Unit (S59)	0.0253	1.0856	H4-1	0.8884	Fusarium dimerum	KT876596
	Oncology Unit (S59)			H4-3	0.0004	Magnusiomyces capitatus	KT876612
H5	Oncology Unit (S60)	1.0856	1.0193	H5-1	1.1148	Fusarium dimerum	KT876593
	Oncology Unit (S60)			H5-3	0.005	Candida tropicalis	KT876574
H6	Oncology Unit (S61)	0.5256	1.1898	H6-1	1.1238	Fusarium dimerum	KT876594
H7	Oncology Unit (S62)	1.0789	1.1588	H7-1	1.1513	Fusarium oxysporum	KT876583
	Oncology Unit (S62)			H7-3	0.0045	Candida tropicalis	KT876575
H8	Oncology Unit (S63)	0.0953	0.0152	H8-1	0.0063	Phoma herbarum	KT876580
	Oncology Unit (S63)			H8-3	0.0126	Candida albicans	KT876577
	Oncology Unit (S63)			H8-4	0.0088	Rhodotorula mucilaginosa	KT876599
H9	Oncology Unit (S64)	0.1926	0.0162	H9-1	0.0152	Exophiala dermatitidis	KT876581
	Oncology Unit (S64)			H9-2	0.0049	Candida orthopsilosis	KT876576
	Oncology Unit (S64)			H9-3	0.0109	Pichia kudriavzevii	KT876579
H10	Oncology Unit (S65)	0.4961	1.1005	H10-1	0.9606	Fusarium dimerum	KT876589
	Oncology Unit (S65)			H10-4	0.0163	Trametes ochracea	KT876608
P1	Oncology Unit (W56)	0.0030	0.0247	P1-2	0.0082	Exophiala dermatitidis	KT876582
	Oncology Unit (W56)			P1-3	0.0024	Trametes versicolor	KT876603
P2	Oncology Unit (W57)	0.0061	1.0891	P2-1	0.8451	Fusarium dimerum	KT876587
	Oncology Unit (W57)			P2-2	0.9429	Fusarium dimerum	KT876597
	Oncology Unit (W57)			P2-3	0.8627	Fusarium dimerum	KT876588
P3	Oncology Unit (W58)	0.0016	0.0202	P3-1	0.0177	Trametes ochracea	KT876607
P4	Oncology Unit (W59)	0.0035	0.0125	P4-1	0.0164	Beauveria bassiana	KT876586
	Oncology Unit (W59)			P4-2	0.0084	Gliomastix polychroma	KT876584

P5	(W60)	0.0025	1.1746	P5-1	0.8563	Fusarium dimerum	KT876591
	Oncology Unit (W60)			P5-2	0.8066	Fusarium dimerum	KT876592
	Oncology Unit (W60)			P5-3	0.0024	Piptoporus betulinus	KT876609
P7	Oncology Unit (W62)	0.0011	0.0417	P7-1	0.0097	Trametes versicolor	KT876605
P8	Oncology Unit (W63)	0.0044	0.0060	P8-1	0.0144	Trametes versicolor	KT876606
	Oncology Unit (W63)			P8-2	0.0106	Stereum gausapatum	KT876601
P9	Oncology Unit (W64)	0.0022	0.0163	P9-1	0.0101	Stereum gausapatum	KT876600
	Oncology Unit (W64)			P9-2	0.0068	Trametes versicolor	KT876604
	Oncology Unit (W64)			P9-3	0.0140	Stereum gausapatum	KT876602
P10	Oncology Unit (W65)	0.0051	0.0280	P10-1	0.0032	Phaeophlebiopsis peniophoroides	KT876610

**a.** S, sink; W, tap water from corresponding sink number; T, water sample from main tank.

**b.** Threshold absorbance value for detection in ELISA  $\geq$ 0.100. Shading indicates earliest point in sampling process at which antigen was detectable in ELISA tests with ED7.

**c.** *Fusarium* strains in bold further characterized by TEF-1 $\alpha$  PCR analysis (**Table 4.3** and **Appendix 4**).

Table 4. 2. Summary of ELISA tests and mycological culture of sink swabs.

Total no. sinks swabbed	No. swab samples yielding fungi after mycological culture (%) <sup>a</sup>	No. samples positive for <i>Fusarium</i> antigen at Swab- ELISA stage (%)	No. samples positive for <i>Fusarium</i> antigen by Mixed culture-ELISA stage (%)	No. samples positive for <i>Fusarium</i> antigen by Axenic culture- ELISA stage (%)	No. antigen- positive samples yielding <i>Fusarium</i> spp. after mycological culture (%)	No. antigen- positive samples not yielding <i>Fusarium</i> spp. after mycological culture (%)
65	65	34	37	54	50	4
05	(100%)	(52%)	(57%)	(83%)	(93%)	(7%)

**a.** *Fusarium* spp. and/or unrelated fungi.

**Table 4. 3.** Summary of species complex identities following TEF-1 $\alpha$  PCR analysis of *Fusarium* isolates recovered from sinks. The TEF-1 $\alpha$  gene sequences corresponding to each isolate are shown in **Appendix 4**.

Isolate	Location	TEF-1α ID			
No.					
A1-1	University	F. oxysporum species complex 33			
A1-2	University	F. oxysporum species complex 33			
A2-1	University	F. solani species complex 1-a			
A2-3	University	F. oxysporum species complex 33			
A2-5	University	F. solani species complex 1-a			
A5-1	University	F. oxysporum species complex 33			
A5-6	University	F. oxysporum species complex 33			
A6-1	University	F. oxysporum species complex 33			
A6-2	University	F. oxysporum species complex 33			
A6-3	University	F. oxysporum species complex 33			
A6-4	University	F. solani species complex 9-a			
A7-3	University	F. oxysporum species complex 183			
A7-4	University	F. oxysporum species complex 126			
A8-1	University	F. oxysporum species complex 33			
A8-2	University	F. oxysporum species complex 33			
A9-1	University	<i>F. solani</i> species complex 5-d			
A9-2	University	<i>F. solani</i> species complex 5-d			
A9-3	University	F. solani species complex 1-c			
A9-4	University	F. solani species complex 1-a			
B1-1	University	F. dimerum species complex ET-gr.			
B1-6	University	F. dimerum species complex ET-gr.			
B2-1	University	F. dimerum species complex ET-gr.			
B2-5	University	F. dimerum species complex ET-gr.			
B4-1	University	F. dimerum species complex ET-gr.			
B5-1	University	F. oxysporum species complex 16			
B5-3	University	F. oxysporum species complex 16			
B6-1	University	F. oxysporum species complex 16			
B6-2	University	F. oxysporum species complex 16			
B7-1	University	F. oxysporum species complex 16			
B7-6	University	F. dimerum species complex ET-gr.			

B8-1	University	F. solani species complex 15-a
B9-2	University	F. oxysporum species complex 99
B9-3	University	F. solani species complex 1-a
B10-1	University	F. oxysporum species complex 33
B10-2	University	F. oxysporum species complex 33
C1-3	University	F. oxysporum species complex 33
C1-4	University	F. dimerum species complex ET-gr.
C2-1	University	F. oxysporum species complex 33
C2-4	University	F. oxysporum species complex 33
C2-7	University	F. oxysporum species complex 33
C3-1	University	F. oxysporum species complex 134
C3-2	University	F. oxysporum species complex 134
C3-4	University	F. oxysporum species complex 134
C4-1	University	F. oxysporum species complex 33
C4-5	University	<i>F. dimerum</i> species complex ET-gr.
C5-1	University	F. oxysporum species complex 33
C5-2	University	F. oxysporum species complex 126
C5-3	University	F. oxysporum species complex 33
C5-4	University	F. oxysporum species complex 33
C5-5	University	F. oxysporum species complex 33
C6-1	University	F. oxysporum species complex 33
C6-2	University	F. oxysporum species complex 33
C6-3	University	F. oxysporum species complex 33
C6-4	University	F. oxysporum species complex 33
C6-5	University	F. oxysporum species complex 33
C7-1	University	F. oxysporum species complex 134
C8-1	University	F. oxysporum species complex 134
C8-2	University	F. oxysporum species complex 134
C8-6	University	F. oxysporum species complex 33
C9-1	University	F. oxysporum species complex 134
C9-2	University	F. oxysporum species complex 134
C9-3	University	F. oxysporum species complex 134
C9-4	University	F. oxysporum species complex 134
C9-5	University	F. oxysporum species complex 134
C10-1	University	F. oxysporum species complex 111
C10-2	University	<i>F. solani</i> species complex 2-v
C10-4	University	F. solani species complex 2-v

C10-7	University	<i>F. solani</i> species complex 2-v
CRT1-1	University	F. oxysporum species complex 33
CRT1-2	University	F. oxysporum species complex 33
CRT1-3	University	F. oxysporum species complex 33
R1-1	ICU	F. solani species complex 1-a
R1-2	ICU	F. solani species complex 1-a
R1-3	ICU	F. solani species complex 1-a
R5-1	ITU	F. dimerum species complex ET-gr.
R5-2	ITU	F. dimerum species complex ET-gr.
R5-3	ITU	F. dimerum species complex ET-gr.
R6-1	ITU	F. dimerum species complex ET-gr.
R6-2	ITU	F. dimerum species complex ET-gr.
R6-3	ITU	F. dimerum species complex ET-gr.
R6-9	ITU	F. solani species complex 20-d
R7-1	ITU	F. dimerum species complex ET-gr.
R7-2	ITU	F. dimerum species complex ET-gr.
R8-1	ITU	F. dimerum species complex ET-gr.
R8-2	ITU	F. dimerum species complex ET-gr.
R8-3	ITU	F. dimerum species complex ET-gr.
X2-2	ITU	F. dimerum species complex ET-gr.
X2-4	ITU	F. dimerum species complex ET-gr.
X2-5	ITU	F. dimerum species complex ET-gr.
X2-6	ITU	F. dimerum species complex ET-gr.
X3-1	Ophthalmology Unit	F. dimerum species complex ET-gr.
X3-3	Ophthalmology Unit	F. dimerum species complex ET-gr.
X4-1	Ophthalmology Unit	F. dimerum species complex ET-gr.
X4-2	Ophthalmology Unit	F. dimerum species complex ET-gr.
X5-2	Ophthalmology Unit	F. dimerum species complex ET-gr.
X5-4	Ophthalmology Unit	F. dimerum species complex ET-gr.
K2-3	Haematology Unit	F. solani species complex 5-k
K2-4	Haematology Unit	<i>F. solani</i> species complex 5-k
K6-1	Haematology Unit	F. oxysporum species complex 33
K8-1	Haematology Unit	<i>F. solani</i> species complex 5-k
K8-2	Haematology Unit	<i>F. solani</i> species complex 5-k
K9-5	Haematology Unit	F. solani species complex 2-a
K9-6	Haematology Unit	<i>F. solani</i> species complex 2-a
K10-1	Haematology Unit	<i>F. solani</i> species complex 2-a

Chapter 4

K10-2	Haematology Unit	<i>F. solani</i> species complex 2-a
H1-1	Oncology Unit	F. dimerum species complex ET-gr.
H2-1	Oncology Unit	F. dimerum species complex ET-gr.
H3-1	Oncology Unit	<i>F. oxysporum</i> species complex 33
H4-1	Oncology Unit	F. dimerum species complex ET-gr.
H5-1	Oncology Unit	F. dimerum species complex ET-gr.
H6-1	Oncology Unit	<i>F. dimerum</i> species complex ET-gr.
H7-1	Oncology Unit	F. oxysporum species complex 33
H10-1	Oncology Unit	<i>F. dimerum</i> species complex ET-gr.
P2-1	Oncology Unit	F. dimerum species complex ET-gr.
P2-2	Oncology Unit	F. dimerum species complex ET-gr.
P2-3	Oncology Unit	F. dimerum species complex ET-gr.
P5-1	Oncology Unit	F. dimerum species complex ET-gr.
P5-2	Oncology Unit	F. dimerum species complex ET-gr.

## 4.4. Discussion

The genus *Fusarium* comprises ubiquitous environmental moulds capable of infecting plants and humans (Zhang *et al.*, 2006). Unlike agriculture, where the most economically damaging pathogens are considered to be *F. graminearum* and *F. oxysporum* (Dean *et al.*, 2012), the species most commonly cited as human pathogens belong to the FSSC, responsible for 50% of reported infections in humans, followed by strains in the FOSC (Torres and Kontoyiannis, 2011). The FDSC is less frequently reported as causing human disease, but it is similarly capable of causing disseminated infections in immunocompromised patients (Bigley *et al.*, 2004; Schroers *et al.*, 2009).

While the natural habitats of plant pathogenic *Fusarium* strains are well characterized as soil and decaying plant material, habitats providing direct human exposure to infectious propagules are largely unexplored. The increasing frequency of opportunistic fungal infections in humans means that improved surveillance methods are needed to identify environmental reservoirs of pathogens to limit the exposure of vulnerable individuals to potentially infective propagules. For *Fusarium*, there is a growing body of evidence to suggest that domestic and municipal water systems are potential reservoirs of human pathogenic strains in the FSSC, FOSC and FDSC groups (Short *et al.*, 2011).

Accurate techniques that can be used to identify the fungus in environmental samples containing mixed populations of fungi are currently lacking and, while nucleic acid-based technologies have been developed for the differentiation of *Fusarium* from other human pathogenic species and to identify *Fusarium* 

species complexes, such techniques have typically been used in retrospective analysis of axenic cultures collected during human and environmental population studies (Bouchara *et al.*, 2009; Steinmann *et al.*, 2011; Lackner *et al.*, 2012). Furthermore, these studies have often employed *Fusarium*-selective medium that eliminate other fungi present in polymicrobial communities (Short *et al.*, 2011). While mAbs and antibody fragments have been developed for detecting and differentiating *Fusarium* species *in vitro* or *in planta* (Wong *et al.*, 1988; Arie *et al.*, 1991, 1995; Danks *et al.*, 1996; Hayashi *et al.*, 1998; Hu *et al.*, 2012, 2013), no attempts have been made to use mAbs to track human pathogenic strains in environmental samples. Jensen *et al.* (2011) recently reported the development of *Fusarium*-specific mAbs for immunohistochemical diagnosis of fusariosis. The IgM mAbs, which recognise 51 and 63 kDa antigens, reacted strongly with fungal elements in both experimentally infected animals and biopsy samples from patients with fusariosis sepsis and dissemination to the skin.

In this prospective study, we set out to determine whether human pathogenic species of *Fusarium* could be identified in sink drains directly by using crude antigen extracts of biofilms and detection using a genus-specific IgM mAb, ED7, that binds to an extracellular ~ 200kDa carbohydrate antigen present on the surface of spores and hyphae (**Chapter 2**). While the function of the antigen is currently unknown we were able, in ELISA tests, to detect its presence in 52% of swab samples and, following biological amplification of biofilms on a non-selective mycological medium, were able to identify additional biofilm samples containing pathogenic strains of *Fusarium*. This is the first time, to our knowledge, that the mAb-based detection method has been used to track

*Fusarium* in environmental samples. The mAb was able to differentiate *Fusarium* from a broad spectrum of unrelated fungi, including the human pathogens *Aspergillus* (Thornton and Wills, 2015), *Candida, Geotrichum, Rhodotorula* and *Trichosporon* (Davies and Thornton, 2014; Miceli *et al.*, 2011), *Cyphellophora* and *Phialophora* (Feng *et al.*, 2014), *Exophiala* (Zeng *et al.*, 2007), *Trichoderma* (Sandoval-Denis *et al.*, 2014), *Engyodontium* (Macêdo *et al.*, 2007; Thamke *et al.*, 2015) and *Mucor* (Petrikkos *et al.*, 2012), several of which have been reported previously to inhabit biofilms in water distribution systems (Dogget, 2000). The 100% accuracy of the ED7 ELISA, confirmed by using ITS sequencing and TEF PCR analysis of recovered isolates, demonstrates its robustness in detecting potentially infectious *Fusarium* species in polymicrobial communities. Importantly, ED7 reacted with all of the species complex strains isolated including the most common clinical pathotypes of *Fusarium*, FSSC 1-a, FOSC 33 and FDSC ET-gr (Schroers *et al.*, 2009; Short *et al.*, 2011).

While the ED7 ELISA was able to identify *Fusarium* to the level of genus only, the simplicity of the mAb-based approach to detection, even when combined with a standard mycological isolation procedure, means that a recognised environmental niche of this group of pathogenic fungi can be monitored readily. The widespread occurrence of human pathogenic *Fusarium* species in sinks of a tertiary care hospital and sinks of a heavily populated university campus, show that indoor plumbing-associated biofilms and water sources are an unseen source of *Fusarium* infectious propagules for nosocomial and community-acquired infections of vulnerable individuals, an observation consistent with previous studies (Annaisie *et al.*, 2011; Short *et al.*, 2011). While

no cases of fusariosis were reported during the course of this study, the close proximity of the patients to hospital sinks colonised with both pathogenic fusaria and with other opportunistic fungal pathogens is a serious concern given the known vulnerability of immunocompromised individuals to invasive fungal infections.

## Summary of Key Findings:

- The mAb ED7 is 100% accurate in detecting *Fusarium* species antigens by ELISA in mixed community of fungal biofilms with no cross-react with unrelated human pathogenic fungi or yeasts.
- 2. Three major human pathogenic *Fusarium* species belong to *F. solani*, *F. oxysporum* and *F. dimerum* were isolated at 52% out of a total number 225 of fungi recovered from sink swabs and water system samples that collected across a University campus and tertiary care hospital units.
- **3.** The ITS sequencing 100% validated identification of *Fusarium* genus by ELISA.
- **4.** The TEF-1α analysis data for identification of *Fusarium* at species complex level showed that FSSC 1-a, FOSC 33 and FDSC ET-gr are the most clinical frequent pathotypes recovered from swabs and water samples.
- 5. The dominant species complex recovered from the University sink drain biofilms related to FOSC (47.6%), followed by FSSC (11.2%) and then FDSC (7.4%). At the RD&E hospital, FDSC (27.1%) was found the most frequent grouping, followed by FSSC (9.3%) and then by FOSC (3.3%).

## Chapter 5. General Discussion

# 5.1 Epidemiology of fungal infections

Over the past decade, the incidence of disseminated infections caused by opportunistic fungal pathogens has increased in line with the ever expanding populations of at-risk patients including BMT and SOT recipients, AIDS patients and those receiving broad-spectrum antibiotics, high-dose corticosteroids and aggressive anti-cancer treatments (Badiee *et al.*, 2009; Crabol *et al.*, 2014; Slavin & Grist, 2013).

Aspergillus and Candida species are the most frequently cited opportunistic pathogens of immune impaired humans (Menzin et al., 2009; Nucci & Marr, 2005; Pagano et al., 2006; Pfaller et al., 2006) which, along with other moulds and yeasts, are responsible for high rates of mortality and morbidity in susceptible patient populations (Dictar et al., 2000; Menzin et al., 2009; Montagna et al., 2013). Indeed, Fusarium species are the second most common opportunistic fungi after Aspergillus, involved in superficial infections of the skin and eyes but also as invasive pathogens of the severely immunocompromised (Boutati & Anaissie, 1997; Nucci et al., 2004; van Diepeningen et al., 2015). The principle portal of entry of Fusarium infectious propagules is the respiratory tract through the inhalation of indoor or outdoor air laden with air-borne conidia, the skin, and the digestive system through ingestion of contaminated water or food (Araujo et al., 2010; Legrand et al., 1991; Lockhart et al., 2009; Nucci & Anaissie, 2007). Fusarium species cause a range of infections including dermatomycosis, keratitis, onychomycosis for both immunocompetent and impaired immune system individuals such neutropenic patients (Brasch & Köppl, 2009; Brasch & Shimanovich, 2012;

Chang *et al.*, 2006; Cuero, 1980; Girmenia *et al.*, 1992; Godoy *et al.*, 2004; Gungel *et al.*, 2011; Sekeroglu *et al.*, 2012; Verma & Tuft, 2002; Zhang *et al.*, 2006). Invasive fusariosis among immunocompromised patients with haematological disorders commonly associated with relatively high mortality rate 50% to ~90% (Dignani & Anaissie, 2004; Horn *et al.*, 2014; Hsiue *et al.*, 2010; Stempel *et al.*, 2015).

The epidemiology of fusariosis infections varies and corresponding to many factors such the host health situation and geographic region (Garnica & Nucci, 2013). Given the ubiquity of the *Fusarium* species in the environment, climate factors such wind and rain are more likely play an effective way in the *Fusarium* spores dispersion by which fusariosis may potentially be acquired in the clinic or non-clinic areas (Dignani & Anaissie, 2004; Garnica & Nucci, 2013; Palmero *et al.*, 2010). In prospective studies, pathogenic *Fusarium* species in the USA were recovered from a hospital water system including sink biofilms, tap water and water storage tanks, shower and sink drains, shower heads and sink faucet aerators from hospital air and other environments (Anaissie *et al.*, 2001; Short *et al.*, 2011). Recently, similar this observation has been reported at a tertiary care hospital in the UK (Al-Maqtoofi & Thornton, 2016). More than 70% of clinical *Fusarium* species that isolated from the environment and that suggested the geographical widespread (O'Donnell *et al.*, 2004).

#### 5.2 Diagnosis and Treatment of *Fusarium* Infections

Diagnosis and treatment of fusariosis in immunocompromised patients is a real challenge due to the lack of accurate diagnostic test and resistance to practically all available antifungal drugs (Muhammed et al., 2011; Thornton, 2011; van Diepeningen et al., 2015). Diagnosis of the Fusarium infections is critical for timely and appropriate treatment. At present, the gold standard for detection of fusariosis and other IFI is mycological culture of the fungus from blood samples or from biopsy samples. As with any IFI, diagnosis must confirm to standards set out in the European Organization for Research and Treatment of Cancer and the the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG diagnostic criteria. In 2002, the EORTC/MSG classified potential cases of IFI into possible, probable and proven case to o facilitate drawing a policy for epidemiological studies, clinical practice guide, treatment and diagnosis tests validation (Ascioglu et al., 2002). Based on that, fungus propagules has to be detected from a specimen of sterile site by histological analysis or culture based method to be considered as proven infection (Ascioglu et al., 2002; De Pauw et al., 2008; Tsitsikas et al., 2012). Possible and probable delimitations depends on a host factor for immune deficiency patients, clinical symptoms and microbiological observations including culture based method with microscopic analysis and non-culturebased diagnostic tests by high resolution scan, molecular detection, and through fungal antigen detection using ELISA test for GM and BDG (De Pauw et al., 2008). Therefore, isolation of Fusarium from blood or other sterile site biopsy with clinical symptoms is recognized as proven invasive infection, while recovering of Fusarium from respiratory tract secretion with demonstrating

clinical signs can be defined as probable (Garnica *et al.*, 2015; Nucci *et al.*, 2004).

Clinically, skin lesions and positive blood cultures for the mould consider characteristic feature of invasive fusariosis (Jain *et al.*, 2011; Nucci & Anaissie, 2007). This procedure is time-consuming, require skilled mycologists and have poor diagnostic sensitivities since *Fusarium* species exhibit similar morphological appearances with other hyalohyphomycete fungi such as *Aspergillus* leading to misdiagnosis (Tortorano *et al.*, 2014; van Diepeningen *et al.*, 2015;). An added complication is that skin lesions, which are the most common clinical presentation associated with disseminated fusariosis, appear at the later stage of infection (Boutati & Anaissie, 1997; Dignani & Anaissie, 2004).

Commercially, GM and BDG assay cross react with other emerging pathogens resulting in losing specificity and sensitivity to use for diagnosis of Fusarium at species or even genus level (Mikulska et al., 2012; Nucci et al., 2014; Tortorano et al., 2012; Yoshida, 2006;). In addition, Recently. an immunochromatographic lateral-flow device (LFD) has been developed using a highly specific mouse mAb, JF5, specific to a protein epitope expressed on an extracellular glycoprotein antigen of Aspergillus in human serum with no cross reactivity with other clinically important fungal pathogens, including Candida, Cryptococcus neoformans, F. solani, Penicillium marneffei, P. boydii, and Rhizopus oryzae (Thornton, 2008). The mAb JF5 has been engineered to draw a new view for monitoring Aspergillus infection and treatment progress

through positron emission tomography and magnetic resonance (immune PET/MR) imaging (Rolle *et al.*, 2016).

Molecular amplification technique using PCR might provide a promising tool for the IFI diagnosis (Lass-Flörl *et al.*, 2013; Lau *et al.*, 2007), with consideration of avoiding misdiagnosis due DNA contamination (Barnes, 2008; Donnelly, 2006; Dornbusch *et al.*, 2010). Using imaging methods such chest radiography and computed tomography (CT) for diagnosis of invasive fusariosis among immunocompromised patients has limited help for early diagnosis and track the treatment progress (Barnes, 2008; van Diepeningen *et al.*, 2015; Marom *et al.*, 2008).

The lack of diagnostic test for the *Fusarium* can be due to missing the general infrequency of the infection cases over world wild (Guarro, 2013). In addition, developing species-specific or genus-specific monoclonal antibodies is problematic because *Fusarium* shares the antigenic cell wall determinants, such as GM and BDG with other related and unrelated pathogenic fungi (Aquino *et al.*, 2007; Kedzierska, 2007; Khan *et al.*, 2008; Mikulska *et al.*, 2012; Odabasi *et al.*, 2004; Ostrosky-Zeichner *et al.*, 2005; Tortorano *et al.*, 2012). There are few studies managed to generate mAb specific for *Fusarium* to quantify fungal biomass in plant hosts (Arie *et al.*, 1995; Gan *et al.*, 1997; Hayashi *et al.*, 1998) or *Fusarium* mycotoxins that affected economical crops (Hill *et al.*, 2006; Maragos *et al.*, 2013). However, these works have never been validated for medical usage against a broad range of clinically important opportunistic pathogenic filamentous fungi or yeasts. Therefore, this study provides powerful findings in developing a rapid and accurate immunodiagnostic test can

specifically recognize epitope with a single glycoprotein epitope expressed on the extracellular carbohydrate antigen and located on the *Fusarium* propagules with a molecular mass of ~200 kDa with no cross reactivity with other pathogenic fungi. This fitful the urgent needs for early, rapid and accurate diagnostic test specific for *Fusarium*, in particular *F. solani*, that can lead to manage fusariosis infections (Araujo *et al.*, 2010; Hue *et al.*, 1999; Nucci *et al.*, 2003; Richardson & Warnock, 2003; Roilides *et al.*, 2007; Stevens, 2002; van Diepeningen *et al.*, 2015). There is only one study mentioned using developed a mAb, IgM, can bind to two antigens of *Fusarium* with 51 and 63 kDa in infected animal model with no cross reactivity with other fungal pathogens including *Aspergillus, Candida* and *Scedesporum* (Jensen *et al.*, 2011).

Macrophages are professional phagocytes that play a key role as the first line of the cellular innate immunity that response to *Fusarium* invaders. AMØs are able to recognize and internalize fungal propagules through phagocytosis leading to eliminate fungal infections and dissemination (Brakhage *et al.*, 2010; Figueiredo *et al.*, 2011; Roilides *et al.*, 2006). Thus, patients with an impaired immune system due to having cytotoxic therapy will be at the highest risk for developing disseminated invasive fusariosis (Cooke *et al.*, 2009; Lucca, 2007; Nucci *et al.*, 2004; Nucci & Anaissie, 2002; Perez-Perez *et al.*, 2007; Tortorano *et al.*, 2014; Yera *et al.*, 2003). Currently, little is known about the interaction between *Fusarium* species and macrophages (Nucci & Anaissie, 2007; Schäfer *et al.*, 2014). Here, in this phagocytosis of *F. solani* by the MH-S murine macrophage cell line was investigated and the findings demonstrate the ability of AMØs for uptaking spores and germinated spores. Moreover, this data highlighted two novel observations. First, the ability of phagocytosed spores to germinate inside

AMØ phagosome resulting in macrophage lysis and escape. Second, scape of internalized spore without macrophage lysis. These observations might indicate to a way of *Fusarium* resist the fungicidal mechanisms of phagosome including reactive oxygen species (ROS) and AMPs for developing disseminated disease. To our knowledge, this is the first analysis of the phagocytosis process for the important emerging opportunist human pathogen *F. solani*. These results suggested the need of more studies on the interaction between *F. solani* and the AMØs to better understand the recogniation and clearnce mechanisms by the cellular innate immunity for managing *Fusarium* infections.

The Fusarium species most commonly cited as human pathogens belong to species complex including FSSC, causes 50% of human infections, followed by FOSC (Torres & Kontoyiannis, 2011). The FDSC is less frequently reported as causing human disease, but it is similarly capable of causing disseminated infections in severely immunosuppressive patients (Bigley et al., 2004; Vismer et al., 2002). Identification the environmental reservoirs of pathogenic Fusarium species complex is essential for understanding the epidemiology of the Fusarium prevalence (Zhang et al., 2006). There is increasing trend of opportunistic fusariosis infections in humans associates with surveillance methods within environmental reservoirs of fungal propagules (Raad et al., 2002). Recent studies showed that domestic and municipal water systems are potential reservoirs of human pathogenic strains in the FSSC, FOSC and FDSC groups (Short et al., 2011). Here, we set out to determine whether human pathogenic species of *Fusarium* could be identified in sink drains directly by using crude antigen extracts of biofilms and detection using the mAb, ED7 by ELISA. The results showed that the mAb ED7 able to react with Fusarium

antigens in swab samples but no other unrelated fungal antigens existed within biofilm structures in water distribution systems such as *Aspergillus* and *Candida*. Interestingly, the *Fusarium* species were predominately recovered from more than 50% of swab and sink samples. Similar observation was reported during screening of *Fusarium* pathogens in hospital water system (Anaissie *et al.*, 2001).

The abundance of the *Fusarium* species in water system indicates to two main noteworthy features. First, pathogenic *Fusarium* species are able to adapt to urban aquatic environment of hospital and the university campus. Second, the *Fusarium* species performed strong resistance to antifungal water supply treatment. These features might result in nosocomial outbreak infections particularly in a hospital area associated with water distribution system. It has been suggested that emerging pathogenic *Fusarium* species are able to adapt in hospital and non-hospital water system (Sautour *et al.*, 2012; Steinberg *et al.*, 2015).

Validation analysis using ITS sequencing and amplification of TEF gene by PCR analysis of recovered isolates confirmed the 100% accuracy and sensitivity of ED7 for detection a unique epitope of the *Fusarium* genus including medically important species and species complex such as FSSC 1-a, FSSC 2, FOSC 33 and FDSC ET-gr in a mixture of fungal biofilms communities in skins of a tertiary care hospital and sinks of a heavily populated university campus. It is worth to mention that all *Fusarium* species were recovered from haematology unit sink drains related to FSSC. Similar observation had been reported (Horn *et al.*, 2014; Scheel *et al.*, 2013). This result revealed an unseen

source and the widespread occurrence of human pathogenic *Fusarium* infectious propagules in sinks and water system of a clinic and non-clinic environments that could cause outbreak nosocomial infections. This observation was reported in previous studies (Anaissie *et al.*, 2001; Short *et al.*, 2011). To this end, detection of opportunistic fungal pathogens including *Fusarium* and other filamentous and yeasts increases awareness of invasive mycosis among immunocompromised individuals.

# **Future Work**

This thesis describes the development of a novel immunodiagnostic assay for tracking the emerging human pathogen *Fusarium*, by using a newly developed genus-specific mAb, ED7. Future studies should attempt to develop a rapid diagnostic test for the pathogen, employing lateral-flow technology already successfully used for other opportunistic pathogens of humans (Thornton, 2008). This technology could have a significant impact in *Fusarium* diagnostics, delivering accurate and fast detection of the pathogen.

To better understand cellular immune responses to *Fusarium solani*, the live cell imaging studies reported here should be extended. Furthermore, the chemical nature of the epitope bound by the spore agglutinating mAb ED7 should be investigated as this may provide insights into the recognition of surface antigens of infectious propagules by cells of the innate immune system.

Finally, by combining mAb ED7 with the molecular methods of species and subspecies identification described here, a better understanding of the epidemiology of *Fusarium* and routes of exposure of susceptible individuals to

human pathogenic strains, may help to control nosocomial and community acquired infections.

# **BIBLIOGRAPHY**

- Abbas, A., Lichtman, A., & Pillai, S. (2007). Cellular and molecular immunology, (International Edition, 6th). West B. Saunders Company.
- Abbas, H. K., Cartwright, R. D., Shier, W. T., Abouzied, M. M., Bird, C. B., Rice,
  L. G., Meredith, F. I. (1998). Natural Occurrence of Fumonisins in Rice
  with *Fusarium* Sheath Rot Disease. *Plant Disease*, *82*(1): 22–25.
- Adams, D. J. (2004). Fungal cell wall chitinases and glucanases. *Microbiology*, *150*(Pt 7): 2029–35.
  - Adams, R. I., Miletto, M., Taylor, J. W., & Bruns, T. D. (2013). The Diversity and Distribution of Fungi on Residential Surfaces. *PLoS ONE*, *8*(11) : e78866.
- Agapov, E., Battaile, J. T., Tidwell, R., Hachem, R., Patterson, G. A., Pierce, R.
  A., Holtzman, M. J. (2009). Macrophage Chitinase 1 Stratifies Chronic
  Obstructive Lung Disease. *American Journal of Respiratory Cell and Molecular Biology*, *41*(4): 379–384.
- Aguirre, J., Hansberg, W., & Navarro, R. (2006). Fungal responses to reactive oxygen species. *Medical Mycology*, *44*(Suppl. 1): S101–S107.
- Ahmet, A. (2011). Checklist of Fusarium Species Reported from Turkey. *Mycotaxon*, *116*(1): 479.
- Aimanianda, V., Clavaud, C., Simenel, C., Fontaine, T., Delepierre, M., & Latgé,
   J. P. (2009). Cell Wall β-(1,6)-Glucan of Saccharomyces cerevisiae.
   The Journal of Biological Chemistry, 284(20): 13401–13412.
- Ajilogba, C. F., & Babalola, O. O. (2013). Integrated Management Strategies for Tomato Fusarium Wilt. *Biocontrol Science*, *18*(3): 117–127.

Al-Maqtoofi, M., & Thornton, C. R. (2016). Detection of human pathogenic

*Fusarium* species in hospital and communal sink biofilms by using a highly specific monoclonal antibody. *Environmental Microbiology*. doi: 10.1111/1462-2920.13233.

- Alexander, B. D., & Pfaller, M. A. (2006). Contemporary Tools for the Diagnosis and Management of Invasive Mycoses. *Clinical Infectious Diseases*, *43*(Suppl. 1): S15–S27.
- Altschul, S. F., Madden, T. L., Schäffer, A. A., Zhang, J., Zhang, Z., Miller, W., & Lipman, D. J. (1997). Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Research*, *25*(17): 3389–3402.
- Alvarez, M., & Casadevall, A. (2006). Phagosome Extrusion and Host-Cell Survival after *Cryptococcus neoformans* Phagocytosis by Macrophages. *Current Biology*, *16*(21): 2161–2165.
- Anaissie, E. J., Bodey, G. P., & Rinaldi, M. G. (1989). Emerging fungal pathogens. *European Journal of Clinical Microbiology and Infectious Diseases*, *8*(4): 323–330.
- Anaissie, E. J., Kuchar, R. T., Rex, J. H., Francesconi, A., Kasai, M., Müller, F.
  M., Walsh, T. J. (2001). Fusariosis associated with pathogenic *Fusarium* species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. *Clinical Infectious Diseases*, 33(11): 1871–8.
- Anaissie, E. J., Penzak SR, & Dignani M. (2002). The hospital water supply as a source of nosocomial infections: A plea for action. *Archives of Internal Medicine*, *162*(13): 1483–1492.
- Anaissie, E. J., Stratton, S. L., Dignani, M. C., Lee, C., Summerbell, R. C., Rex, J. H., Walsh, T. J. (2003). Pathogenic molds (including *Aspergillus*

species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies. *Blood*, *101*(7): 2542–2546.

- Anaissie, E. J., Stratton, S. L., Dignani, M. C., Summerbell, R. C., Rex, J. H., Monson, T. P., Walsh, T. J. (2002). Pathogenic *Aspergillus* Species Recovered from a Hospital Water System: A 3-Year Prospective Study. *Clinical Infectious Diseases*, *34*(6): 780–789.
- Anaissie, E., & Bodey. (1989). Nosocomial fungal infections. Old problems and new challenges. *Infectious Disease Clinics of North America*, *3*(4) : 867–882.
- Aquino, V. R., Goldani, L. Z., & Pasqualotto, A. C. (2007). Update on the contribution of galactomannan for the diagnosis of invasive aspergillosis. *Mycopathologia*, *163*(4): 191–202.
- Araujo, R., Pina-Vaz, C., & Rodrigues, A. G. (2010). Mould Infections: A Global Threat to Immunocompromised Patients. In *Combating Fungal Infections: Problems and Remedy* (pp. 1–19). Springer-Verlag, Berlin, Heidelberg: Springer.
- Arie, T., Hayashi, Y., Nagatani, A., Furuya, M., & Yamaguchi, I. (1991).
   Production and partial characterization of monoclonal antibodies against
   *Fusarium oxysporum* 860926a. *Annals of the Phytopathological Society of Japan*, 57.
- Arie, T., Hayashi, Y., Yoneyama, K., Nagatani, A., Furuya, M., & Yamaguchi, I.
  (1995). Detection of *Fusarium* spp. in plants with monoclonal antibody. *Annals of the Phytopathological Society of Japan*, 61.
- Arrese, J. E., Piérard-Franchimont, C., & Piérard, G. E. (1996). Fatal hyalohyphomycosis following *Fusarium* onychomycosis in an

immunocompromised patient. *The American Journal of Dermatopathology*, *18*(2): 196–198.

- Arthur, R. R., Drew, R. H., & Perfect, J. R. (2004). Novel modes of antifungal drug administration. *Expert Opinion on Investigational Drugs*, *13*(8) : 903–932.
- Arvanitidou, M., Kanellou, K., Constantinides, T. C., & Katsouyannopoulos, V. (1999). The occurrence of fungi in hospital and community potable waters. *Letters in Applied Microbiology*, *29*(2): 81–84.
- Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. (2002). Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 34(1)* : 7–14.
- Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. (2002). Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. *Clinical Infectious Diseases:*
- Ashley, E. S. D., Lewis, R., Lewis, J. S., Martin, C., & Andes, D. (2006).
   Pharmacology of Systemic Antifungal Agents. *Clinical Infectious Diseases*, *43*(Suppl. 1): S28–S39.
- Ashman, R. B., Farah, C. S., Wanasaengsakul, S., Hu, Y., Pang, G., & Clancy,
  R. L. (2004). Innate versus adaptive immunity in *Candida albicans* infection. *Immunology and Cell Biology*, *82*(2): 196–204.

- Aulik, N. A., Hellenbrand, K. M., & Czuprynski, C. J. (2012). Mannheimia haemolytica and its leukotoxin cause macrophage extracellular trap formation by bovine macrophages. *Infection and Immunity*, *80*(5) : 1923–1933.
- Azor, M., Gené, J., Cano, J., & Guarro, J. (2007). Universal In Vitro Antifungal Resistance of Genetic Clades of the *Fusarium solani* Species Complex.
   *Antimicrobial Agents and Chemotherapy*, *51*(4): 1500–1503.
- Azor, M., Gené, J., Cano, J., Manikandan, P., Venkatapathy, N., & Guarro, J. (2009). Less-Frequent *Fusarium* Species of Clinical Interest: Correlation between Morphological and Molecular Identification and Antifungal Susceptibility. *Journal of Clinical Microbiology*, *47*(5): 1463–1468.
- Bachmeyer, C. (2007). Deep cutaneous infection by *Fusarium solani* in a healthy child. *Journal of the American Academy of Dermatology.*, *57*(6): 1095–1096.
- Badiee, P., Kordbacheh, P., Alborzi, A., Malekhoseini, S., Ramzi, M., Mirhendi,
  H., Shakiba, E. (2009). Study on invasive fungal infections in immunocompromised patients to present a suitable early diagnostic procedure. *International Journal of Infectious Diseases*, *13*(1): 97–102.
- Bae, Y. S., & Knudsen, G. R. (2000). Cotransformation of *Trichoderma harzianum* with β-Glucuronidase and Green Fluorescent Protein Genes
   Provides a Useful Tool for Monitoring Fungal Growth and Activity in Natural Soils. *Applied and Environmental Microbiology*, *66*(2): 810–815.
- Bain, J. M., Lewis, L. E., Okai, B., Quinn, J., Gow, N. A. R., & Erwig, L. P. (2012). Non-lytic expulsion/exocytosis of *Candida albicans* from macrophages. *Fungal Genetics and Biology*, *49*(9): 677–678.

Bain, J., Gow, N. A. R., & Erwig, L. P. (2014). Novel insights into host-fungal

pathogen interactions derived from live-cell imaging. Seminars in *Immunopathology*, *37*(2): 131–139.

- Balajee, S. A., Borman, A. M., Brandt, M. E., Cano, J., Cuenca-Estrella, M., Dannaoui, E., Wickes, B. L. (2009). Sequence-Based Identification of *Aspergillus, Fusarium*, and *Mucorales* Species in the Clinical Mycology Laboratory: Where Are We and Where Should We Go from Here? *Journal of Clinical Microbiology*, *47*(4): 877–884.
- Balmas, V., Scherm, B., Marcello, A., Beyer, M., Hoffmann, L., Migheli, Q., & Pasquali, M. (2015). *Fusarium* species and chemotypes associated with Fusarium head blight and Fusarium root rot on wheat in Sardinia. *Plant Pathology*, 64(4): 972–979.
- Banks, J. N., Rizvi, R. H., Barker, I., Turner, J. A., Rahman, S., & Northway, B.
  J. (1996). Specific monoclonal antibodies to *Fusarium* species and microdochium nivale. *Food and Agricultural Immunology*, *8*(4) : 249–268.
- Barelle, C. J., Manson, C. L., MacCallum, D. M., Odds, F. C., Gow, N. A. R., &Brown, A. J. P. (2004). GFP as a quantitative reporter of gene regulation in *Candida albicans*. *Yeast*, 21(4): 333-40.
- Barnes, R. A. (2008). Early diagnosis of fungal infection in immunocompromised patients. *Journal of Antimicrobial Chemotherapy*, *61*(suppl 1): i3–i6.
- Barreto-Bergter, E., & Figueiredo, R. T. (2014). Fungal glycans and the innate immune recognition. *Frontiers in Cellular and Infection Microbiology*, *4* : 145.
- Bérdy, J. (2005). Bioactive Microbial Metabolites. *The Journal of Antibiotics*, *58*(1): 1–26.

- Bigley, V. H., Duarte, R. F., Gosling, R. D., Kibbler, C. C., Seaton, S., & Potter,
  M. (2004). *Fusarium dimerum* infection in a stem cell transplant
  recipient treated successfully with voriconazole. *Bone Marrow Transplantation*, 34(9): 815–817.
- Blanco, J. L. & Garcia, M. E (2008). Immune response to fungal infections. Veterinary Immunology and Immunopathology, 125: 47–70.
- Blanco, J. L., & Garcia, M. E. (2008). Immune response to fungal infections.
- Blyth, C. C., Gilroy, N. M., Guy, S. D., Chambers, S. T., Cheong, E. Y., Gottlieb,
  T., Thursky, K. A. (2014). Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014. *Internal Medicine Journal*, *44*(12b): 1333–1349.
- Bodey, G. P., Boktour, M., Mays, S., Duvic, M., Kontoyiannis, D., Hachem, R., &
  Raad, I. (2002). Skin lesions associated with *Fusarium* infection. *Journal of the American Academy of Dermatology*, *47*(5): 659–666.
- Boonyuen, N., Chuaseeharonnachai, C., Suetrong, S., Sri-indrasutdhi, V., Sivichai, S., Jones, E. B. G., & Pang, K. L. (2011). Savoryellales (Hypocreomycetidae, Sordariomycetes): a novel lineage of aquatic ascomycetes inferred from multiple-gene phylogenies of the genera *Ascotaiwania, Ascothailandia*, and *Savoryella. Mycologia*, 103(6) : 1351–1371.
- Booth, C. (1971). *The genus Fusarium*. Commonwealth Agricultural Bureaux.
- Bottalico, A. (1998). *Fusarium* diseases of cereals: species complex and related mycotoxin profiles, in Europe. *Journal of Plant Pathology*, *80*(2):85–103.
- Bouchara, J. P., Oumeziane, N. A., Lissitzky, J. C., Larcher, G., Tronchin, G., & Chabasse, D. (1996). Attachment of spores of the human pathogenic

fungus Rhizopus oryzae to extracellular matrix components. *European Journal of Cell Biology*, *70*(1): 76–83.

- Bouchara, J.-P., Hsieh, H. Y., Croquefer, S., Barton, R., Marchais, V., Pihet, M.,
  & Chang, T. C. (2009). Development of an Oligonucleotide Array for
  Direct Detection of Fungi in Sputum Samples from Patients with Cystic
  Fibrosis. *Journal of Clinical Microbiology*, *47*(1): 142–152.
- Boutati, E. I., & Anaissie, E. J. (1997). *Fusarium*, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. *Blood*, *90*(3): 999–1008.
- Bowman, S. M., & Free, S. J. (2006). The structure and synthesis of the fungal cell wall. *Bioessays*, *28*(8): 799–808.
- Brakhage, A. A., Bruns, S., Thywissen, A., Zipfel, P. F., & Behnsen, J. (2010). Interaction of phagocytes with filamentous fungi. *Current Opinion in Microbiology*, *13*(4): 409–415.
- Brandt, M. E., & Warnock, D. W. (2003). Laboratory aspects of medical mycology. In W. E. Dismukes, P. G. Pappas, & J. D. Sobel (Eds.): *Clinical Mycology* (pp. 3–22). Oxford University Press.
- Branzk, N., Lubojemska, A., Hardison, S. E., Wang, Q., Gutierrez, M. G., Brown, G. D., & Papayannopoulos, V. (2014). Neutrophils sense microbe size and selectively release neutrophil extracellular traps in response to large pathogens. *Nature Immunology*, *15*(11): 1017–1025.
- Brasch, J., & Köppl, G. (2009). Persisting onychomycosis caused by *Fusarium solani* in an immunocompetent patient. *Mycoses*, *52*(3): 285–6.
- Brasch, J., & Shimanovich, I. (2012). Persistent fingernail onychomycosis caused by *Fusarium proliferatum* in a healthy woman. *Mycoses*, *55*(1)

: 86–89.

- Brase, S., Encinas, A., Keck, J., & Nising, C. F. (2009). Chemistry and biology of mycotoxins and related fungal metabolites. *Chem Rev*, 109(9) : 3903–90.
- Brieland, J. K., Jackson, C., Menzel, F., Loebenberg, D., Cacciapuoti, A.,
  Halpern, J., O'Garra, A. (2001). Cytokine Networking in Lungs of
  Immunocompetent Mice in Response to Inhaled Aspergillus fumigatus.
  Infection and Immunity, 69(3): 1554–1560.
- Brinkmann, V., Reichard, U., Goosmann, C., Fauler, B., Uhlemann, Y., Weiss,
  D. S., Zychlinsky, A. (2004). Neutrophil Extracellular Traps Kill Bacteria. *Science*, *303*(5663): 1532–1535.
- Brown, A. J. P., Brown, G. D., Netea, M. G., & Gow, N. A. R. (2014). Metabolism impacts upon Candida immunogenicity and pathogenicity at multiple levels. *Trends in Microbiology*, 22(11): 614–622.
- Brown, G. D. (2011). Innate Antifungal Immunity: The Key Role of Phagocytes. Annual Review of Immunology, 29, 1–21.
- Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012). Hidden killers: human fungal infections. *Science Translational Medicine*, *4*(165): 165rv13.
- Bruns, S., Kniemeyer, O., Hasenberg, M., Aimanianda, V., Nietzsche, S., Thywißen, A., Gunzer, M. (2010). Production of Extracellular Traps against *Aspergillus fumigatus* In Vitro and in Infected Lung Tissue Is Dependent on Invading Neutrophils and Influenced by Hydrophobin RodA. *PLoS Pathogens*, *6*(4): e1000873.
- Bruns, S., Kniemeyer, O., Hasenberg, M., Aimanianda, V., Nietzsche, S., Thywißen, A., Gunzer, M. (2010). Production of Extracellular Traps

against *Aspergillus fumigatus* In Vitro and in Infected Lung Tissue Is Dependent on Invading Neutrophils and Influenced by Hydrophobin RodA. *PLoS Pathogens*, *6*(4): e1000873.

- Bryan, G. T., Daniels, M. J., & Osbourn, A. E. (1995). Comparison of fungi within the Gaeumannomyces-Phialophora complex by analysis of ribosomal DNA sequences. *Applied and Environmental Microbiology*, 61(2): 681–689.
- Burgess, L. W., Knight, T. E., Tesoriero, L., & Phan, H. T. (2008). *Diagnostic manual for plant diseases in Vietnam* (Australian Centre for International Agricultural Research, Vols. 1–ACIAR Monograph No. 129,). Canberra 2008.
- Bushelman, S. J., Callen, J. P., Roth, D. N., & Cohen, L. M. (1995). Disseminated *Fusarium solani* infection. *Journal of the American Academy of Dermatology*, *32*(2, Part 2): 346–351.
- Campbell, C. K., Johnson, E. M., & Warnock, D. W. (2013). *Identification of Pathogenic Fungi* (2nd Edition). A John Wiley & Sons, Ltd., Publication.
- Campbell, S., & Landry, M. L. (2006). Rapid Antigen Tests. In Advanced Techniques in Diagnostic Microbiology (pp. 23–41). Springer US.
- Carneiro, H. A., Coleman, J. J., Restrepo, A., & Mylonakis, E. (2011). *Fusarium* Infection in Lung Transplant Patients. *Medicine*, *90*(1): 69–80.
- Carvalho, A., Cunha, C., Pasqualotto, A. C., Pitzurra, L., Denning, D. W., & Romani, L. (2010). Genetic variability of innate immunity impacts human susceptibility to fungal diseases. *International Journal of Infectious Diseases*, *14*(6): e460–e468.
- Casadevall, A., & Pirofski, L. (2007). Antibody-Mediated Protection through Cross-Reactivity Introduces a Fungal Heresy into Immunological

Dogma. Infection and Immunity, 75(11): 5074–5078.

- Casadevall, A., & Pirofski, L. (2012). A new synthesis for antibody-mediated immunity. *Nature Immunology*, *13*(1): 21–28.
- Chalfie, M., Tu, Y., Euskirchen, G., Ward, W. W., & Prasher, D. C. (1994). Green fluorescent protein as a marker for gene expression. *Science*, *263*(5148): 802–805.
- Champion, J. A., & Mitragotri, S. (2006). Role of target geometry in phagocytosis. *Proceedings of the National Academy of Sciences of the United States of America*, *103*(13): 4930–4934.
- Chandra, J., Kuhn, D. M., Mukherjee, P. K., Hoyer, L. L., McCormick, T., & Ghannoum, M. A. (2001). Biofilm Formation by the Fungal Pathogen *Candida albicans*: Development, Architecture, and Drug Resistance. *Journal of Bacteriology*, *183*(18): 5385–5394.
- Chang, D. C., Grant, G. B., O'Donnell, K., Wannemuehler, K. A., Noble-Wang, J., Rao, C. Y., Lewis, F. M. (2006). Multistate outbreak of *Fusarium* keratitis associated with use of a contact lens solution. *JAMA: The Journal of the American Medical Association*, 296(8): 953–963.
- Chen, K., & Kolls, J. K. (2013). T Cell–Mediated Host Immune Defenses in the Lung. *Annual Review of Immunology*, *31*, 605–633.
- Cho, C. T., Vats, T. S., Lowman, J. T., Brandsberg, J. W., & Tosh, F. E. (1973). *Fusarium solani* infection during treatment for acute leukemia. *Journal of Pediatrics*, *83*(6): 1028–1031.
- Chotirmall, S. H., Al-Alawi, M., Mirkovic, B., Lavelle, G., Logan, P. M., Greene,
  C. M., McElvaney, N. G. (2013). *Aspergillus*-Associated Airway
  Disease, Inflammation, and the Innate Immune Response, *Aspergillus*-Associated Airway
  Disease, Inflammation, and the Innate Immune Response, *Aspergillus*-Associated Airway
Response. BioMed Research International, BioMed Research International, 2013, e723129.

- Chow, T. Y. K., & Käfer, E. (1993). A rapid method for isolation of total nucleic acids from *Aspergillus nidulans*. *Fungal Genet. Newsl.*, *40*, 25–27.
- Church, D., Elsayed, S., Reid, O., Winston, B., & Lindsay, R. (2006). Burn Wound Infections. *Clinical Microbiology Reviews*, *19*(2): 403–434.
- Cooke, N. S., Feighery, C., Armstrong, D. K., Walsh, M., & Dempsey, S. (2009). Cutaneous *Fusarium solani* infection in childhood acute lymphoblastic leukaemia. *Clin Exp Dermatol*, *34*(5): e117–9.
- Cormack, B. P., Bertram, G., Egerton, M., Gow, N. A. R., Falkow, S., & Brown,
  A. J. P. (1997). Yeast-enhanced green fluorescent protein (yEGFP):
  a reporter of gene expression in Candida albicans. *Microbiology*, *143*(2): 303–311.
- Crabol, Y., Lortholary, O., Crabol, Y., & Lortholary, O. (2014). Invasive Mold Infections in Solid Organ Transplant Recipients, Invasive Mold Infections in Solid Organ Transplant Recipients. *Scientifica, Scientifica,* 2014, e821969.
- *Cryptococcus neoformans* Escapes Macrophages by a Phagosome Emptying Mechanism That Is Inhibited by Arp2/3 Complex-Mediated Actin Polymerisation. *PLoS Pathog*, *6*(8): e1001041.
- Cuero, R. G. (1980). Ecological distribution of *Fusarium solani* and its opportunistic action related to mycotic keratitis in Cali, Colombia. *Journal of Clinical Microbiology*, *12*(3): 455–61.
- Dagenais, T. R. T., & Keller, N. P. (2009). Pathogenesis of Aspergillus fumigatus in Invasive Aspergillosis. Clinical Microbiology Reviews, 22(3): 447–465.

161

- Davies, G. E., & Thornton, C. R. (2014). Differentiation of the Emerging Human Pathogens *Trichosporon asahii* and *Trichosporon asteroides* from Other Pathogenic Yeasts and Moulds by Using Species-Specific Monoclonal Antibodies. *PLoS ONE*, *9*(1): e84789
- De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Bennett, J. E. (2008). Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*, 46(12): 1813–1821.
- Dean, R., Van Kan, J. A., Pretorius, Z. A., Hammond-Kosack, K. E., Di Pietro, A., Spanu, P. D., Foster, G. D. (2012). The Top 10 fungal pathogens in molecular plant pathology. *Mol Plant Pathol*, *13*(4): 414–30.
- Defra, (Department for Environment Food & Rural Affairs). (2011). A Review of Fungi in Drinking Water and the Implications for Human Health (Final report No. Reference: WD 0906) (pp. 1–107). Bio Intelligence Service, Paris, France.
- Deorukhkar, S. C., Saini, S., Mathew, S., Deorukhkar, S. C., Saini, S., & Mathew, S. (2014). Virulence Factors Contributing to Pathogenicity of *Candida tropicalis* and Its Antifungal Susceptibility Profile, Virulence Factors Contributing to Pathogenicity of *Candida tropicalis* and Its Antifungal Susceptibility Profile. *International Journal of Microbiology, International Journal of Microbiology, 2014, 2014*, e456878.

Desjardins, A. E., & Proctor, R. H. (2007). Molecular biology of Fusarium

mycotoxins. Int J Food Microbiol, 119(1-2): 47–50.

- Dictar, M. O., Maiolo, E., Alexander, B., Jacob, N., & Verón, M. T. (2000). Mycoses in the transplanted patient. *Medical Mycology*, *38 Suppl 1*, 251–258.
- Dignani, M., & Anaissie, E. (2004). Human Fusariosis. *Clinical Microbiology and Infection*, *10*(s1): 67–75.
- Dixon, D. M., & Walsh, T. J. (1996). Antifungal Agents. In S. Baron (Ed.), Medical Microbiology (4th ed.). Galveston (TX): University of Texas Medical Branch at Galveston.
- Dóczi, I., Gyetvai, T., Kredics, L., & Nagy, E. (2004). Involvement of *Fusarium* spp. in fungal keratitis. *Clinical Microbiology and Infection*, *10*(9), 773–776.
- Doggett, M. S. (2000). Characterization of Fungal Biofilms within a Municipal Water Distribution System. *Applied and Environmental Microbiology*, *66*(3): 1249–1251.
- Donnelly, J. P. (2006). Polymerase Chain Reaction for Diagnosing Invasive Aspergillosis: Getting Closer but Still a Ways to Go. *Clinical Infectious Diseases*, *42*(4): 487–489.
- Donnio, A., Van Nuoi, D. N. 'Guyen, Catanese, M., Desbois, N., Ayeboua, L., & Merle, H. (2007). Outbreak of keratomycosis attributable to *Fusarium solani* in the French West Indies. *American Journal of Ophthalmology*, 143(2): 356–358.
- Dornbusch, H. J., Groll, A., & Walsh, T. J. (2010). Diagnosis of invasive fungal infections in immunocompromised children. *Clinical Microbiology and Infection*, *16*(9): 1328–1334.

Dursun, D., Fernandez, V., Miller, D., & Alfonso, E. C. (2003). Advanced

*Fusarium* keratitis progressing to endophthalmitis. *Cornea*, 22(4) : 300–303.

- Edelstein, S. L., Akduman, L., Durham, B. H., Fothergill, A. W., & Hsu, H. Y. (2012). Resistant *Fusarium* keratitis progressing to endophthalmitis. *Eye & Contact Lens*, *38*(5): 331–335.
- Epstein, A. B. (2007). In the aftermath of the *Fusarium* keratitis outbreak: What have we learned? *Clinical Ophthalmology (Auckland, N.Z.)*, 1(4) : 355–366.
- Epstein, L., & Nicholson, R. L. (2006). Adhesion and Adhesives of Fungi and Oomycetes. In D. A. M. Smith & D. J. A. Callow (Eds.), *Biological Adhesives* (pp. 41–62). Springer Berlin Heidelberg.
- Erwig, L. P., & Gow, N. A. R. (2016). Interactions of fungal pathogens with phagocytes. *Nature Reviews Microbiology*, *14*(3): 163–176.
- Esnakula, A. K., Summers, I., & Naab, T. J. (2013). Fatal Disseminated Infection in a Human Immunodeficiency Virus Positive Patient. *Case Reports in Infectious Diseases*, *2013*, e379320.
- Feng, P., Lu, Q., Najafzadeh, M. J., Ende, A. H. G. G. van den, Sun, J., Li, R., Hoog, G. S. de. (2014). *Cyphellophora* and its relatives in *Phialophora*: biodiversity and possible role in human infection. *Fungal Diversity*, 65(1): 17–45.
- Figueiredo, R. T., Carneiro, L. A. M., & Bozza, M. T. (2011). Fungal Surface and Innate Immune Recognition of Filamentous Fungi. *Frontiers in Microbiology*, 2(248): 1–14.
- Folds, J. D. (2008). Overview of Immunity. In M. R. G. O'Gorman & A. D. Donnenberg (Eds.), *Handbook of Human Immunology* (2nd edition, pp. 1–28). CRC Press.

- Fontaine, T., Simenel, C., Dubreucq, G., Adam, O., Delepierre, M., Lemoine, J., Latge, J. P. (2000). Molecular organization of the alkali-insoluble fraction of Aspergillus fumigatus cell wall. Journal of Biological Chemistry. 8;275(36): 27594-607.
- Fontana, C., Gaziano, R., Favaro, M., Casalinuovo, I., Pistoia, E., & Di Francesco, P. (2012). (1-3)-β-D-Glucan vs Galactomannan Antigen in Diagnosing Invasive Fungal Infections (IFIs). *The Open Microbiology Journal*, 6, 70–73.
- Francis, R. G., & Burgess, L. W. (1977). Characteristics of two populations of *Fusarium roseum* "Graminearum" in Eastern Australia. *Transactions of the British Mycological Society*, 68(3): 421–427.
- Free, S. J. (2013). Fungal cell wall organization and biosynthesis. *Advances in Genetics*, *81*, 33–82.
- Fridkin, S. K., & Jarvis, W. R. (1996). Epidemiology of nosocomial fungal infections. *Clinical Microbiology Reviews*, *9*(4): 499–511.
- Gan, Z., Marquardt, R. R., Abramson, D., & Clear, R. M. (1997). The characterization of chicken antibodies raised against *Fusarium* spp. by enzyme-linked immunosorbent assay and immunoblotting. *International Journal of Food Microbiology*, 38(2-3): 191–200.
- Gangneux, J. P., Bretagne, S., Cordonnier, C., Datry, A., Derouin, F., Grillot, R.,
  Poirot, J. L. (2002). Prevention of Nosocomial Fungal Infection: The
  French Approach. *Clinical Infectious Diseases*, *35*(3): 343–346.
- Garnica, M., & Nucci, M. (2013). Epidemiology of Fusariosis. *Current Fungal Infection Reports*, 7(4): 301–305.
- Garnica, M., Cunha, M. O. da, Portugal, R., Maiolino, A., Colombo, A. L., & Nucci, M. (2015). Risk Factors for Invasive Fusariosis in Patients With

Acute Myeloid Leukemia and in Hematopoietic Cell Transplant Recipients. *Clinical Infectious Diseases*, *60*(6): 875–880.

- Gauthier, G. M., & Keller, N. P. (2013). Crossover fungal pathogens: the biology and pathogenesis of fungi capable of crossing kingdoms to infect plants and humans. *Fungal Genetics and Biology: FG & B*, *61*, 146–157.
- Gaviria, J. M., van Burik, J. A., Dale, D. C., Root, R. K., & Liles, W. C. (1999a).
  Comparison of interferon-gamma, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor for priming leukocyte-mediated hyphal damage of opportunistic fungal pathogens. *J Infect Dis*, *179*(4): 1038–41.
- Gaviria, J. M., van Burik, J. A., Dale, D. C., Root, R. K., & Liles, W. C. (1999b).
  Modulation of neutrophil-mediated activity against the pseudohyphal form of Candida albicans by granulocyte colony-stimulating factor (G-CSF) administered in vivo. *J Infect Dis*, *179*(5): 1301–4.
- Geiser, D. M., del Mar Jiménez-Gasco, M., Kang, S., Makalowska, I., Veeraraghavan, N., Ward, T. J., O'donnell, K. (2004). FUSARIUM-ID v.
  1.0: A DNA Sequence Database for Identifying *Fusarium. European Journal of Plant Pathology*, *110*(5/6): 473–479.
- Gersuk, G. M., Underhill, D. M., Zhu, L., & Marr, K. A. (2006). Dectin-1 and TLRs Permit Macrophages to Distinguish between Different Aspergillus fumigatus Cellular States. *The Journal of Immunology*, *176*(6): 3717– 3724.
- Ghannoum, M. A., & Rice, L. B. (1999). Antifungal Agents: Mode of Action,
   Mechanisms of Resistance, and Correlation of These Mechanisms with
   Bacterial Resistance. *Clinical Microbiology Reviews*, *12*(4): 501–517.

- Giacchino, M., Chiapello, N., Bezzio, S., Fagioli, F., Saracco, P., Alfarano, A.,
  Girmenia, C. (2006). *Aspergillus* Galactomannan Enzyme-Linked
  Immunosorbent Assay Cross-Reactivity Caused by Invasive
  Geotrichum capitatum. *Journal of Clinical Microbiology*, *44*(9): 3432–3434.
- Gil-Lamaignere, C., Roilides, E., Mosquera, J., Maloukou, A., & Walsh, T. J. (2002). Antifungal Triazoles and Polymorphonuclear Leukocytes Synergize To Cause Increased Hyphal Damage to Scedosporium prolificans and Scedosporium apiospermum. Antimicrobial Agents and Chemotherapy, 46(7): 2234–2237.
- Gilbert, A. S., Wheeler, R. T., & May, R. C. (2015). Fungal Pathogens: Survival and Replication within Macrophages. *Cold Spring Harbor Perspectives in Medicine*, *5*(7): a019661.
- Girmenia, C., Arcese, W., Micozzi, A., Martino, P., Bianco, P., & Morace, G. (1992). Onychomycosis as a possible origin of disseminated *Fusarium solani* infection in a patient with severe aplastic anemia. *Clinical Infectious Diseases*, *14*(5): 1167–1167.
- Girmenia, C., Pagano, L., Corvatta, L., Mele, L., Del Favero, A., & Martino for the Gimema Infection Programme, P. (2000). The epidemiology of fusariosis in patients with haematological diseases. *British Journal of Haematology*, *111*(1): 272–276.
- Godoy, P., Nunes, E., Silva, V., Tomimori-Yamashita, J., Zaror, L., & Fischman,
  O. (2004). Onychomycosis caused by *Fusarium solani* and *Fusarium oxysporum* in São Paulo, Brazil. *Mycopathologia*, *157*(3): 287–90.
- Gordon, S., & Read, R. (2002). Macrophage defences against respiratory tract infections The immunology of childhood respiratory infections. *British*

Medical Bulletin, 61(1): 45–61.

- Gorscak, J. J., Ayres, B. D., Bhagat, N., Hammersmith, K. M., Rapuano, C. J., Cohen, E. J., Chu, D. S. (2007). An Outbreak of *Fusarium* Keratitis Associated With Contact Lens Use in the Northeastern United States: *Cornea*, *26*(10): 1187–1194.
- Goswami, R. S., & Kistler, H. C. (2004). Heading for disaster: *Fusarium* graminearum on cereal crops. *Mol Plant Pathol*, *5*(6): 515–25.
- Goswami, R. S., & Kistler, H. C. (2004). Heading for disaster: *Fusarium* graminearum on cereal crops. *Molecular Plant Pathology*, *5*(6): 515–25.
- Grazziutti, M., Anaissie, E. J., & Wingard, J. R. (2005). Overview of Host Defenses: Innate and Acquired Immunity. In J. R. Wingard & E. J. Anaissie (Eds.), *Fungal Infections in the Immunocompromised Patient* (pp. 1–44). Boca Raton London New York Singapore: Taylor & Francis Group.
- Green, B. J., Beezhold, D. H., Green, B. J., & Beezhold, D. H. (2011). Industrial Fungal Enzymes: An Occupational Allergen Perspective, Industrial Fungal Enzymes: An Occupational Allergen Perspective. *Journal of Allergy, Journal of Allergy, 2011,* e682574.
- Guarro, J. (2013). Fusariosis, a complex infection caused by a high diversity of fungal species refractory to treatment. *European Journal of Clinical Microbiology & Infectious Diseases: Official Publication of the European Society of Clinical Microbiology, 32*(12): 1491–1500.
- Guarro, J., Nucci, M., Akiti, T., & Gené, J. (2000). Mixed Infection Caused by Two Species of *Fusarium* in a Human Immunodeficiency Virus-Positive Patient. *J. Clin. Microbiol.*, *38*(9): 3460–3462.

Gubbins, P. O., & Anaissie, E. J. (2009). CHAPTER 7 - Antifungal therapy. In

*Clinical Mycology (Second Edition)* (pp. 161–195). Edinburgh: Churchill Livingstone.

- Gungel, H., Eren, M. H., Pinarci, E. Y., Altan, C., Baylancicek, D. O., Kara, N., Susever, S. (2011). An outbreak of *Fusarium solani* endophthalmitis after cataract surgery in an eye training and research hospital in Istanbul. *Mycoses*, 54(6): e767–74.
- Guo, H., Wu, X., Fu-shin, X. Y., & Zhao, J. (2008). Toll-like receptor 2 mediates the induction of IL-10 in corneal fibroblasts in response to *Fusarium solu*. *Immunology and Cell Biology*, 86(3): 271–276.
- Gupta, A. K., Baran, R., & Summerbell, R. C. (2000). *Fusarium* infections of the skin. *Curr Opin Infect Dis*, *13*(2): 121–128.
- Gupta, V. K., Misra, A. K., Gaur, R., Pandey, R., & Chauhan, U. (2009). Studies of genetic polymorphism in the isolates of *Fusarium solani*. *Australian Journal Crop Science*, *3*, 101–106.
- Gurusidappa, S., & Mamatha, H. (2011). Fusarial skin lesion in immunocompromised. *Indian Journal of Cancer*, *48*(1): 116.
- Hageskal, G., Knutsen, A. K., Gaustad, P., Hoog, G. S. de, & Skaar, I. (2006).
  Diversity and Significance of Mold Species in Norwegian Drinking
  Water. *Applied and Environmental Microbiology*, 72(12): 7586–7593.
- Hall, R. A., Bates, S., Lenardon, M. D., MacCallum, D. M., Wagener, J., Lowman, D. W., Gow, N. A. R. (2013). The Mnn2 Mannosyltransferase
  Family Modulates Mannoprotein Fibril Length, Immune Recognition and Virulence of Candida albicans. *PLOS Pathog*, *9*(4): e1003276.
- Harrow, S. A., Farrokhi-Nejad, R., Pitman, A. R., Scott, I. A. W., Bentley, A.,Hide, C., & Cromey, M. G. (2010). Characterisation of New Zealand*Fusarium* populations using a polyphasic approach differentiates the *F.*

avenaceum/F. acuminatum/F. tricinctum species complex in cereal and grassland systems. *Fungal Biology*, *114*(4): 293–311.

- Hayashi, Y., Arie, T., Yoneyama, K., & Yamaguchi, I. (1998). Characterization of the antigenic determinant on *Fusarium oxysporum* recognized by a genus-specific monoclonal antibody. *The Journal of General and Applied Microbiology*, *44*(1): 43–47.
- Hegedüs, N., & Marx, F. (2013). Antifungal proteins: More than antimicrobials? *Fungal Biology Reviews*, *26*(4): 132–145.
- Heinekamp, T., Thywißen, A., Macheleidt, J., Keller, S., Valiante, V., & Brakhage, A. A. (2013). *Aspergillus fumigatus* melanins: interference with the host endocytosis pathway and impact on virulence. *Frontiers in Microbiology*, 3, 440.
- Held, J., Schmidt, T., Thornton, C. R., Kotter, E., & Bertz, H. (2013).
  Comparison of a novel Aspergillus lateral-flow device and the Platelia® galactomannan assay for the diagnosis of invasive aspergillosis following haematopoietic stem cell transplantation. *Infection*, *41*(6): 1163–1169.
- Hellenbrand, K. M., Forsythe, K. M., Rivera-Rivas, J. J., Czuprynski, C. J., & Aulik, N. A. (2013). *Histophilus somni* causes extracellular trap formation by bovine neutrophils and macrophages. *Microbial Pathogenesis*, 54, 67–75.
- Hill, N. S., Schwarz, P., Dahleen, L. S., Neate, S. M., Horsley, R., Glenn, A. E.,
  & O'Donnell, K. (2006). ELISA Analysis for in Barley. *Crop Science*, 46(6): 2636.
- Hohl, T. M., & Feldmesser, M. (2007). *Aspergillus fumigatus*: Principles of Pathogenesis and Host Defense. *Eukaryotic Cell*, *6*(11): 1953–1963.

Horn, D. L., Freifeld, A. G., Schuster, M. G., Azie, N. E., Franks, B., &

Kauffman, C. A. (2014). Treatment and outcomes of invasive fusariosis: review of 65 cases from the PATH Alliance® registry. *Mycoses*, *57*(11): 652–658.

- Houang, E., Lam, D., Fan, D., & Seal, D. (2001). Microbial keratitis in Hong Kong: relationship to climate, environment and contact-lens disinfection. *Transactions of The Royal Society of Tropical Medicine and Hygiene*, 95(4): 361–367.
- Hsiue, H. C., Ruan, S. Y., Kuo, Y. L., Huang, Y. T., & Hsueh, P. R. (2010). Invasive infections caused by non-*Aspergillus* moulds identified by sequencing analysis at a tertiary care hospital in Taiwan, 2000–2008. *Clinical Microbiology and Infection*, *16*(8): 1204–1206.
- Hu, Y., Farah, C. S., & Ashman, R. B. (2006). Effector function of leucocytes from susceptible and resistant mice against distinct isolates of Candida albicans. *Immunology and Cell Biology*, *84*(5): 455–460.
- Hu, Z. Q., Li, H. P., Zhang, J. B., Huang, T., Liu, J. L., Xue, S., Liao, Y. C. (2013). A phage-displayed chicken single-chain antibody fused to alkaline phosphatase detects *Fusarium* pathogens and their presence in cereal grains. *Analytica Chimica Acta*, 764, 84–92.
- Hu, Z. Q., Liu, J. L., Li, H. P., Xing, S., Xue, S., Zhang, J. B., Liao, Y. C. (2012).
  Generation of a highly reactive chicken-derived single-chain variable
  fragment against *Fusarium verticillioides* by phage display. *International Journal of Molecular Sciences*, *13*(6): 7038–7056.
- Huang, Y. T., Hung, C. C., & Hsueh, P.-R. (2007). *Aspergillus* galactomannan antigenemia in penicilliosis marneffei: *AIDS*, *21*(14): 1990–1991.
- Hue, F.-X., Huerre, M., Rouffault, M. A., & De Bievre, C. (1999). Specific detection of *Fusarium* species in blood and tissues by a PCR technique.

J. Clin. Microbiol., 37(8): 2434–2438.

Ibrahim-Granet, O., Philippe, B., Boleti, H., Boisvieux-Ulrich, E., Grenet, D., Stern, M., & Latgé, J. P. (2003). Phagocytosis and Intracellular Fate of Aspergillus fumigatus Conidia in Alveolar Macrophages. Infection and Immunity, 71(2): 891–903.

- Ibrahim, M. M., Vanini, R., Ibrahim, F. M., Martins, W. de P., Carvalho, R. T. de C., Castro, R. S. de, & Rocha, E. M. (2011). Epidemiology and medical prediction of microbial keratitis in southeast Brazil. *Arquivos Brasileiros de Oftalmologia*, 74(1): 7–12.
- Imamura, Y., Chandra, J., Mukherjee, P. K., Lattif, A. A., Szczotka-Flynn, L. B., Pearlman, E., Ghannoum, M. A. (2008). *Fusarium* and *Candida albicans* Biofilms on Soft Contact Lenses: Model Development, Influence of Lens Type, and Susceptibility to Lens Care Solutions. *Antimicrobial Agents and Chemotherapy*, 52(1): 171–182.
- Inoue, I., Namiki, F., & Tsuge, T. (2002). Plant Colonization by the Vascular Wilt Fungus *Fusarium oxysporum* Requires FOW1, a Gene Encoding a Mitochondrial Protein. *The Plant Cell*, *14*(8): 1869–1883.
- Jain, P. K., Gupta, V. K., Misra, A. K., Gaur, R., Bajpai, V., & Issar, S. (2011). Current Status of *Fusarium* Infection in Human and Animal. *Asian Journal of Animal and Veterinary Advances*, 6(3): 201–227.
- Jensen, H. M. E., Aalbæk, B., Jungersen, G., Hartvig, T., Moser, C., Rozell, B.,
  & Blennow, O. (2011). Immunohistochemical diagnosis of fusariosis with monoclonal antibodies. *Mycoses-Free Communications*, *54* (Poster in 5th Congress on Trends in Medical Mycology, Valencia, Spain) : 51–60.

Jensen, T. G., Gahrn-Hansen, B., Arendrup, M., & Bruun, B. (2004). Fusarium

fungaemia in immunocompromised patients. *Clinical Microbiology and Infection*, *10*(6): 499–501.

- Jiménez, M., Logrieco, A., & Bottalico, A. (1993). Occurrence and Pathogenicity of *Fusarium* Species in Banana Fruits. *Journal of Phytopathology*, 137(3): 214–220.
- Jin, X., Qin, Q., Tu, L., Zhou, X., Lin, Y., & Qu, J. (2007). Toll-like receptors (TLRs) expression and function in response to inactivate hyphae of *Fusarium solani* in immortalized human corneal epithelial cells. *Molecular Vision*, 13, 1953.
- Johnston, S. A., & May, R. C. (2010). The Human Fungal Pathogen *Cryptococcus neoformans* Escapes Macrophages by a Phagosome Emptying Mechanism That Is Inhibited by Arp2/3 Complex-Mediated Actin Polymerisation. *PLoS Pathog*, 6(8): e1001041.
- Jones, M. J., & Epstein, L. (1990). Adhesion of Macroconidia to the Plant Surface and Virulence of Nectria haematococca. *Applied and Environmental Microbiology*, *56*(12): 3772–3778.
- Jung, B., Lee, S., Ha, J., Park, J.-C., Han, S.-S., Hwang, I., Lee, J. (2013).
   Development of a Selective Medium for the Fungal Pathogen *Fusarium* graminearum Using Toxoflavin Produced by the Bacterial Pathogen Burkholderia glumae. *The Plant Pathology Journal*, 29(4): 446–450.
- Jurkunas, U., Behlau, I., & Colby, K. (2009). Fungal keratitis: changing pathogens and risk factors. *Cornea*, *28*(6): 638–643.
- Kanafani, Z. A., & Perfect, J. R. (2008). Resistance to Antifungal Agents: Mechanisms and Clinical Impact. *Clinical Infectious Diseases*, 46(1): 120–128.

173

- Kappe, R., & Schulzeberge, A. (1993). New cause for false-positive results with the pastorex Aspergillus antigen latex agglutination-test. Journal of Clinical Microbiology, 31(9): 2489–2490.
- Karthikeyan, R. S., Leal, S. M., Prajna, N. V., Dharmalingam, K., Geiser, D. M.,
  Pearlman, E., & Lalitha, P. (2011). Expression of innate and adaptive immune mediators in human corneal tissue infected with *Aspergillus* or *Fusarium*. *The Journal of Infectious Diseases*, *204*(6): 942–50.
- Kathiravan, M. K., Salake, A. B., Chothe, A. S., Dudhe, P. B., Watode, R. P., Mukta, M. S., & Gadhwe, S. (2012). The biology and chemistry of antifungal agents: A review. *Bioorganic & Medicinal Chemistry*, 20(19): 5678–5698.
- Katoh, K., & Standley, D. M. (2013). MAFFT multiple sequence alignment software version 7: improvements in performance and usability.
   *Molecular Biology and Evolution*, *30*(4): 772–80.
- Katragkou, A., Kruhlak, M. J., Simitsopoulou, M., Chatzimoschou, A., Taparkou,
  A., Cotten, C. J., Roilides, E. (2010). Interactions between Human
  Phagocytes and Candida albicans Biofilms Alone and in Combination
  with Antifungal Agents. *Journal of Infectious Diseases*, 201(12)
  : 1941–1949.
- Kauffman, C. A. (2004). Zygomycosis: Reemergence of an Old Pathogen. *Clinical Infectious Diseases*, *39*(4): 588–590.
- Kaur, S., & Singh, S. (2014). Biofilm formation by *Aspergillus fumigatus*. *Medical Mycology*, *5*2(1): 2–9.
- Kawamura, S., Maesaki, S., Tomono, K., Tashiro, T., & Kohno, S. (2000).
   Clinical Evaluation of 61 Patients with Pulmonary Aspergilloma. *Internal Medicine*, *39*(3): 209–212.

- Kedzierska, A. (2007). (1 --> 3)-beta-D-glucan--a new marker for the early serodiagnosis of deep-seated fungal infections in humans. Polish Journal of Microbiology / Polskie Towarzystwo Mikrobiologów = The Polish Society of Microbiologists, 56(1): 3–9.
- Khan, Z. U., Ahmad, S., & Theyyathel, A. M. (2008). Diagnostic value of DNA and (1 -> 3)-beta-D-glucan detection in serum and bronchoalveolar lavage of mice experimentally infected with *Fusarium oxysporum*. J. Med. Microbiol., 57(1): 36–42.
- Khor, W. B., Aung, T., Saw, S. M., Wong, T. Y., Tambyah, P. A., Tan, A. L., Tan, D. T. H. (2006). AN outbreak of *Fusarium* keratitis associated with contact lens wear in singapore. *JAMA*, 295(24): 2867–2873.
- Klis, F. M., de Groot, P., & Hellingwerf, K. (2001). Molecular organization of the cell wall of Candida albicans. *Medical Mycology*, *39 Suppl 1*: 1–8.
- Knudsen, G. R., & Dandurand, L. M. C. (2014). Ecological Complexity and the Success of Fungal Biological Control Agents, Ecological Complexity and the Success of Fungal Biological Control Agents. *Advances in Agriculture, Advances in Agriculture, 2014,* e542703.
- Koehler, P., Tacke, D., & Cornely, O. A. (2014). Bone and joint infections by *Mucorales, Scedosporium, Fusarium* and even rarer fungi. *Critical Reviews in Microbiology*, *42*(*1*): 158-171.
- Köhler, G., & Milstein, C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. *Nature*, *256*: 495–497.
- Kolar, S. S. N., Baidouri, H., Hanlon, S., & McDermott, A. M. (2013). Protective Role of Murine β-Defensins 3 and 4 and Cathelin-Related Antimicrobial Peptide in *Fusarium solani* Keratitis. *Infection and Immunity*, *81*(8):

2669–2677.

- Kontoyiannis, D. P., Marr, K. A., Park, B. J., Alexander, B. D., Anaissie, E. J., Walsh, T. J., Pappas, P. G. (2010). Prospective Surveillance for Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients, 2001–2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. *Clinical Infectious Diseases*, *50*(8): 1091–1100.
- Kozel, T. R., & Wickes, B. (2014). Fungal Diagnostics. *Cold Spring Harbor Perspectives in Medicine*, *4*(4): a019299.
- Krcmery, V., Jesenska, Z., Spanik, S., Gyarfas, J., Nogova, J., Botek, R., Trupl,
  J. (1997). Fungaemia due to *Fusarium* spp. in cancer patients. *J Hosp Infect*, *36*(3): 223–8.
- Kriengkauykiat, J., Ito, J. I., & Dadwal, S. S. (2011). Epidemiology and treatment approaches in management of invasive fungal infections. *Clinical Epidemiology*, 3, 175–191.
- Kristensen, R., Torp, M., Kosiak, B., & Holst-Jensen, A. (2005). Phylogeny and toxigenic potential is correlated in *Fusarium* species as revealed by partial translation elongation factor 1 alpha gene sequences. *Mycological Research*, *109*(2): 173–186.
- Kwon, Y. H., & Epstein, L. (1993). A 90-kDa glycoprotein associated with adhesion of *Nectria haematococca* macroconidia to substrata. *Molecular Plant Microbe Interactions*, 6, 481–481.
- Kwon, Y. H., & Epstein, L. (1997). Involvement of the 90 kDa glycoprotein in adhesion of Nectria haematococca macroconidia. Physiological and Molecular Plant Pathology, 51(5): 287–303.

Lackner, M., Najafzadeh, M. J., Sun, J., Lu, Q., & de Hoog, G. S. (2012). Rapid

Identification of *Pseudallescheria* and *Scedosporium* Strains by Using Rolling Circle Amplification. *Applied and Environmental Microbiology*, *78*(1): 126–133.

- Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature*, *227*(5259): 680–685.
- Lagopodi, A. L., Ram, A. F. J., Lamers, G. E. M., Punt, P. J., Van den Hondel,
  C. A. M. J. J., Lugtenberg, B. J. J., & Bloemberg, G. V. (2002). Novel
  Aspects of Tomato Root Colonization and Infection by *Fusarium oxysporum* f. sp. *radicis-lycopersici* Revealed by Confocal Laser
  Scanning Microscopic Analysis Using the Green Fluorescent Protein as a Marker. *Molecular Plant-Microbe Interactions*, *15*(2): 172–179.
- Lass-Flörl, C., Mutschlechner, W., Aigner, M., Grif, K., Marth, C., Girschikofsky,
  M., Nachbaur, D. (2013). Utility of PCR in Diagnosis of Invasive Fungal
  Infections: Real-Life Data from a Multicenter Study. *Journal of Clinical Microbiology*, *51*(3): 863–868.
- Latenser, B. A. (2003). *Fusarium* infections in burn patients: a case report and review of the literature. *The Journal of Burn Care & Rehabilitation*, *24*(5): 285–288.
- Latgé, J. P. (2001). The pathobiology of *Aspergillus fumigatus*. *Trends in Microbiology*, *9*(8): 382–389.
- Latgé, J. P. (2010). Tasting the fungal cell wall. *Cellular Microbiology*, *12*(7): 863–872.
- Latge, J. P., Kobayashi, H., Debeaupuis, J. P., Diaquin, M., Sarfati, J., Wieruszeski, J. M., Fournet, B. (1994). Chemical and immunological characterization of the extracellular galactomannan of *Aspergillus fumigatus*. *Infect Immun*, *62*(12): 5424–5433.

- Lattif, A., & Swindell, K. (2010). History of Antifungals. In *Antifungal therapy* (pp. 1–10). New York [u.a.: Informa Healthcare.
- Lau, A., Chen, S., Sorrell, T., Carter, D., Malik, R., Martin, P., & Halliday, C. (2007). Development and Clinical Application of a Panfungal PCR Assay To Detect and Identify Fungal DNA in Tissue Specimens. *Journal of Clinical Microbiology*, *45*(2): 380–385.
- Lavigne, L. M., Albina, J. E., & Reichner, J. S. (2006). Beta-glucan is a fungal determinant for adhesion-dependent human neutrophil functions. *Journal of Immunology (Baltimore, Md.: 1950)*, *177*(12): 8667–8675.
- Leck, A. K., Thomas, P. A., Hagan, M., Kaliamurthy, J., Ackuaku, E., John, M., Johnson, G. J. (2002). Aetiology of suppurative corneal ulcers in Ghana and south India, and epidemiology of fungal keratitis. *The British Journal of Ophthalmology*, 86(11): 1211–1215.
- Leeflang, M. M., Debets-Ossenkopp, Y. J., Visser, C. E., Scholten, R. J. P. M., Hooft, L., Bijlmer, H. A., Vandenbroucke-Grauls, C. M. (2008).
  Galactomannan detection for invasive aspergillosis in immunocompromized patients. *The Cochrane Database of Systematic Reviews*, (4): CD007394.
- Legrand, C., Anaissie, E., Hashem, R., Nelson, P., Bodey, G. P., & Ro, J. (1991). Experimental fusarial hyalohyphomycosis in a murine model. *Journal of Infectious Diseases*, *164*(5): 944–948.
- Leonard, G., Stevens, J. R., & Richards, T. A. (2009). REFGEN and TREENAMER: Automated Sequence Data Handling for Phylogenetic Analysis in the Genomic Era. *Evolutionary Bioinformatics*, 2009(5): 1–5.
  Leslie, J. F., & Summerell, B. A. (2006). *The Fusarium laboratory manual*.

Blackwell Publishing.

Levitz, S. M. (1992). Overview of host defenses in fungal infections. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 14 Suppl 1,* S37–42.

- Levitz, S. M. (2010). Innate recognition of fungal cell walls. *PLoS Pathogens*, *6*(4): e1000758.
- Levitz, S. M., Huang, H., Ostroff, G. R., & Specht, C. A. (2014). Exploiting fungal cell wall components in vaccines. *Seminars in Immunopathology*, *37*(2): 199–207.
- Li, X. S., Sato, T., Ooiwa, Y., Kusumi, A., Gu, J. D., & Katayama, Y. (2010). Oxidation of elemental sulfur by *Fusarium solani* strain THIF01 harboring endobacterium *Bradyrhizobium* sp. *Microb Ecol*, *60*(1): 96– 104.
- Li, Y., Wang, Z., Beier, R. C., Shen, J., De Smet, D., De Saeger, S., & Zhang, S. (2011). T-2 toxin, a trichothecene mycotoxin: review of toxicity, metabolism, and analytical methods. *Journal of Agricultural and Food Chemistry*, 59(8): 3441–3453.
- Lin, H. C., Chu, P. H., Kuo, Y. H., & Shen, S. C. (2005). Clinical experience in managing *Fusarium solani* keratitis. *Int J Clin Pract*, *59*(5): 549–54.
- Lindow, J. C., Fimlaid, K. A., Bunn, J. Y., & Kirkpatrick, B. D. (2011). Antibodies in Action: Role of Human Opsonins in Killing *Salmonella enterica* Serovar Typhi. *Infection and Immunity*, *79*(8): 3188–3194.
- Litvack, M. L., Post, M., & Palaniyar, N. (2011). IgM Promotes the Clearance of Small Particles and Apoptotic Microparticles by Macrophages. *PLoS ONE*, 6(3): e17223.

Litvinov, N., Silva, M. T. N. da, Heijden, I. M. van der, Graça, M. G., Oliveira, L.

M. de, Fu, L., Levin, A. S. (2015). An outbreak of invasive fusariosis in a children's cancer hospital. *Clinical Microbiology and Infection*, *21*(3): 268.e1–268.e7.

- Liu, P., Wu, X., Liao, C., Liu, X., Du, J., Shi, H., Liu, M. (2014). Escherichia coli and Candida albicans Induced Macrophage Extracellular Trap-Like Structures with Limited Microbicidal Activity. *PLoS ONE*, *9*(2): e90042.
- Liu, X. C., Lu, B. H., Wang, Xue, & Gao, J. (2015). First Report of Fusarium solani Causing Stem and Root Rot on Foeniculum vulgare in Jilin Province of China. Plant Disease, 100(1): 210.
- Liu, Y. S., Wang, N. C., Ye, R. H., & Kao, W. Y. (2014). Disseminated *Fusarium* infection in a patient with acute lymphoblastic leukemia: A case report and review of the literature. *Oncology Letters*, *7*(2): 334–336.
- Lockhart, S. R., Diekema, D. J., & Pfaller, M. A. (2009). CHAPTER 1 The epidemiology of fungal infections. In E. J. A. R. M. A. Pfaller (Ed.), *Clinical Mycology (second edition)* (pp. 1–14). Edinburgh: Churchill Livingstone.
- Lorang, J., Tuori, R., Martinez, J., Sawyer, T., Redman, R., Rollins, J., Dickman, M. (2001). Green fluorescent protein is lighting up fungal biology. *Applied and Environmental Microbiology*, *67*(5): 1987–1994.
- Low, C. Y., & Rotstein, C. (2011). Emerging fungal infections in immunocompromised patients. *F1000 Medicine Reports*, *3*.
- Lowe, R. G. T., & Howlett, B. J. (2012). Indifferent, Affectionate, or Deceitful: Lifestyles and Secretomes of Fungi. *PLoS Pathogens*, *8*(3).
- Lu, X., Gao, Y., Zhang, L., Du, M., Li, S., Wang, T., & Gao, H. (2013). Aetiology analyses of 334 cases fungal keratitis. *[Zhonghua Yan Ke Za Zhi]*

Chinese Journal of Ophthalmology, 49(1): 12–15.

- Lucca, A. J. D. (2007). Harmful fungi in both Agriculture and Medicine. *Revista Iberoamericana de Micología*, *24*, 3–13.
- Luther, K., & Ebel, F. (2006). Toll-like receptors: Recent advances, open questions and implications for aspergillosis control. *Medical Mycology*, *44*(Suppl. 1): S219–S227.
- Ma, H., Croudace, J. E., Lammas, D. A., & May, R. C. (2006). Expulsion of Live
  Pathogenic Yeast by Macrophages. *Current Biology*, *16*(21): 2156–2160.
- Macêdo, D. P. C., Neves, R. P., Souza-Motta, C. M. de, & Magalhães, O. M. C.
  (2007). Engyodontium album fungaemia: the first reported case.
  Brazilian Journal of Microbiology, 38(1): 110–112.
- Mach, R. L., Kullnig-Gradinger, C. M., Farnleitner, A. H., Reischer, G., Adler, A.,
  & Kubicek, C. P. (2004). Specific detection of *Fusarium langsethiae* and related species by DGGE and ARMS-PCR of a β-tubulin (tub1) gene fragment. *International Journal of Food Microbiology*, *95*(3): 333–339.
- Maciá-Vicente, J. G., Jansson, H.-B., Talbot, N. J., & Lopez-Llorca, L. V. (2009). Real-time PCR quantification and live-cell imaging of endophytic colonization of barley (Hordeum vulgare) roots by *Fusarium equiseti* and *Pochonia chlamydosporia*. *The New Phytologist*, *182*(1): 213–228.
- Maragos, C. M., Kurtzman, C., Busman, M., Price, N., & McCormick, S. (2013). Development and Evaluation of Monoclonal Antibodies for the Glucoside of T-2 Toxin (T2-Glc). *Toxins*, *5*(7): 1299–1313.
- Margolin, W. (2000). Green fluorescent protein as a reporter for macromolecular localization in bacterial cells. *Methods (San Diego, Calif.)*, *20*(1): 62–72.

- Marom, E. M., Holmes, A. M., Bruzzi, J. F., Truong, M. T., O'Sullivan, P. J., & Kontoyiannis, D. P. (2008). Imaging of Pulmonary Fusariosis in Patients with Hematologic Malignancies. *American Journal of Roentgenology*, *190*(6): 1605–1609.
- Martinez, L. R., & Casadevall, A. (2005). Specific Antibody Can Prevent Fungal Biofilm Formation and This Effect Correlates with Protective Efficacy. *Infection and Immunity*, *73*(10): 6350–6362.
- Masuoka, J. (2004). Surface Glycans of Candida albicans and Other Pathogenic Fungi: Physiological Roles, Clinical Uses, and Experimental Challenges. *Clinical Microbiology Reviews*, *17*(2): 281–310.
- Mayayo, E., Pujol, I., & Guarro, J. (1999). Experimental pathogenicity of four opportunist *Fusarium* species in a murine model. *J Med Microbiol*, *48*(4): 363–6.
- Mbawuike, I. N., & Herscowitz, H. B. (1989). MH-S, a murine alveolar macrophage cell line: morphological, cytochemical, and functional characteristics. *Journal of Leukocyte Biology*, *46*(2): 119–127.
- McCann, F., Carmona, E., Puri, V., Pagano, R. E., & Limper, A. H. (2005). Macrophage internalization of fungal beta-glucans is not necessary for initiation of related inflammatory responses. *Infection and Immunity*, 73(10): 6340–6349.
- McClenny, N. (2005). Laboratory detection and identification of *Aspergillus* species by microscopic observation and culture: the traditional approach. *Medical Mycology*, *43*(S1): 125–128.
- McCullough, K. C., Parkinson, D., & Crowther, J. R. (1988). Opsonizationenhanced phagocytosis of foot-and-mouth disease virus. *Immunology*, *65*(2): 187–191.

- McDermott, A. M. (2009). The Role of Antimicrobial Peptides at the Ocular Surface. *Ophthalmic Research*, *41*(2): 60–75.
- Mehl, H. L., & Epstein, L. (2007). *Fusarium solani* species complex isolates conspecific with *Fusarium solani* f. sp. *cucurbitae* race 2 from naturally infected human and plant tissue and environmental sources are equally virulent on plants, grow at 37 degrees C and are interfertile. *Environ Microbiol*, *9*(9): 2189–99.
- Mehl, H. L., & Epstein, L. (2008). Sewage and community shower drains are environmental reservoirs of *Fusarium solani* species complex group 1, a human and plant pathogen. *Environ Microbiol*, *10*(1): 219–27.
- Menzin, J., Meyers, J. L., Friedman, M., Perfect, J. R., Langston, A. A., Danna,
  R. P., & Papadopoulos, G. (2009). Mortality, length of hospitalization,
  and costs associated with invasive fungal infections in high-risk
  patients. *American Journal of Health-System Pharmacy: AJHP: Official Journal of the American Society of Health-System Pharmacists*, 66(19):
  1711–1717.
- Mesquita-Rocha, S., Godoy-Martinez, P. C., Gonçalves, S. S., Urrutia, M. D., Carlesse, F., Seber, A., Colombo, A. L. (2013). The water supply system as a potential source of fungal infection in paediatric haematopoietic stem cell units. *BMC Infectious Diseases*, *13*, 289.
- Miceli, M. H., Díaz, J. A., & Lee, S. A. (2011). Emerging opportunistic yeast infections. *The Lancet. Infectious Diseases*, *11*(2): 142–151.
- Mikulska, M., Furfaro, E., Del Bono, V., Gualandi, F., Raiola, A. M., Molinari, M.
  P., Viscoli, C. (2012). Galactomannan testing might be useful for early diagnosis of fusariosis. *Diagn Microbiol Infect Dis*, 72(4): 367–9.

- Mishra, N. N., Ali, S., & Shukla, P. K. (2014). A monoclonal antibody against 47.2 kDa cell surface antigen prevents adherence and affects biofilm formation of *Candida albicans*. *World Journal of Microbiology and Biotechnology*, 31(1): 11–21.
- Modjtahedi, H., Ali, S., & Essapen, S. (2012). Therapeutic application of monoclonal antibodies in cancer: advances and challenges. *British Medical Bulletin*, *104*(1): 41–59.
- Montagna, M. T., Caggiano, G., Lovero, G., De Giglio, O., Coretti, C., Cuna, T., Puntillo, F. (2013). Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project). *Infection*, 41(3): 645–653.
- Moore, D., Robson, G. D., & Trinci, A. P. (2011). *21st Century Guidebook to Fungi with CD*. Cambridge University Press.
- Moretti, A. (2009). Taxonomy of *Fusarium* genus: A continuous fight between lumpers and splitters. *Zbornik Matice Srpske Za Prirodne Nauke*, (117): 7–13.
- Moretti, A., Belisario, A., Tafuri, A., Ritieni, A., Corazza, L., & Logrieco, A. (2002). Production of Beauvericin by Different Races of *Fusarium Oxysporum* f. sp. *Melonis*, The *Fusarium* Wilt Agent of Muskmelon. *European Journal of Plant Pathology*, *108*(7): 661–666.
- Morgan, G., & Levinsky, R. J. (1985). Monoclonal antibodies in diagnosis and treatment. *Archives of Disease in Childhood*, *60*(2): 96–98.
- Morrison, C. J., & Warnock, D. W. (2007). Serodiagnosis: antibody and antigen detection. In J. A. Maertens & K. A. Marr (Eds.) (Vol. 47, pp. 65–119). informa healthcare.

Mossavi-Ayatolahi, S., Farajzadeh, S., Fekri, A., Vares, B., & Fekri, S. (2009).

Cutaneous infection by *Fusarium solani* in an addict man with active hepatitis C. *Iranian Journal of Dermatology*, *12*(Suppl. 3): S12–S15.

- Muhammed, M., Anagnostou, T., Desalermos, A., Kourkoumpetis, T. K., Carneiro, H. A., Glavis-Bloom, J., Mylonakis, E. (2013). *Fusarium* Infection. *Medicine*, *92*(6): 305–316.
- Muhammed, M., Carneiro, H., Coleman, J., & Mylonakis, E. (2011). The challenge of managing fusariosis. *Virulence*, *2*(2): 91–96.
- Mukherjee, P. K., Chandra, J., Yu, C., Sun, Y., Pearlman, E., & Ghannoum, M.
  A. (2012). Characterization of *Fusarium* keratitis outbreak isolates: contribution of biofilms to antimicrobial resistance and pathogenesis. *Invest Ophthalmol Vis Sci*, *53*(8): 4450–7.
- Mulè, G., Susca, A., Stea, G., & Moretti, A. (2004). A Species-Specific PCR Assay Based on the Calmodulin Partial Gene for Identification of *Fusarium Verticillioides*, *F. Proliferatum* and *F. Subglutinans. European Journal of Plant Pathology*, 110(5-6): 495–502.
- Musa, Al Eisa, Halim, Sahovic, Gyger, Chaudhri, Aljurf. (2000). The spectrum of *Fusarium* infection in immunocompromised patients with haematological malignancies and in non-immunocompromised patients: a single institution experience over 10 years. *British Journal of Haematology*, *108*(3): 544–548.
- Naef, A., & Défago, G. (2006). Population structure of plant-pathogenic *Fusarium* species in overwintered stalk residues from Bt-transformed and non-transformed maize crops. *European Journal of Plant Pathology*, *116*(2): 129–143.
- Naznin, H. A., Kimura, M., Miyazawa, M., & Hyakumachi, M. (2013). Analysis of Volatile Organic Compounds Emitted by Plant Growth-Promoting

Fungus *Phoma* sp. GS8-3 for Growth Promotion Effects on Tobacco. *Microbes and Environments*, *28*(1): 42–49.

- Nelson, P. E., Desjardins, A. E., & Plattner, R. D. (1993). Fumonisins, Mycotoxins Produced by *Fusarium* Species: Biology, Chemistry, and Significance. *Annual Review of Phytopathology*, *31*(1): 233–252.
- Nelson, P. E., Dignani, M. C., & Anaissie, E. J. (1994). Taxonomy, biology, and clinical aspects of *Fusarium* species. *Clin. Microbiol. Rev.*, 7(4): 479– 503.
- Netea, M. G., Joosten, L. A. B., van der Meer, J. W. M., Kullberg, B. J., & van de Veerdonk, F. L. (2015). Immune defence against Candida fungal infections. *Nature Reviews Immunology*, *15*(10): 630–642.
- Nganje, W. E., Bangsund, D. A., Leistritz, F. L., Wilson, W. W., & Tiapo, N. M. (2004). Regional Economic Impacts of *Fusarium* Head Blight in Wheat and Barley. *Review of Agricultural Economics*, 26(3): 332–347.
- Nguyen, M. H., Wissel, M. C., Shields, R. K., Salomoni, M. A., Hao, B., Press,
  E. G., Clancy, C. J. (2012). Performance of Candida Real-time
  Polymerase Chain Reaction, β-D-Glucan Assay, and Blood Cultures in
  the Diagnosis of Invasive Candidiasis. *Clinical Infectious Diseases*, 54(9): 1240–1248.
- Nicola, A. M., Casadevall, A., & Goldman, D. L. (2008). Fungal killing by mammalian phagocytic cells. *Current Opinion in Microbiology*, 11(4): 313–317.
- Noble, J. A., Crow, S. A., Ahearn, D. G., & Kuhn, F. A. (1997). Allergic fungal sinusitis in the southeastern USA: involvement of a new agent *Epicoccum nigrum* Ehrenb. ex Schlecht. 1824. *J Med Vet Mycol*, 35(6): 405–9.

- Nucci, M., & Anaissie, E. (2002). Cutaneous infection by *Fusarium* species in healthy and immunocompromised hosts: implications for diagnosis and management. *Clinical Infectious Diseases*, *35*(8): 909–920.
- Nucci, M., & Anaissie, E. (2007). *Fusarium* infections in immunocompromised patients. *Clinical Microbiology Reviews*, *20*(4): 695–704.
- Nucci, M., & Anaissie, E. (2009). Hyalohyphomycosis. In E. J. Anaissie, M. R.
  McGinnis, & M. A. Pfaller (Eds.), *Clinical mycology* (pp. 313–332).
  Elsevier Health Sciences.
- Nucci, M., & Marr, K. A. (2005). Emerging Fungal Diseases. *Clinical Infectious Diseases*, *41*(4): 521–526.
- Nucci, M., Anaissie, E. J., Queiroz-Telles, F., Martins, C. A., Trabasso, P., Solza, C., Souza, C. A. (2003). Outcome predictors of 84 patients with hematologic malignancies and *Fusarium* infection. *Cancer*, *98*(2): 315– 319.
- Nucci, M., Carlesse, F., Cappellano, P., Varon, A. G., Seber, A., Garnica, M.,
   Colombo, A. L. (2014). Earlier Diagnosis of Invasive Fusariosis with
   Aspergillus Serum Galactomannan Testing. *PLoS ONE*, *9*(1): e87784.
- Nucci, M., Marr, K. A., Queiroz-Telles, F., Martins, C. A., Trabasso, P., Costa,
   S., Pasquini, R. (2004). *Fusarium* infection in hematopoietic stem cell
   transplant recipients. *Clinical Infectious Diseases*, *38*(9): 1237–1242.
- Nucci, M., Marr, K. A., Vehreschild, M. J. G. T., de Souza, C. A., Velasco, E., Cappellano, P., Anaissie, E. (2013). Improvement in the outcome of invasive fusariosis in the last decade. *Clinical Microbiology and Infection*, 20(6): 580–585.
- Nucci, M., Tiyomi, A., Gloria, B., Fernanda, S., Revankar, S. G., Brian, L. W., Patterson, T. F. (2002). Nosocomial Outbreak of *Exophiala jeanselmei*

Fungemia Associated with Contamination of Hospital Water. *Clinical Infectious Diseases*, *34*(11): 1475–1480.

- O'Donnell, K. (1996). Progress towards a phylogenetic classification of *Fusarium*. *Sydowia*, *48*(1): 57–70.
- O'Donnell, K. (2000). Molecular phylogeny of the Nectria haematococca-Fusarium solani species complex. *Mycologia*, *92*(5): 919–938.
- O'Donnell, K., & Cigelnik, E. (1997). Two Divergent Intragenomic rDNA ITS2 Types within a Monophyletic Lineage of the Fungus *Fusarium* Are Nonorthologous. *Molecular Phylogenetics and Evolution*, 7(1): 103–116.
- O'Donnell, K., Cigelnik, E., & Casper, H. H. (1998). Molecular Phylogenetic, Morphological, and Mycotoxin Data Support Reidentification of the Quorn Mycoprotein Fungus as *Fusarium venenatum*. *Fungal Genetics and Biology*, *23*(1): 57–67.
- O'Donnell, K., Cigelnik, E., & Nirenberg, H. I. (1998). Molecular Systematics and Phylogeography of the *Gibberella fujikuroi* Species Complex. *Mycologia*, *90*(3): 465–493.
- O'Donnell, K., Gueidan, C., Sink, S., Johnston, P. R., Crous, P. W., Glenn, A., Sarver, B. A. J. (2009). A two-locus DNA sequence database for typing plant and human pathogens within the *Fusarium oxysporum* species complex. *Fungal Genetics and Biology: FG & B, 46*(12): 936–948.
- O'Donnell, K., Kistler, H. C., Cigelnik, E., & Ploetz, R. C. (1998). Multiple evolutionary origins of the fungus causing Panama disease of banana: concordant evidence from nuclear and mitochondrial gene genealogies. *Proceedings of the National Academy of Sciences of the United States of America*, 95(5): 2044–9.

- O'Donnell, K., Sarver, B. A. J., Brandt, M., Chang, D. C., Noble-Wang, J., Park,
  B. J., Ward, T. J. (2007). Phylogenetic Diversity and Microsphere ArrayBased Genotyping of Human Pathogenic Fusaria, Including Isolates
  from the Multistate Contact Lens-Associated U.S. Keratitis Outbreaks of
  2005 and 2006. *Journal of Clinical Microbiology*, *45*(7): 2235–2248.
- O'Donnell, K., Sutton, D. A., Fothergill, A., McCarthy, D., Rinaldi, M. G., Brandt,
  M. E., Geiser, D. M. (2008). Molecular phylogenetic diversity, multilocus
  haplotype nomenclature, and in vitro antifungal resistance within the *Fusarium solani* species complex. *J Clin Microbiol*, *46*(8): 2477–90.
- O'Donnell, K., Sutton, D. A., Rinaldi, M. G., Magnon, K. C., Cox, P. A., Revankar, S. G., Robinson, J. S. (2004). Genetic Diversity of Human Pathogenic Members of the *Fusarium oxysporum* Complex Inferred from Multilocus DNA Sequence Data and Amplified Fragment Length Polymorphism Analyses: Evidence for the Recent Dispersion of a Geographically Widespread Clonal Lineage and Nosocomial Origin. *Journal of Clinical Microbiology*, *42*(11): 5109–5120.
- O'Donnell, K., Sutton, D. A., Rinaldi, M. G., Sarver, B. A. J., Balajee, S. A., Schroers, H. J., Geiser, D. M. (2010). Internet-Accessible DNA Sequence Database for Identifying Fusaria from Human and Animal Infections. *Journal of Clinical Microbiology*, *48*(10): 3708–3718.
- Odabasi, Z., Mattiuzzi, G., Estey, E., Kantarjian, H., Saeki, F., Ridge, R. J., Ostrosky-Zeichner, L. (2004). beta-D-glucan as a diagnostic adjunct for invasive fungal infections: Validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. *Clinical Infectious Diseases*, *39*(2) : 199–205.

- Oh, Y. W., Effmann, E. L., & Godwin, J. D. (2000). Pulmonary Infections in Immunocompromised Hosts: The Importance of Correlating the Conventional Radiologic Appearance with the Clinical Setting. *Radiology*, 217(3): 647–656.
- Ojha, S., Tandon, A., Shukla, D., Saraswat, N., & Joshi, S. (2015). Etiology of suppurative corneal ulcers in rural population of Northern India. *Indian Journal of Clinical and Experimental Ophthalmology*, *1*(2): 62–67.
- Oren, L., Ezrati, S., Cohen, D., & Sharon, A. (2003). Early Events in the *Fusarium verticillioides*-Maize Interaction Characterized by Using a Green Fluorescent Protein-Expressing Transgenic Isolate. *Applied and Environmental Microbiology*, 69(3): 1695–1701.
- Ostrosky-Zeichner, L., Alexander, B. D., Kett, D. H., Vazquez, J., Pappas, P. G.,
  Saeki, F., Rex, J. H. (2005). Multicenter clinical evaluation of the (1 -> 3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. *Clinical Infectious Diseases*, *41*(5): 654–659.
- Pagano, L., Caira, M., Candoni, A., Offidani, M., Fianchi, L., Martino, B., Nosari,
  A. (2006). The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. *Haematologica*, *91*(8): 1068–1075.
- Palmero, D., Iglesias, C., de Cara, M., Lomas, T., Santos, M., & Tello, J. C. (2009). Species of *Fusarium* Isolated from River and Sea Water of Southeastern Spain and Pathogenicity on Four Plant Species. *Plant Disease*, *93*(4): 377–385.
- Palmero, D., Rodríguez, J. M., Cara, M. de, Camacho, F., Iglesias, C., & Tello,J. C. (2010). Fungal microbiota from rain water and pathogenicity of *Fusarium* species isolated from atmospheric dust and rainfall dust.

Journal of Industrial Microbiology & Biotechnology, 38(1): 13–20.

- Pan, X., Wang, Y., Zhou, Q., Chen, P., Xu, Y., Chen, H., & Xie, L. (2011). Activation of focal adhesion kinase enhances the adhesion of *Fusarium solani* to human corneal epithelial cells via the tyrosine-specific protein kinase signaling pathway. *Mol Vis*, *17*, 638–46.
- Park, S. J., & Mehrad, B. (2009). Innate Immunity to Aspergillus Species. Clinical Microbiology Reviews, 22(4): 535–551.
- Parks, L. W., & Casey, W. M. (1995). Physiological Implications of Sterol Biosynthesis in Yeast. *Annual Review of Microbiology*, *49*(1): 95–116.
- Pasanen, A.-L., Yli-Pietilä, K., Pasanen, P., Kalliokoski, P., & Tarhanen, J. (1999). Ergosterol Content in Various Fungal Species and Biocontaminated Building Materials. *Applied and Environmental Microbiology*, 65(1): 138–142.
- Peiqian, L., Xiaoming, P., Huifang, S., Jingxin, Z., Ning, H., & Birun, L. (2014). Biofilm formation by *Fusarium oxysporum* f. sp. *cucumerinum* and susceptibility to environmental stress. *FEMS Microbiology Letters*, 350(2), 138–145.
- Pemán, J., Cantón, E., & Espinel-Ingroff, A. (2009). Antifungal drug resistance mechanisms. *Expert Review of Anti-Infective Therapy*, *7*(4), 453–460.
- Pérez Vicente, L., Dita, M., & Martinez De La Parte, E. (2014). Technical Manual: Prevention and diagnostic of Fusarium Wilt (Panama disease) of banana caused by Fusarium oxysporum f. sp. cubense Tropical Race 4 (TR4). FAORegional Workshop on the Diagnosis of Fusarium Wilt (Panama disease) caused by Fusarium oxysporum f. sp. cubense Tropical Race Tropical Race 4: Mitigating the Threat and Preventing its Spread in the

Caribbean, St. Augustine, Trinidad and Tobago, 05-09/05/2014: FAO.

- Perez-Perez, L., Pereiro, M., Jr., Sanchez-Aguilar, D., & Toribio, J. (2007). Ulcerous lesions disclosing cutaneous infection with *Fusarium solani*. *Acta Derm Venereol*, *87*(5): 422–4.
- Perfect, J. R. (2012). The impact of the host on fungal infections. *American Journal of Medicine*, *125*(1 Suppl.): S39–51.
- Petrikkos, G., Skiada, A., Lortholary, O., Roilides, E., Walsh, T. J., & Kontoyiannis, D. P. (2012). Epidemiology and Clinical Manifestations of Mucormycosis. *Clinical Infectious Diseases*, *54*(Suppl. 1): S23–S34.
- Pfaller, M. A., & Diekema, D. J. (2004). Rare and Emerging Opportunistic Fungal Pathogens: Concern for Resistance beyond Candida albicans and Aspergillus fumigatus. Journal of Clinical Microbiology, 42(10): 4419–4431.
- Pfaller, M. A., Pappas, P. G., & Wingard, J. R. (2006). Invasive Fungal Pathogens: Current Epidemiological Trends. *Clinical Infectious Diseases*, 43(Suppl. 1): S3–S14.
- Phadke, A. P., & Mehrad, B. (2005). Cytokines in host defense against
  Aspergillus: recent advances. Medical Mycology, 43(Suppl. 1)
  : S173–S176.
- Pierce, C. G., Uppuluri, P., Tristan, A. R., Wormley, F. L., Mowat, E., Ramage, G., & Lopez-Ribot, J. L. (2008). A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. *Nature Protocols*, *3*(9): 1494–1500.
- Pilotti, M., Ponzio, V., & Motta, E. (2002). Disorders of Platanus acerifolia in Italy associated with *Fusarium solani*. *Forest Pathology*, *3*2, 249–264.

- Ponton, J., Rüchel, R., Clemons, K. V., Coleman, D. C., Grillot, R., Guarro, J., Sullivan, D. J. (2000). Emerging pathogens. *Medical Mycology*, *38*(Suppl. 1): 225–236.
- Poole, G. J., Smiley, R. W., Walker, C., Huggins, D., Rupp, R., Abatzoglou, J., Paulitz, T. C. (2013). Effect of Climate on the Distribution of *Fusarium* spp. Causing Crown Rot of Wheat in the Pacific Northwest of the United States. *Phytopathology*, *103*(11): 1130–1140.
- Pujol, I., Guarro, J., Gené, J., & Sala, J. (1997). In-vitro antifungal susceptibility of clinical and environmental *Fusarium* spp. strains. *J Antimicrob Chemother*, 39(2): 163–7.
- Raad, I., Tarrand, J., Hanna, H., Albitar, M., Janssen, E., Boktour, M., Rolston,
  K. (2002). Epidemiology, Molecular Mycology, and Environmental
  Sources of Fusarium Infection in Patients with Cancer. *Infection Control & Hospital Epidemiology*, 23(09): 532–537.
- Rajendran, R., Sherry, L., Nile, C. J., Sherriff, A., Johnson, E. M., Hanson, M.
  F., Ramage, G. (2016). Biofilm formation is a risk factor for mortality in patients with *Candida albicans* bloodstream infection—Scotland, 2012–2013. *Clinical Microbiology and Infection*, 22(1): 87–93.
- Ramage, G., Mowat, E., Jones, B., Williams, C., & Lopez-Ribot, J. (2009). Our Current Understanding of Fungal Biofilms. *Critical Reviews in Microbiology*, 35(4): 340–355.
- Ramage, G., Rajendran, R., Gutierrez-Correa, M., Jones, B., & Williams, C. (2011). Aspergillus biofilms: clinical and industrial significance. FEMS Microbiology Letters, 324(2): 89–97.
- Ramage, G., Rajendran, R., Sherry, L., Williams, C., Ramage, G., Rajendran, R., Williams, C. (2012). Fungal Biofilm Resistance, Fungal Biofilm

Resistance. International Journal of Microbiology, International Journal of Microbiology, e528521.

- Richardson, D. M., & Warnock, D. W. (2003). *Fungal Infection: Diagnosis and Management*.
- Roilides, E., Dotis, J., & Katragkou, A. (2007). Fusarium and Scedosporium: emerging fungal pathogens. In K. Kavanagh (Ed.), New Insights in Medical Mycology (pp. 267–285). Springer.
- Roilides, E., Lyman, C. A., Armstrong, D., Stergiopoulou, T., Petraitiene, R., & Walsh, T. J. (2006). Deoxycholate amphotericin B and amphotericin B lipid complex exert additive antifungal activity in combination with pulmonary alveolar macrophages against *Fusarium solani*. *Mycoses*, *49*(2): 109–13.
- Roilides, E., Lyman, C. A., Armstrong, D., Stergiopoulou, T., Petraitiene, R., & Walsh, T. J. (2006). Deoxycholate amphotericin B and amphotericin B lipid complex exert additive antifungal activity in combination with pulmonary alveolar macrophages against Fusarium solani. *Mycoses*, *49*(2): 109–113.
- Rolle, A.-M., Hasenberg, M., Thornton, C. R., Solouk-Saran, D., Männ, L., Weski, J., Wiehr, S. (2016). ImmunoPET/MR imaging allows specific detection of *Aspergillus fumigatus* lung infection in vivo. *Proceedings of the National Academy of Sciences*, *113*(8): E1026–E1033.

Romani, L. (2004). Immunity to fungal infections. *Nat Rev Immunol*, 4(1): 1–23.

- Romani, L. (2011). Immunity to fungal infections. *Nature Reviews Immunology*, *11*(4): 275–288.
- Rougeron, A., Schuliar, G., Leto, J., Sitterlé, E., Landry, D., Bougnoux, M. E., Giraud, S. (2015). Human-impacted areas of France are environmental

reservoirs of the *Pseudallescheria boydii/Scedosporium apiospermum* species complex. *Environmental Microbiology*, *17*(4): 1039–1048.

- Roy, K. (1997). Fusarium solani on soybean roots: nomenclature of the causal agent of sudden death syndrome and identity and relevance of *F. solani* form B. *Plant Disease*, *81*(3): 259–266.
- Sandoval-Denis, M., Sutton, D. A., Cano-Lira, J. F., Gené, J., Fothergill, A. W.,
  Wiederhold, N. P., & Guarro, J. (2014). Phylogeny of the Clinically
  Relevant Species of the Emerging Fungus *Trichoderma* and Their
  Antifungal Susceptibilities. *Journal of Clinical Microbiology*, *52*(6): 2112–2125.
- Sanz, F., Soledad Cuétara, M., del Palacio, A., Campbell, C. K., Johnson, L., Urruzunu, P., & Pía Roiz, M. (1993). [Problems found in the isolation of mycelial fungi (*Fusarium solani*) from blood culture (Bacter NR-860)]. *Enferm Infecc Microbiol Clin*, 11(9): 490–3.
- Sautour, M., Edel-Hermann, V., Steinberg, C., Sixt, N., Laurent, J., Dalle, F., Bonnin, A. (2012). *Fusarium* species recovered from the water distribution system of a French university hospital. *International Journal of Hygiene and Environmental Health*, 215(3): 286–292.
- Schäfer, K., Bain, J. M., Di Pietro, A., Gow, N. A. R., & Erwig, L. P. (2014). Hyphal growth of phagocytosed *Fusarium oxysporum* causes cell lysis and death of murine macrophages. *PLoS ONE*, *9*(7).
- Scheel, C. M., Hurst, S. F., Barreiros, G., Akiti, T., Nucci, M., & Balajee, S. A. (2013). Molecular analyses of *Fusarium* isolates recovered from a cluster of invasive mold infections in a Brazilian hospital. *BMC Infectious Diseases*, *13*(1): 49.

Schmidig, D. (2012). Epidemiology and Outcome of Human Fusariosis as

Reflected in Published Cases of the Disease. University of Zurich.

- Schroers, H. J., O'Donnell, K., Lamprecht, S. C., Kammeyer, P. L., Johnson, S., Sutton, D. A., Summerbell, R. C. (2009). Taxonomy and phylogeny of the *Fusarium dimerum* species group. *Mycologia*, 101(1): 44–70.
- Schuerger, A., & Mitchell, D. (1993). Influence of Mucilage Secreted by Macroconidia of *Fusarium solani* f. sp. *phaseoli* on Spore Attachment to Roots of *Vigna radiata* in Hydroponic Nutrient Solution. *Phytopathology*, *83*(11): 1162–1170.
- Segal, A. W. (2005). How Neutrophils Kill Microbes. Annual Review of Immunology, 23, 197–223.
- Seifert, K. A. (2009). Progress towards DNA barcoding of fungi. *Molecular Ecology Resources*, 9: 83–89.
- Seifert, K. A., & Lévesque, C. A. (2004). Phylogeny and Molecular Diagnosis of Mycotoxigenic Fungi. *European Journal of Plant Pathology*, *110*(5-6): 449–471.
- Sesma, A., & Osbourn, A. E. (2004). The rice leaf blast pathogen undergoes developmental processes typical of root-infecting fungi. *Nature*, 431(7008): 582–586.
- Sganga, G. (2011). Fungal infections in immunocompromised patients. *Mycoses*, *54*, 1–3.
- Shoham, S., & Levitz, S. M. (2005). The immune response to fungal infections. *Br J Haematol*, *129*(5): 569–82.
- Short, D. P., O'Donnell, K., Zhang, N., Juba, J. H., & Geiser, D. M. (2011). Widespread occurrence of diverse human pathogenic types of the fungus *Fusarium* detected in plumbing drains. *J Clin Microbiol*, 49(12): 4264–72.
- Silva, R. F. e. (2010). Chapter 8 Fungal infections in immunocompromised patients. *Jornal Brasileiro de Pneumologia*, *36*(1): 142–147.
- Skadsen, R. W., & Hohn, T. M. (2004). Use of Fusarium graminearum transformed with gfp to follow infection patterns in barley and Arabidopsis. Physiological and Molecular Plant Pathology, 64(1): 45– 53.
- Skiada, A., Pagano, L., Groll, A., Zimmerli, S., Dupont, B., Lagrou, K., Petrikkos, G. (2011). Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. *Clinical Microbiology and Infection*, *17*(12): 1859–1867.
- Slavin, M. A., & Grist, L. M. (2013). Invasive Fungal Infections: A Continuing Challenge Report from the 17th International Symposium on Infections in the Immunocompromised Host, Genoa, Italy, 24–27 July 2012. *Current Fungal Infection Reports*, 7(1): 83–88.
- Slesiona, S., Gressler, M., Mihlan, M., Zaehle, C., Schaller, M., Barz, D., Brock,
  M. (2012). Persistence versus Escape: Aspergillus terreus and
  Aspergillus fumigatus Employ Different Strategies during Interactions
  with Macrophages. PLoS ONE, 7(2).
- Spellig, T., Bottin, A., & Kahmann, R. (1996). Green fluorescent protein (GFP) as a new vital marker in the phytopathogenic fungus *Ustilago maydis*.
  Molecular and General Genetics MGG, 252(5): 503–509.
- Spellig, T., Bottin, A., & Kahmann, R. (1996). Green fluorescent protein (GFP) as a new vital marker in the phytopathogenic fungusUstilago maydis. *Molecular and General Genetics MGG*, 252(5): 503–509.

- Spiess, B., Seifarth, W., Hummel, M., Frank, O., Fabarius, A., Zheng, C.,
   Buchheidt, D. (2007). DNA Microarray-Based Detection and
   Identification of Fungal Pathogens in Clinical Samples from Neutropenic
   Patients. *Journal of Clinical Microbiology*, *45*(11): 3743–3753.
- Srinivasan, A., Lopez-Ribot, J. L., & Ramasubramanian, A. K. (2014). Overcoming antifungal resistance. *Drug Discovery Today. Technologies*, *11*, 1–116.
- Srinoulprasert, Y., Pongtanalert, P., Chawengkirttikul, R., & Chaiyaroj, S. C. (2009). Engagement of *Penicillium marneffei* conidia with multiple pattern recognition receptors on human monocytes. *Microbiology and Immunology*, *53*(3): 162–172.
- Stanzani, M., Tumietto, F., Vianelli, N., & Baccarani, M. (2007). Update on the treatment of disseminated fusariosis: Focus on voriconazole. *Therapeutics and Clinical Risk Management*, 3(6): 1165.
- Steinberg, C., Laurent, J., Edel-Hermann, V., Barbezant, M., Sixt, N., Dalle, F., Sautour, M. (2015). Adaptation of *Fusarium oxysporum* and *Fusarium dimerum* to the specific aquatic environment provided by the water systems of hospitals. *Water Research*, *76*, 53–65.
- Steinmann, J., Schmidt, D., Buer, J., & Rath, P. M. (2011). Discrimination of Scedosporium prolificans against Pseudallescheria boydii and Scedosporium apiospermum by semiautomated repetitive sequencebased PCR. Medical Mycology, 49(5): 475–483.
- Stempel, J. M., Hammond, S. P., Sutton, D. A., Weiser, L. M., & Marty, F. M.
  (2015). Invasive Fusariosis in the Voriconazole Era: Single-Center 13Year Experience. Open Forum Infectious Diseases, 2(3): ofv099.

- Stephens, A. E., Gardiner, D. M., White, R. G., Munn, A. L., & Manners, J. M. (2008). Phases of Infection and Gene Expression of *Fusarium* graminearum During Crown Rot Disease of Wheat. *Molecular Plant-Microbe Interactions*, 21(12): 1571–1581.
- Stevens, D. A. (2002). Diagnosis of fungal infections: current status. *The Journal of Antimicrobial Chemotherapy*, *49 Suppl 1*, 11–19.
- Stynen, D., Goris, A., Sarfati, J., & Latgé, J. P. (1995). A new sensitive sandwich enzyme-linked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis. *Journal of Clinical Microbiology*, 33(2): 497–500.
- Stynen, D., Sarfati, J., Goris, A., Prévost, M. C., Lesourd, M., Kamphuis, H., Latgé, J. P. (1992). Rat monoclonal antibodies against *Aspergillus* galactomannan. *Infection and Immunity*, *60*(6): 2237–2245.
- Sucher, A. J., Chahine, E. B., & Balcer, H. E. (2009). Echinocandins: the newest class of antifungals. *The Annals of Pharmacotherapy*, *43*(10): 1647–1657.
- Summerell, B. A., Salleh, B., & Leslie, J. F. (2003). A Utilitarian Approach to *Fusarium* Identification. *Plant Disease*, *87*(2): 117–128.
- Sutula, C. L., Gillett, J. M., Morrisey, S. M., & Ramsdell, D. C. (1986). Interpreting ELISA data and establishing the positive-negative threshold. *Plant Disease*, *70*, 722–726.
- Swanink, C. M., Meis, J. F., Rijs, A. J., Donnelly, J. P., & Verweij, P. E. (1997). Specificity of a sandwich enzyme-linked immunosorbent assay for detecting *Aspergillus* galactomannan. *Journal of Clinical Microbiology*, 35(1): 257–260.

Tanriover, M. D., Ascioglu, S., Altun, B., & Uzun, O. (2008). Galactomannan on

the stage: prospective evaluation of the applicability in routine practice and surveillance. *Mycoses*, *53*(1): 16–25.

- Tarabishy, A. B., Aldabagh, B., Sun, Y., Imamura, Y., Mukherjee, P. K., Lass, J.
  H., Pearlman, E. (2008). MyD88 regulation of *Fusarium* keratitis is dependent on TLR4 and IL-1R1 but not TLR2. *The Journal of Immunology*, 181(1): 593–600.
- Taylan Sekeroglu, H., Erdem, E., Yagmur, M., Gumral, R., Ersoz, R., Ilkit, M., & Harbiyeli, I. (2012). Successful medical management of recalcitrant *Fusarium solani* keratitis: molecular identification and susceptibility patterns. *Mycopathologia*, 174(3): 233–7.
- Terra, L., Abreu, P. A., Teixeira, V. L., Paixão, I. C. P., Pereira, R., Leal, B., Castro, H. C. (2014). Mycoses and Antifungals: reviewing the basis of a current problem that still is a biotechnological target for marine products. *Marine Biotechnology*, *1*, 12.
- Tewari, J., & Skoropad, W. (1975). Fine structure of the macroconidia of *Fusarium solani. Canadian Journal of Botany*, *53*(19): 2134–2146.
- Thamke, D., Mendiratta, D., Dhabarde, A., & Shukla, A. (2015). Mycotic keratitis due to Engyodontium album: First case report from India. *Indian Journal of Medical Microbiology*, *33*(2): 303.
- Theel, E. S., & Doern, C. D. (2013). β-d-Glucan Testing Is Important for Diagnosis of Invasive Fungal Infections. *Journal of Clinical Microbiology*, 51(11): 3478–3483.
- Thornton, C. R. (2001). Immunological methods for fungi. In N. J. Talbot (Ed.), Molecular and cellular biology of filamentous fungi: a practical approach (Vol. 249, pp. 227–257). Oxford: Oxford University Press.

Thornton, C. R. (2008). Development of an immunochromatographic lateral-flow

device for rapid serodiagnosis of invasive aspergillosis. *Clin Vaccine Immunol*, *15*(7): 1095–105.

- Thornton, C. R. (2008). Development of an Immunochromatographic Lateral-Flow Device for Rapid Serodiagnosis of Invasive Aspergillosis. *Clinical and Vaccine Immunology*, *15*(7): 1095–1105.
- Thornton, C. R. (2009). Tracking the emerging human pathogen *Pseudallescheria boydii* by using highly specific monoclonal antibodies. *Clinical and Vaccine Immunology*, *16*(5): 756–764.
- Thornton, C. R. (2010a). Detection of invasive aspergillosis. *Advances in Applied Microbiology*, *70*, 187–216.
- Thornton, C. R. (2010b). Environmental fungi as a cause of human mycoses. *Cultue*, *31*(2): 1–8.
- Thornton, C. R. (2011). Environmental fungi as a cause of human mycoses. *Biomedical Scientist*, *55*(10): 716–21.
- Thornton, C. R. (2012). Serological techniques for diagnosis. In *Fungal Plant Pathogens (Principles and Protocols Series)* (Vols. 1, The Food and Environment Research Agency (Fera), P. Beales, The Food and Environment Research Agency (Fera), K. Hughes, The Food and Environment Research Agency (Fera), UK, pp. 159–177). Wallingford, UK: CABI.
- Thornton, C. R., & Talbot, N. J. (2006). Immunofluorescence microscopy and immunogold EM for investigating fungal infections of plants. *Nat. Protoc.*, *5*, 2506–2511.
- Thornton, C. R., & Wills, O. E. (2015). Immunodetection of Fungal and Oomycete Pathogens: Established and Emerging Threats to Human Health, Animal Welfare and Global Food Security. *Critical Reviews in*

Microbiology, 41(1): 27-51.

- Thornton, C. R., Pitt, D., Wakley, G. E., & Talbot, N. J. (2002). Production of a monoclonal antibody specific to the genus *Trichoderma* and closely related fungi, and its use to detect *Trichoderma* spp. in naturally infested composts. *Microbiology*, *148*(5): 1263–1279.
- Thornton, C. R., Ryder, L. S., Le Cocq, K., & Soanes, D. M. (2015). Identifying the emerging human pathogen *Scedosporium prolificans* by using a species-specific monoclonal antibody that binds to the melanin biosynthetic enzyme tetrahydroxynaphthalene reductase. *Environmental Microbiology*, *17*(4): 1023–1038.
- Timling, I., Walker, D. A., Nusbaum, C., Lennon, N. J., & Taylor, D. L. (2014). Rich and cold: diversity, distribution and drivers of fungal communities in patterned-ground ecosystems of the North American Arctic. *Molecular Ecology*, *23*(13): 3258–3272.
- Torres, H. A., & Kontoyiannis, D. P. (2011). Hyalohyphomycoses (Hyaline Moulds). In C. A. Kauffman, P. G. Pappas, J. D. Sobel, & W. E. Dismukes (Eds.), *Essentials of Clinical Mycology* (pp. 281–304). Springer New York.
- Tortorano, A. M., Esposto, M. C., Prigitano, A., Grancini, A., Ossi, C., Cavanna, C., & Cascio, G. L. (2012). Cross-Reactivity of *Fusarium* spp. in the *Aspergillus* Galactomannan Enzyme-Linked Immunosorbent Assay. *Journal of Clinical Microbiology*, *50*(3): 1051–1053.
- Tortorano, A. M., Prigitano, A., Esposto, M. C., Arsic Arsenijevic, V., Kolarovic, J., Ivanovic, D., ECMM Working Group. (2014). European Confederation of Medical Mycology (ECMM) epidemiological survey on invasive infections due to *Fusarium* species in Europe. *European*

Journal of Clinical Microbiology & Infectious Diseases: Official Publication of the European Society of Clinical Microbiology, 33(9): 1623–1630.

- Tortorano, A. M., Richardson, M., Roilides, E., van Diepeningen, A., Caira, M., Munoz, P., Lass-Flörl, C. (2014). ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: *Fusarium* spp., *Scedosporium* spp. and others. *Clinical Microbiology and Infection*, 20, 27–46.
- Tournu, H., & Van Dijck, P. (2011). Candida Biofilms and the Host: Models and New Concepts for Eradication. *International Journal of Microbiology*, 2012, e845352.
- Tsitsikas, D. A., Morin, A., Araf, S., Murtagh, B., Johnson, G., Vinnicombe, S., Agrawal, S. G. (2012). Impact of the revised (2008) EORTC/MSG definitions for invasive fungal disease on the rates of diagnosis of invasive aspergillosis. *Medical Mycology*, 50(5): 538–542.
- Tucker, S. L., & Talbot, N. J. (2001). Surface Attachment and Pre-Penetration Stage Development by Plant Pathogenic Fungi. Annual Review of Phytopathology, 39(1): 385–417.
- Tumbarello, M., Posteraro, B., Trecarichi, E. M., Fiori, B., Rossi, M., Porta, R., Sanguinetti, M. (2007). Biofilm Production by *Candida* Species and Inadequate Antifungal Therapy as Predictors of Mortality for Patients with Candidemia. *Journal of Clinical Microbiology*, *45*(6): 1843–1850.
- van Diepeningen, A. D. van, Al-Hatmi, A. M. S., Brankovics, B., & Hoog, G. S. de. (2014). Taxonomy and Clinical Spectra of *Fusarium* Species: Where

Do We Stand in 2014? Current Clinical Microbiology Reports, 1(1-2)

- van Diepeningen, A. D. van, Brankovics, B., Iltes, J., Lee, T. A. J. van der, & Waalwijk, C. (2015). Diagnosis of Infections: Approaches to Identification by the Clinical Mycology Laboratory. *Current Fungal Infection Reports*, *9*(3): 135–143.
- van Diepeningen, A. D., Feng, P., Ahmed, S., Sudhadham, M., Bunyaratavej,
   S., & de Hoog, G. S. (2015). Spectrum of *Fusarium* infections in tropical dermatology evidenced by multilocus sequencing typing diagnostics.
   *Mycoses*, 58(1): 48–57.
- van Kessel, K. P. M., Bestebroer, J., & van Strijp, J. A. G. (2014). Neutrophilmediated phagocytosis of Staphylococcus aureus. *Microbial Immunology*, *5*, 467.
- Verma, S., & Tuft, S. J. (2002). *Fusarium solani* keratitis following LASIK for myopia. *Br J Ophthalmol*, *86*(10): 1190–1.
- Verweij, P. E., & Mennink-Kersten, M. A. (2006). Issues with galactomannan testing. *Medical Mycology*, *44*(s1): 179–183.
- Vismer, H. F., Marasas, W. F. O., Rheeder, J. P., & Joubert, J. J. (2002). *Fusarium dimerum* as a cause of human eye infections. *Medical Mycology*, *40*(4): 399–406.
- Wallander, H., Ekblad, A., Godbold, D. L., Johnson, D., Bahr, A., Baldrian, P., Rudawska, M. (2013). Evaluation of methods to estimate production, biomass and turnover of ectomycorrhizal mycelium in forests soils – A review. *Soil Biology and Biochemistry*, *57*, 1034–1047.
- Walsh, T., & Groll, A. (1999). Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. *Transplant Infectious Disease*, 1(4): 247–261.

- Walsh, T., Groll, A., Hiemenz, J., Fleming, R., Roilides, E., & Anaissie, E. (2004). Infections due to emerging and uncommon medically important fungal pathogens. *Clinical Microbiology and Infection*, *10*(s1): 48–66.
- Wang, H., Qi, M., & Cutler, A. J. (1993). A simple method of preparing plant samples for PCR. *Nucleic Acids Research*, *21*(17): 4153–4.
- Wang, H., Xiao, M., Kong, F., Chen, S., Dou, H. T., Sorrell, T., Xu, Y. C. (2011).
   Accurate and practical identification of 20 *Fusarium* species by sevenlocus sequence analysis and reverse line blot hybridization, and an in vitro antifungal susceptibility study. *J Clin Microbiol*, *49*(5): 1890–8.
- Wang, H., Xu, Z., Gao, L., & Hao, B. (2009). A fungal phylogeny based on 82 complete genomes using the composition vector method. BMC Evolutionary Biology, 9(1): 195.
- Wasylnka, J. A., & Moore, M. M. (2000). Adhesion of *Aspergillus* species to extracellular matrix proteins: evidence for involvement of negatively charged carbohydrates on the conidial surface. *Infection and Immunity*, *68*(6): 3377–3384.
- Wasylnka, J. A., & Moore, M. M. (2002). Uptake of Aspergillus fumigatus Conidia by phagocytic and nonphagocytic cells in vitro: quantitation using strains expressing green fluorescent protein. *Infection and Immunity*, 70(6): 3156–3163.
- Wellington, M., Bliss, J. M., & Haidaris, C. G. (2003). Enhanced Phagocytosis of Candida Species Mediated by Opsonization with a Recombinant Human Antibody Single-Chain Variable Fragment. *Infection and Immunity*, *71*(12): 7228–7231.
- Wellington, M., Dolan, K., & Haidaris, C. G. (2007). Monocyte responses to Candida albicans are enhanced by antibody in cooperation with

antibody-independent pathogen recognition. *FEMS Immunology* & *Medical Microbiology*, *51*(1): 70–83.

- Wheat, L. J., Goldman, M., & Sarosi, G. A. (2002). Fungal Infections in the Immunocompromised Host. In Robert H Rubin, Lowell S Young (Eds.), *Clinical Approach to Infection in the Compromised Host* (pp. 215–247).
  Springer US.
- Wheat, L. J., Hackett, E., Durkin, M., Connolly, P., Petraitiene, R., Walsh, T. J.,
  Hage, C. (2007). Histoplasmosis-Associated Cross-Reactivity in the
  BioRad Platelia Aspergillus Enzyme Immunoassay. *Clinical and Vaccine Immunology*, *14*(5): 638–640.
- White, T., Bruns, T., Lee, S., & Taylor, J. (1990). Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics, 315 322.
- Williams, A. E., Hussell, T., & Lloyd, C. (2012). *Immunology: mucosal and body surface defences* (1st ed.). A John Wiley & Sons, Ltd., Publication.
- Wong, W. c., White, M., & Wright, I. g. (1988). Production of monoclonal antibodies to *Fusarium oxysporum* f.sp. *cubense* race 4. *Letters in Applied Microbiology*, *6*(3): 39–42.
- Wüthrich, M., Deepe, G. S., & Klein, B. (2012). Adaptive Immunity to Fungi. Annual Review of Immunology, 30, 115–148.
- Xia, Y., Větvička, V., Yan, J., Hanikýřová, M., Mayadas, T., & Ross, G. D. (1999). The β-Glucan-Binding Lectin Site of Mouse CR3 (CD11b/CD18) and Its Function in Generating a Primed State of the Receptor That Mediates Cytotoxic Activation in Response to iC3b-Opsonized Target Cells. *The Journal of Immunology*, *162*(4): 2281–2290.

- Yang, Z., Jaeckisch, S. M., & Mitchell, C. G. (2000). Enhanced binding of *Aspergillus fumigatus* spores to A549 epithelial cells and extracellular matrix proteins by a component from the spore surface and inhibition by rat lung lavage fluid. *Thorax, 55(7):* 579–584.
- Yazar, S., & Omurtag, G. Z. (2008). Fumonisins, Trichothecenes and Zearalenone in Cereals. *International Journal of Molecular Sciences*, 9(11): 2062–2090.
- Yera, H., Bougnoux, M. E., Jeanrot, C., Baixench, M. T., De Pinieux, G., & Dupouy-Camet, J. (2003). Mycetoma of the Foot Caused by *Fusarium solani*: Identification of the Etiologic Agent by DNA Sequencing. *Journal of Clinical Microbiology*, *41*(4): 1805–1808.
- Yli-Mattila, T. (2010). Ecology and evolution of toxigenic *Fusarium* species in cereals in northern europe and asia. *Journal of Plant Pathology*, 92(1): 7–18.
- Yli-Mattila, T., Mach, R. L., Alekhina, I. A., Bulat, S. A., Koskinen, S., Kullnig-Gradinger, C. M., Klemsdal, S. S. (2004). Phylogenetic relationship of *Fusarium langsethiae* to *Fusarium poae* and *Fusarium sporotrichioides* as inferred by IGS, ITS, β-tubulin sequences and UP-PCR hybridization analysis. *International Journal of Food Microbiology*, 95(3), 267–285.
- Yli-Mattila, T., Paavanen-Huhtala, S., Bulat, S. A., Alekhina, I. A., & Nirenberg,
  H. I. (2002). Molecular, morphological and phylogenetic analysis of the *Fusarium avenaceum/F. arthrosporioides/F. tricinctum* species complex –a polyphasic approach. *Mycological Research*, *106*(6): 655–669.
- Yoshida, M. (2006). Usefulness of determination of beta-D-glucan in the diagnosis of deep mycosis - Experience in Japan. *Medical Mycology*, 44, S185–S189.

- Yoshida, M., Obayashi, T., Iwama, A., Ito, M., Tsunoda, S., Suzuki, T., Miura, Y. (1997). Detection of plasma  $(1 \rightarrow 3)$ - $\beta$ -d-glucan in patients with *Fusarium*, *Trichosporon*, *Saccharomyces* and *Acremonium fungaemias*. *Medical Mycology*, *35*(5): 371–374.
- Zeng, J. S., Sutton, D. A., Fothergill, A. W., Rinaldi, M. G., Harrak, M. J., & de Hoog, G. S. (2007). Spectrum of Clinically Relevant *Exophiala* Species in the United States. *Journal of Clinical Microbiology*, 45(11): 3713– 3720.
- Zhang, J., Bruton, B. D., & Biles, C. L. (1999). Fusarium solani endopolygalacturonase from decayed muskmelon fruit: purification and characterization. *Physiological and Molecular Plant Pathology*, 54(5-6) : 171–186.
- Zhang, N., O'Donnell, K., Sutton, D. A., Nalim, F. A., Summerbell, R. C., Padhye, A. A., & Geiser, D. M. (2006). Members of the *Fusarium solani* Species Complex That Cause Infections in Both Humans and Plants Are Common in the Environment. *Journal of Clinical Microbiology*, 44(6): 2186–2190.
- Zhang, S., Zhao, B., Liu, X., Gao, Z., & Huang, X. (2013). Construction of a new GFP vector and its use for *Fusaruim oxysporum* transformation. *Saudi Journal of Biological Sciences*, 20(1): 23–27.





**Figure 5.1.** Agglutination of *Fusarium* species microconidia. (**A**) *F. sacchari* (CBS183.32), (**B**) *F. verticilliodes* (CBS102.699), (**C**) *F. oxysporum* var. *vasinfectum* (CBS409.96), (**D**) *F. solani* var. *petroliphilum* (CBS102256), (**E**) *F. anthothilum* (CBS222.76), (**F**) *F. solani* (CBS188.34), (**G**) *F. solani* (CBS117.608) and (**H**) *F. solani* (CBS109.696) spores suspended at 10<sup>6</sup> spore ml<sup>-1</sup> in ED7 TCS and 10% TCM. Each point is the mean of 3 replicates  $\pm$  S.E. Note rapid decrease in absorbance of light at 555nm due to agglutination of spores by mAb ED7.



**Figure 5.2.** Agglutination of *Fusarium* species microconidia. (**A**) *F. proliferatum* var. *proliferatum* (CBS181.30), (**B**) *F. nygami* (CBS140.93), (**C**) *F. oxysporum* f.sp. *radicis-lycopersici* (CBS872.95) and (**D**) *F. oxysporum* f.sp. *lycopersici* (CBS167.30) spores suspended at  $10^6$  spore ml<sup>-1</sup> in ED7 TCS and 10% TCM. Each point is the mean of 3 replicates ± S.E. Note weak agglutination of spores of these strains by mAb ED7 compared to above strains (**Figure 5.1**).



**Figure 5.3.** Agglutination of *Fusarium* species microconidia. (**A**) *F. oxysporum* f.sp. *cucurbitacearum* (CBS254.52), (**B**) *F. incarnatum* (CBS678.77), (**C**) *F. solani* (CBS115.659) and (**D**) *F. chlamydosporium* var. *chlamydosporium* (CBS491.77) spores suspended at  $10^6$  spore ml<sup>-1</sup> in ED7 TCS and 10% TCM. Each point is the mean of 3 replicates ± S.E. Note lack of spore agglutination of these strains compared to *F. solani* (CBS224.34).

# **APPENDIX 2: Phylogeny Trees**



cont.













Figure 5. 4. Phylogram of the recovered fungal isolates from sink drains and water system based on ITS compare with reference isolates from NCBI. The trees are divided based on location of swab samples (**A** and **B**): University, (**C**): ICU, (**D**): ITU, (**E**): Ophthalmology Unit, (**F**): Haematology Unit and (**G**): Oncology Unit.

### **APPENDIX 3: ITS Sequences**

>Seq1 [organism=*Candida parapsilosis*] [isolate X9-2] internal transcribed spacer 1, 5.8S ribosomal RNA gene, and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq2 [organism=*Candida parapsilosis*] [isolate X9-3] internal transcribed spacer 1, 5.8S ribosomal RNA gene, and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq3 [organism=*Candida parapsilosis*] [isolate X3-2] internal transcribed spacer 1, 5.8S ribosomal RNA gene, and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq4 [organism=*Candida parapsilosis*] [isolate X6-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq5 [organism=*Fusarium dimerum*] [isolate X4-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq6 [organism=*Rhodotorula mucilaginosa*] [isolate X5-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq7 [organism=*Exophiala pisciphila*] [isolate X9-7] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq8 [organism=*Exophiala dermatitidis*] [isolate X9-4] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

CTCTCAGGCCGACCTCCCAACCCTTTGTTTACCCGACCCATGTTGCTTCGGCGGGCCCGC CGTTTCGACGGCCGCCGGAGGACCGCCTATTCAGGTCCTCTGGCCCGCGCCGCCGGTA GCCAATTCTACCAAACTCTTGAATCAAATCGTGTCCAATGTCTGAGTATATTACAAAATAA AAGCAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGAACGCAGCGAAAT GCGATAAGTAATGCGAATTGCAGAATTCCAGTGAGTCATCGAATCTTTGAACGCACATTG CGCCCTTTGGTATTCCGAAGGGCATGCCTGTTCGAGCGTCATTATCACCCCTCAAGCCCC CCGGCTTGGTGTTGGACGGTCTGGTCGAGCGTTTCCGCGCGACCCCTCCCAAAGACAATG ACGGCGGCCTGGTTGGACCCCCGGTACACGGAGCTTCTTCACTGAGCACGTATCGGTTTC AAGGTGTCCCCGGGACCCGGTCGACCTCTCTTGCTCCCCTGCGGGAGTGGGAGAGAACC CCCCTTTTATCAAGGTTGACCTCGGATCAGGTAGGAATACCCGCTGAACTTAAGCATATC AATAAGCGAGGGAAAAA

>Seq9 [organism=*Exophiala phaeomuriformis*] [isolate X6-4] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

TCAGGCCGACCTCCCAACCCTTTGTCTATTGAACCCTTGTTGCTTCGGCGGGCCCGTCGT TATACGGCCGCCGGAGGACCGACTCCAGGTCCTCTGGCCCGCGCCGCCGGCGGTAGCCAAA ATCACCAAACTCTTGAATAATCGTGTCTATGATGTCTGAGTACTTTTATTAAAATTAAGCA AAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGAACGCAGCGAAATGCGAT AAGTAATGCGAATTGCAGAATTCCAGTGAGTCATCGAATCTTTGAACGCACATTGCGCCC TTTGGTATTCCGAAGGGCATGCCTGTTCGAGCGTCATTATCACCCCTCAAGCCCTCCGGC TTGGTGTTGGACGGTCTGGTCGAGCTGCTCGACCCCTCCCAAAGACAATGACGGCGGCCT GGTTGGACCCCCGGTACATGGAGCTTCTTGATTGAGCACGTATCGGTTTCAAGGCGTCCC

## CGGGACCCGGTCTCACTCTCCCCTCGCGGGAGGGAACCCCCCTTTTTTCTAAGGTTGA CCTCGGATCAGGTAGGAATACCCGCTGAACTTAAGCATATCAATAACGAAGG

>Seq10 [organism=*Coniothyrium fuckelii*] [isolate W1-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq11 [organism=*Cladosporium macrocarpum*] [isolate X8-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

CGACGCCGGGCTTCGGCCTGGTTATTCATAACCCTTTGTTGTCCGACTCTGTTGCCTCCG GGGCGACCCTGCCTTCGGGCGGGGGCTCCGGGTGGACACTTCAAACTCTTGCGTAACTTT GCAGTCTGAGTAAACTTAATTAATAAATTAAAACTTTTAACAACGGATCTCTTGGTTCTG GCATCGATGAAGAACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAAT CATCGAATCTTTGAACGCACATTGCGCCCCCTGGTATTCCGGGGGGGCATGCCTGTTCGAG CGTCATTTCACCACTCAAGCCTCGCTTGGTATTGGGCAACGCGGTCCGCCGCGTGCCTCA AATCGTCCGGCTGGGTCTTCTGTCCCCTAAGCGTTGTGGAAACTATTCGCTAAAGGGTGT TCGGGAGGCTACGCCGTAAAACAACCCCATTTCTAAGGTTGACCTCGGATCAGGTAGGGA TACCCGCTGAACTTAAGCATATCAATAAGCGGAGGGAAAAAGAAATGTCCTAA

>Seq12 [organism=*Cladosporium sphaerospermum*] [isolate X10-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

CGGCCCTCGGGCCGGGATGTTCACAACCCTTTGTTGTCCGACTCTGTTGCCTCCGGGGGG ACCCTGCCTCCGGGCGGGGGCCCCGGGTGGACATCTCAAACTCTTGCGTAACTTTGCAGT CTGAGTAAATTTAATTAATAAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATC GATGAAGAACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCG AATCTTTGAACGCACATTGCGCCCCCTGGTATTCCGGGGGGGCATGCCTGTTCGAGCGTCA TTTCACCACTCAAGCCTCGCTTGGTATTGGGCGACGCGGTCCGCCGCGCGCCTCAAATCG ACCGGCTGGGTCTTTCGTCCCCTCAGCGTTGTGGAAACTATTCGCTAAAGGGTGCCGCGG GAGGCCACGCCGTAAAACAACCCCATTTCTAAGGTTGACCTCGGATCAGGTAGGGATACC

#### CGCTGAACTTAAGCATATCAATAAGCGGGGGAAAA

>Seq13 [organism=*Candida parapsilosis*] [isolate X4-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

CTGTGGACATACCTACACGTTGCCTCGGCGGACCCCCGCCTCCCCGTAACACGGGAGCG GCCCGCCAGAGGACCCAACAAACCCTGTTATTTTCAGTATCTTCTGAGTGAAAAACACAATC AATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGAACGCAGCGAAAT GCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGAACGCACATTGC GCCCGCCAGTACTCTGGCGGGGCATGCCTGTTCGAGCGTCATTACATCCCTCAAGCCCCTT CGGGCTTGGTGTTGGGCATCGGCCGTCCCTCCAGCGGCGGCCGTGCCCCAAATACAGTG GCGGTCTCGCCCCGGCTCCTCTGCGTAGTAGTAACATCTCGCACTGGGACGGAGCGTA GGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCGGATCAGGTAGGAATACCC GCTGAACTTAAGCATATCAATAAGCGAGGGAAAAAGAAAACCAAA

>Seq14 [organism=*Fusarium dimerum*] [isolate X3-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

GATACAACTCCCAACCCTGTGACATACCTACAACGTTGCCTCGGCGGACCCCCGCCTCCC CGTAACACGGGAGCGGCCCGCCAGAGGACCCAACAAACCCTGTTATTTTCAGTATCTTCT GAGTGAAAACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATG AAGAACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATC TTTGAACGCACATTGCGCCCGCCAGTACTCTGGCGGGCATGCCTGTTCGAGCGTCATTAC ATCCCTCAAGCCCCTTCGGGCTTGGTGTTGGGCATCGGCCGTCCCTCCAGCGGCGGCCG TGCCCCAAATACAGTGGCGGTCTCGCCCCGGCTCCTCTGCGTAGTAGTAACATCTCGCA CTGGGACGGAGCGTAGGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCGGA TCAGGTAGGAATACCGCTGAACTTAAGCATATCAATAAGCGAGGGAAAAAGAAAACCCA

>Seq15 [organism=*Fusarium dimerum*] [isolate X5-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

ACCTCCCAACCCCTGTGACATACCTACAACGTTGCCTCGGCGGACCCCCGCCTCCCCGTA ACACGGGAGCGGCCCGCCAGAGGACCCAACAAACCCTGTTATTTTCAGTATCTTCTGAGT GAAAACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGA ACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTG AACGCACATTGCGCCCGCCAGTACTCTGGCGGGGCATGCCTGTTCGAGCGTCATTACATCC CTCAAGCCCCTTCGGGCTTGGTGTTGGGCATCGGCCGTCCCTCCAGCGGCGGCCGTGCC CCAAATACAGTGGCGGTCTCGCCCCGGCCCCCGGCCCTCTGCGTAGTAGTAACATCTCGCACTGG GACGGAGCGTAGGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCGGATCAG GTAGGAATACCCGCTGAACTTAAGCATATCAATAAGCGGGGGGAA >Seq16 [organism=*Fusarium dimerum*] [isolate X4-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

GATCACTCCAACCCCTGTGACATACCTACACGTTGCCTCGGCGGACCCCCGCCTCCCCGT AACACGGGAGCGGCCCGCCAGAGGACCCAACAAACCCTGTTATTTTCAGTATCTTCTGAG TGAAAACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAG AACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTT GAACGCACATTGCGCCCGCCAGTACTCTGGCGGGGCATGCCTGTTCGAGCGTCATTACATC CCTCAAGCCCCTTCGGGCTTGGTGTTGGGCATCGGCCGTCCCTCCAGCGGCGGCCGTGC CCCAAATACAGTGGCGGTCTCGCCCCGGCTCCTCTGCGTAGTAGTAACATCTCGCACTG GGACGGAGCGTAGGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCGGATCA GGTAGGAATACCGCTGAACTTAAGCATATCAATAAGCGGAGGGAAAAGAAAACGAC

>Seq17 [organism=*Fusarium dimerum*] [isolate X3-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

GATCACTCCCAACCCCTGTGACATACCTACAACGTTGCCTCGGCGGACCCCCGCCTCCCC GTAACACGGGAGCGGCCCGCCAGAGGACCCAACAAACCCTGTTATTTTCAGTATCTTCTG AGTGAAAACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGA AGAACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCT TTGAACGCACATTGCGCCCGCCAGTACTCTGGCGGGCATGCCTGTTCGAGCGTCATTACA TCCCTCAAGCCCCTTCGGGCTTGGTGTTGGGCATCGGCCGTCCCTCCAGCGGCGGCCGT GCCCCAAATACAGTGGCGGTCTCGCCCCGGCTCCTCTGCGTAGTAGTAACATCTCGCAC TGGGACGGAGCGTAGGCCACGCCGTAAAACAACCAACCCAACTTTCTGAATGTTGACCTCGGAT CAGGTAGGAATACCCGCTGAACTTAAGCATATCAATAAGCGAGGGAAAAAGAAAACCCC

>Seq18 [organism=*Fusarium dimerum*] [isolate X5-4] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

CATCACTCCAACCCTGTGACATACCTACAACGTTGCCTCGGCGGACCCCCGCCTCCCCGT AACACGGGAGCGGCCCGCCAGAGGACCCAACAAACCCTGTTATTTTCAGTATCTTCTGAG TGAAAACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAG AACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTT GAACGCACATTGCGCCCGCCAGTACTCTGGCGGGGCATGCCTGTTCGAGCGTCATTACATC CCTCAAGCCCCTTCGGGCTTGGTGTTGGGCATCGGCCGTCCTCCCAGCGGCCGTGC CCCAAATACAGTGGCGGTCTCGCCCCGGCTCCTCTGCGTAGTAACATCTCGCACTG GGACGGAGCGTAGGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCGGATCA GGTAGGAATACCGCTGAACTTAAGCATATCAATAAGCGAGGGAAAAAGAAAACCC >Seq19 [organism=*Gloeotinia temulenta*] [isolate X8-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq20 [organism=*Gloeotinia temulenta*] [isolate X4-4] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq21 [organism=*Engyodontium album*] [isolate W1-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq22 [organism=*Engyodontium album*] [isolate W1-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq23 [organism=*Engyodontium album*] [isolate X10-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq24 [organism=*Engyodontium album*] [isolate X9-5] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

## 

>Seq25 [organism=*Engyodontium album*] [isolate X9-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq26 [organism=*Engyodontium album*] [isolate X6-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq27 [organism=*Engyodontium album*] [isolate X6-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

CATGTGACATACCTACAAGTTGCTTCGGCGGAGCCGCCCCGGCGCCCCGGAACGTCTGTTT CGCGGCCCGGAACCAGGTGCCCGCCGGAGACCACAAACTCTTTTGTATTTACAGTATCTT CTGAGTGTGCCGCAAGGCAACAAACAAATGAATCAAAACTTTCAACAACGGATCTCTTGG TTCTGGCATCGATGAAGAACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAG TGAATCATCGAATCTTTGAACGCACATTGCGCCCGCCAGAATTCTGGCGGGCATGCCTGT TCGAGCGTCATTTCAACCCTCGGTCTCCCTCCGGGAGAGACCGGCGTTGGGGGACCGGCA CTTACCCCGCCGGCCCCGAAATGGAGTGGCGGCCCGTCCGCGGCGACCTCTGCGTAGTA AATCCACTCGCACCGGGACCCGGGCGCGCGCCACGCCGTAAAACCCCCCACCTTCCGAATG TTGACCTCGAATCAGGTAGGAATACCCGCTGAACTTAAGCATATCAATAAGCGGAGGAAAA GAAAATCTCT

>Seq28 [organism=*Engyodontium album*] [isolate X8-4] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq29 [organism=*Candida parapsilosis*] [isolate K6-4] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq30 [organism=*Candida parapsilosis*] [isolate K9-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

## TTCGACCTCAAATCAGGTAGGACTACCCGCTGAACTTAAGCATATCAATAAGCGGAGGAA AAGAAAATCCCCGT

>Seq31 [organism=*Rhodotorula dairenensis*] [isolate K9-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq32 [organism=*Exophiala castellanii*] [isolate G7-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq33 [organism=*Exophiala castellanii*] [isolate G6-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq34 [organism=*Exophiala pisciphila*] [isolate G1-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq35 [organism=*Exophiala pisciphila*] [isolate G2-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq36 [organism=*Cadophora fastigiata*] [isolate K8-6] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

TACGGTCTCTCTGGCCCGACCTCCCAACCCTATGTCTACTTGACCATCGTTGCTTCGGCG AGCCCGTCCTCACGGACCGCCGGAGGGACCTTCACCGGCCCTCTGGTCCGCGCTCGTCG GTAGCCCAACCATTAAAATCTTTAACCAAACGTGCCTTAATCTAAGTACAATTATTAAATA AAAGCAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGAACGCAGCGAAA
TGCGATAAGTAATGCGAATTGCAGAATTCCAGTGAGTCATCGAATCTTTGAACGCACATT GCGCCCTTTGGTATTCCGAAGGGCATGCCTGTTCGAGCGTCATTATCACCCCTCAAGCCC CTGGCTTGGTGTTGGACGGTTTGGTGGAGGCCCCCTCGGGGGGCTCCTGCCCCTCCAAA GACAATGACGGCGGCCTCGTTGGACCCCCGGTACACTGAGTTCTTCACGGGACACGTATC GGATACATGGGTTTACGGGACACGGTCTGCCTCCCCTCAGGGAGAATCTTTCTAAGGTTG ACCTCGGATCAGGTAGGGATACCCGCTGAACTTAAGCATATCAATAAGCGAGGGAAAAAAA AAAA

>Seq37 [organism=*Cadophora fastigiata*] [isolate K9-4] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

TACGGTCTCTCTGGCCCGACCTCCCAACCCTATGTCTACTTGACCATCGTTGCTTCGGCG AGCCCGTCCTCACGGACCGCCGGAGGGACCTTCACCGGCCCTCTGGTCCGCGCTCGTCG GTAGCCCAACCATTAAAATCTTTAACCAAACGTGCCTTAATCTAAGTACAATTATTAAATA AAAGCAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGAACGCAGCGAAA TGCGATAAGTAATGCGAATTGCAGAATTCCAGTGAGTCATCGAATCTTTGAACGCACATT GCGCCCTTTGGTATTCCGAAGGGCATGCCTGTTCGAGCGTCATTATCACCCCTCAAGCCC CTGGCTTGGTGTTGGACGGTTTGGTGGAGGCCCCCTCGGGGGCTCCTGCCCCTCCAAA GACAATGACGGCGGCCTCGTTGGACCCCCGGTACACTGAGTTCTTCACGGGACACGTATC GGATACATGGGTTTACGGGACACCGGTCTGCCTCCCCTCAGGGAGAATCTTTCTAAGGTTG ACCTCGGATCAGGTAGGGATACCCGCTGAACTTAAGCATATCAATAAGCGGAGGAAAAAG AAAAAG

>Seq38 [organism=*Trichoderma viride*] [isolate K2-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq39 [organism=*Trichoderma asperellum*] [isolate K1-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

ACCTCCCAACCCAATGTGAACGTTACCAAACTGTTGCCTCGGCGGGGTCACGCCCCGGGT

>Seq40 [organism=*Trichoderma asperellum*] [isolate K8-7] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq41 [organism=*Gloeotinia temulenta*] [isolate G4-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq42 [organism=*Gloeotinia temulenta*] [isolate G9-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq43 [organism=*Engyodontium album*] [isolate G8-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq44 [organism=*Engyodontium album*] [isolate G10-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq45 [organism=*Engyodontium album*] [isolate G2-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq46 [organism=*Fusarium oxysporum*] [isolate K6-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq47 [organism=*Fusarium solani*] [isolate K2-4] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

CCTGTGAACATACCTAAACGTTGCTTCGGCGGGGAACAGACGGCCCCGTAACACGGGCCG CCCCCGCAGAGGACCCCCTAACTCTGTTTCTATAAATGTTTTTTCTGAGTAAACAAGCAA ATAAATTAAAACTTTCAACAACGGATCTCTTGGCTCTGGCATCGATGAAGAACGCAGCGA AATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGAACGCACAT TGCGCCCGCCAGTATTCTGGCGGGGCATGCCTGTTCGAGCGTCATTACAACCCTCAGGCCC CCGGGCCTGGCGTTGGGGATCGGCGGAGCCCCCCGTGGGCACACGCCGTCCTCCAAATA CAGTGGCGGTCCCGCCGCAGCTTCCATTGCGTAGTAGCTAACACCTCGCAACTGGAGAGC GGCGCGGCCACGCCGTAAAACACCCAACTTCTGAATGTTGACCTCGAATCAGGTAGGAAT ACCCGCTGAACTTAAGCATATCAATAAGCGGAGGGAAAAGAAAACCGAA >Seq48 [organism=*Fusarium solani*] [isolate K2-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq49 [organism=*Fusarium solani*] [isolate K10-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq50 [organism=*Fusarium solani*] [isolate K9-6] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq51 [organism=*Fusarium solani*] [isolate K10-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq52 [organism=*Fusarium solani*] [isolate K9-5] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq53 [organism=*Trichoderma asperellum*] [isolate R3-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq54 [organism=*Fusarium solani*] [isolate R1-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq55 [organism=*Fusarium solani*] [isolate R1-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq56 [organism=*Fusarium solani*] [isolate R1-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq57 [organism=*Bionectria ochroleuca*] [isolate R2-4] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq58 [organism=*Bionectria ochroleuca*] [isolate R2-5] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq59 [organism=*Bionectria ochroleuca*] [isolat R2-6] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

CCATGTGACATACCTACTGTTGCTTCGGCGGGGATTGCCCCGGGCGCCTCGTGTGCCCCG GATCAGGCGCCCGCCTAGGAAACTTAATTCTTGTTTTATTTTGGAATCTTCTGAGTAGTTT TTACAAATAAATAAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGAACG CAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGAAC GCACATTGCGCCCGCCAGTATTCTGGCGGGCATGCCTGTCTGAGCGTCATTTCAACCCTC ATGCCCCTAGGGCGTGGTGTTGGGGATCGGCCAAAGCCCGCGAGGGACGGGCGGCCCC TAAATCTAGTGGCGGACCCGTCGTGGCCTCCTCTGCGAAGTAGTGATATTCCGCATCGGA TAGCGACGAGCCCCTGCCGTTAAACCCCCAACTTTCCAAGGTTGACCTCAGATCAG

>Seq60 [organism=*Exophiala phaeomuriformis*] [isolate R9-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq61 [organism=*Cadophora fastigiata*] [isolate R10-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq62 [organism=*Fusarium oxysporum*] [isolate R6-9] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq63 [organism=*Fusarium dimerum*] [isolate R8-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

CATTCACTCCAACCCCCTGTGAAACATACCTACACGTTGCCTCGGCGGACCCCCGCCTCC CCGTAACACGGGAGCGGCCCGCCAGAGGACCCAACAAACCCTGTTATTTTCAGTATCTTC TGAGTGAAAACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGAT GAAGAACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAAT CTTTGAACGCACATTGCGCCCGCCAGTACTCTGGCGGGCATGCCTGTTCGAGCGTCATTA CATCCCTCAAGCCCCTTCGGGCTTGGTGTTGGGCATCGGCCGTCCCTCCAGCGGCGGCC GTGCCCCAAATACAGTGGCGGTCTCGCCCCGGCTCCTCTGCGTAGTAGTAACATCTCGC ACTGGGACGGAGCGTAGGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCGG ATCAGGTAGGAATACCCGCTGAACTTAAGCATATCAATAAGCGGAGGAAAAAGAAAACCCC C

>Seq64 [organism=*Fusarium dimerum*] [isolate X2-6] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

CCCCTGTGACATACCTACACGTTGCCTCGGCGGACCCCCGCCTCCCCGTAACACGGGAG CGGCCCGCCAGAGGACCCAACAAACCCTGTTATTTTCAGTATCTTCTGAGTGAAAAACACAA TCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGAACGCAGCGAA ATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGAACGCACATT GCGCCCGCCAGTACTCTGGCGGGCATGCCTGTTCGAGCGTCATTACATCCCTCAAGCCCC TTCGGGCTTGGTGTTGGGCATCGGCCGTCCCTCCAGCGGCGGCCGTGCCCCAAATACAG TGGCGGTCTCGCCCCGGCTCCTCTGCGTAGTAGTAACATCTCGCACTGGGACGGAGCG TAGGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCGGATCAGGTAGGAATAC CCGCTGAACTTAAGCATATCAATAAGCGGAAGAAACAACCCCCC

>Seq65 [organism=*Fusarium dimerum*] [isolate X2-4] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

CTCCCAAACCCCTGTGACATACCTACAACGTTGCCTCGGCGGACCCCCGCCTCCCCGTAA CACGGGAGCGGCCCGCCAGAGGACCCAACAAACCCTGTTATTTTCAGTATCTTCTGAGTG AAAACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGAA CGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGA ACGCACATTGCGCCCGCCAGTACTCTGGCGGGCATGCCTGTTCGAGCGTCATTACATCCC TCAAGCCCCTTCGGGCTTGGTGTTGGGCATCGGCCGTCCCTCCAGCGGCGGCCGTGCCC CAAATACAGTGGCGGTCTCGCCCCGGCTCCTCTGCGTAGTAGTAACATCTCGCACTGGG ACGGAGCGTAGGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCGGATCAGG TAGGAATACCCGCTGAACTTAAGCATATCAATAAGCGGAGGAAAAGAAACCG

>Seq66 [organism=*Fusarium dimerum*] [isolate R5-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

TCACTCAAACCCCTGTGACATACCTACAACGTTGCCTCGGCGGACCCCCGCCTCCCCGTA ACACGGGAGCGGCCCGCCAGAGGACCCAACAAACCCTGTTATTTTCAGTATCTTCTGAGT GAAAACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGA ACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTG

>Seq67 [organism=*Fusarium dimerum*] [isolate R6-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

GTACTCCAACCCCTGTGACATACCTACAACGTTGCCTCGGCGGACCCCCGCCTCCCCGTA ACACGGGAGCGGCCCGCCAGAGGACCCAACAAACCCTGTTATTTTCAGTATCTTCTGAGT GAAAACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGA ACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTG AACGCACATTGCGCCCGCCAGTACTCTGGCGGGGCATGCCTGTTCGAGCGTCATTACATCC CTCAAGCCCCTTCGGGCTTGGTGTTGGGCATCGGCCGTCCTCCAGCGGCGGCCGTGCC CCAAATACAGTGGCGGTCTCGCCCCGGCTCCTCTGCGTAGTAGTAACATCTCGCACTGG GACGGAGCGTAGGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCGGATCAG GTAGGAATACCCGCTGAACTTAAGCATATCAATAAGCGGAGGAAAAGAAAATTTCC

>Seq68 [organism=*Fusarium dimerum*] [isolate R6-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

ACAATAACTCCCCAACCCCTGTGACATACCTAAACGTTGCCTCGGCGGACCCCCGCCTCC CCGTAACACGGGAGCGGCCCGCCAGAGGGACCCAACAAACCCTGTTATTTTCAGTATCTTC TGAGTGAAAACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGAT GAAGAACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAAT CTTTGAACGCACATTGCGCCCGCCAGTACTCTGGCGGGCATGCCTGTTCGAGCGTCATTA CATCCCTCAAGCCCCTTCGGGCTTGGTGTTGGGCATCGGCCGTCCCTCCAGCGGCGGCC GTGCCCCAAATACAGTGGCGGTCTCGCCCCGGCTCCTCTGCGTAGTAGTAACATCTCGC ACTGGGACGGAGCGTAGGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCGG ATCAGGTAGGAATACCCGCTGAACTTAAGCATATCAATAAGCGGAGGAAAAGAAAAATGGA

>Seq69 [organism=*Fusarium dimerum*] [isolate R7-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

ACTCAACCCCTGTGACATACCTACAACGTTGCCTCGGCGGACCCCCGCCTCCCCGTAACA CGGGAGCGGCCCGCCAGAGGACCCAACAAACCCTGTTATTTTCAGTATCTTCTGAGTGAA AACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGAACG CAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGAAC GCACATTGCGCCCGCCAGTACTCTGGCGGCGCATGCCTGTTCGAGCGTCATTACATCCCTC AAGCCCCTTCGGGCTTGGTGTTGGGCATCGGCCGTCCCTCCAGCGGCGGCCGTGCCCCA AATACAGTGGCGGTCTCGCCCCGGCTCCTCTGCGTAGTAGTAACATCTCGCACTGGGAC GGAGCGTAGGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCGGATCAGGTA GGAATACCCGCTGAACTTAAGCAA

>Seq70 [organism=*Fusarium dimerum*] [isolate R5-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

CTAACTCCCAACCCCTGTGACATACCTACAACGTTGCCTCGGCGGACCCCCGCCTCCCCG TAACACGGGAGCGGCCCGCCAGAGGGACCCAACAAACCCTGTTATTTTCAGTATCTTCTGA GTGAAAACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAA GAACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTT TGAACGCACATTGCGCCCGCCAGTACTCTGGCGGGCATGCCTGTTCGAGCGTCATTACAT CCCTCAAGCCCCTTCGGGCTTGGTGTTGGGCATCGGCCGTCCCTCCAGCGGCGGCCGTG CCCCAAATACAGTGGCGGTCTCGCCCCGGCTCCTCTGCGTAGTAGTAACATCTCGCACT GGGACGGAGCGTAGGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCGGATC AGGTAGGAATACCCGCTGAACTTAAGCATATCAATAAGCGGAGGAAAAGAAA

>Seq71 [organism=*Fusarium dimerum*] [isolate R8-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

AGTTTACTCCCAACCCCTGTGACATACCTACAACGTTGCCTCGGCGGACCCCCGCCTCCC CGTAACACGGGAGCGGCCCGCCAGAGGACCCAACAAACCCTGTTATTTTCAGTATCTTCT GAGTGAAAACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATG AAGAACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATC TTTGAACGCACATTGCGCCCGCCAGTACTCTGGCGGGCATGCCTGTTCGAGCGTCATTAC ATCCCTCAAGCCCCTTCGGGCTTGGTGTTGGGCATCGGCCGTCCTCCAGCGGCGGCCG TGCCCCAAATACAGTGGCGGTCTCGCCCCCGGCTCCTCTGCGTAGTAGTAACATCTCGCA CTGGGACGGAGCGTAGGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCGGA TCAGGTAGGAATACCGCTGAACTTAAGCATATCAATAAGCGGAGGAAAAGAAAATGTTAT

>Seq72 [organism=*Fusarium dimerum*] [isolate R5-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

CCTCCCAACCCCTGTGACATACCTACAACGTTGCCTCGGCGGACCCCCGCCTCCCCGTAA CACGGGAGCGGCCCGCCAGAGGACCCAACAAACCCTGTTATTTTCAGTATCTTCTGAGTG AAAACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGAA CGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGA ACGCACATTGCGCCCGCCAGTACTCTGGCGGGCATGCCTGTTCGAGCGTCATTACATCCC TCAAGCCCCTTCGGGCTTGGTGTTGGGCATCGGCCGTCCCTCCAGCGGCGGCCGTGCCC CAAATACAGTGGCGGTCTCGCCCCCGGCTCCTCTGCGTAGTAGTAACATCTCGCACTGGG

## ACGGAGCGTAGGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCGGATCAGG TAGGAATACCCGCTGAACTTAAGCATATCAATAAGCGGAGGGAAAAGAAA

>Seq73 [organism=*Fusarium dimerum*] [isolate R8-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

ATTTACTCCCAACCCCTGTGACATACCTACACGTTGCCTCGGCGGACCCCCGCCTCCCCG TAACACGGGAGCGGCCCGCCAGAGGGACCCAACAAACCCTGTTATTTTCAGTATCTTCTGA GTGAAAACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAA GAACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTT TGAACGCACATTGCGCCCGCCAGTACTCTGGCGGGCATGCCTGTTCGAGCGTCATTACAT CCCTCAAGCCCCTTCGGGCTTGGTGTTGGGCATCGGCCGTCCCTCCAGCGGCGGCCGTG CCCCAAATACAGTGGCGGTCTCGCCCCGGCTCCTCTGCGTAGTAGTAACATCTCGCACT GGGACGGAGCGTAGGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCGGATC AGGTAGGAATACCCGCTGAACTTAAGCATATCAATAAGCGGAGGAAAAGAAAAGTTATT

>Seq74 [organism=*Fusarium dimerum*] [isolate X2-5] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

AGTTACTCCCAACCCCTGTGACATACCTACACGTTGCCTCGGCGGACCCCCGCCTCCCCG TAACACGGGAGCGGCCCGCCAGAGGGACCCAACAAACCCTGTTATTTTCAGTATCTTCTGA GTGAAAACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAA GAACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTT TGAACGCACATTGCGCCCGCCAGTACTCTGGCGGGCATGCCTGTTCGAGCGTCATTACAT CCCTCAAGCCCCTTCGGGCTTGGTGTTGGGCATCGGCCGTCCCTCCAGCGGCGGCCGTG CCCCAAATACAGTGGCGGTCTCGCCCCGGGCTCCTCTGCGTAGTAGTAACATCTCGCACT GGGACGGAGCGTAGGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCGGATC AGGTAGGAATACCCGCTGAACTTAAGCATATCAATAAGCGGAGGAAAAGAAAATGTTT

>Seq75 [organism=*Fusarium dimerum*] [isolate R7-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

AGTAAACTCCAACCCCTGTGACATACCTACACGTTGCCTCGGCGGACCCCCGCCTCCCCG TAACACGGGAGCGGCCCGCCAGAGGGACCCAACAAACCCTGTTATTTTCAGTATCTTCTGA GTGAAAACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAA GAACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTT TGAACGCACATTGCGCCCGCCAGTACTCTGGCGGGGCATGCCTGTTCGAGCGTCATTACAT CCCTCAAGCCCCTTCGGGCTTGGTGTTGGGCATCGGCCGTCCCTCCAGCGGCGGCCGTG CCCCAAATACAGTGGCGGTCTCGCCCCGGCTCCTCTGCGTAGTAGTAACATCTCGCACT GGGACGGAGCGTAGGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCGGATC AGGTAGGAATACCCGCTGAACTTAAGCATATCAATAAGCGGAGGAAAAGAAACTGTTG >Seq76 [organism=*Fusarium dimerum*] [isolate X2-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

ACCCCTGTGACATACCTACACGTTGCCTCGGCGGACCCCGCCTCCCCGTAACACGGGA GCGGCCCGCCAGAGGACCCAACAAACCCTGTTATTTTCAGTATCTTCTGAGTGAAAAACACA ATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGAACGCAGCGA AATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGAACGCACAT TGCGCCCGCCAGTACTCTGGCGGGGCATGCCTGTTCGAGCGTCATTACATCCCTCAAGCCC CTTCGGGCTTGGTGTTGGGCATCGGCCGTCCCTCCAGCGGCGGCCGTGCCCCAAATACA GTGGCGGTCTCGCCCCGGCTCCTCTGCGTAGTAGTAACATCTCGCACTGGGACGGAGC GTAGGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCGGATCAGGTAGGAATA CCCGCTGAACTTAAGCATATCAATAAGCGGAGGAAAAAGAAACGGGTTT

>Seq77 [organism=*Fusarium dimerum*] [isolate R6-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

ACTCCAACCCCTGTGACATACCTACACGTTGCCTCGGCGGACCCCCGCCTCCCCGTAACA CGGGAGCGGCCCGCCAGAGGACCCAACAAACCCTGTTATTTTCAGTATCTTCTGAGTGAA AACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGAACG CAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGAAC GCACATTGCGCCCGCCAGTACTCTGGCGGGGCATGCCTGTTCGAGCGTCATTACATCCCTC AAGCCCCTTCGGGCTTGGTGTTGGGCATCGGCCGTCCCTCCAGCGGCGGCCGTGCCCCA AATACAGTGGCGGTCTCGCCCCGGCTCCTCTGCGTAGTAACATCTCGCACTGGGAC GGAGCGTAGGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCCGGATCAGGTA GGAATACCCGCTGAACTTAAGCATATCAATAAGCGGAGGAAAAGAAACGTTTT

>Seq78 [organism=*Candida palmioleophila*] [isolate H3-4] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq79 [organism=*Candida tropicalis*] [isolate H5-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq80 [organism=*Candida tropicalis*] [isolate H7-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq81 [organism=*Candida orthopsilosis*] [isolate H9-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq82 [organism=*Candida albicans*] [isolate H8-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

TTGCACCACATGTGTTTTTCTTTGAAACAAACTTGCTTTGGCGGTGGGCCCAGCCTGCCG

>Seq83 [organism=*Pichia kudriavzevii*] [isolate H1-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq84 [organism=*Pichia kudriavzevii*] [isolate H9-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq85 [organism=*Phoma herbarum*] [isolate H8-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

GAGTTGTGGGCTTTGCCTGCTATCTCTTACCCATGTCTTTTGAGTACTTACGTTTCCTCG GTGGGTTCGCCCGCCGATTGGACAATTTAAACCCTTTGCAGTTGCAATCAGCGTCTGAAA AACATAATAGTTACAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGAACGC AGCGAAATGCGATAAGTAGTGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGAACG CACATTGCGCCCCTTGGTATTCCATGGGGCATGCCTGTTCGAGCGTCATTTGTACCTTCA AGCATTGCTTGGTGTTGGGTGTTTGTCTCGCCTTTGCGTGTAGACTCGCCTTAAAACAAT TGGCAGCCGGCGTATTGATTTCGGAGCGCAGTACATCTCGCGCTTTGCACTCATAACGAC GACGTCCAAAAGTACATTTTAACACTCTTGACCTCGGATCAGGTAGGGATACCCGCTGAA CTTAAGCATATCAATAAGCGGGGGGAAA

>Seq86 [organism=*Exophiala dermatitidis*] [isolate H9-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq87 [organism=*Exophiala dermatitidis*] [isolate P1-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

TAGGCCCGACCTCCCAACCCTTTGTTTACCCGACCCATGTTGCTTCGGCGGGCCCGCCGCCG TTCGACGGCCGCCGAGGACCGCCTATTCAGGTCCTCTGGCCCGCGCCGCCGCGGTAGCC AATTCTACCAAACTCTCGAATCAAATCGTGTCCAATGTTCTGAGTATATTCCAAAATAAAA GCAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGAACGCAGCGAAATGC GATAAGTAATGCGAATTGCAGAATTCCAGTGAGTCATCGAATCTTTGAACGCACATTGCG CCCTTTGGTATTCCGAAGGGCATGCCTGTTCGAGCGTCATTATCACCCCTCAAGCCCCCC GGCTTGGTGTTGGACGGTCTGGTCGAGCGTTTCCGCGCGACCCCTCCAAAGACAATGAC GGCGGCCTGGTTGGACCCCCGGTACACGGAGCTTCTTCACTGAGCACGTATCGGTTTCAA GGTGTCCCCGGGGACCCGGTCGACCTCTTTGTCCCCTGCGGGAGTGGGAGAGAACCCC CCTTTTATCAAGGTTGACCTCGGATCAGGTAGGAATACCCGCTGAACTTAAGCATATCAA TAAGCGGGGGA

>Seq88 [organism=*Fusarium oxysporum*] [isolate H7-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

CCTCCCAACCCCTGTGACATACCACTTGTTGCCTCGGCGGATCAGCCCGCTCCCGGTAAA ACGGGACGGCCCGCCAGAGGACCCCTAAACTCTGTTTCTATATGTAACTTCTGAGTAAAA CCATAAATAAATCAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGAACG

>Seq89 [organism=*Fusarium oxysporum*] [isolate H3-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq90 [organism=*Gliomastix polychroma*] [isolate P4-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq91 [organism=*Beauveria bassiana*] [isolate P4-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

CTCCCAACCCTTATGTGAACCTACCTATCGTTGCTTCGGCGGACTCGCCCCAGCCGGACG CGGACTGGACCAGCGGCCGCCGGGGGACCATCAAACTCTTGTATTATCAGCATCTTCTGAA TACGCCGCAAGGCAAAACAAATAAATTAAAACTTTCAACAACGGATCTCTTGGCTCTGGC ATCGATGAAGAACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATCCAGTGAATCA TCGAATCTTTGAACGCACATTGCGCCCGCCAGCATTCTGGCGGGCATGCCTGTTCGAGCG TCATTTCAACCCTCGACCTCCCTTTGGGGAAGTCGGCGTTGGGGACCGGCAGCACACCGC CGGCCCTGAAATGGAGTGGCGGCCCGTCCGCGGCGACCTCTGCGTAGTAAACCAACTCG CACCGGAACCCCGACGTGGCCACGCCGTAAAACACCCAACTTCTGAACGTTGACCTCGAA TCAGGTAGGACTACCCGCTGAACTTAAGCATATCAATAAGCGGAGGGAAAAGAAA

>Seq92 [organism=*Fusarium dimerum*] [isolate P2-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

AACTCCCAACCCCTGTGACATACCTACAACGTTGCCTCGGCGGACCCCCGCCTCCCCGTA ACACGGGAGCGGCCCGCCAGAGGACCCAACAAACCTGTTATTTTCAGTATCTTCTGAGT GAAAACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGA ACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTG AACGCACATTGCGCCCGCCAGTACTCTGGCGGGGCATGCCTGTTCGAGCGTCATTACATCC CTCAAGCCCCTTCGGGCTTGGTGTTGGGCATCGGCCGTCCTCCAGCGGCGGCCGTGCC CCAAATACAGTGGCGGTCTCGCCCCGGCTCCTCTGCGTAGTAGTAACATCTCGCACTGG GACGGAGCGTAGGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCGGATCAG GTAGGAATACCCGCTGAACTTAAGCATATCAATAAGCGGGGGGAAAAAGAAA

>Seq93 [organism=*Fusarium dimerum*] [isolate P2-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq94 [organism=*Fusarium dimerum*] [isolate H10-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

CCTCCCAACCCCTGTGACATACCTACAACGTTGCCTCGGCGGACCCCCGCCTCCCCGTAA CACGGGAGCGGCCCGCCAGAGGACCCAACAAACCCTGTTATTTTCAGTATCTTCTGAGTG AAAACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGAA CGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGA ACGCACATTGCGCCCGCCAGTACTCTGGCGGGCATGCCTGTTCGAGCGTCATTACATCCC TCAAGCCCCTTCGGGCTTGGTGTTGGGCATCGGCCGTCCCTCCAGCGGCGGCCGTGCCC CAAATACAGTGGCGGTCTCGCCCCGGCTCCTCTGCGTAGTAGTAACATCTCGCACTGGG ACGGAGCGTAGGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCGGATCAGG TAGGAATACCCGCTGAACTTAAGCATATCAATAAGCGGAGGGAAAAGAAA

>Seq95 [organism=*Fusarium dimerum*] [isolate H2-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

CCTCCCAACCCCTGTGACATACCTACAACGTTGCCTCGGCGGACCCCCGCCTCCCCGTAA CACGGGAGCGGCCCGCCAGAGGACCCAACAAACCCTGTTATTTTCAGTATCTTCTGAGTG AAAACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGAA CGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGA ACGCACATTGCGCCCGCCAGTACTCTGGCGGGCATGCCTGTTCGAGCGTCATTACATCCC TCAAGCCCCTTCGGGCTTGGTGTTGGGCATCGGCCGTCCCTCCAGCGGCGGCCGTGCCC CAAATACAGTGGCGGTCTCGCCCCGGCTCCTCTGCGTAGTAGTAACATCTCGCACTGGG ACGGAGCGTAGGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCGGATCAGG TAGGAATACCCGCTGAACTTAAGCATATCAATAAGCGGGGGGAA

>Seq96 [organism=*Fusarium dimerum*] [isolate P5-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

ACCTCCCAACCCCTGTGACATACCTACAACGTTGCCTCGGCGGACCCCCGCCTCCCCGTA ACACGGGAGCGGCCCGCCAGAGGACCCAACAAACCCTGTTATTTTCAGTATCTTCTGAGT GAAAACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGA ACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTG AACGCACATTGCGCCCGCCAGTACTCTGGCGGGGCATGCCTGTTCGAGCGTCATTACATCC CTCAAGCCCCTTCGGGCTTGGTGTTGGGCATCGGCCGTCCCTCCAGCGGCGGCCGTGCC CCAAATACAGTGGCGGTCTCGCCCCGGCCCCCGGCCCTCTGCGTAGTAACATCTCGCACTGG GACGGAGCGTAGGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCGGATCAG GTAGGAATACCCGCTGAACTTAAGCATATCAATAAGCGGGGGGAAAAGAAAACGGAGA

>Seq97 [organism=*Fusarium dimerum*] [isolate P5-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

CTCCCAACCCCTGTGACATACCTACAACGTTGCCTCGGCGGACCCCCGCCTCCCCGTAAC ACGGGAGCGGCCCGCCAGAGGACCCAACAAACCCTGTTATTTTCAGTATCTTCTGAGTGA AAACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGAAC GCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGAA CGCACATTGCGCCCGCCAGTACTCTGGCGGGCATGCCTGTTCGAGCGTCATTACATCCCT CAAGCCCCTTCGGGCTTGGTGTTGGGCATCGGCCGTCCCTCCAGCGGCGGCCGTGCCCC AAATACAGTGGCGGTCTCGCCCCCGGCTCCTCTGCGTAGTAACATCTCGCACTGGGA CGGAGCGTAGGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCGGATCAGGT A

## GGAATACCCGCTGAACTTAAGCATATCAATAAGCGGGGAAAAAGAA

>Seq98 [organism=*Fusarium dimerum*] [isolate H5-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

ACTCCCAACCCCTGTGACATACCTACAACGTTGCCTCGGCGGACCCCCGCCTCCCCGTAA CACGGGAGCGGCCCGCCAGAGGACCCAACAAACCCTGTTATTTTCAGTATCTTCTGAGTG AAAACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGAA CGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGA ACGCACATTGCGCCCGCCAGTACTCTGGCGGGCATGCCTGTTCGAGCGTCATTACATCCC TCAAGCCCCTTCGGGCTTGGTGTTGGGCATCGGCCGTCCCTCCAGCGGCGGCCGTGCCC CAAATACAGTGGCGGTCTCGCCCCGGCTCCTCTGCGTAGTAGTAACATCTCGCACTGGG ACGGAGCGTAGGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCGGATCAGG TAGGAATACCCGCTGAACTTAAGCATATCAATAAGCGGGGGAAAAGAA

>Seq99 [organism=*Fusarium dimerum*] [isolate H6-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

ACCTCCCAACCCCTGTGACATACCTACAACGTTGCCTCGGCGGACCCCCGCCTCCCCGTA ACACGGGAGCGGCCCGCCAGAGGACCCAACAAACCCTGTTATTTTCAGTATCTTCTGAGT GAAAACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGA ACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTG AACGCACATTGCGCCCGCCAGTACTCTGGCGGGGCATGCCTGTTCGAGCGTCATTACATCC CTCAAGCCCCTTCGGGCTTGGTGTTGGGCATCGGCCGTCCCTCCAGCGGCGGCGTGCC CCAAATACAGTGGCGGTCTCGCCCCGGCTCCTCTGCGTAGTAGTAACATCTCGCACTGG GACGGAGCGTAGGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCGGATCAG GTAGGAATACCCGCTGAACTTAAGCATATCAATAAGCGGGGGGAA

>Seq100 [organism=*Fusarium dimerum*] [isolate H1-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

ACCTCCCAACCCCTGTGACATACCTACAACGTTGCCTCGGCGGACCCCCGCCTCCCCGTA ACACGGGAGCGGCCCGCCAGAGGACCCAACAAACCCTGTTATTTTCAGTATCTTCTGAGT GAAAACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGA ACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTG AACGCACATTGCGCCCGCCAGTACTCTGGCGGGCATGCCTGTTCGAGCGTCATTACATCC CTCAAGCCCCTTCGGGCTTGGTGTTGGGCATCGGCCGTCCCTCCAGCGGCGGCCGTGCC CCAAATACAGTGGCGGTCTCGCCCCCGGCTCCTCTGCGTAGTAACATCTCGCACTGG

## GACGGAGCGTAGGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCGGATCAG GTAGGAATACCCGCTGAACTTAAGCATATCAATAAGCGGGGGGAA

>Seq101 [organism=*Fusarium dimerum*] [isolate H4-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

ACTCCCAACCCCTGTGACATACCTACAACGTTGCCTCGGCGGACCCCCGCCTCCCCGTAA CACGGGAGCGGCCCGCCAGAGGACCCAACAAACCCTGTTATTTTCAGTATCTTCTGAGTG AAAACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGAA CGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGA ACGCACATTGCGCCCGCCAGTACTCTGGCGGGCATGCCTGTTCGAGCGTCATTACATCCC TCAAGCCCCTTCGGGCTTGGTGTTGGGCATCGGCCGTCCCTCCAGCGGCGGCCGTGCCC CAAATACAGTGGCGGTCTCGCCCCGGCTCCTCTGCGTAGTAACATCTCGCACTGGG ACGGAGCGTAGGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCGGATCAGG TAGGAATACCCGCTGAACTTAAGCATATCAATAAGCGGGGGAAAAAGAAA

>Seq102 [organism=*Fusarium dimerum*] [isolate P2-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq103 [organism=*Rhodotorula glutinis*] [isolate H3-5] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

## TACCCGCTGAACTTAAGCATATCAATAAGCGAGGGAAAAAGAAAATAA

>Seq104 [organism=*Rhodotorula mucilaginosa*] [isolate H8-4] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

GGACGTCCACTTACTTGGAGTCCGAACTCTCACTTTCTAACCCTGTGCACTTGTTTGGGA TAGTAACTCTCGCAAGAGAGCGAACTCCTATTCACTTATAAACACAAAGTCTATGAATGT ATTAAATTTTATAACAAAATAAAACTTTCAACAACGGATCTCTTGGCTCTCGCATCGATG AAGAACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATC TTTGAACGCACCTTGCGCTCCATGGTATTCCGTGGAGCATGCCTGTTTGAGTGTCATGAA TACTTCAACCCTCCTCTTTCTTAATGATTGAAGAGGGTGTTTGGTTTCTGAGCGCTGCTGG CCTTTACGGTCTAGCTCGTTCGTAATGCATTAGCATCCGCAATCGAACTTCGGATTGACT TGGCGTAATAGACTATTCGCTGAGGAATTCTAGTCTTCGGACTAGAGCCGGGTTGGGTTA AAGGAAGCTTCTAATCAGAATGTCTACATTTAAGATTAGATCTCAAATCAGGTAGGACT ACCCGCTGAACTTAAGCATATCAATAAGCGAGGGAAAAAGAAAAGGAG

>Seq105 [organism=*Stereum gausapatum*] [isolate P9-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

TATGACTGGAGTTGTAGCTGGCCTTTAAAACGGCATGTGCACGCTCCTTTCACTAATCCA CACACACCTGTGCACCTTCGCGGGGGTCTCTTCGTTAACTCGAAGAGGGCTCGCGTCCCTT TACACACCCTTTGTATGTCTTAAGAATGTCTACTCGATGTAATAAAACGCATCTAATACA ACTTTCAACAACGGATCTCTTGGCTCTCGCATCGATGAAGAACGCAGCGAAATGCGATAA GTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGAACGCACCTTGCGCCCTTT GGTATTCCGAAGGGCACACCTGTTTGAGTGTCGTGAAATTCTCAACCCTCTTCACTTTTG TGAACGTAGTGGATTGGACTTGGAGGCTTTGCCGGGGCTTCACCGCTCGGCTCCTCTCAAA TGCATTAGTGCGTCTTGTTGCGACGTGCGCCCCGGTGTGATAATTATCTACGCTGTGGTG TGCTTGCTTCTGTGGAGACGCGCTTTCAACCGTCCGAAAGGACAGCTTTCATCGAACTT TGACCTCAAATCAGGTGGGACTACCCGCTGAACTTAAGCATATCAATAAGCGAGGGAAAA AGAAAAA

>Seq106 [organism=*Stereum gausapatum*] [isolate P8-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

ATTATGACTGGAGTTGTAGCTGGCCTTTAAAAACGGCATGTGCACGCTCCTTTCACTAAT CCACACACCTGTGCACCTTCGCGGGGGTCTCTTCGTTAACTCGAAGAGGGCTCGCGTCC CTTTACACACCCTTTGTATGTCTTAAGAATGTCTACTCGATGTAATAAAACGCATCTAAT ACAACTTTCAACAACGGATCTCTTGGCTCTCGCATCGATGAAGAACGCAGCGAAATGCGA TAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGAACGCACCTTGCGCCC TTTGGTATTCCGAAGGGCACACCTGTTTGAGTGTCGTGAAATTCTCAACCCTCTTCACTT TTGTGAACGTAGTGGATTGGACTTGGAGGCTTTGCCGGGGCTTCACCGCTCGGCTCCTCTC AAATGCATTAGTGCGTCTTGTTGCGACGTGCGCCTCGGTGTGATAATTATCTACGCTGTG GTGTGCTTGCTTCTGTGGAGACGCGCTTTCTAACCGTCCGAAAGGACAGCTTTCATCGAAC TTTGACCTCAAATCAGGTGGGACTACCCGCTGAACTTAAGCATATCAATAAGCGGGGGAA

>Seq107 [organism=*Stereum gausapatum*] [isolate P9-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

TGACTGGAGTTGTAGCTGGCCTTTAAAAACGGCATGTGCACGCTCCTTTCACTAATCCAC ACACACCTGTGCACCTTCGCGGGGGTCTCTTTGTTAAACTCGAAGAGGCTCGCGTCCCTT TACACACCCTTTGTATGTCTTAAGAATGTCTACTCGATGTAATAAAACGCATCTAATACA ACTTTCAACAACGGATCTCTTGGCTCTCGCATCGATGAAGAACGCAGCGAAATGCGATAA GTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGAACGCACCTTGCGCCCTTT GGTATTCCGAAGGGCACACCTGTTTGAGTGTCGTGAAATTCTCAACCCTCTTCACTTTTG TGAACGTAGTGGATTGGACTTGGAGGCTTTGCCGGGGCTTCACCGCTCGGCTCCTCTCAAA TGCATTAGTGCGTCTTGTTGCGACGTGCGCCCCGGTGTGATAATTATCTACGCTGTGGTG TGCTTGCTTCTGTGGAGACGCGCCTTCACCGTCCGAAAGGACAGCTTTCATCGAACTT TGACCTCAAATCAGGTGGGACTACCCGCTGAACTTAAGCATATCAATAAGCGGAGGAAAA AGAAATTG

>Seq108 [organism=*Trametes versicolor*] [isolate P1-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

GACGAGTTGTAGCTGGCCTTCCGAGGCATGTGCACGCTCTGCTCATCCACTCTACCCCTG TGCACTTACTGTAGGTTGGCGTGGGCTCCTTAACGGGAGCATTCTGCCGGCCTATGTATA CTACAAACACTTTAAAGTATCAGAATGTAAACGCGTCTAACGCATCTATAATACAACTTT TAGCAACGGATCTCTTGGCTCTCGCATCGATGAAGAACGCAGCGAAATGCGATAAGTAAT GTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGAACGCACCTTGCGCTCCTTGGTAT TCCGAGGAGCATGCCTGTTTGAGTGTCATGGAATTCTCAACTTATAAATCCTTGTGATCT ATAAGCTTGGACTTGGAGGCTTGCTGGCCCTTGCGGTCGGCTCCTCTTGAATGCATTAGC TCGATTCCGTACGGATCGGCTCTCAGTGTGATAATTGTCTACGCTGTGACCGTGAAGTGT TTTGGCGAGCTTCTAATCGTCCATTAGGACAACTTTTTAACATCTGACCTCAAATCAGGT AGGACTACCCGCTGAACTTAAGCATATCAATAAGCGAGGGAAAAAA

>Seq109 [organism=*Trametes versicolor*] [isolate P9-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

AACGAGTTGTAGCTGGCCTTCCGAGGCATGTGCACGCTCTGCTCATCCACTCTACCCCTG TGCACTTACTGTAGGTTGGCGTGGGCTCCTTAACGGGAGCATTCTGCCGGCCTATGTATA CTACAAACACTTTAAAGTATCAGAATGTAAACGCGTCTAACGCATCTATAATACAACTTT TAGCAACGGATCTCTTGGCTCTCGCATCGATGAAGAACGCAGCGAAATGCGATAAGTAAT GTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGAACGCACCTTGCGCTCCTTGGTAT TCCGAGGAGCATGCCTGTTTGAGTGTCATGGAATTCTCAACTTATAAATCCTTGTGATCT ATAAGCTTGGACTTGGAGGCTTGCTGGCCCTTGTTGGTCGGCTCCTCTTGAATGCATTAG CTCGATTCCGTACGGATCGGCTCTCAGTGTGATAATTGTCTACGCTGTGACCGTGAAGTG TTTTGGCGAGCTTCTAACCGTCCATTAGGACAACTTTTTAACATCTGACCTCAAATCAGG TAGGACTACCCGCTGAACTTAAGCATATCAATAAGCGGAGGGAAAAGAAAA

>Seq110 [organism=*Trametes versicolor*] [isolate P7-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

GTTGACGAGTTGTAGCTGGCCTTCCGAGGCATGTGCACGCTCTGCTCATCCACTCTACCC CTGTGCACTTACTGTAGGTTGGCGTGGGCTCCTTAACGGGAGCATTCTGCCGGCCTATGT ATACTACAAACACTTTAAAGTATCAGAATGTAAACGCGTCTAACGCATCTATAATACAAC TTTTAGCAACGGATCTCTTGGCTCTCGCATCGATGAAGAACGCAGCGAAATGCGATAAGT AATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGAACGCACCTTGCGCTCCTTGG TATTCCGAGGAGCATGCCTGTTTGAGTGTCATGGAATTCTCAACTTATAAATCCTTGTGA TCTATAAGCTTGGACTTGGAGGCTTGCTGGCCCTTGTTGGTCGGCTCCTCTGAATGCAT TAGCTCGATTCCGTACGGATCGGCTCTCAGTGTGATAATTGTCTACGCTGTGACCGTGAA GTGTTTTGGCGAGCTTCTAACCGTCCATTAGGACAATTTTTTAACATCTGACCTCAAATC AGGTAGGACTACCCGCTGAACTTAAGCATATCAATAAGCGGGGGGAAA

>Seq111 [organism=*Trametes versicolor*] [isolate P8-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

TTGACGAGTTGTAGCTGGCCTTCCGAGGCATGTGCACGCTCTGCTCATCCACTCTACCCC TGTGCACTTACTGTAGGTTGGCGTGGGCTCCTTAACGGGAGCATTCTGCCGGCCTATGTA TACTACAAACACTTTAAAGTATCAGAATGTAAACGCGTCTAACGCATCTATAATACAACT TTTAGCAACGGATCTCTTGGCTCTCGCATCGATGAAGAACGCAGCGAAATGCGATAAGTA ATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGAACGCACCTTGCGCTCCTTGGT ATTCCGAGGAGCATGCCTGTTTGAGTGTCATGGAATTCTCAACTTATAAATCCTTGTGAT CTATAAGCTTGGACTTGGAGGCTTGCTGGCCCTTGTTGGTCGGCTCCTCTTGAATGCATT AGCTCGATTCCGTACGGATCGGCTCTCAGTGTGATAATTGTCTACGCTGTGACCGTGAAG TGTTTTGGCGAGCTTCTAACCGTCCATTAGGACAATTTTTTAACATCTGACCTCAAATCA GGTAGGACTACCCGCTGAACTTAAGCATATCAATAAGCGAGGGAAAAAGAAAAGA

>Seq112 [organism=*Trametes ochracea*] [isolate P3-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

TGACGAGTTGTAGCTGGCCTTCCGAGGCATGTGCACGCTCTGCTCATCCACTCTACCCCT GTGCACTTACTGTAGGTTGGCGTGGGCTCCTTAACGGGAGCATTCTGCCGGCCTATGTAT ACTACAAACACTTTAAAGTATCAGAATGTAAACGCGTCTAACGCATCTATAATACAACTT TTAGCAACGGATCTCTTGGCTCTCGCATCGATGAAGAACGCAGCGAAATGCGATAAGTAA TGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGAACGCACCTTGCGCTCCTTGGTA TTCCGAGGAGCATGCCTGTTTGAGTGTCATGGAATTCTCAACTTATAAATCCTTGTGATC TATAAGCTTGGACTTGGAGGCTTGCTGGCCCTCGTTGGTCGGCTCCTCTTGAATGCATTA GCTCGATTCCGTACGGATCGGCTCTCAGTGTGATAATTGTCTACGCTGTGACCGTGAAGT GTTTTGGCGAGCTTCTAACCGTCCATTAGGACAACTTTTTAACATCTGACCTCAAATCAG GTAGGACTACCCGCTGAACTTAAGCATATCAATAAGCGAGGGAAAAAGAAAAGA

>Seq113 [organism=*Trametes ochracea*] [isolate H10-4] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

TGACGAGTTGTAGCTGGCCTTCCGAGGCATGTGCACGCTCTGCTCATCCACTCTACCCCT GTGCACTTACTGTAGGTTGGCGTGGGCTCCTTAACGGGAGCATTCTGCCGGCCTATGTAT ACTACAAACACTTTAAAGTATCAGAATGTAAACGCGTCTAACGCATCTATAATACAACTT TTAGCAACGGATCTCTTGGCTCTCGCATCGATGAAGAACGCAGCGAAATGCGATAAGTAA TGTGAATTGCAGAATTCAGTGAATCATCGAATGTTTGAACGCACCTTGCGCTCCTTGGTA TTCCGAGGAGCATGCCTGTTTGAGTGTCATGGAATTCTCAACTTATAAATCCTTGTGATC TATAAGCTTGGACTTGGAGGCTTGCTGGCCCTCGTTGGTCGGCTCCTCTGAATGCATTA GCTCGATTCCGTACGGATCGGCTCTCAGTGTGATAATTGTCTACGCTGTGACCGTGAAGT GTTTTGGCGAGCTTCTAACCGTCCATTAGGACAACTTTTTAACATCTGACCGTGAAGT GTTTTGGCGAGCTTCTAACCGTCCATTAGGACAACTTTTTAACATCTGACCTCAAATCAG GTAGGACTACCCGCTGAACTTAAGCATATCAATAAGCGGGGGAAAA

>Seq114 [organism=*Piptoporus betulinus*] [isolate P5-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

CCTTCCTATGTTTTTACTACAAACGCTTTAGTTATAGAATGTCATACGCGTATAACGCAT TTATATACAACTTTCAGCAACGGATCTCTTGGCTCTCGCATCGATGAAGAACGCAGCGAA ATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGAACGCACCTT GCGCTCCCTGGTATTCCGGGGAGCATGCCTGTTTGAGTATCATGGAATTCTCAACCTTCA ATACTTTTTTAAAAAGAGTGTCGAAGGCTTGGACTTGGAGGCTTTGTGCTGGCTCTGTAT TGAGTCGGCTCCTCTGAAATGTATTAGCGTGAATCACTATGGATCGCTTCGGTGTGATAA TTATCTGCGCCGTGGTCGTGAAGTATTAATTCAAGTTCGCGCTTCTAATCGTCCTTCATG GGACAATTACATTGAACTTTTGATCTCAAATCAGGTAGGACTACCCGCTGAACTTAAGCA TATCAATAAGCGGGGGG

>Seq116 [organism=*Magnusiomyces capitatus*] [isolate H2-5] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

ATATATTTTATATTACTTTGTGGAACATTTGGTTGAATTTACATGTTTTATTACAAAAAA TTAATTATAATTAAAAAAAATAATTTTAAGAAAACCTCCAACAACGGATCTCTTGGTTCCC AGATCGATGAAGAGCGCAGCGAATTGCGAAATGTGATGTGTATTGCAGTGAATCATCAAT TCTTGAACGCACATGGCACCCCTTTTAGGGGTATGCTTGTATGAGGGGTGTTTAATATGAA ATTGCTTTGGCTTTTTTTAAATAAATGGTTTTTCAAATTGTTACTAATAGACGAAAGAAT CAGTGCAACAAGCTGTGTTGAATCTTTCATTAAATCTTTTAGTTAACTACTTTAACTATT TGCACCTCATATCAAGCAAGACTACCCGCTGAACTTAAGCATATCAATAAGCGGAGGAAA AGAAAAGCCTTGT

>Seq117 [organism=*Magnusiomyces capitatus*] [isolate H4-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq119 [organism=*Cyphellophora oxyspora*] [isolate A3-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq120 [organism=*Cyphellophora oxyspora*] [isolate A5-8] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq121 [organism=*Cadophora fastigiata*] [isolate A3-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

GTAGGGTCTCTCTGGCCCGACCTCCCAACCCTTTGTCTACTTGACCATCGTTGCTTCGGC GAGCCCGTCCTCACGGACCGCCGGAGGGACCTTCACCGGCCCTCTGGTCCGCGCTCGTC GGTAGCCCAACCATTAAAATCTTTAACCAAACGTGCCTTAATCTAAGTACAATTATTAAAT AAAAGCAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGAACGCAGCGAA ATGCGATAAGTAATGCGAATTGCAGAATTCCAGTGAGTCATCGAATCTTTGAACGCACAT TGCGCCCTTTGGTATTCCGAAGGGCATGCCTGTTCGAGCGTCATTATCACCCCTCAAGCC CCTGGCTTGGTGTTGGACGGTTTGGTGGAGGCCCCCTCGGGGGGCTCCTGCCCCTCCAA AGACAATGACGGCGGCCTCGTTGGACCCCCGGTACACTGAGTTCTTCACGGGACACGTAT CGGATACATGGGTTTACGGGACACGGTCTGCCTCCCCTCAGGGAGAATCTTTCTAAGGTT GACCTCGGATCAGGTAGGGATACCCGCTGAACTTAAGCATATCAATAAGCGGAGGGAAAA GAA

>Seq122 [organism=*Exophiala pisciphila*] [isolate A10-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq123 [organism=*Exophiala pisciphila*] [isolate C1-7] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq124 [organism=*Exophiala pisciphila*] [isolate A7-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

GATGAAAAACGCAGCGAAATGCGATAAGTAATGCGAATTGCAAAATTCCAGTGAGTCATC GAATCTTTGAACGCACATTGCGCCCTTTGGCATTCCGAAGGGCATGCCTGTTCGAGCGTC ATTATCACCTCTCAAGCCCCCCTTTTCTGGGGCTTGGTGTTGGACGGCCTGGCGTCGGCGA CGACCCCACCTCCCAAAGACAATGACGGCGGCTTCGTGAGACCCCCGGTACACTGAGTTC CTCACCGAACACGTACTGGATCAAGGGTAGACGGAGCCCCGGTCGACCTCCCCTCACAG GGAGACACTTTTTTACAAGGTTGACCTCGGATCAGGTAGGAATACCCGCTGAACTTAAGCA TATCAATAAGCGGAGGGAAAAGAAA

>Seq125 [organism=*Trichoderma asperellum*] [isolate CRT2-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq126 [organism=*Trichoderma asperellum*] [isolate A4-6] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq127 [organism=*Trichoderma asperellum*] [isolate CRT2-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

AACTCCCAACCCAATGTGAACGTTACCAAACTGTTGCCTCGGCGGGGTCACGCCCCGGGT

>Seq128 [organism=*Trichoderma atroviride*] [isolate A8-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq129 [organism=*Fusarium dimerum*] [isolate B7-6] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

AACTCCCAACCCCTGTGACATACCTACAACGTTGCCTCGGCGGACCCCCGCCTCCCCGTA ACACGGGAGCGGCCCGCCAGAGGACCCAACAAACCCTGTTATTTTCAGTATCTTCTGAGT GAAAACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGA ACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTG AACGCACATTGCGCCCGCCAGTACTCTGGCGGGGCATGCCTGTTCGAGCGTCATTACATCC CTCAAGCCCCTTCGGGCTTGGTGTTGGGCATCGGCCGTCCTCCAGCGGCGGCCGTGCC CCAAATACAGTGGCGGTCTCGCCCCGGCTCCTCTGCGTAGTAGTAACATCTCGCACTGG GACGGAGCGTAGGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCGGATCAG GTAGGAATACCCGCTGAACTTAAGCATATCAATAAGCGGAGGGAAAAGAA

>Seq130 [organism=*Fusarium dimerum*] [isolate B2-5] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

ACTCCCAACCCCTGTGACATACCTACAACGTTGCCTCGGCGGACCCCCGCCTCCCCGTAA

CACGGGAGCGGCCCGCCAGAGGACCCAACAAACCCTGTTATTTTCAGTATCTTCTGAGTG AAAACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGAA CGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGA ACGCACATTGCGCCCGCCAGTACTCTGGCGGGGCATGCCTGTTCGAGCGTCATTACATCCC TCAAGCCCCTTCGGGCTTGGTGTTGGGCATCGGCCGTCCCTCCAGCGGCGGCCGTGCCC CAAATACAGTGGCGGTCTCGCCCCGGCTCCTCTGCGTAGTAGTAACATCTCGCACTGGG ACGGAGCGTAGGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCGGATCAGG TAGGAATACCCGCTGAACTTAAGCATATCAATAAGCGGAGGGAAAAGAAACCTCTGTG

>Seq131 [organism=*Fusarium dimerum*] [isolate B1-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

TAACTCCCAACCCCTGTGACATACCTACAACGTTGCCTCGGCGGACCCCCGCCTCCCCGT AACACGGGAGCGGCCCGCCAGAGGACCCAACAAACCCTGTTATTTTCAGTATCTTCTGAG TGAAAACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAG AACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTT GAACGCACATTGCGCCCGCCAGTACTCTGGCGGGGCATGCCTGTTCGAGCGTCATTACATC CCTCAAGCCCCTTCGGGCTTGGTGTTGGGCATCGGCCGTCCCTCCAGCGGCGGCCGTGC CCCAAATACAGTGGCGGTCTCGCCCCGGCTCCTCTGCGTAGTAGTAACATCTCGCACTG GGACGGAGCGTAGGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCGGATCA GGTAGGAATACCGCTGAACTTAAGCATATCAATAAGCGGAGGGAAAAGAAA

>Seq132 [organism=*Fusarium dimerum*] [isolate B2-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

TCATAAACTCCAACCCCTGTGACATACCTACAACGTTGCCTCGGCGGACCCCCGCCTCCC CGTAACACGGGAGCGGCCCGCCAGAGGACCCAACAAACCCTGTTATTTTCAGTATCTTCT GAGTGAAAACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATG AAGAACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATC TTTGAACGCACATTGCGCCCGCCAGTACTCTGGCGGGCATGCCTGTTCGAGCGTCATTAC ATCCCTCAAGCCCCTTCGGGCTTGGTGTTGGGCATCGGCCGTCCCTCCAGCGGCGGCCG TGCCCCAAATACAGTGGCGGTCTCGCCCCGGCTCCTCTGCGTAGTAGTAACATCTCGCA CTGGGACGGAGCGTAGGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCGGA TCAGGTAGGAATACCGCTGAACTTAAGCATATCAATAAGCGGAGGGAAAAGAAAACCCC C

>Seq133 [organism=*Fusarium dimerum*] [isolate B4-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

AGTCACTCCCAACCCCTGTGACATACCTACAACGTTGCCTCGGCGGACCCCCGCCTCCCC GTAACACGGGAGCGGCCCGCCAGAGGACCCCAACAAACCCTGTTATTTTCAGTATCTTCTG

>Seq134 [organism=*Fusarium dimerum*] [isolate B1-6] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

CATCACTCCCAACCCCTGTGACATACCTACAACGTTGCCTCGGCGGACCCCCGCCTCCCC GTAACACGGGAGCGGCCCGCCAGAGGACCCAACAAACCCTGTTATTTTCAGTATCTTCTG AGTGAAAACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGA AGAACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCT TTGAACGCACATTGCGCCCGCCAGTACTCTGGCGGGGCATGCCTGTTCGAGCGTCATTACA TCCCTCAAGCCCCTTCGGGCTTGGTGTTGGGCATCGGCCGTCCCTCCAGCGGCGGCCGT GCCCCAAATACAGTGGCGGTCTCGCCCCGGCTCCTCTGCGTAGTAGTAACATCTCGCAC TGGGACGGAGCGTAGGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCGGAT CAGGTAGGAATACCCGCTGAACTTAAGCATATCAATAAGCGGAGGGAAAAGAAAACCCCC

>Seq135 [organism=*Fusarium dimerum*] [isolate C1-4] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

ACCTCCCAACCCCTGTGACATACCTACAACGTTGCCTCGGCGGACCCCCGCCTCCCCGTA ACACGGGAGCGGCCCGCCAGAGGACCCAACAAACCCTGTTATTTTCAGTATCTTCTGAGT GAAAACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGA ACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTG AACGCACATTGCGCCCGCCAGTACTCTGGCGGGGCATGCCTGTTCGAGCGTCATTACATCC CTCAAGCCCCTTCGGGCTTGGTGTTGGGCATCGGCCGTCCTCCAGCGGCGGCCGTGCC CCAAATACAGTGGCGGTCTCGCCCCGGCTCCTCTGCGTAGTAGTAACATCTCGCACTGG GACGGAGCGTAGGCCACGCCGTAAAACAACCCAACTTTCTGAATGTTGACCTCGGATCAG GTAGGAATACCCGCTGAACTTAAGCATATCAATAAGCGGGGGGAAAAAGAA

>Seq136 [organism=*Fusarium dimerum*] [isolate C4-5] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

AACTCCCAACCCCTGTGACATACCTACAACGTTGCCTCGGCGGACCCCCGCCTCCCCGTA ACACGGGAGCGGCCCGCCAGAGGACCCAACAAACCCTGTTATTTTCAGTATCTTCTGAGT GAAAACACAATCAATTAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGA ACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTG

>Seq137 [organism=*Fusarium solani*] [isolate A2-5] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq138 [organism=*Fusarium solani*] [isolate A9-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq139 [organism=*Fusarium solani*] [isolate (CBS224.34)] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

CTCAGGCCCCCGGGCCTGGCGTTGGGGATCGGCGGAGCGCCCCTCGTGGGCGCACGCC GTCCCCCAAATACAGTGGCGGTCCCGCCGCAGCTTCCATCGCGTAGTAGCTAACACCTCG CGACTGGAGAGCGGCGCGCGCCACGCCGTAAAACACCCCCAACTCTTCTGAAGTTGACCTCG AATCAGGTAGGAATACCCGCTGAACTTAAGCATATCAATAAGCGGGGGGAAAAGAAA

>Seq140 [organism=*Fusarium solani*] [isolate B9-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq141 [organism=*Fusarium solani*] [isolate A2-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq142 [organism=*Fusarium solani*] [isolate A9-4] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

CTCAGGCCCCCGGGCCTGGCGTTGGGGATCGGCGGAGCGCCCCTCGTGGGCGCACGCC GTCCCCCAAATACAGTGGCGGTCCCGCCGCAGCTTCCATCGCGTAGTAGCTAACACCTCG CGACTGGAGAGCGGCGCGCGCCACGCCGTAAAACACCCCCAACTCTTCTGAAGTTGACCTCG AATCAGGTAGGAATACCCGCTGAACTTAAGCATATCAATAAGCGGAGGGAAAAGAAA

>Seq143 [organism=*Fusarium solani*] [isolate B8-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq144 [organism=*Fusarium solani*] [isolate A9-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq145 [organism=*Fusarium solani*] [isolate A9-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence
>Seq146 [organism=*Fusarium solani*] [isolate A6-4] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq147 [organism=*Fusarium solani*] [isolate C10-4] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq148 [organism=*Fusarium solani*] [isolate C10-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

CTCAGGCCCCCGGGCCTGGCGTTGGGGATCGGCGAGGCGCCCCCTGCGGGCACACGCC GTCCCCCAAATACAGTGGCGGTCCCGCCGCAGCTTCCATTGCGTAGTAGCTAACACCTCG CAACTGGAGAGCGGCGCGCGCCACGCCGTAAAACACCCCAACTTCTGAATGTTGACCTCGAA TCAGGTAGGAATACCCGCTGAACTTAAGCATATCAATAAGCGGGGGAAA

>Seq149 [organism=*Fusarium solani*] [isolate C10-7] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq150 [organism=*Fusarium oxysporum*] [isolate C3-4] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq151 [organism=*Fusarium oxysporum*] [isolate C9-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq152 [organism=*Fusarium oxysporum*] [isolate C6-5] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq153 [organism=*Fusarium oxysporum*] [isolate C9-4] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq154 [organism=*Fusarium oxysporum*] [isolate A6-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq155 [organism=*Fusarium oxysporum*] [isolate C5-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq156 [organism=*Fusarium oxysporum*] [isolate CRT1-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq157 [organism=*Fusarium oxysporum*] [isolate C9-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq158 [organism=*Fusarium oxysporum*] [isolate C5-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq159 [organism=*Fusarium oxysporum*] [isolate CRT1-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq160 [organism=*Fusarium oxysporum*] [isolate A8-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq161 [organism=*Fusarium oxysporum*] [isolate C8-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

TACTCCAACCCCTGTGACATACCACTTGTTGCCTCGGCGGATCAGCCCGCTCCCGGTAAA ACGGGACGGCCCGCCAGAGGACCCCTAAACTCTGTTTCTATATGTAACTTCTGAGTAAAA

>Seq162 [organism=*Fusarium oxysporum*] [isolate C5-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq163 [organism=*Fusarium oxysporum*] [isolate B9-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq164 [organism=*Fusarium oxysporum*] [isolate C2-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence ACTCCCAACCCCTGTGAACATACCACTTGTTGCCTCGGCGGATCAGCCCGGCTCCCGGTAA AACGGGACGGCCCGCCAGAGGACCCCTAAACTCTGTTTCTATATGTAACTTCTGAGTAAA ACCATAAATAAATCAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGAAC GCAGCAAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGAA

>Seq165 [organism=*Fusarium oxysporum*] [isolate B10-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq166 [organism=*Fusarium oxysporum*] [isolate C5-5] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq167 [organism=*Fusarium oxysporum*] [isolate B6-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

CACGTCGAGCTTCCATAGCGTAGTAGTAGAAACCCTCGTTACTGGTAATCGTCGCGGCCAC GCCGTTAAACCCCCAACTTCTGAATGTTGACCTCGGATCAGGTAGGAATACCCGCTGAACT TAAGCATATCAATAAGCGGGGGAAAAAAGAAA

>Seq168 [organism=*Fusarium oxysporum*] [isolate A1-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq169 [organism=*Fusarium oxysporum*] [isolate C9-5] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq170 [organism=*Fusarium oxysporum*] [isolate C9-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

## AAGCATATCAATAAGCGGGGGGA

>Seq171 [organism=*Fusarium oxysporum*] [isolate C6-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq172 [organism=*Fusarium oxysporum*] [isolate C7-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq173 [organism=*Fusarium oxysporum*] [isolate A5-6] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq174 [organism=*Fusarium oxysporum*] [isolate A1-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq175 [organism=*Fusarium oxysporum*] [isolate C5-4] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq176 [organism=*Fusarium oxysporum*] [isolate C4-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq177 [organism=*Fusarium oxysporum*] [isolate A7-4] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq178 [organism=*Fusarium oxysporum*] [isolate A8-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq179 [organism=*Fusarium oxysporum*] [isolate C6-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq180 [organism=*Fusarium oxysporum*] [isolate B5-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq181 [organism=*Fusarium oxysporum*] [isolate B7-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq182 [organism=*Fusarium oxysporum*] [isolate B6-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq183 [organism=*Fusarium oxysporum*] [isolate B5-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq184 [organism=*Fusarium oxysporum*] [isolate A6-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq185 [organism=*Fusarium oxysporum*] [isolate C8-6] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq186 [organism=*Fusarium oxysporum*] [isolate B10-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq187 [organism=*Fusarium oxysporum*] [isolate C6-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq188 [organism=*Fusarium oxysporum*] [isolate C1-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq189 [organism=*Fusarium oxysporum*] [isolate C3-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq190 [organism=*Fusarium oxysporum*] [isolate A7-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq191 [organism=*Fusarium oxysporum*] [isolate C8-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq192 [organism=*Fusarium oxysporum*] [isolate C6-4] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq193 [organism=*Fusarium oxysporum*] [isolate C2-7] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq194 [organism=*Fusarium oxysporum*] [isolate A6-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq195 [organism=*Fusarium oxysporum*] [isolate C10-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq196 [organism=*Fusarium oxysporum*] [isolate A2-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq197 [organism=*Fusarium oxysporum*] [isolate CRT1-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq198 [organism=*Fusarium oxysporum*] [isolate A5-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq199 [organism=*Fusarium oxysporum*] [isolate C3-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq200 [organism=*Fusarium oxysporum*] [isolate C2-4] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq201 [organism=*Penicillium brevicompactum*] [isolate A7-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq202 [organism=*Phoma herbarum*] [isolate B3-4] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq203 [organism=*Phoma herbarum*] [isolate A4-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

AGTTTGTGGGCTTTGCCTGCTATCTCTTACCCATGTCTTTTGAGTACTTACGTTTCCTCG GTGGGTTCGCCCGCCGATTGGACAATTTAAACCCTTTGCAGTTGCAATCAGCGTCTGAAA AACATAATAGTTACAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGAACGC AGCGAAATGCGATAAGTAGTGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGAACG CACATTGCGCCCCTTGGTATTCCATGGGGCATGCCTGTTCGAGCGTCATTTGTACCTTCA AGCATTGCTTGGTGTTGGGTGTTTGTCTCGCCTTTGCGTGTAGACTCGCCTTAAAACAAT TGGCAGCCGGCGTATTGATTTCGGAGCGCAGTACATCTCGCGCTTTGCACTCATAACGAC GACGTCCAAAAGTACATTTTAACACTCTTGACCTCGGATCAGGTAGGGATACCCGCTGAA CTTAAGCATATCAATAAGCGGAAGGAAAAGAAATGCTCATA

>Seq204 [organism=*Phoma herbarum*] [isolate C8-4] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

TGAGTGTGGGCTTTGCCTGCTATCTCTTACCCATGTCTTTTGAGTACTTACGTTTCCTCG GTGGGTTCGCCCGCCGATTGGACAATTTAAACCCTTTGCAGTTGCAATCAGCGTCTGAAA AACATAATAGTTACAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGAACGC AGCGAAATGCGATAAGTAGTGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGAACG CACATTGCGCCCCTTGGTATTCCATGGGGCATGCCTGTTCGAGCGTCATTTGTACCTTCA AGCATTGCTTGGTGTTGGGTGTTTGTCTCGCCTTTGCGTGTAGACTCGCCTTAAAACAAT TGGCAGCCGGCGTATTGATTTCGGAGCGCAGTACATCTCGCGCTTTGCACTCATAACGAC GACGTCCAAAAGTACATTTTAACACTCTTGACCTCGGATCAGGTAGGGATACCCGCTGAA CTTAAGCATATCAATAAGCGGGGGGAAAAAGAA

>Seq205 [organism=*Phoma herbarum*] [isolate CRT3-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

AGAGTTGTGGGCTTTGCCTGCTATCTCTTACCCATGTCTTTTGAGTACTTACGTTTCCTC GGGGGGTTCGCCCGCCGATTGGACAATTTAAACCCTTTGCAGTTGCAATCAGCGTCTGAA AAACATAATAGTTACAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGAACG CAGCGAAATGCGATAAGTAGTGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGAAC GCACATTGCGCCCCTTGGTATTCCATGGGGCATGCCTGTTCGAGCGTCATTTGTACCTTC AAGCATTGCTTGGTGTTGGGTGTTTGTCTCGCCTTTGCGTGTAGACTCGCCTTAAAACAA TTGGCAGCCGGCGTATTGATTTCGGAGCGCAGTACATCTCGCGCTTTGCACTCATAACGA CGACGTCCAAAAGTACATTTTAACACTCTTGACCTCGGATCAGGTAGGGATACCCGCTGA ACTTAAGCATATCAATAAGCGGAGGGAAAAGAAA

>Seq206 [organism=*Rhodotorula mucilaginosa*] [isolate A5-7] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

AGGACGTCCACTTAACTTGGAGTCCGAACTCTCACTTTCTAACCCTGTGCACTTGTTTGG GATAGTAACTCTCGCAAGAGAGCGAACTCCTATTCACTTATAAACACAAAGTCTATGAAT GTATTAAATTTTATAACAAAATAAAACTTTCAACAACGGATCTCTTGGCTCTCGCATCGA TGAAGAACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAA TCTTTGAACGCACCTTGCGCTCCATGGTATTCCGTGGAGCATGCCTGTTTGAGTGTCATG AATACTTCAACCCTCCTCTTTCTTAATGATTGAAGAGGTGTTTGGTTTCTGAGCGCTGCT GGCCTTTACGGTCTAGCTCGTTCGTAATGCATTAGCATCCGCAATCGAACTTCGGATTGA CTTGGCGTAATAGACTATTCGCTGAGGAATTCTAGTCTTCGGATTAGAGCCGGGTTGGGT TAAAGGAAGCTTCTAATCAGAATGTCTACATTTTAAGATTAGATCTCAAATCAGGTAGGA CTACCCGCTGAACTTAAGCATATCAATAAGCGAGGGAAAAAGAAAATTTTT >Seq207 [organism=*Mucor circinelloides*] [isolate B5-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq208 [organism=*Aspergillus niger*] [isolate A5-5] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq209 [organism=*Candida parapsilosis*] [isolate B10-6] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq210 [organism=*Rhodotorula slooffiae*] [isolate A4-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq211 [organism=*Rhodotorula slooffiae*] [isolate A10-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq212 [organism=*Rhodosporidium babjevae*] [isolate B8-7] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

## GCTCCTAATCCTAAAGTCTATTTTTGATTAGATCTCAAATCAGGTAGGACTACCCGCTG AACTTAAGCATATCAATAAGCGGGGGGAA

>Seq213 [organism=*Meyerozyma guilliermondii*] [isolate B9-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq214 [organism=*Clavispora lusitaniae*] [isolate C1-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq215 [organism=*Candida intermedia*] [isolate C4-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq216 [organism=*Penicillium echinulatum*] [isolate A4-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

GATGAGGCTCTGGGTCACCTCCCACCCGTGTTTATTTTACCTTGTTGCTTCGGCGGGCCC

>Seq217 [organism=*Meyerozyma guilliermondii*] [isolate B10-7] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq218 [organism=*Rhodotorula slooffiae*] [isolate B10-9] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq219 [organism=*Trichosporon asteroides*] [isolate B10-12] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq220 [organism=*Penicillium crustosum*] [isolate A3-4] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq221 [organism=*Penicillium crustosum*] [isolate A5-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq222 [organism=*Ochroconis mirabilis*] [isolate C8-7] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

GTGCTGTATTCGTGCTTCTCTCGGAGACGCGAAGCTACCCGACCTGATGTCATTTTATC CGAGGGCGCGCCCGCTTGAGAAGACAGCGGTTTGACGTTGTGGTGTTACCCGGACGAGG CGCTTGTCTCGTAAGGGGAAGGGTCGG

>Seq223 [organism=*Penicillium expansum*] [isolate C8-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq224 [organism=*Trichosporon domesticum*] [isolate A3-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq225 [organism=*Penicillium expansum*] [isolate A1-4] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq226 [organism=*Penicillium crustosum*] [isolate A1-3] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq227 [organism=*Penicillium crustosum*] [isolate B9-5] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq228 [organism=*Lecythophora fasciculata*] [isolate R10-6] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

ATGCCTGTTCGAGCGTCATTTCAACCCTCAAGCCCTGCTTGGTGTTGGGGCCCTACGGCT GCCGTAGGCCCTGAAAGGAAGTGGCGGGGCTCGCTACAACTCCGAGCGTAGTAATTCATTA TCTCGCTAGGGACGTTGCGGCGCGCGCCCCTGCCGTTAAAGACCATCTTTAACTCAAGGTTG ACCTCGGATCAGGTAGGAATACCCGCTGAACTTAAGCATATCAATAAGCGGAGGAAAAGAA A

>Seq229 [organism=*Fusarium solani*] [isolate K8-1] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

>Seq230 [organism=*Fusarium solani*] [isolate K8-2] internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and 28S ribosomal RNA gene, partial sequence

## APPENDIX 4: TEF-1α Sequences

>Seq1 [organism=*Fusarium dimerum*] [isolate X4-2](X4-3) translation elongation factor 1 alpha (tef) gene, partial cds

1 alpha (tef) gene, partial cds

>Seq2 [organism=*Fusarium dimerum*] [isolate X3-1] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq3 [organism=*Fusarium dimerum*] [isolate X5-2] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq4 [organism=*Fusarium dimerum*] [isolate X3-3] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq5 [organism=*Fusarium dimerum*] [isolate X5-4] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq6 [organism=*Fusarium oxysporum*] [isolate K6-1] translation elongation factor 1 alpha (tef) gene, partial cds

AGTCGACGCACTGTGAGTACTCTCCTCGACAATGAGCTTATCTGCCATCGTCAATCCTGA CCAGGACCTGGTGGGGTATTTCTCAAAGTCAACATACTGACATCGTTTCACAGACCGGTC ACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAGAAGTTCGAGAAGGTTA GTCACTTTCCCTTCGATCGCGCGCTCCTTTGCCCATCGATTTCCCCTACGACTCGAAACGT ACCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCGTAATTTTTTTGGTGGGG CACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAACCATTCTCACAACCTC AATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAACAATAGGAAGCCGCTGA GCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAGCTCAAGGCCGAGCGTGA GCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTCCTCGCTACTATGTCAC CGTCATTGGTATGTTGTCGCTCATGCTTCATCTACTTCTCTCGTACTAACATATCACT CAGACGCTCCCGGTCACCGTGATTTCATCACAAGAACATGATCCGG

>Seq7 [organism=*Fusarium solani*] [isolate K2-4] translation elongation factor 1 alpha (tef) gene, partial cds

GGCCGTCGACTCTGGCAAGTCGACCACCGTAAGTCAAACCCTCCATCGCGATCTGCTTAT CTCGGGTCGTGGAACCCCGCCTGGCATCACGGGCGGGGGTACTCATCAGTCACTTCATGCT GACAATCATCTACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACC ATCGAGAAGTTCGAGAAGGTTGGTGACATCTCCCCCGATCGCGCCTTGCTATTCCACATC GAATTCCCCGTCGAATTCCCTCCTCGCGACACGCTCTGCGCCCGCTTCTCTCGAGTTCCA AAAATTTTGCGGTCCGACCGTAATTTTTTTGGTGGGGCATTTACCCCGCCACTCGGGTGA CGTTGGACAAAGCCCTGATCCCTGCACACAAATAACACGAAACCCTCTTGGCGCGCATCA TCACGTGGTTCACAACAGACGCTAACCGACTCAACAATAGGAAGCCGCTGAGCTCGGTAA GGGTTCCTTCAAGTACGCCTGGGTCCTTGACAAGCTCAAGGCCGAGCGTGAGCGTGGTAT CACCATCGACATTGCCCTCTGGAAGTTCGAGACTCCCCGCTACTATGTCACCGTCATTGG TATGTCGCTGTCACAGTCTCACTCATGTCTCACCACTAACAGTCAACAGACCGCCCGG CCACCGTGACTTCATCAAGAACATGATACGGGGT

>Seq8 [organism=*Fusarium solani*] [isolate K2-3] translation elongation factor 1 alpha (tef) gene, partial cds

GGCCGTCGACTCTGGCAGTCGACCACCGTAAGTCAAACCCTCCATCGCGATCTGCTTATC TCGGGTCGTGGAACCCCGCCTGGCATCACGGGCGGGGGTACTCATCAGTCACTTCATGCTG ACAATCATCTACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCA TCGAGAAGTTCGAGAAGGTTGGTGACATCTCCCCCGATCGCGCCTTGCTATTCCACATCG AATTCCCCGTCGAATTCCCTCCTCGCGACACGCTCTGCGCCCGCTTCTCTCGAGTTCCAA AAATTTTGCGGTCCGACCGTAATTTTTTTGGTGGGGGCATTTACCCCGCCACTCGGGTGAC GTTGGACAAAGCCCTGATCCCTGCACACAAATAACACGAAACCCTCTTGGCGCGCATCAT CACGTGGTTCACAACAGACGCTAACCGACTCAACAATAGGAAGCCGCTGAGCTCGGTAAG GGTTCCTTCAAGTACGCCTGGGTCCTTGACAAGCTCAAGGCCGAGCGTGAGCGTGGTATC ACCATCGACATTGCCCTCTGGAAGTTCGAGACTCCCCGCTACTATGTCACCGTCATTGGT ATGTCGCTGTCACGTCTCTCACTCATGTCTCACCACTAACAGTCAACAGACGCCCCCGGC CACCGTGACTTCATCAAGAACATGATACGGGGG

>Seq9 [organism=*Fusarium solani*] [isolate K10-2] translation elongation factor 1 alpha (tef) gene, partial cds

GGCAACGTCGACTCTGGCAAGTCGACCACCGTAAGTCAAACCCTCATCGCGATCTGCTTA TCTCAGGTCGTGGAACCCCGCCTGGTATCTCGGGCGGGGTATTCATCAGTCACTTCATGC TGACAATCATCTACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAAC CATCGAGAAGTTCGAGAAGGTTGGTGACATCTCCCTCGATCGCGCCTTGCTATTCCACAT CGAATTCTCTCCCTCGCGATACGGTCTGCGCCCGCTTCTCCCGAGTCCCAAAATTTTTGC GGTCCGACCGTAATTTTTTTGGTGGGGCCATTTACCCCGCCACTCGGGCGACGTTGGACAA AGCCCTGATCCCTGCACACAAAAAACACCAAACCCTCTTGGCGCGCATCATCACGTGGTT CACAACAGACGCTAACCGGTCCAACAATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTC AAGTACGCCTGGGTCCTTGACAAGCTCAAGGCCGAGCGTGAGCGTGGTATCACCATCGAC ATTGCCCTCTGGAAGTTCGAGACTCCCCGCTACTATGTCACCGTCATTGCTG TCACCTCTCACACATGTCTCACCACTAACAATCAACAGACGCCCCGGCCACCGTGAT TTCATCAAGAACATGATCATGGGG

>Seq10 [organism=*Fusarium solani*] [isolate K9-6] translation elongation factor 1 alpha (tef) gene, partial cds

GGCCGTCGACTCTGGCAAGTCGACCACCGTAAGTCAAACCCTCATCGCGATCTGCTTATC TCAGGTCGTGGAACCCCGCCTGGTATCTCGGGCGGGGGTATTCATCAGTCACTTCATGCTG ACAATCATCTACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCA TCGAGAAGTTCGAGAAGGTTGGTGACATCTCCCTCGATCGCGCCTTGCTATTCCACATCG AATTCTCTCCCTCGCGATACGGTCTGCGCCCGCTTCTCCCGAGTCCCAAAATTTTTGCGG TCCGACCGTAATTTTTTTGGTGGGGCATTTACCCCGCCACTCGGGCGACGTTGGACAAAG CCCTGATCCCTGCACACAAAAAACACCAAACCCTCTTGGCGCGCATCATCACGTGGTTCA CAACAGACGCTAACCGGTCCAACAATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAA GTACGCCTGGGTCCTTGACAAGGCTCAAGGCCGAGCGTGAGCGTGGTATCACCATCGACAT TGCCCTCTGGAAGTTCGAGACTCCCCGCTACTATGTCACCGTCATTGCTGTC ACCTCTTCACACATGTCTCACCACTAACAATCAACAGACGCCCCGGCCACCGTGATTT CATCAAGAACATGATCCGGGGT >Seq11 [organism=*Fusarium solani*] [isolate K10-1] translation elongation factor 1 alpha (tef) gene, partial cds

GGCCGTCGACTCTGGCAGTCGACCACCGTAAGTCAAACCCTCATCGCGATCTGCTTATCT CAGGTCGTGGAACCCCGCCTGGTATCTCGGGCGGGGTATTCATCAGTCACTTCATGCTGA CAATCATCTACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCAT CGAGAAGTTCGAGAAGGTTGGTGACATCTCCCTCGATCGCGCCTTGCTATTCCACATCGA ATTCTCTCCCTCGCGATACGGTCTGCGCCCGCTTCTCCCGAGTCCCAAAATTTTTGCGGT CCGACCGTAATTTTTTTGGTGGGGGCATTTACCCCGCCACTCGGGCGACGTTGGACAAAGC CCTGATCCCTGCACACAAAAAACACCCAAACCCTCTTGGCGCGCATCATCACGTGGTTCAC AACAGACGCTAACCGGTCCAACAATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAG TACGCCTGGGTCCTTGACAAGCTCAAGGCCGAGCGTGAGCGTGGTATCACCATCGACATT GCCCTCTGGAAGTTCGAGACTCCCGCTACTATGTCACCGTCATTGGTATGTTGCTGTCA CTCTCTCACACATGTCTCACCACTAACAATCAACAGACGCCCCGGCCACCGTGATTTC ATCAAGAACATGATCACTGGGTACTT

>Seq12 [organism=*Fusarium solani*] [isolate K9-5] translation elongation factor 1 alpha (tef) gene, partial cds

GCCACGTCGACTCTGGCAAGTCGACCACCGTAAGTCAAACCCTCATCGCGATCTGCTTAT CTCAGGTCGTGGAACCCCGCCTGGTATCTCGGGCGGGGGTATTCATCAGTCACTTCATGCT GACAATCATCTACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACC ATCGAGAAGTTCGAGAAGGTTGGTGACATCTCCCTCGATCGCGCCTTGCTATTCCACATC GAATTCTCTCCCTCGCGATACGGTCTGCGCCCGCTTCTCCCGAGTCCCAAAATTTTTGCG GTCCGACCGTAATTTTTTTGGTGGGGGCATTTACCCCGCCACTCGGGCGACGTTGGACAAA GCCCTGATCCCTGCACACAAAAAACACCAAACCCTCTTGGCGCGCATCATCACGTGGTTC ACAACAGACGCTAACCGGTCCAACAATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCA AGTACGCCTGGGTCCTTGACAAGCTCAAGGCCGAGCGTGAGCGTGGTATCACCATCGACA TTGCCCTCTGGAAGTTCGAGACTCCCCGCTACTATGTCACCGTCATTGTTGCTGT CACCTCTCTCACACATGTCTCACCACTAACAATCAACAGACGCCCCCGGCCACCGTGATT TCATCAAGAACATGATCATGG

>Seq13 [organism=*Fusarium solani*] [isolate R1-3] translation elongation factor 1 alpha (tef) gene, partial cds

CGGCACGTCGACTCTGGCAAGTCGACCACCGTAAGTCAAACCCTCATCGCGATCTGCTTA TCTTGGGTCGTGGAACCCCACCTGGTATCTCGGGCGGGGGTATTCATCAGTCACTTCATGC TGACAATCATCTACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAAC CATCGAGAAGTTCGAGAAGGTTGGTGACATATCTCCCGATCGCGCCTTGCTATTCCACAT CGAATTCCCCGTCGAATTCCCTCCTCCGCGACACGCTCTGCGCCCGCTTCTCCCGAGTCC CAAAAATTTTGCGGTTCGACCGTAATTTTTTTTGGTGGGGCATTTACCCCGCCACTCGGG CGACGTTGGACAAAGCCCTGATCCCTGCACACAAAAACACCCAAACCCTCTTGGCGCGCAT CACGTGGTTCACAACAGACACTGACTCGTTCAACAATAGGAAGCCGCTGAGCTCGGTAAG GGTTCCTTCAAGTACGCCTGGGTCCTTGACAAGCTCAAGGCCGAGCGTGAGCGTGGTATC ACCATCGATATTGCTCTCTGGAAGTTCGAGACTCCCCGCTACTATGTCACCGTCATTGGT ATGTCGCCGTCATGTCTCTCACTCACGTCTCATCACTAACAATCCACAGACGCCCCGGC CACCGTGATTTCATCAAGAACATGATCTG

>Seq14 [organism=*Fusarium solani*] [isolate R1-1] translation elongation factor 1 alpha (tef) gene, partial cds

GCACGTCGACTCTGGCAAGTCGACCACCGTAAGTCAAACCCTCATCGCGATCTGCTTATC TTGGGTCGTGGAACCCCACCTGGTATCTCGGGCGGGGGTATTCATCAGTCACTTCATGCTG ACAATCATCTACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCA TCGAGAAGTTCGAGAAGGTTGGTGACATATCTCCCGATCGCGCCTTGCTATTCCACATCG AATTCCCCGTCGAATTCCCTCCTCCGCGACACGCTCTGCGCCCGCTTCTCCCGAGTCCCA AAAATTTTGCGGTTCGACCGTAATTTTTTTTGGTGGGGGCATTTACCCCGCCACTCGGGCG ACGTTGGACAAAGCCCTGATCCCTGCACACAAAAACACCAAACCCTCTTGGCGCGCATCA CGTGGTTCACAACAGACACTGACTCGTTCAACAATAGGAAGCCGCTGAGCTCGGTAAGGG TTCCTTCAAGTACGCCTGGGTCCTTGACAAGCTCAAGGCCGAGCGTGAGCGTGGTATCAC CATCGATATTGCTCTCTGGAAGTTCGAGACTCCCCGCTACTATGTCACCGTCATTGGTAT GTCGCCGTCATGTCTCTCACCACGTCTCATCACAATACAATCCACAGACGCCCCGGCCA CCGTGATTTCATCAAGAACATGATCCGGGGGAC

>Seq15 [organism=*Fusarium solani*] [isolate R1-2] translation elongation factor 1 alpha (tef) gene, partial cds

GCACGTCGACTCTGGCAAGTCGACCACCGTAAGTCAAACCCTCATCGCGATCTGCTTATC TTGGGTCGTGGAACCCCACCTGGTATCTCGGGCGGGGGTATTCATCAGTCACTTCATGCTG ACAATCATCTACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCA TCGAGAAGTTCGAGAAGGTTGGTGACATATCTCCCGATCGCGCCTTGCTATTCCACATCG AATTCCCCGTCGAATTCCCTCCTCCGCGACACGCTCTGCGCCCGCTTCTCCCGAGTCCCA AAAATTTTGCGGTTCGACCGTAATTTTTTTTGGTGGGGGCATTTACCCCGCCACTCGGGCG ACGTTGGACAAAGCCCTGATCCCTGCACACAAAAACACCAAACCCTCTTGGCGCGCATCA CGTGGTTCACAACAGACACTGACTCGTTCAACAATAGGAAGCCGCTGAGCTCGGTAAGGG TTCCTTCAAGTACGCCTGGGTCCTTGACAAGCTCAAGGCCGAGCGTGAGCGTGGTATCAC CATCGATATTGCTCTCTGGAAGTTCGAGACTCCCCGCTACTATGTCACCGTCATTGGTAT GTCGCCGTCATGTCTCTCACTACGTCTCATCACAAACACCACAGACGCCCCGGCCA CCGTGATTTCATCAAGAACATGATCATGG >Seq16 [organism=*Fusarium solani*] [isolate R6-9] translation elongation factor 1 alpha (tef) gene, partial cds

CGGCCGTCGACTCTGGCAGTCGACCACCGTAAGTCAAACCCTCATCGCGATCTACTTATC TCGGGTCGTGGAACCCCGCCTGGCATCTCGGGCGGGGGTATTCATCATCATTCACTTCATGCTG ACAATCATCTACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCA TCGAGAAGTTCGAGAAGGTTGGTGACATCTCCCCCGATCGCGCCTTGCTATTCCACATCG AATCCCCTCCCTCGCGATACGCTCTGCGCCCGCTTCTCCCGAGTTCCAAAATTTTTGCGG TCCGACCGTAATTTTTTTGGTGGGGGCATTTACCCCGCCACTCGGGCGACGTTGGACAAAG CCCTGATCCCTGCACACAAAACACCAAACCCTCTTGGCGCGCATCATCACGTGGTTCAC AACAGACGCTAACCGGTCCAACAATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAG TACGCCTGGGTCCTTGACAAGCTCAAGGCCGAGCGTGAGCGTGGTATCACCATCGACATT GCCCTCTGGAAGTTCGAGACTCCCCGCTACTATGTCACCGTCATTGGTATGTTGCTGTCA CCTCTCACACATGTCTCACCACTAACAATCAACAGACGCCCCGGCCACCGTGACTTCAT CAAGAACATGATCTG

>Seq17 [organism=*Fusarium dimerum*] [isolate R8-3] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq18 [organism=*Fusarium dimerum*] [isolate X2-6] translation elongation factor 1 alpha (tef) gene, partial cds
>Seq19 [organism=*Fusarium dimerum*] [isolate X2-4] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq20 [organism=*Fusarium dimerum*] [isolate R5-1] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq21 [organism=*Fusarium dimerum*] [isolate R6-3] translation elongation factor 1 alpha (tef) gene, partial cds

TCGGACCGTCGACTCCGGAAGTCCACCACTGTAAGTTCTCACTCCATGACTGCTCACTAT CAGTCTTACCCCGCCATCCTATCTGGTGGGAGTCCTTGCAACAGTATACTGACATCTACA

>Seq22 [organism=*Fusarium dimerum*] [isolate R6-2] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq23 [organism=*Fusarium dimerum*] [isolate R7-2] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq24 [organism=*Fusarium dimerum*] [isolate R5-2] translation elongation factor 1 alpha (tef) gene, partial cds

ΤG

>Seq25 [organism=*Fusarium dimerum*] [isolate R8-2] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq26 [organism=*Fusarium dimerum*] [isolate R5-3] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq27 [organism=*Fusarium dimerum*] [isolate R8-1] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq28 [organism=*Fusarium dimerum*] [isolate X2-5] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq29 [organism=*Fusarium dimerum*] [isolate R7-1] translation elongation factor 1 alpha (tef) gene, partial cds

ATCGGACCGTCGACTCCGGAAGTCCACCACTGTAAGTTCTCACTCCATGACTGCTCACTA TCAGTCTTACCCCGCCATCCTATCTGGTGGGAGTCCTTGCAACAGTATACTGACATCTAC ACCTAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAGAAG

>Seq30 [organism=*Fusarium dimerum*] [isolate X2-2] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq31 [organism=*Fusarium dimerum*] [isolate R6-1] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq32 [organism=*Fusarium dimerum*] [isolate H4-1] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq33 [organism=*Fusarium oxysporum*] [isolate H7-1] translation elongation factor 1 alpha (tef) gene, partial cds

TCGGCCGTCGACTCTGGCAAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATC TGCCATCGTCAATCCTGACCAGGACCTGGTGGGGTATTTCTCAAAGTCAACATACTGACA TCGTTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCG AGAAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTC CCCTACGACTCGAAACGTACCCGGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACC GTAATTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTT AACCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCA ACAATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAA GCTCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGAC TCCTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTT TCGTACTAACATATCACTCAGACGCTCCCGGTCACCGTGATTTCATCAAGAACATGACC

>Seq34 [organism=*Fusarium oxysporum*] [isolate H3-1] translation elongation factor 1 alpha (tef) gene, partial cds

GGCCGTCGACTCTGGCAAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCTG CCATCGTCAATCCTGACCAGGACCTGGTGGGGTATTTCTCAAAGTCAACATACTGACATC GTTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAG AAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCC CTACGACTCGAAACGTACCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCGT AATTTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAA CCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAAC AATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAGC TCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTC CTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTCTC GTACTAACATATCACTCAGACGCTCCCGGTCACCGTGATTTCATCAAGAACATGATCAGGGGGGAC

>Seq35 [organism=*Fusarium dimerum*] [isolate P2-1] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq36 [organism=*Fusarium dimerum*] [isolate P2-3] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq37 [organism=*Fusarium dimerum*] [isolate H10-1] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq38 [organism=*Fusarium dimerum*] [isolate H2-1] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq39 [organism=*Fusarium dimerum*] [isolate P5-1] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq40 [organism=*Fusarium dimerum*] [isolate P5-2] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq41 [organism=*Fusarium dimerum*] [isolate H1-1] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq42 [organism=*Fusarium dimerum*] [isolate H5-1] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq43 [organism=*Fusarium dimerum*] [isolate H6-1] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq44 [organism=*Fusarium dimerum*] [isolate P2-2] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq45 [organism=*Fusarium dimerum*] [isolate B7-6] translation elongation factor 1 alpha (tef) gene, partial cds

ACATTGTGGTGGGGGGTTCTTACCCCGCCGAACATGAGAAGCTGGCATTTTGCCCCACCA CAAAAATTTTCACATCCCTTCTCATGGCTCGTCACAAGCAATCAAGACATGATGCTAACA ACCCACCAATAGGAAGCCGCCGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTT GACAAGCTCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATCGCTCTCTGGAAGTTC

>Seq46 [organism=*Fusarium dimerum*] [isolate B2-5] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq47 [organism=*Fusarium dimerum*] [isolate B1-1] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq48 [organism=*Fusarium dimerum*] [isolate B2-1] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq49 [organism=*Fusarium dimerum*] [isolate B4-1] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq50 [organism=*Fusarium dimerum*] [isolate B1-6] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq51 [organism=*Fusarium dimerum*] [isolate C1-4] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq52 [organism=*Fusarium dimerum*] [isolate C4-5] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq53 [organism=*Fusarium solani*] [isolate A2-5] translation elongation factor 1 alpha (tef) gene, partial cds

GCACGTCGACTCTGGCAAGTCGACCACCGTAAGTCAAACCCTCATCGCGATCTGCTTATC TTGGGTCGTGGAACCCCACCTGGTATCTCGGGCGGGGGTATTCATCAGTCACTTCATGCTG ACAATCATCTACAGACCGGTCACTTGATCTACCAGTGCGGGGGTATCGACAAGCGAACCA TCGAGAAGTTCGAGAAGGTTGGTGACATATCTCCCGATCGCGCCTTGCTATTCCACATCG AATTCCCCGTCGAATTCCCTCCTCCGCGACACGCTCTGCGCCCGCTTCTCCCGAGTCCCA AAAATTTTGCGGTTCGACCGTAATTTTTTTTGGTGGGGCATTTACCCCGCCACTCGGGCG ACGTTGGACAAAGCCCTGATCCCTGCACACAAAACACCAAACCCTCTTGGCGCGCATCA CGTGGTTCACAACAGACACTGACTCGTTCAACAATAGGAAGCCGCTGAGCTCGGTAAGGG TTCCTTCAAGTACGCCTGGGTCCTTGACAAGCTCAAGGCCGAGCGTGAGCGTGGTATCAC CATCGATATTGCTCTCTGGAAGTTCGAGACTCCCCGCTACTATGTCACCGTCATTGGTAT GTCGCCGTCATGTCTCTCACTCACGTCTCATCACTAACAATCCACAGACGCCCCCGGCCA CCGTGATTTCATCAAGAACATGATCCGGGGTAC

>Seq54 [organism=*Fusarium solani*] [isolate A9-3] translation elongation factor 1 alpha (tef) gene, partial cds

CGGCACGTCGACTCTGGCAAGTCGACCACCGTAAGTCAAACCCTCATCGCGATCTGCTTA TCTTGGGTCGTGGAACCCCACCTGGTATCTCGGGCGGGGTATTCATCAGTCACTTCATGC TGATAATCATCTACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATTGACAAGCGAAC CATCGAGAAGTTCGAGAAGGTTGGTGACATATCTCCCGATCGCGCCTTGCTATTCCACAT CGAATTCCCCGTCGAATTCCCTCCTCCGCGACACGCTCTGCGCCCGCTTCTCCCGAGTCC CAAAAATTTTGCGGTTCGACCGTAATTTTTTTTGGTGGGGGCATTTACCCCGCCACTCGGG CGACGTTGGACAAAGCCCTGATCCCTGCACACAAAAACACCAAACCCTCTTGGCGCGCAT CACGTGGTTCACAACAGACACTGACTCGTTCAACAATAGGAAGCCGCTGAGCTCGGTAAG GGTTCCTTCAAGTACGCCTGGGTCCTTGACAAGCTCAAGGCCGAGCGTGAGCGTGGTATC ACCATCGATATTGCTCTCTGGAAGTTCGAGACTCCCCGCTACTATGTCACCGTCATTGGT ATGTCGCCGTCATGTCTCTCACCACGTCTCACCAACAATCCACAGACGCCCCGGC CACCGTGATTTCATCAAGAACATGATCAT

>Seq55 [organism=*Fusarium solani*] [isolate B9-3] translation elongation factor 1 alpha (tef) gene, partial cds

CGTTCGACTCTGGCAAGTCGACCACCGTAAGTCAAACCCTCATCGCGATCTGCTTATCTT GGGTCGTGGAACCCCACCTGGTATCTCGGGCGGGGGTATTCATCAGTCACTTCATGCTGAC AATCATCTACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATC GAGAAGTTCGAGAAGGTTGGTGACATATCTCCCGATCGCGCCTTGCTATTCCACATCGAA TTCCCCGTCGAATTCCCTCCTCCGCGACACGCTCTGCGCCCGCTTCTCCCGAGTCCCAAA AATTTTGCGGTTCGACCGTAATTTTTTTGGTGGGGGCATTTACCCCGCCACTCGGGCGAC GTTGGACAAAGCCCTGATCCCTGCACACAAAAACACCAAACCCTCTTGGCGCGCACTCACG TGGTTCACAACAGACACTGACTCGTTCAACAATAGGAAGCCGCTGAGCTCGGTAAGGGTT CCTTCAAGTACGCCTGGGTCCTTGACAAGCTCAAGGCCGAGCGTGAGCGTGGTATCACCA TCGATATTGCTCTCTGGAAGTTCGAGACTCCCCGCTACTATGTCACCGTCATTGGTATGT CGCCGTCATGTCTCTCACCACGTCTCATCACTAACAATCCACAGACGCCCCGGCCACC GTGATTTCATCAAGAACATGATCACTGGGTACCTCCA >Seq56 [organism=*Fusarium solani*] [isolate A2-1] translation elongation factor 1 alpha (tef) gene, partial cds

CGGCACGTCGACTCTGGCAAGTCGACCACCGTAAGTCAAACCCTCATCGCGATCTGCTTA TCTTGGGTCGTGGAACCCCACCTGGTATCTCGGGCGGGGTATTCATCAGTCACTTCATGC TGACAATCATCTACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAAC CATCGAGAAGTTCGAGAAGGTTGGTGACATATCTCCCGATCGCGCCTTGCTATTCCACAT CGAATTCCCCGTCGAATTCCCTCCTCCGCGACACGCTCTGCGCCCGCTTCTCCCGAGTCC CAAAAATTTTGCGGTTCGACCGTAATTTTTTTTGGTGGGGGCATTTACCCCGCCACTCGGG CGACGTTGGACAAAGCCCTGATCCCTGCACACAAAAACACCAAACCCTCTTGGCGCGCAT CACGTGGTTCACAACAGACACTGACTCGTTCAACAATAGGAAGCCGCTGAGCTCGGTAAG GGTTCCTTCAAGTACGCCTGGGTCCTTGACAAGCTCAAGGCCGAGCGTGAGCGTGGTATC ACCATCGATATTGCTCTCTGGAAGTTCGAGACTCCCCGCTACTATGTCACCGTCATTGGT ATGTCGCCGTCATGTCTCTCACCACGTCTCATCACAATACAATCCACAGACGCCCCGGC CACCGTGATTTCATCAAGAACATGTCGGG

>Seq57 [organism=*Fusarium solani*] [isolate A9-4] translation elongation factor 1 alpha (tef) gene, partial cds

GCACGTCGACTCTGGCAAGTCGACCACCGTAAGTCAAACCCTCATCGCGATCTGCTTATC TTGGGTCGTGGAACCCCACCTGGTATCTCGGGCGGGGGTATTCATCAGTCACTTCATGCTG ACAATCATCTACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCA TCGAGAAGTTCGAGAAGGTTGGTGACATATCTCCCGATCGCGCCTTGCTATTCCACATCG AATTCCCCGTCGAATTCCCTCCTCCGCGACACGCTCTGCGCCCGCTTCTCCCGAGTCCCA AAAATTTTGCGGTTCGACCGTAATTTTTTTTTGGTGGGGCATTTACCCCGCCACTCGGGCG ACGTTGGACAAAGCCCTGATCCCTGCACACAAAAACACCAAACCCTCTTGGCGCGCATCA CGTGGTTCACAACAGACACTGACTCGTTCAACAATAGGAAGCCGCTGAGCTCGGTAAGGG TTCCTTCAAGTACGCCTGGGTCCTTGACAAGCTCAAGGCCGAGCGTGAGCGTGGTATCAC CATCGATATTGCTCTCTGGAAGTTCGAGACTCCCCGCTACTATGTCACCGTCATTGGTAT GTCGCCGTCATGTCTCTCACCACGTCTCATCACAATACAACACCACAGACGCCCCGGCCA CCGTGATTTCATCAAGAACATGATCCGGGGGAC

>Seq58 [organism=*Fusarium solani*] [isolate B8-1] translation elongation factor 1 alpha (tef) gene, partial cds

GCACGTCGACTCTGGCAAGTCGACCACCGTAAGTCAAGCCCTCATCGCGATCTGCTTATC TCGGGTCGTGGAACCCCGCCTGGTATCTCGGGCGGGGGTACTCATCAGTCACTTCATGCTG ACAATCATCTACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCA TCGAGAAGTTCGAGAAGGTTGGTCACATCTCCCCCGATCGCGCCTTGCTATCCCACATCG AATTCCCCGTCGAATTCCCTCCTCCGCGACACGCTCTGCGCCCGCTTCTCCCGAGTCCCA AAAATTTTGCGGTTCGACCGTAAATTTTTTTGGTGGGGGCATTTACCCCGCCACTCGGGCG ACGTTGGACAAAGCCCTGATCCCTGCACACAAAAACACCCAAACCCTCTTGGCGCGCATCA CGTGGTTCACAACAGACACTGACTGGTTCAACAATAGGAAGCCGCTGAGCTCGGTAAGGG TTCCTTCAAGTACGCCTGGGTCCTTGACAAGCTCAAGGCCGAGCGTGAGCGTGGTATCAC CATCGATATTGCTCTCTGGAAGTTCGAGACTCCCCGCTACTATGTCACCGTCATTGGTAC GTCGCCGTCATCTCTCACTCACGTCTCATCACTAACAATCAACAGACGCCCCCGGCCACC GTGATTTCATCAAGAACATGACCGGGGG

>Seq59 [organism=*Fusarium solani*] [isolate A9-2] translation elongation factor 1 alpha (tef) gene, partial cds

GGCCGTCGACTCTGGCAGTCGACCACCGTAAGTCAAACCCTCATCGCGATCTGCTTATCT CGGGTCGTGGAACCCCGCCTGGCATCTCGGGCGGGGGTATTCATCATTCACTTCATGCTGA CAATCATCTACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCAT CGAGAAGTTCGAGAAGGTTGGTGACATCTGCCCCCGATCGCGCCTTGATATTCCACATCG AATTCCCCGTCGAATTCCCTCCATCGCGATACGCTCTGCGCCCGCTTCTCCCGAGGTCCCA AAATTTTTGCGGTCCGACCGTAATTTTTTTGGTGGGGGCATTTACCCCGCCACTCGGGCGA CGTTGGACAAAGCCCTGATCCCTGCACACAAAAACACCAAACCCTCTTGGCGCGCATCAT CACGTGGTTCACGACAGACGCTAACCGGTCCAACAATAGGAAGCCGCTGAGCTCGGTAAG GGTTCCTTCAAGTACGCCTGGGTCCTTGACAAGCTCAAGGCCGAGCGTGAGCGTGGTATC ACCATCGACATTGCCCTCTGGAAGTTCGAGACTCCCGCTACTATGTCACCGTCATTGGT ATGTTGCTGTCACCTCTCTCACACATGTCTCACCACTAACAATCAACAACAACAACAACAACACCCGGCCCCGGC CACCGTGACTTCATCAAGAACATGATCCGG

>Seq60 [organism=*Fusarium solani*] [isolate A9-1] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq61 [organism=*Fusarium solani*] [isolate A6-4] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq62 [organism=*Fusarium solani*] [isolate C10-4] translation elongation factor 1 alpha (tef) gene, partial cds

CGGCCGTCGACTCTGGCAAGTCGACCACCGTAAGTCAAACCCTCATCGCGATCTGCTTAT CTCAGGTCGTGGAACCCCGCCTGGTATCTCGGGCGGGGTATTCATCAGTCACTTCATGCT GACAATCATCTACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACC ATCGAGAAGTTCGAGAAGGTTGGTGACATCTCCCTCGATCGCGCTTTGCTATTCCACATC GAATTCTCTCCCTCGCGATACGGTCTGCGCCCGCTTCTCCCGAGTCCCAAAATTTTTGCG GTCCGACCGTAATTTTTTTTGGTGGGGGCATTTACCCCGCCACTCGGGCGACGTTGGACAA AGCCCTGATCCCTGCACACAAAAAACACCAAACCCTCTTGGCGCGCATCATCACGTGGTT CACAACAGACGCTAACCGGTCCAACAATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTC AAGTACGCCTGGGTCCTTGACAAGCTCAAGGCCGAGCGTGAGCGTGGTATCACCATCGAC ATTGCCCTCTGGAAGTTCGAGACTCCCCGCTACTATGTCACCGTCATTGTTGCTG TCACCTCTCTCACACATGTCTCACCACTAACAATCAACAGACGCCCCGGCCACCGTGAT TTCATCAAGAACATGATCATGG

>Seq63 [organism=*Fusarium solani*] [isolate C10-2] translation elongation factor 1 alpha (tef) gene, partial cds

CGGCACGTCGACTCTGGCAAGTCGACCACCGTAAGTCAAACCCTCATCGCGATCTGCTTA TCTCAGGTCGTGGAACCCCGCCTGGTATCTCGGGCGGGGGTATTCATCAGTCACTTCATGC TGACAATCATCTACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAAC CATCGAGAAGTTCGAGAAGGTTGGTGACATCTCCCTCGATCGCGCTTTGCTATTCCACAT CGAATTCTCTCCCTCGCGATACGGTCTGCGCCCGCTTCTCCCGAGTCCCAAAATTTTTGC GGTCCGACCGTAATTTTTTTTGGTGGGGCATTTACCCCGCCACTCGGGCGACGTTGGACA AAGCCCTGATCCCTGCACACAAAAAACACCCAAACCCTCTTGGCGCGCATCATCACGTGGT TCACAACAGACGCTAACCGGTCCAACAATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTT CAAGTACGCCTGGGTCCTTGACAAGCTCAAGGCCGAGCGTGAGCGTGGTATCACCATCGA CATTGCCCTCTGGAAGTTCGAGACTCCCCGCTACTATGTCACCGTCATTGGTATGTTGCT GTCACCTCTCACACATGTCTCACCACTAACAATCAACAGACGCCCCCGGCCACCGTGA TTTCATCAAGAACATGATCATGG

>Seq64 [organism=*Fusarium solani*] [isolate C10-7] translation elongation factor 1 alpha (tef) gene, partial cds

CGGCACGTCGACTCTGGCAAGTCGACCACCGTAAGTCAAACCCTCATCGCGATCTGCTTA TCTCAGGTCGTGGAACCCCGCCTGGTATCTCGGGCGGGGTATTCATCAGTCACTTCATGC TGACAATCATCTACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAAC CATCGAGAAGTTCGAGAAGGTTGGTGACATCTCCCTCGATCGCGCTTTGCTATTCCACAT CGAATTCTCTCCCTCGCGATACGGTCTGCGCCCGCTTCTCCCGAGTCCCAAAATTTTTGC GGTCCGACCGTAATTTTTTTTGGTGGGGCATTTACCCCGCCACTCGGGCGACGTTGGACA AAGCCCTGATCCCTGCACACAAAAAACACCAAACCCTCTTGGCGCGCATCATCACGTGGT TCACAACAGACGCTAACCGGTCCAACAATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTT CAAGTACGCCTGGGTCCTTGACAAGCTCAAGGCCGAGCGTGAGCGTGGTATCACCATCGA CATTGCCCTCTGGAAGTTCGAGACTCCCCGCTACTATGTCACCGTCGTATGTTGCT GTCACCTCTCTCACACATGTCTCACCACTAACAATCAACAGACGCCCCCGGCCACCGTGA TTTCATCAAGAACATGATCT

>Seq65 [organism=*Fusarium oxysporum*] [isolate C3-4] translation elongation factor 1 alpha (tef) gene, partial cds

GGACGTCGACTCTGGCAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCTGC CATCGTCAATCCCGGCCAAGACCTGGTGGGGGTATTTCTCAAAGTCAACATACTGACATCG TTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAGA AGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCCC TACGACTCGAAACGTACCCGGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCGTA ATTTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAAC CATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAACA ATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAGCT CAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTCC TCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATCTACTTCTCTTCG TACTAACATATCACTCAGACGCTCCCGGTCACCGTGATTTCATCAAGAACATGATCCGGG GGAAC >Seq66 [organism=*Fusarium oxysporum*] [isolate C9-2] translation elongation factor 1 alpha (tef) gene, partial cds

TCGGCCGTCGACTCTGGCAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCT GCCATCGTCAATCCCGGCCAAGACCTGGTGGGGGTATTTCTCAAAGTCAACATACTGACAT CGTTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGA GAAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCC CCTACGACTCGAAACGTACCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCG TAATTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTA ACCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAA CAATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAG CTCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACT CCTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTTT CGTACTAACATATCACTCAGACGCTCCCGGTCACCGTGATTTCATCAAGAACATGATCTG

>Seq67 [organism=*Fusarium oxysporum*] [isolate C6-5] translation elongation factor 1 alpha (tef) gene, partial cds

GGCCGTCGACTCTGGCAAGTCGACCACTGTGAGTACTCTCCTGGACAATGAGCTTATCTG CCATCGTCAATCCTGACCAGGACCTGGTGGGGGTATTTCTCAAAGTCAACATACTGACATC GTTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAG AAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCC CTACGACTCGAAACGTACCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCGT AATTTTTTTGGTGGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAA CCATTCTCACATCCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAAC AATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAGC TCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTC CTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCAAGAACATGATCATGGGG GTACTAACATATCACTCAGACGCTCCCGGTCACCGTGATTTCATCAAGAACATGATCATGGGG

>Seq68 [organism=*Fusarium oxysporum*] [isolate C9-4] translation elongation factor 1 alpha (tef) gene, partial cds

GCCCCGTCGACTCTGGCAAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCT GCCATCGTCAATCCCGGCCAAGACCTGGTGGGGTATTTCTCAAAGTCAACATACTGACAT CGTTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGA GAAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCC CCTACGACTCGAAACGTACCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCG TAATTTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTA ACCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAA CAATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAG CTCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACT CCTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTCTT CGTACTAACATATCACTCAGACGCTCCCGGTCACCGTGATTTCATCAAGAACATGATCAC TGGGTACCTCCA

>Seq69 [organism=*Fusarium oxysporum*] [isolate A6-1] translation elongation factor 1 alpha (tef) gene, partial cds

GCACGTCGACTCTGGCAAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCTG CCATCGTCAATCCTGACCAGGACCTGGTGGGGTATTTCTCAAAGTCAACATACTGACATC GTTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAG AAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCC CTACGACTCGAAACGTACCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCGT AATTTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAA CCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAAC AATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAGC TCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTC CTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCTTCTTC GTACTAACATATCACTCAGACGCTCCCGGTCACCGTGATTTCATCAAGAACATGACCGGG GGACCCTTC

>Seq70 [organism=*Fusarium oxysporum*] [isolate C5-3] translation elongation factor 1 alpha (tef) gene, partial cds

GGCCGTCGACTCTGGCAGTCGACCACTGTGAGTACTCTCCTGGACAATGAGCTTATCTGC CATCGTCAATCCTGACCAGGACCTGGTGGGGTATTTCTCAAAGTCAACATACTGACATCG TTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAGA AGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCCC TACGACTCGAAACGTACCCGGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCGTA ATTTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAAC CATTCTCACATCCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAACA ATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAGCT CAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTCC TCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATCTACTTCTCTCG TACTAACATATCACTCAGACGCTCCCGGTCACCGTGATTTCATCAAGAACATGATCCGGGGAA

>Seq71 [organism=*Fusarium oxysporum*] [isolate CRT1-2] translation elongation factor 1 alpha (tef) gene, partial cds

CGGCACGTCGACTCTGGCAAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATC TGCCATCGTCAATCCTGACCAGGACCTGGTGGGGTATTTCTCAAAGTCAACATACTGACA TCGTTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCG AGAAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTC CCCTACGACTCGAAACGTACCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACC GTAATTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTT AACCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCA ACAATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAA GCTCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGAC TCCTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTCTTCGTAC TAACATATCACTCAGACGCTCCGGTCACCGTGATTTCATCAAGAACATGATGCTG

>Seq72 [organism=*Fusarium oxysporum*] [isolate C9-1] translation elongation factor 1 alpha (tef) gene, partial cds

CGGCCGTCGACTCTGGCAAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCT GCCATCGTCAATCCCGGCCAAGACCTGGTGGGGGTATTTCTCAAAGTCAACATACTGACAT CGTTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGA GAAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCC CCTACGACTCGAAACGTACCCGGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCG TAATTTTTTTGGTGGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTA ACCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAA CAATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGGCTGGGTTCTTGACAAG CTCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACT CCTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTCTTCGTACT AACATATCACTCAGACGCTCCGGTCACCGTGATTTCATCAAGAACATGATCCGGG

>Seq73 [organism=*Fusarium oxysporum*] [isolate C5-1] translation elongation factor 1 alpha (tef) gene, partial cds

GCACGTCGACTCTGGCAAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCTG CCATCGTCAATCCTGACCAGGACCTGGTGGGGTATTTCTCAAAGTCAACATACTGACATC GTTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAG AAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCC CTACGACTCGAAACGTACCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCGT AATTTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAA CCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAAC AATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAGC TCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTC CTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTTC GTACTAACATATCACTCAGACGCTCCCGGTCACCGTGATTTCATCAAGAACATGATCACT GGGTACCTTCC >Seq74 [organism=*Fusarium oxysporum*] [isolate CRT1-3] translation elongation factor 1 alpha (tef) gene, partial cds

CGGCACGTCGACTCTGGCAAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATC TGCCATCGTCAATCCTGACCAGGACCTGGTGGGGGTATTTCTCAAAGTCAACATACTGACA TCGTTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCG AGAAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTC CCCTACGACTCGAAACGTACCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACC GTAATTTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTT AACCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCA ACAATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAA GCTCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGAC TCCTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTTCGTAC TAACATATCACTCAGACGCTCCGGTCACCGTGATTTCATCAAGAACATGATCATGG

>Seq75 [organism=*Fusarium oxysporum*] [isolate A8-2] translation elongation factor 1 alpha (tef) gene, partial cds

GCACGTCGACTCTGGCAAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCTG CCATCGTCAATCCTGACCAGGACCTGGTGGGGGTATTTCTCAAAGTCAACATACTGACATC GTTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAG AAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCC CTACGACTCGAAACGTACCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCGT AATTTTTTTGGTGGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAA CCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAAC AATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAGC TCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTC CTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTCTCGTACTA ACATATCACTCAGACGCTCCGGTCACCGTGATTTCATCAAGAACATGATCCGGGGGAA

>Seq76 [organism=*Fusarium oxysporum*] [isolate C8-2] translation elongation factor 1 alpha (tef) gene, partial cds

CGGCACGTCGACTCTGGCAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCT GCCATCGTCAATCCCGGCCAAGACCTGGTGGGGGTATTTCTCAAAGTCAACATACTGACAT CGTTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGA GAAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCC CCTACGACTCGAAACGTACCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCG TAATTTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTA ACCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAA CAATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAG CTCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACT CCTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTCTT CGTACTAACATATCACTCAGACGCTCCCGGTCACCGTGATTTCATCAAGAACATGATGCG

>Seq77 [organism=*Fusarium oxysporum*] [isolate C5-2] translation elongation factor 1 alpha (tef) gene, partial cds

CCGTCGACTCTGGCAAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCTGCC ATCGTCAATCCCGACCAAGACCTGGTGGGGTATTTCTCGAAGTCAACATACTGACATCGT TTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAGAA GTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCCCT ACGACTCGAAATGTGCCTGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCGTAA TTTTTTTGGTGGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAACC ATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAACAA TAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAGCTC AAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTCCT CGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTCTCGTACTAAC ATATCACTCAGACGCTCCGGTCACCGTGATTTCATCAAGAACATGATCACTGGGTTA

>Seq78 [organism=*Fusarium oxysporum*] [isolate B9-2] translation elongation factor 1 alpha (tef) gene, partial cds

GCACGTCGACTCTGGCAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCATATCTGC CATCGTCAATCCCGACCAAGACCTGGCGGGGGTATTTCTCAAAGTCAACATACTAACATCG TTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAGA AGTTCGAGAAGGTTAGTCACTTTCCCTTCAATCGCGCGTCCTTTGCCCATCGATTTCCCC TACGACTCGAAACGTGCCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCGTA ATTTTTTTTGGTGGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTA CCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAAC AATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAGC TCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTC CTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTCTC GTACTAACATATCACTCAGACGCTCCCGGTCACCGTGATTTCATCAAGAACATGATCTT

>Seq79 [organism=*Fusarium oxysporum*] [isolate C2-1] translation elongation factor 1 alpha (tef) gene, partial cds

GCCCGTCGACTCTGGCAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCTGC CATCGTCAATCCTGACCAGGACCTGGTGGGGGTATTTCTCAAAGTCAACATACTGACATCG TTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAGA AGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCCC TACGACTCGAAACGTACCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCGTA ATTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAAC CATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAACA ATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAGCT CAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTCC TCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTCTTCGTACTAA CATATCACTCAGACGCTCCGGTCACCGTGATTTCATCAAGAACATGATCCGGGGGAACCCT

>Seq80 [organism=*Fusarium oxysporum*] [isolate B10-2] translation elongation factor 1 alpha (tef) gene, partial cds

GGCCGTCGACTCTGGCAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCTGC CATCGTCAATCCTGACCAGGACCTGGTGGGGTATTTCTCAAAGTCAACATACTGACATCG TTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAGA AGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCCC TACGACTCGAAACGTACCCGGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCGTA ATTTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAAC CATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAACA ATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAGCT CAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTCC TCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATCACAGAACATGATCTGGG TACTAACATATCACTCAGACGCTCCCGGTCACCGTGATTTCATCAAGAACATGATCTGGG

>Seq81 [organism=*Fusarium oxysporum*] [isolate C5-5] translation elongation factor 1 alpha (tef) gene, partial cds

CTCTGGCAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCTGCCATCGTCAA TCCTGACCAGGACCTGGTGGGGTATTTCTCAAAGTCAACATACTGACATCGTTTCACAGA CCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAGAAGTTCGAGA AGGTTAGTCACTTTCCCTTCGATCGCGCGCGTCCTTTGCCCATCGATTTCCCCTACGACTCG AAACGTACCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCGTAATTTTTTTG GTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAACCATTCTCAC AACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAACAATAGGAAGC CGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAGCTCAAGGACGA GCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTCCTCGCTACTA TGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATCAAGAACATGATCACTGGGTACTTACC

>Seq82 [organism=*Fusarium oxysporum*] [isolate B6-2] translation elongation factor 1 alpha (tef) gene, partial cds

GCACGTCGACTCTGGCAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCTGC CATCGTCAATCCCGACCAAGACCTGGTGGGGTATTTCTCAAAGTCAACATACTGACATCG TTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGATAAGCGAACCATCGAGA AGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCCC TACGACTCGAAACGTGCCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACTGTA ATTTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAA CCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGTAGTCACTAACCATTCAAC AATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAGC TCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTC CTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTCTC GTACTAACATCACTCAGACGCTCCCGGTCACCGTGATTTCATCAAGAACATGATCCGGG

>Seq83 [organism=*Fusarium oxysporum*] [isolate A1-2] translation elongation factor 1 alpha (tef) gene, partial cds

CCCGTCGACTCTGGCAAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCTGC CATCGTCTATCCTGACCAGGACCTGGTGGGGGTATTTCTCAAAGTCAACATACTGACATCG TTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAGA AGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCCC TACGACTCGAAACGTACCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCGTA ATTTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAAC CATTC

>Seq84 [organism=*Fusarium oxysporum*] [isolate C9-5] translation elongation factor 1 alpha (tef) gene, partial cds

CGGCCGTCGACTCTGGCAAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCT GCCATCGTCAATCCCGGCCAAGACCTGGTGGGGTATTTCTCAAAGTCAACATACTGACAT CGTTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGA GAAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGGCGTCCTTTGCCCATCGATTTCC CCTACGACTCGAAACGTACCCGGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCG TAATTTTTTTGGTGGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTA ACCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAA CAATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAG CTCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACT CCTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTCTT CGTACTAACATATCACTCAGACGCTCCCGGTCACCGTGATTTCATCAAGAACATGATCAT GGGG >Seq85 [organism=*Fusarium oxysporum*] [isolate C9-3] translation elongation factor 1 alpha (tef) gene, partial cds

GCACGTCGACTCTGGCAAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCTG CCATCGTCAATCCCGGCCAAGACCTGGTGGGGGTATTTCTCAAAGTCAACATACTGACATC GTTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAG AAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCC CTACGACTCGAAACGTACCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCGT AATTTTTTTGGTGGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAA CCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAAC AATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAGC TCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTC CTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTCTTC GTACTAACATATCACTCAGACGCTCCCGGTCACCGTGATTTCATCAAGAACATGATCCTG GGGT

>Seq86 [organism=*Fusarium oxysporum*] [isolate C6-1] translation elongation factor 1 alpha (tef) gene, partial cds

GCACGTCGACTCTGGCAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCTGC CATCGTCAATCCTGACCAGGACCTGGTGGGGGTATTTCTCAAAGTCAACATACTGACATCG TTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAGA AGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCCC TACGACTCGAAACGTACCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCGTA ATTTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAAC CATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAACA ATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAGCT CAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTCC TCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCAAGAACATGATCATGGGT

>Seq87 [organism=*Fusarium oxysporum*] [isolate C7-1] translation elongation factor 1 alpha (tef) gene, partial cds

CGGCACGTCGACTCTGGCAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCT GCCATCGTCAATCCCGGCCAAGACCTGGTGGGGGTATTTCTCAAAGTCAACATACTGACAT CGTTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGA GAAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCC CCTACGACTCGAAACGTACCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCG TAATTTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTA ACCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAA CAATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAG CTCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACT CCTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTCTT CGTACTAACATATCACTCAGACGCTCCCGGTCACCGTGATTTCATCAAGAACATGATCTG

>Seq88 [organism=*Fusarium oxysporum*] [isolate A5-6] translation elongation factor 1 alpha (tef) gene, partial cds

GGCCGTCGACTCTGGCAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCTGC CATCGTCAATCCTGACCAGGACCTGGTGGGGGTATTTCTCAAAGTCAACATACTGACATCG TTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAGA AGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCCC TACGACTCGAAACGTACCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCGTA ATTTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAAC CATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAACA ATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAGCT CAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTCC TCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCAAGAACATGATCCG TACTAACATATCACTCAGACGCTCCGGTCACCGTGATTTCATCAAGAACATGATCCG

>Seq89 [organism=*Fusarium oxysporum*] [isolate A1-1] translation elongation factor 1 alpha (tef) gene, partial cds

GCACGTCGACTCTGGCAAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCTG CCATCGTCAATCCTGACCAGGACCTGGTGGGGTATTTCTCAAAGTCAACATACTGACATC GTTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAG AAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCC CTACGACTCGAAACGTACCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCGT AATTTTTTGGTGGGGCACTTACCCGGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAA CCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAAC AATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAGC TCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTC CTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTTC GTACTAACATATCACTCAGACGCTCCCGGTCACCGTGATTTCATCAAGAACATGATCACG GGGTACCTCCA

>Seq90 [organism=Fusarium oxysporum] [isolate C5-4] translation elongation factor 1 alpha (tef) gene, partial cds GCCCGTCGACTCTGGCAAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCTG GTTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAG AAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCC CTACGACTCGAAACGTACCCGGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCGT AATTTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAA CCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAAC AATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAGC TCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTC CTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTCT GTACTAACATATCACTCAGACGCTCCCGGTCACCGTGATTTCATCAAGAACATGATCACT GGGTACCC

>Seq91 [organism=*Fusarium oxysporum*] [isolate C4-1] translation elongation factor 1 alpha (tef) gene, partial cds

GGCCGTCGACTCTGGCAAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCTG CCATCGTCAATCCTGACCAGGACCTGGTGGGGTATTTCTCAAAGTCAACATACTGACATC GTTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAG AAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCC CTACGACTCGAAACGTACCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCGT AATTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAA CCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAAC AATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAGC TCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTC CTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATCTACTTCTCTC GTACTAACATATCACTCAGACGCTCCCGGTCACCGTGATTTCATCAAGAACATGATCTG

>Seq92 [organism=*Fusarium oxysporum*] [isolate A8-1] translation elongation factor 1 alpha (tef) gene, partial cds

GCACGTCGACTCTGGCAAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCTG CCATCGTCAATCCTGACCAGGACCTGGTGGGGGTATTTCTCAAAGTCAACATACTGACATC GTTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAG AAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCC CTACGACTCGAAACGTACCCGGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCGT AATTTTTTTGGTGGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAA CCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAAC AATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAGC TCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTC CTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTCTTCGTACTA ACATATCACTCAGACGCTCCGGTCACCGTGATTTCATCAAGAACATGATCCGGGGGAA >Seq93 [organism=*Fusarium oxysporum*] [isolate C6-3] translation elongation factor 1 alpha (tef) gene, partial cds

GGCCGTCGACTCTGGCAAGTCGACCACTGTGAGTACTCTCCTGGACAATGAGCTTATCTG CCATCGTCAATCCTGACCAGGACCTGGTGGGGGTATTTCTCAAAGTCAACATACTGACATC GTTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAG AAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCC CTACGACTCGAAACGTACCCGGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCGT AATTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAA CCATTCTCACATCCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAAC AATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAGC TCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTC CTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTCTC GTACTAACATATCACTCAGACGCTCCCGGTCACCGTGATTTCATCAAGAACATGATCAT

>Seq94 [organism=*Fusarium oxysporum*] [isolate B5-1] translation elongation factor 1 alpha (tef) gene, partial cds

GCACGTCGACTCTGGCAAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCTG CCATCGTCAATCCCGACCAAGACCTGGTGGGGGTATTTCTCAAAGTCAACATACTGACATC GTTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGATAAGCGAACCATCGAG AAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCC CTACGACTCGAAACGTGCCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACTGT AATTTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTA ACCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGTAGTCACTAACCATTCAA CAATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAG CTCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACT CCTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTTT CGTACTAACATCACTCAGACGCTCCGGTCACCGTGATTTCATCAAGAACATGATCTGG

>Seq95 [organism=*Fusarium oxysporum*] [isolate B7-1] translation elongation factor 1 alpha (tef) gene, partial cds

GCACGTCGACTCTGGCAAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCTG CCATCGTCAATCCCGACCAAGACCTGGTGGGGTATTTCTCAAAGTCAACATACTGACATC GTTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGATAAGCGAACCATCGAG AAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCC CTACGACTCGAAACGTGCCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACTGT AATTTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTA ACCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGTAGTCACTAACCATTCAA CAATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAG CTCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACT CCTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTCTTCGTACT AACATCACTCAGACGCTCCCGGTCACCGTGATTTCATCAAGAACATGACCGGGGGA

>Seq96 [organism=*Fusarium oxysporum*] [isolate B6-1] translation elongation factor 1 alpha (tef) gene, partial cds

GCACGTCGACTCTGGCAAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCTG CCATCGTCAATCCCGACCAAGACCTGGTGGGGGTATTTCTCAAAGTCAACATACTGACATC GTTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGATAAGCGAACCATCGAG AAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCC CTACGACTCGAAACGTGCCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACTGT AATTTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTA ACCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGTAGTCACTAACCATTCAA CAATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAG CTCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACT CCTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATCTACTTCTCTTCGTACT AACATCACTCAGACGCTCCGGTCACCGTGATTTCATCAAGAACATGATCCGGGGAA

>Seq97 [organism=*Fusarium oxysporum*] [isolate B5-3] translation elongation factor 1 alpha (tef) gene, partial cds

GGCCGTCGACTCTGGCAAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCTG CCATCGTCAATCCCGACCAAGACCTGGTGGGGTATTTCTCAAAGTCAACATACTGACATC GTTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGATAAGCGAACCATCGAG AAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCC CTACGACTCGAAACGTGCCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACTGT AATTTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTA ACCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGTAGTCACTAACCATTCAA CAATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAG CTCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACT CCTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTTT CGTACTAACATCACTCAGACGCTCCCGGTCACCGTGATTTCATCAAGAACATGATCCGGG GGACCCCT

>Seq98 [organism=*Fusarium oxysporum*] [isolate A6-2] translation elongation factor 1 alpha (tef) gene, partial cds

GCACGTCGACTCTGGCAAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCTG CCATCGTCAATCCTGACCAGGACCTGGTGGGGGTATTTCTCAAAGTCAACATACTGACATC GTTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAG AAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCC CTACGACTCGAAACGTACCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCGT AATTTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAA CCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAAC AATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAGC TCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTC CTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTCTC GTACTAACATATCACTCAGACGCTCCCGGTCACCGTGATTTCATCAAGAACATGATCTGG

>Seq99 [organism=*Fusarium oxysporum*] [isolate C8-6] translation elongation factor 1 alpha (tef) gene, partial cds

GTCAATCCTGACCAGGACCTGGTGGGGTATTTCTCAAAGTCAACATACTGACATCGTTTC ACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAGAAGTT CGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGCGTCCTTTGCCCATCGATTTCCCCTACG ACTCGAAACGTACCCGGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCGTAATTT TTTTGGTGGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAACCATT CTCACATCCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAACAATAG GAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAGCTCAAG GCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTCCTCGC TACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATCACAATGACCATGACCATGGGTAC AACATATCACTCAGACGCTCCGGTCACCGTGATTTCATCAAGAACATGATCATGGGTAC CTCCAACCA

>Seq100 [organism=*Fusarium oxysporum*] [isolate B10-1] translation elongation factor 1 alpha (tef) gene, partial cds

GACGTCGACTCTGGCAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCTGCC ATCGTCAATCCTGACCAGGACCTGGTGGGGTATTTCTCAAAGTCAACATACTGACATCGT TTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAGAA GTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCCCT ACGACTCGAAACGTACCCGGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCGTAA TTTTTTTGGTGGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAACC ATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAACAA TAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAGCTC AAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTCCT CGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTCTTCGTACTAAC ATATCACTCAGACGCTCCGGTCACCGTGATTTCATCAACAAGAACATGATCCGGGGTA >Seq101 [organism=*Fusarium oxysporum*] [isolate C6-2] translation elongation factor 1 alpha (tef) gene, partial cds

GCACGTCGACTCTGGCAGTCGACCACTGTGAGTACTCTCCTGGACAATGAGCTTATCTGC CATCGTCAATCCTGACCAGGACCTGGTGGGGTATTTCTCAAAGTCAACATACTGACATCG TTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAGA AGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCCC TACGACTCGAAACGTACCCGGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCGTA ATTTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAAC CATTCTCACATCCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAACA ATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAGCT CAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTCC TCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATCTACTTCTCTCGTACTAA CATATCACTCAGACGCTCCGGTCACCGTGATTTCATCAAGAACATGATCACGGGTT

>Seq102 [organism=*Fusarium oxysporum*] [isolate C1-3] translation elongation factor 1 alpha (tef) gene, partial cds

TCGGCCGTCGACTCTGGCAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCT GCCATCGTCAATCCTGACCAGGACCTGGTGGGGTATTTCTCAAAGTCAACATACTGACAT CGTTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGA GAAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCC CCTACGACTCGAAACGTACCCGGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCG TAATTTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTA ACCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAA CAATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAG CTCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACT CCTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTCTTCGTACT AACATATCACTCAGACGCTCCGGTCACCGTGATTTCATCAAGAACATGATGTGG

>Seq103 [organism=*Fusarium oxysporum*] [isolate C3-1] translation elongation factor 1 alpha (tef) gene, partial cds

GGCCGTCGACTCTGGCAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCTGC CATCGTCAATCCCGGCCAAGACCTGGTGGGGGTATTTCTCAAAGTCAACATACTGACATCG TTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAGA AGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCCC TACGACTCGAAACGTACCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCGTA ATTTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAAC CATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAACA ATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAGCT CAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTCC TCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTCTCG TACTAACATATCACTCAGACGCTCCCGGTCACCGTGATTTCATCAAGAACATGATGCG

>Seq104 [organism=*Fusarium oxysporum*] [isolate A7-3] translation elongation factor 1 alpha (tef) gene, partial cds

GGCCGTCGACTCTGGCAAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCTG CCATCGTCAATCCCGACCAAGACCTGGTGGGGGTATTTCTCAAAGTCAACATACTGACATC GTTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAG AAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCC CTACGACTCGAAACGTACCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCGT AATTTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAA CCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAAC AATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAGC TCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTC CTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATACTTCTACTTCTTC GTACTAACATATCACTCAGACGCTCCCGGTCACCGTGATTTCATCAAGAACATGATCCGG GGTACCTCCA

>Seq105 [organism=*Fusarium oxysporum*] [isolate C8-1] translation elongation factor 1 alpha (tef) gene, partial cds

GGCCGTCGACTCTGGCAAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCTG CCATCGTCAATCCCGGCCAAGACCTGGTGGGGGTATTTCTCAAAGTCAACATACTGACATC GTTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAG AAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCC CTACGACTCGAAACGTACCCGGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCGT AATTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAA CCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAAC AATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAGC TCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTC CTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTTC GTACTAACATATCACTCAGACGCTCCCGGTCACCGTGATTTCATCAAGAACATGATGCG

>Seq106 [organism=*Fusarium oxysporum*] [isolate C6-4] translation elongation factor 1 alpha (tef) gene, partial cds

CGGCCGTCGACTCTGGCAAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCT GCCATCGTCAATCCTGACCAGGACCTGGTGGGGGTATTTCTCAAAGTCAACATACTGACAT CGTTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGA GAAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCC CCTACGACTCGAAACGTACCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCG TAATTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTA ACCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAA CAATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAG CTCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACT CCTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTCTCGTACT AACATATCACTCAGACGCTCCGGTCACCGTGATTTCATCAAGAACATGATGCGG

>Seq107 [organism=*Fusarium oxysporum*] [isolate C2-7] translation elongation factor 1 alpha (tef) gene, partial cds

TCGGCACGTCGACTCTGGCAAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTAT CTGCCATCGTCAATCCTGACCAGGACCTGGTGGGGGTATTTCTCAAAGTCAACATACTGAC ATCGTTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATC GAGAAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTT CCCCTACGACTCGAAACGTACCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGAC CGTAATTTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCT TAACCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTC AACAATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACA AGCTCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGA CTCCTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTCTTCGTA CTAACATATCACTCAGACGCTCCGGTCACCGTGATTTCATCAAGAACATGATCCG

>Seq108 [organism=*Fusarium oxysporum*] [isolate A6-3] translation elongation factor 1 alpha (tef) gene, partial cds

GCACGTCGACTCTGGCAAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCTG CCATCGTCAATCCTGACCAGGACCTGGTGGGGGTATTTCTCAAAGTCAACATACTGACATC GTTTCACAGACCGGTCACTTGATCTACCAGTGCGGGGGGTATCGACAAGCGAACCATCGAG AAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCC CTACGACTCGAAACGTACCCGGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCGT AATTTTTTTGGTGGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAA CCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAAC AATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAGC TCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTC CTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTCTTCGTACTA ACATATCACTCAGACGCTCCGGTCACCGTGATTTCATCAAGAACATGATCCGGGGGA >Seq109 [organism=*Fusarium oxysporum*] [isolate C10-1] translation elongation factor 1 alpha (tef) gene, partial cds

GCACGTCGACTCTGGCAAGTCGACCACTGTGAGTACTCTCCTCGACAATGGGCTTATCTG CCATCGTCAATCCCGACCAAGACCTGGCGGGGGTATTTCTCAAAGTCAACATACTGACATC GTTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAG AAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCACGTCCTTTGCCCATCGATTTCCC CTACGACTCGAAACGTGCCCGCTACCCCGCTCGAGACCAAAATTTTTGCAATACGACCGT AATTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAC CCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAAC AATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGACGGGTTCTTGACAAGC TCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTC CTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTTC GTACTAACATGTCACTCAGACGCTCCCGGTCACCGTGATTTCATCAAGAACATGATCATG GGTACCTCCAAAA

>Seq110 [organism=*Fusarium oxysporum*] [isolate A2-3] translation elongation factor 1 alpha (tef) gene, partial cds

GCACGTCGACTCTGGCAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCTGC CATCGTCAATCCTGACCAGGACCTGGTGGGGGTATTTCTCAAAGTCAACATACTGACATCG TTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAGA AGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCCC TACGACTCGAAACGTACCCGGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCGTA ATTTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAAC CATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAACA ATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAGCT CAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTCC TCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTTCGTACTAA CATATCACTCAGACGCTCCGGTCACCGTGATTTCATCAAGAACATGACCGGGGGA

>Seq111 [organism=*Fusarium oxysporum*] [isolate CRT1-1] translation elongation factor 1 alpha (tef) gene, partial cds

TCGGCCGTCGACTCTGGCAAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATC TGCCATCGTCAATCCTGACCAGGACCTGGTGGGGGTATTTCTCAAAGTCAACATACTGACA TCGTTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCG AGAAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTC CCCTACGACTCGAAACGTACCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACC GTAATTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTT AACCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCA ACAATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAA GCTCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGAC TCCTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTCT TCGTACTAACATATCACTCAGACGCTCCCGGTCACCGTGATTTCATCAAGAACATGATCTG

>Seq112 [organism=*Fusarium oxysporum*] [isolate A5-1] translation elongation factor 1 alpha (tef) gene, partial cds

CACGTCGACTCTGGCAAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCTGC CATCGTCAATCCTGACCAGGACCTGGTGGGGGTATTTCTCAAAGTCAACATACTGACATCG TTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAGA AGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCCC TACGACTCGAAACGTACCCGGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCGTA ATTTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAAC CATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAACA ATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAGCT CAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTCC TCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATCTACTTCTCTTCG TACTAACATATCACTCAGACGCTCCGGTCACCGTGATTTCATCAAGAACATGATCATGG GTACCTCCAAATGTTT

>Seq113 [organism=*Fusarium oxysporum*] [isolate C3-2] translation elongation factor 1 alpha (tef) gene, partial cds

GGCACGTCGACTCTGGCAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCTG CCATCGTCAATCCCGGCCAAGACCTGGTGGGGGTATTTCTCAAAGTCAACATACTGACATC GTTTCACAGACCGGTCACTTGATCTACCAGTGCGGGTGGTATCGACAAGCGAACCATCGAG AAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCCC CTACGACTCGAAACGTACCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCGT AATTTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTAA CCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAAC AATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAGC TCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACTC CTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATCTACTTCTCTC GTACTAACATATCACTCAGACGCTCCCGGTCACCGTGATTTCATCAAGAACATGATCTG >Seq114 [organism=*Fusarium oxysporum*] [isolate C2-4] translation elongation factor 1 alpha (tef) gene, partial cds

CGGCACGTCGACTCTGGCAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTATCT GCCATCGTCAATCCTGACCAGGACCTGGTGGGGGTATTTCTCAAAGTCAACATACTGACAT CGTTTCACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGA
GAAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTTCC CCTACGACTCGAAACGTACCCGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGACCG TAATTTTTTGGTGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCTTA ACCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTCAA CAATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACAAG CTCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGACT CCTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATCTACTTCTCT CGTACTAACATATCACTCAGACGCTCCCGGTCACCGTGATTTCATCAAGAACATGACAG

>Seq115 [organism=*Fusarium solani*] [isolate K8-1] translation elongation factor 1 alpha (tef) gene, partial cds

CCGTCGACTCTGGCAAGTCGACCACCGTAAGTCAAACCCTCCATCGCGATCTGCTTATCT CGGGTCGTGGAACCCCGCCTGGCATCACGGGCGGGGGTACTCATCAGTCACTTCATGCTGA CAATCATCTACAGACCGGTCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCAT CGAGAAGTTCGAGAAGGTTGGTGACATCTCCCCCGATCGCGCCTTGCTATTCCACATCGA ATTCCCCGTCGAATTCCCTCCTCGCGACACGCTCTGCGCCCGCTTCTCTCGAGTTCCAAA AATTTTGCGGTCCGACCGTAATTTTTTTGGTGGGGGCATTTACCCCGCCACTCGGGTGACG TTGGACAAAGCCCTGATCCCTGCACACAAATAACACGAAACCCTCTTGGCGCGCATCATC ACGTGGTTCACAACAGACGCTAACCGACTCAACAATAAGAAGCCGCTGAGCTCGGTAAGG GTTCCTTCAAGTACGCCTGGGTCCTTGACAAGCTCAAGGACGCCGAGCGTGAGCGTGGTATCA CCATCGACATTGCCCTCTGGAAGTTCGAGACTCCCCGCTACTATGTCACCGTCATTGGTA TGTCGCTGTCACGTCTCTCACTCATGTCTCACCACTAACAGTCAACAGACGCCCCGGCC ACCGTGACTTCATCAAGAACATGATCACGGGT

>Seq116 [organism=*Fusarium solani*] [isolate K8-2] translation elongation factor 1 alpha (tef) gene, partial cds

TACCACCGTAAAGTCAAACCCTCCATCGCGATCTGCTTATCTCGGGTCGTGGAACCCCGC CTGGCATCACGGGCGGGGTACTCATCAGTCACTTGATGTGACAATCATCTACAGACCGG TCACTTGATCTACCAGTGCGGTGGTATCGACAAGCGAACCATCGAGAAGTTCGAGAAGGT TGGTGACATCTCCCCCGATCGCGCCTTGCTATTCCACATCGAATTCCCCGTCGAATTCCC TCCTCGCGACACGCTCTGCGCCCGCTTCTCTCGAGTTCCAAAAATTTTGCGGTCCGAACCG TAATTTTTTGGTGGGGGCATTTACCCCGCCACTCGGGTGACGTTGGACAAAGCCCTGATC CCTGCACACAAATAACACGAAACCCTCTTGGCGCGCATCATCACGTGGTTCACAACAGAC GCTAACCGACTCAACAATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCT GGGTCCTTGACAAGCTCAAGGACGCGAGCGTGAGCGTGGTATCACCATCGACATTGCCCTCT CACTCATGTCTCACCACTAACAGTCAACAGTCAACAGACGCCCGGCACCGTGACTTCGTCACGACATTGCCCTCT TCACTCATGTCTCACCACTAACAGTCAACAGACGCCCCGGCACCGTGACTTCATCAACAAGA ACATTGATCACTGGTACCCTCCA >Seq117 [organism=*Fusarium dimerum*] [isolate X4-1] translation elongation factor 1 alpha (tef) gene, partial cds

>Seq118 [organism=*Fusarium oxysporum*] [isolate A7-4] translation elongation factor 1 alpha (tef) gene, partial cds

CTCGGCCGTCGACTCTGGCAAGTCGACCACTGTGAGTACTCTCCTCGACAATGAGCTTAT CTGCCATCGTCAATCCCGACCAAGACCTGGTGGGGGTATTTCTCGAAGTCAACATACTGAC ATCGTTTCACAGACCGGTCACTTGATCTACCAGTGCGGGTGGTATCGACAAGCGAACCATC GAGAAGTTCGAGAAGGTTAGTCACTTTCCCTTCGATCGCGCGTCCTTTGCCCATCGATTT CCCCTACGACTCGAAATGTGCCTGCTACCCCGCTCGAGACCAAAAATTTTGCAATATGAC CGTAATTTTTTTGGTGGGGGCACTTACCCCGCCACTTGAGCGACGGGAGCGTTTGCCCTCT TAACCATTCTCACAACCTCAATGAGTGCGTCGTCACGTGTCAAGCAGTCACTAACCATTC AACAATAGGAAGCCGCTGAGCTCGGTAAGGGTTCCTTCAAGTACGCCTGGGTTCTTGACA AGCTCAAGGCCGAGCGTGAGCGTGGTATCACCATCGATATTGCTCTCTGGAAGTTCGAGA CTCCTCGCTACTATGTCACCGTCATTGGTATGTTGTCGCTCATGCTTCATTCTACTTCTCTTCGTA

## **APPENDIX 5: Published Article**

## environmental microbiology

Environmental Microbiology (2016) 00(00), 00–00



doi:10.1111/1462-

## Detection of human pathogenic *Fusarium* species in hospital and communal sink biofilms by using a highly specific monoclonal antibody

Marwan Al-Maqtoofi<sup>1,2</sup> and Christopher R. Thornton<sup>1</sup>\* <sup>1</sup>Biosciences, Geoffrey Pope Building, University of Exeter, Stocker Road, Exeter, EX4 4QD, UK.

<sup>2</sup>University of Basrah, College of Science, Biology Department, Basrah, Iraq.

### Summary

The fungus *Fusarium* is well known as a plant pathogen, but has recently emerged as an opportunistic pathogen of humans. Habitats providing direct human exposure to infectious propagules are largely unknown, but there is growing evidence that plumbing systems are sources of human pathogenic strains in the Fusarium solani species complex (FSSC) and Fusarium oxysporum species complex (FOSC), the most common groups infecting humans. Here, a newly developed Fusarium-specific monoclonal antibody (mAb ED7) was used to track FSSC and FOSC strains in sink drain biofilms by detecting its target antigen, an extracellular 200 kDa carbohydrate, in saline swabs. The antigen was detectable in 52% of swab samples collected from sinks across a University campus and a tertiary care hospital. The mAb was 100% accurate in detecting FSSC, FOSC, and F. dimerum species complex (FDSC) strains that were present, as mixed fungal communities, in 83% of sink drain biofilms. Specificity of the ELISA was confirmed by sequencing of the internally transcribed spacer 1 (ITS1)-5.8S-ITS2 rRNA-encoding regions of culturable yeasts and moulds that were recovered using mycological culture, while transla-tion elongation factor (TEF)-1α analysis of Fusarium isolates included FSSC 1a, FOSC 33, and FDSC ET-gr, the most common clinical patho-types in each group.

### Introduction

Species in the fungal genus Fusarium are ubiquitous environmental moulds, and pathogens of both plants and animals (Zhang et al., 2006; Thornton and Wills, 2015). In immunocompromised humans, such as patients with hematological malignancies and hematopoietic stem cell and solid organ transplant recipients, Fusarium species are significant emerging pathogens, causing a frequently fatal disseminated disease known as fusariosis with an associated mortality rate of 50%-75% (Boutati and Anaissie, 1997; Girmenia et al., 2000; Musa et al., 2000; Dignani and Anaissie, 2004; Jensen et al., 2004; Nucci and Anaissie, 2007). In some tertiary cancer cen-ters, Fusarium has emerged as the second most common mould pathogen after Aspergillus (Walsh and Groll, 1999; Muhammed et al., 2011). Regardless of human immune status, Fusarium species can cause localized nail infections (onychomycosis) (Arrese et al., 1996), bone and joint infections (Koehler et al., 2014), infections of burn wounds (Latenser, 2003), skin infec-tions (Nucci and Anaissie, 2002; Gurusidappa and Mamatha, 2011) and are the most frequent cause of mycotic eye infections known as fungal keratitis (Jurkunas et al., 2009), leading to progressive corneal destruction and endophthalmitis, with loss of vision or even loss of the affected eye (Dursun et al., 2003; Edelstein et al., 2012).

A recent multistate outbreak of fungal keratitis in the United States and in Singapore and Hong Kong was associated with contact lens solution contaminated with multiple strains of *Fusarium* and which led to visual loss in many patients and the need for corneal transplantation (Chang et al., 2006). While such outbreaks are rare, disseminated *Fusarium* infections and keratomycoses have increased in frequency over the past decade (Koehler et al., 2014) and an increasing body of evidence suggests that the main environmental sources of human pathogenic *Fusarium* species are contaminated water systems (Doggett, 2000; Anaissie et al., 2002; Mehl and Epstein, 2008; Anaissie et al., 2011). A number of studies have recovered pathogenic

Received 3 November, 2015; accepted 15 January, 2016. \*For correspondence: E-mail C.R.Thornton@ex.ac.uk; Tel. 144 (0)1392 725172; Fax 144 (0)1392 263434.

*Fusarium* species from plumbing fixtures and it is hypothesized that microbial biofilms on fixtures may serve as important reservoirs of infectious *Fusarium* propagules in hospitals and homes (Mehl and Epstein, 2008; Short et al., 2011).

Identification of environmental reservoirs of human pathogenic moulds including Fusarium has typically relied on nucleic acid-based technologies following recovery of fungi using selective media (Anaissie et al., 2002; Mehl and Epstein, 2008; Short et al., 2011; Anaissie et al., 2011; Rougeron et al., 2014). Recently, highly specific monoclo-nal antibodies (mAb) have been used to identify pathogenic species or species complexes in environmental samples containing mixed populations of yeasts and moulds (Thornton, 2009; Davies and Thornton, 2014; Thornton et al., 2015). While mAb-based approaches similarly rely on culture for recovery of fungi from environmental samples, detection of diagnostic antigens in crude culture extracts using genus- or species-specific mAbs offers an attractive alternative approach to pathogen detection, particularly combined with unsophisticated when diagnostic modalities such as lateral-flow technology (Thornton, 2008. 2012).

In this study, we set out to determine whether a newly developed *Fusarium*-specific mAb (ED7) could be used to track the fungus by detecting a water-soluble diagnostic antigen in swabs of communal and hospital sinks. By using the mAb in an enzyme-linked immunsorbent assay (ELISA), we show that it can differentiate *Fusarium* species from other unrelated yeast and mould pathogens of humans present in mixed fungal communities encountered in sink biofilms. The ELISA represents a simple method for specific detection of *Fusarium* species in environmental reservoirs and for identifying plumbing systems contami-nated with the fungus.

### Results

# Production of hybridoma cell lines, isotyping of mAb and specificity

A single fusion was performed and 389 hybridoma cell lines were screened for specificity against a range of clini-cally relevant yeasts and moulds (Supporting Information Table S1). The aim was to identify cell lines secreting mAbs specific to *Fusarium* that could be used to track the fungus in environmental samples containing mixed species of human pathogenic fungi. To this end, a single cell line, ED7, was identified that produced mAb belonging to the immunoglobulin class M (IgM), which was genus-specific, reacting in ELISA tests with antigens from *Fusarium* species and with the *F. solani* teleomorph *Haematonectria haematococca* only (Fig. 1A and B). It did not cross-react with antigens from a wide range of unrelated mould and yeast species (Fig. 1A). Western blotting of the ED7 antigen and epitope characterization

Gel electrophoresis and Western blotting studies showed that ED7 binds to a major antigen with molecular weight of 200 kDa which is secreted extracellularly by both F. solani and F. oxysporum (Fig. 2A). Fusarium solani antigens were subjected to enzymatic (Fig. 2B and C), heat (Fig. 2D) and chemical (Fig. 2E) modifications in order to char-acterize the epitope bound by ED7. Reductions in mAb binding following treatment with pronase shows that its epi-tope consists of protein, while reductions with trypsin indicate a protein epitope containing positively charged lysine and arginine side chains. The lack of reduction in ED7 binding following digestion of immobilized antigen with trypsin (Fig. 2B) and pronase (Fig. 2C) shows that it does not bind to a protein epitope. Reductions in mAb binding following heat treatment shows that an epitope is heat labile. There was no significant reduction in ED7 bind-ing over 70 min of heating, showing that its epitope is heat stable (Fig. 2D). Reductions in mAb binding following chemical digestion of an antigen with periodate shows that its epitope is carbohydrate and contains vicinal hydroxyl groups. The pronounced reductions in ED7 binding follow-ing periodate oxidation shows that its epitope consists of carbohydrate residues (Fig. 2E). Taken together, these results indicate that ED7 binds to an extracellular antigen and that its epitope is a heat stable carbohydrate moeity containing vicinal hydroxyl aroups.

# Immunofluorescence and immunogold electron microscopy

Immuno-localization studies using IF showed that the ED7 antigen was present on the surface of spores and hyphae (Fig. 2F–I), while IEM showed that the antigen was present in the spore and hyphal cell wall and in an extracellular fibrillar matrix surrounding both (Fig. 2J–L). In the TEM image shown in Fig. 2J, 56% of gold particles were distrib-uted in the fibrillar matrix surrounding the cell, while 40% and 4% of gold particles were distributed in the cell wall and cytoplasm respectively. This shows that the ED7 anti-gen is predominantly extracellular or located within the cell wall. Immunodetection of *Fusarium* species in sink swabs and identification of fungi by analysis of the ITS regions of the rRNA-encoding gene unit and by translation elongation factor-1 $\alpha$  PCR

Monoclonal antibody ED7 was highly specific for the three human pathogenic species of Fusarium, *F. solani, F. oxy-sporum* and *F. dimerum*, which were culturable from 75% of the sink swabs (Table 1 and Supporting Information Table S2). ELISA tests of the saline sink swabs showed



Fig. 1. Specificity of ED7 determined by ELISA tests of surface washings containing water-soluble antigens from *Fusarium* species and related and unrelated yeasts and moulds. (A) ELISA absorbance values at 450 nm for antigens from *F. solani* and unrelated yeasts and moulds and (B) for antigens from the *F. solani* teleomorph Haematonectria haematococca and related *Fusarium* species. Wells were coated with 60 Ig protein ml<sup>21</sup> buffer. Bars are the means of three biological replicates 6 standard errors and the threshold absorbance value for detection of antigen in ELISA is 0.100 (indicated by lines on graphs). Numbers in parentheses after species names denote strain numbers with further details of strains provided in Supporting Information Table S1.

4 M. Al-Maqtoofi and C. R. Thornton



that 52% contained detectable levels of *Fusarium* antigen (Table 1 and Supporting Information Table S2), with ELISA absorbance values in the range 0.100 (the threshold value for antigen detection) and up to 1.500. In four hospi-tal samples (samples S47, S48 and S49 from ophthalmology and sample S64 from oncology) *Fusarium* strains could not be recovered for identification by ITS sequencing despite detection of the

diagnostic antigen in swab samples with absorbance values of 0.264, 0.530, 0.187 and 0.193 respectively (Table 1). This was likely due to the *Fusarium* isolates being outgrown in the mixed cul-ture plates by faster growing or more abundant unrelated fungi. Importantly, ED7 was shown not to cross-react with unrelated fungi (axenic culture absorbance values of 0.100 in all cases) including the human pathogenic yeast or yeast-like fungi *Candida*, *Exophiala*, *Meyerozyma*, *Rhodotorula*, *Trichosporon*, the human pathogenic hyaline or dematiaceous moulds *Aspergillus*, *Phialophora*, *Phoma*,

Fig. 2. Characterization of the ED7 antigen and its epitope and spatial distribution of the antigen in spores and hyphae.

(A) Western immunoblot with ED7 using culture fluid from 2-day-old PDB cultures of F. solani (CBS224.34) (lane 1) and F. oxysporum f.sp. lycopersici CBS167.30 (lane 2). Wells were loaded with 1.6 lg of protein.  $M_r$  denotes molecular weight in kDa. Note the major extracellular antigen with molecular weight of approximately 200 kDa.

(B) Absorbance values from ELISA tests with ED7 using surface washings containing water-soluble antigens immobilized to the wells of microtitre plates and treated with trypsin or PBS only (control) at  $4^{\circ}$ C and 378C. Bars are the means of three biological replicates 6 standard errors and bars with the same letter are not significantly different at p < 0.001 (ANOVA and Tukey–Kramer test).

(C) Absorbance values from ELISA tests with ED7 using surface washings containing water-soluble antigens immobilized to the wells of microtitre plates and treated with pronase or Milli-Q H<sub>2</sub>O only (control) at 4°C and 378C. Bars are the means of three biological replicates 6 standard errors and bars with the same letter are not significantly different at p < 0.001 (ANOVA and Tukey–Kramer test).

(D) Stability of the water-soluble ED7 antigen following heating of surface washings at 1008C over a 70-minute period. Treated antigen was subsequently immobilized to the wells of microtitre plates and assayed by ELISA. Bars are the means of three biological replicates 6 standard errors and bars with the same letter are not significantly different at p < 0.001 (ANOVA and Tukey–Kramer test).

(E) Absorbance values from ELISA tests with ED7 using surface washings containing water-soluble antigens immobilized to the wells of microtitre plates and treated with periodate (open circles) or with acetate only control (closed circles) at 4°C over a 20-hour period. Each point is the mean of three biological replicates 6 standard errors.

(F to I) Photomicrographs of F. solani CBS224.34 immunostained with ED7 or TCM control and goat anti-mouse polyvalent Ig fluorescein isothiocyanate (FITC) conjugate. (F) Brightfield image of germinated conidium with hypha probed with ED7 followed by fluorochrome conjugate (scale bar 5 6 Im); (G) Same field of view as panel F but examined under epifluorescence. Note intense staining of the cell wall of microconidium and hypha; (H) Brightfield image of germinated conidium with hypha probed with TCM (negative control) followed by FITC conjugate (scale bar 5 3 Im); (I) Same field of view as panel H but examined under epifluorescence. Note lack of staining, demonstrating specific binding of ED7 to surface antigen.

(J to L) Immunogold labeling of sections of conidia and hyphae of *F. solani* CBS224.34. (J) Transverse section of conidium incubated with ED7 and anti-mouse immunoglobulin 20 nm gold particles, showing antigen in the cell wall and in an extracellular fimbrial matrix surrounding the spore (scale bar 5 250 nm); (K) Longitudinal section of hypha incubated with ED7 and anti-mouse immunoglobulin 20 nm gold particles, showing antigen in the cell (scale bar 5 100 nm); (L) Transverse section of a conidium incubated with TCM (negative control) and anti-mouse immunoglobulin 20 nm gold particles, showing lack of staining by the secondary gold conjugate (scale bar 5 180 nm).

Trichoderma and the human pathogenic mucormycete Mucor (Table 1). The remaining 93% of samples positive for Fusarium antigen, either at the swab stage or following periods of biological amplification in mixed or axenic cultures (Supporting Information Table S2), yielded strains of the three Fusarium species. There was 100% concordance between Fusarium genus identification by ELISA and species identification by ITS sequencing (Table 1). The species of F. solani and F. oxysporum recovered from sink swabs were subsequently shown by TEF-1a PCR (Supporting Information Data Set 1) to belong to F. solani species complex (FSSC) 1-a, 1-c, 2-a, 2-v, 5-d, 5-k, 9-a, 15a, 20-d and F. oxysporum (FOSC) species complexes 16, 33, 99, 111, 126, 134, 183 (Supporting Information Table S3). All of the recovered F. dimerum isolates belonged to the F. dimerum species complex (FDSC) ET-gr (Supporting Information Table S3). ITS analysis of axenic cultures (Table 1) showed that a number of sink samples (e.g., S2, S6, S17, S19, S21, S24, S30, S38) contained mixtures of Fusarium species, while ITS and TEF-PCR analysis (Table 1 and Supporting Information Table S3) showed that others contained mixtures of species complexes of the same species (e.g., S8, S9, S25, S28). Monoclonal antibody ED7 was able to detect all of the Fusarium species complexes recovered in this study.

In addition to drain swabs, water samples were collected from the taps of sinks in the hospital haematology and oncology units and from the main water tanks feeding the ophthalmology unit. The ED7 diagnostic antigen could not be detected in any of the water samples directly and, while all of the samples yielded fungi, only two of the tap samples (oncology W57 and W60) contained *Fusarium* strains that belonged to FDSC ET-gr. and which were detectable by ELISA at the mixed culture stage (Table 1). The sink biofilms corresponding to these water samples were also positive at the swab ELISA stage (Table 1).

### Discussion

The genus *Fusarium* comprises ubiquitous environmental moulds capable of infecting plants and humans (Zhang et al., 2006). Unlike agriculture, where the most economically damaging pathogens are considered to be

*F. graminearum* and *F. oxysporum* (Dean et al., 2012), the species most commonly cited as human pathogens belong to the *Fusarium solani* species complex (FSSC), responsible for 50% of reported infections in humans, followed by strains in the FOSC (Torres and Kontoyiannis, 2011). The FDSC is less frequently reported as causing human dis-ease, but it is similarly capable of causing disseminated infections in immunocompromised patients (Bigley et al., 2004; Schroers et al., 2009).

While the natural habitats of plant pathogenic *Fusarium* strains are well characterized as soil and decaying plant material, habitats providing direct human exposure to infectious propagules are largely unexplored. The increasing frequency of opportunistic fungal infections in human means that improved surveillance methods are needed to identify environmental reservoirs of pathogens to limit the exposure of vulnerable individuals to potentially infective propagules. For *Fusarium*, there is a growing body of evidence to suggest that domestic and municipal water

### 6 M. Al-Maqtoofi and C. R. Thornton

Table 1. Locations and identifies of sink swabs and water samples and results of ELISA tests and fungal identification based on ITS sequencing.

	Location	Swab ELISA abs	Mixed culture ELISA abs	Isolate	Axenic culture ELISA abs	Identification based	GenBank accession
Sink ID	(Source) <sup>a</sup>	(450 nm) <sup>b</sup>	(450 nm) <sup>b</sup>	no.	(450 nm) <sup>b</sup>	sequencing <sup>c</sup>	no.
A1	University (S1)	0.0763	0.0575	A1-1	1.3736	Fusarium oxysporum	KT876668
	University (S1)			A1-2	0.7646	Fusarium oxysporum	KT876662
	University (S1)			A1-3	0.0196	Penicillium crustosum	KT876719
	University (S1)			A1-4	0.0139	Penicillium expansum	KT876718
A2	University (S2)	0.5472	0.0045	A2-1	1.5723	Fusarium solani	KT876635
	University (S2)			A2-3	0.6554	Fusarium oxysporum	K1876690
۸ <b>۵</b>	University (S2)	0.0052	0.0077	AZ-5	1.1312	Fusarium solani Triebeeneren demoetieum	K18/0031
AS	University (S3)	0.0055	0.0077	A3-1 A2-2	0.0062	Cadaphora fastigiata	KT070717
	University (S3)			A3-2 A3-3	0.0102		KT070013
	University (S3)			A3-3 A3-4	0.0014	Penicillium crustosum	KT876714
Δ4	University (S4)	0 0297	0 0049	A4-1	0.0000	Phoma herbarum	KT876697
	University (S4)	0.0201	0.0010	A4-2	0.0079	Penicillium echinulatum	KT876710
	University (S4)			A4-3	0.0029	Cvtobasidium slooffiae	KT876704
	University (S4)			A4-6	0.0060	Trichoderma asperellum	KT876620
A5	University (S5)	0.0206	0.0039	A5-1	1,1815	Fusarium oxysporum	KT876692
	University (S5)			A5-2	0.0034	Penicillium crustosum	KT876715
	University (S5)			A5-5	0.0088	Aspergillus niger	KT876702
	University (S5)			A5-6	1.0630	Fusarium oxysporum	KT876667
	University (S5)			A5-7	0.0037	Rhodotorula mucilaginosa	KT876700
	University (S5)			A5-8	0.0088	Cyphellophora oxyspora	KT876614
A6	University (S6)	0.0251	0.0412	A6-1	1.1130	Fusarium oxysporum	KT876648
	University (S6)			A6-2	0.9410	Fusarium oxysporum	KT876678
	University (S6)			A6-3	0.6377	Fusarium oxysporum	KT876688
	University (S6)			A6-4	1.0020	Fusarium solani	KT876640
A7	University (S7)	0.1716	0.0082	A7-1	0.0098	Exophiala pisciphila	KT876618
	University (S7)			A7-2	0.0096	Penicillium brevicompactum	KT876695
	University (S7)			A7-3	1.0556	Fusarium oxysporum	K1876684
4.0	University (S7)	0.0424	0.0000	A7-4	1.0077	Fusarium oxysporum	K18/66/1
Aδ	University (S8)	0.0431	0.0008	A8-1	1.1045	Fusarium oxysporum	K18/00/2
	University (S8)			A8-2	0.9707	Fusarium oxysporum Triebodormo otrovirido	K18/6654
40	University (S0)	0.2906	0.0052	A0-3	0.0091	Fusarium solani	KT070022
A9	University (S9)	0.3606	0.0052	A9-1 A9-2	0.9067	Fusarium solani Fusarium solani	KT876638
	University (S9)			A9-3	0.9004	Fusarium solani	KT876632
	University (S9)			A9-4	0.8093	Fusarium solani	KT876636
A10	University (S10)	0.0034	0.0028	A10-1	0.0188	Rhodotorula slooffiae	KT876705
	University (S10)			A10-2	0.0020	Exophiala pisciphila	KT876616
B1	University (S11)	0.0231	0.0005	B1-1	0.6064	Fusarium dimerum	KT876625
	University (S11)			B1-6	0.8138	Fusarium dimerum	KT876628
B2	University (S12)	0.0200	0.0020	B2-1	0.5678	Fusarium dimerum	KT876626
	University (S12)			B2-5	0.4827	Fusarium dimerum	KT876624
B3	University (S13)	0.0091	0.0023	B3-4	0.0026	Phoma herbarum	KT876696
B4	University (S14)	0.0163	0.0008	B4-1	0.6992	Fusarium dimerum	KT876627
B5	University (S15)	0.0132	0.0003	B5-1	0.8008	Fusarium oxysporum	KT876674
	University (S15)			B5-2	0.0048	Mucor circinelloides	KT876701
	University (S15)			B5-3	0.8851	Fusarium oxysporum	KT876677
B6	University (S16)	0.0229	0.0002	B6-1	0.8193	Fusarium oxysporum	KT876676
D7	University (S16)	0.0005	0.0011	B6-2	0.7582	Fusarium oxysporum	KT876661
В/	University (S17)	0.0395	0.0014	B7-1	0.8201	Fusarium oxysporum	K1876675
Do	University (S17)	0.0400	0.0044	B/-6	0.7758	Fusarium aimerum	K18/6623
BS	University (S18)	0.0133	0.0011	88-1 80 7	0.7347	Fusarium solani Phodooporidium hobiovoo	K18/6637
BO	University (S10)	0.0212	0.0049	B0-1	0.0095	Moverozuma quilliermendii	KT076707
55	Liniversity (\$19)	0.0212	0.0040	B0-2	0.8104		KTOTEET
	Oniversity (OTS)			03-2	0.0104		1 COD 10171

### Appendix 5

### Fusarium-specific monclonal antibody 7

Table 1. cont.

			Mixed		Axenic		
		Swab	ELISA		ELISA	Identification based	GenBank
	Location	ELISA abs	abs	Isolate	abs	on ITS	accession
Sink ID	(Source) <sup>a</sup>	(450 nm) <sup>b</sup>	(450 nm) <sup>b</sup>	no.	(450 nm) <sup>b</sup>	sequencing <sup>c</sup>	no.
	University (S19)			B9-3	0.6302	Fusarium solani	KT876634
	University (S19)			B9-5	0.0017	Penicillium crustosum	KT876720
B10	University (S20)	0.5467	0.0394	B10-1	0.7467	Fusarium oxysporum	KT876680
	University (S20)			B10-2	0.7667	Fusarium oxysporum	K18/6659
	University (S20)			B10-0	0.0071	Candida parapsilosis Moverozyma guilliermondii	KT070703
	University (S20)			B10-7	0.0231	Cystobasidium slooffiae	KT876712
	University (S20)			B10-12	0.0251	Trichosporon asteroides	KT876713
C1	University (S21)	0.0083	0.0269	C1-1	0.0044	Clavispora lusitaniae	KT876708
	University (S21)			C1-3	0.8875	Fusarium oxysporum	KT876682
	University (S21)			C1-4	0.8884	Fusarium dimerum	KT876629
	University (S21)			C1-7	0.0003	Exophiala pisciphila	KT876617
C2	University (S22)	0.2977	0.0047	C2-1	0.9443	Fusarium oxysporum	KT876658
	University (S22)			C2-4	0.9825	Fusarium oxysporum	KT876694
_	University (S22)			C2-7	0.8677	Fusarium oxysporum	KT876687
C3	University (S23)	0.0808	0.0116	C3-1	0.9853	Fusarium oxysporum	KT876683
	University (S23)			03-2	1.0160	Fusarium oxysporum	K18/6693
~	University (S23)	0.4440	0.0000	C3-4	0.7485	Fusarium oxysporum	K18/0044
64	University (S24)	0.1113	0.0202	C4-1 C4-2	0.8930	Fusarium oxysporum Candida intermedia	KT876709
	University (S24)			C4-5	0.9008	Eusarium dimerum	KT876630
C5	University (S25)	0.5741	0.0097	C5-1	0.9874	Fusarium oxysporum	KT876652
	University (S25)	0.07.11	0.0001	C5-2	1.0996	Fusarium oxysporum	KT876656
	University (S25)			C5-3	1.1236	Fusarium oxysporum	KT876649
	University (S25)			C5-4	1.0355	Fusarium oxysporum	KT876669
	University (S25)			C5-5	1.0672	Fusarium oxysporum	KT876660
C6	University (S26)	0.0603	0.0348	C6-1	1.0135	Fusarium oxysporum	KT876665
	University (S26)			C6-2	0.9362	Fusarium oxysporum	KT876681
	University (S26)			C6-3	0.8898	Fusarium oxysporum	K18/66/3
	University (S26)			C6-4	1.0577	Fusarium oxysporum	K1876686
C7	University (S26)	0 1279	0.0113	C6-5 C7-1	0.9445	Fusarium oxysporum Fusarium oxysporum	K1876666
C8	University (S28)	0.0607	0.0035	C8-1	0.8694	Fusarium oxysporum	KT876685
00	University (S28)	0.0001	0.0000	C8-2	0.9599	Fusarium oxysporum	KT876655
	University (S28)			C8-3	0.0031	Penicillium expansum	KT876716
	University (S28)			C8-4	0.0049	Phoma herbarum	KT876698
	University (S28)			C8-6	0.9003	Fusarium oxysporum	KT876679
C9	University (S29)	0.0310	0.0001	C9-1	1.0488	Fusarium oxysporum	KT876651
	University (S29)			C9-2	0.9254	Fusarium oxysporum	KT876645
	University (S29)			C9-3	0.9711	Fusarium oxysporum	KT876664
	University (S29)			C9-4	1.035	Fusarium oxysporum	KT876647
0.40	University (S29)	0.4000		C9-5	0.9604	Fusarium oxysporum	KT876663
C10	University (S30)	0.1002	0.0333	C10-1	0.9254	Fusarium oxysporum	K1876689
	University (S30)			C10-2	1.0198	Fusarium solani	K18/0042
	University (S30)			C10-4	1 0697	Fusarium solani	KT876643
CRT1	University (S31)	0.6175	0 1129	CRT1-1	0.4639	Fusarium oxysporum	KT876691
0.011	University (S31)	5.0110	3.1120	CRT1-2	0.9086	Fusarium oxysporum	KT876650
	University (S31)			CRT1-3	0.7503	Fusarium oxysporum	KT876652
CRT2	University (S32)	0.0303	0.0021	CRT2-1	0.0040	Trichoderma asperellum	KT876619
	University (S32)			CRT2-2	0.0417	Trichoderma asperellum	KT876621
CRT3	University (S33)	0.0663	0.0028	CRT3-1	0.0256	Phoma herbarum	KT876699
R1	ICU (S34)	0.0285	0.3620	R1-1	1.5057	Fusarium solani	KT876550
	ICU (S34)			R1-2	1.5154	Fusarium solani	KT876551
	ICU (S34)			R1-3	1.5555	Fusarium solani	KT876549

Table 1. cont.

			Mixed		Axenic		
		Quark	culture		culture	later (Construction and	Oran
	Logation	SWAD ELISA aba	ELISA	looloto	ELISA	Identification based	GenBank
Cink ID	(Source) <sup>a</sup>	(450 pm) <sup>b</sup>	(450 pm) <sup>b</sup>	ISUIALE	$(450 \text{ pm})^{b}$	on no	accession
SINK ID	(Source)	(450 mm)	(450 1111)	no.	(450 mm)	sequencing	no.
R2	ICU (S35)	0.0071	0.0147	R2-4	0.0096	Clonostachys rosea	KT876552
	ICU (S35)			R2-5	0.0018	Clonostachys rosea	KT876553
	ICU (S35)			R2-6	0.0035	Clonostachys rosea	KT876554
R3	ICU (S36)	0.0391	0.045	R3-1	0.0006	Trichoderma asperellum	KT876548
R5	ITU (S37)	0.7291	0.7724	R5-1	1.5606	Fusarium dimerum	KT876561
	ITU (S37)			R5-2	1.3481	Fusarium dimerum	KT876565
	ITU (S37)			R5-3	1.4990	Fusarium dimerum	KT876567
R6	ITU (S38)	1.2086	0.3691	R6-1	1.3388	Fusarium dimerum	KT876572
	ITU (S38)			R6-2	1.4734	Fusarium dimerum	KT876563
	ITU (S38)			R6-3	1.4312	Fusarium dimerum	KT876562
	ITU (S38)			R6-9	1.2648	Fusarium oxysporum	KT876557
R7	ITU (S39)	0.1121	0.8186	R7-1	1.3266	Fusarium dimerum	KT876570
	ITU (S39)			R7-2	1.2352	Fusarium dimerum	KT876564
R8	ITU (S40)	1.0157	0.3612	R8-1	1.2399	Fusarium dimerum	KT876568
	ITU (S40)			R8-2	1.1552	Fusarium dimerum	KT876566
	ITU (S40)			R8-3	1.1856	Fusarium dimerum	KT876558
R9	ITU (S41)	0.0391	0.0477	R9-3	0.0113	Exophiala phaeomuriformis	KT876555
R10	ITU (S42)	0.0549	0.0097	R10-2	0.0072	Cadophora fastigiata	KT876556
	ITU (S42)			R10-6	0.0124	Coniochaeta fasciculata	KT876721
X2	ITU (S43)	0.0630	1.5751	X2-2	1.1492	Fusarium dimerum	KT876571
	ITU (S43)			X2-4	1.2505	Fusarium dimerum	KT876560
	ITU (S43)			X2-5	1.1397	Fusarium dimerum	KT876569
	ITU (S43)			X2-6	1.1716	Fusarium dimerum	KT876559
Х3	Ophthalmology Unit (S44)	1.0313	1.5035	X3-1	1.1353	Fusarium dimerum	KT876509
	Ophthalmology Unit (S44)			X3-2	0.0224	Candida parapsilosis	KT876498
	Ophthalmology Unit (S44)			X3-3	1.1856	Fusarium dimerum	KT876512
X4	Ophthalmology Unit (S45)	1.4582	1.4049	X4-1	1.1322	Fusarium dimerum	KT876511
	Ophthalmology Unit (S45)			X4-2	1.1523	Fusarium dimerum	KT876500
	Ophthalmology Unit (S45)			X4-3	0.0622	Candida parapsilosis	KT876508
	Ophthalmology Unit (S45)			X4-4	0.1245	Gloeotinia temulenta	KT876515
X5	Ophthalmology Unit (S46)	0.3325	1.4466	X5-2	1.0654	Fusarium dimerum	KT876510
	Ophthalmology Unit (S46)			X5-3	0.0599	Rhodotorula mucilaginosa	KT876501
	Ophthalmology Unit (S46)			X5-4	1.0862	Fusarium dimerum	KT876513
X6	Ophthalmology Unit (S47)	0.2640	1.3729	X6-1	0.0616	Candida parapsilosis	KT876499
	Ophthalmology Unit (S47)			X6-2	0.063	Engyodontium album	KT876522
	Ophthalmology Unit (S47)			X6-3	0.0603	Engyodontium album	KT876521
	Ophthalmology Unit (S47)			X6-4	0.0657	Exophiala phaeomuriformis	KT876504
X8	Ophthalmology Unit (S48)	0.5299	0.0223	X8-2	0.0118	Cladosporium macrocarpum	KT876506
	Ophthalmology Unit (S48)			X8-3	0.0985	Gloeotinia temulenta	KT876514
	Ophthalmology Unit (S48)			X8-4	0.0662	Engyodontium album	KT876523
X9	Ophthalmology Unit (S49)	0.1872	0.0061	X9-1	0.0686	Engyodontium album	KT876520
	Ophthalmology Unit (S49)			X9-2	0.0611	Candida parapsilosis	KT876496
	Ophthalmology Unit (S49)			X9-3	0.0641	Candida parapsilosis	KT876497
	Ophthalmology Unit (S49)			X9-4	0.0677	Exophiala dermatitidis	KT876503
	Ophthalmology Unit (S49)			X9-5	0.0705	Engyodontium album	KT876519
	Ophthalmology Unit (S49)			X9-7	0.0660	Exophiala pisciphila	KT876502
X10	Ophthalmology Unit (T1)	0.0132	0.0159	X10-1	0.0868	Cladosporium sphaerospermum	KT876507
	Ophthalmology Unit (T1)			X10-3	0.0130	Engyodontium album	KT876518
W1	Ophthalmology Unit (T2)	0.0117	0.0883	W1-1	0.0114	Paraconiothyrium fuckelii	KT876505
	Ophthalmology Unit (T2)			W1-2	0.0139	Engyodontium album	KT876517
	Ophthalmology Unit (T2)			W1-3	0.0108	Engyodontium album	KT876516
K1	Haematology Unit (S50)	0.2694	0.0093	K1-1	0.0172	Trichoderma asperellum	KT876534
K2	Haematology Unit (S51)	0.7466	1.1746	K2-1	0.0144	Trichoderma viride	KT876533
	Haematology Unit (S51)			K2-3	1.1385	Fusarium solani	KT876543
	Haematology Unit (S51)			K2-4	1.2487	Fusarium solani	KT876542

### Appendix 5

### Fusarium-specific monclonal antibody 9

Table 1. cont.

			Mixed		Axenic		
		<b>a</b> .	culture		culture		
	Location	Swab ELISA aba	ELISA	leolato	ELISA	Identification based	GenBank
Sink ID	(Source) <sup>a</sup>	$(450 \text{ nm})^{b}$	$(450 \text{ nm})^{b}$	no	(450 nm) <sup>b</sup>	sequencing <sup>c</sup>	no
K6	Haematology Unit (S52)	1.0621	1.3090	K6-1	1.1544	Fusarium oxysporum	KT876541
	Haematology Unit (S52)			K6-4	0.0071	Candida parapsilosis	K1876524
K8	Haematology Unit (S53)	1.0120	1.2628	K8-1	1.2376	Fusarium solani	KT876722
	Haematology Unit (S53)			N0-2	1.2903	Fusanum solarii	KT070723
	Haematology Unit (S53)			K8-7	0.0054	Trichoderma asperellum	KT876535
KO	Haematology Unit (S54)	0.0843	1 2003	K0-1	0.0031	Candida paransilosis	KT876525
1.9	Haematology Unit (S54)	0.9643	1.2903	K9-1 K9-2	0.0040	Rhodotorula dairenensis	KT876526
	Haematology Unit (S54)			K9-4	0.0073	Cadophora fastigiata	KT876532
	Haematology Unit (S54)			K9-5	1.1652	Fusarium solani	KT876547
	Haematology Unit (S54)			K9-6	1.0316	Fusarium solani	KT876545
K10	Haematology Unit (S55)	0.8638	1.0753	K10-1	1.0684	Fusarium solani	KT876546
	Haematology Unit (S55)			K10-2	1.0386	Fusarium solani	KT876544
G1	Haematology Unit (W50)	0.0082	0.0451	G1-2	0.0097	Exophiala pisciphila	KT876529
G2	Haematology Unit (W51)	0.0581	0.0553	G2-1	0.0104	Engyodontium album	KT876540
0.0	Haematology Unit (W51)	0.0405	0.0440	G2-3	0.0062	Exophiala pisciphila	KT876530
GG	Haematology Unit (W52)	0.0125	0.0118	G6-2	0.0161	Exophiala castellanii	K1876528
G8	Haematology Unit (W53)	0.0075	0.0219	G8-1	0.0065	Engyodontium album	K1876538
G9	Haematology Unit (W54)	0.0002	0.0164	G9-2	0.0005		K18/053/
G10	Charlen (115)	0.0021	0.0182		0.0051	Engyodontium album	K18/0339
пі	Oncology Unit (S56)	0.4022	1.2207	П I- I Н1_3	0.9022	Pusanum umerum Pichia kudriavzevii	KT876578
H2	Oncology Unit (S57)	1 0579	1 1650	H2_1	0.0131	Fusarium dimerum	KT876500
112	Oncology Unit (S57)	1.0079	1.1000	H2-5	0.0061	Magnusiomyces capitatus	KT876611
H3	Oncology Unit (S58)	1.0938	1.2091	H3-1	0.8909	Fusarium oxysporum	KT876584
	Oncology Unit (S58)			H3-4	0.0075	Candida palmioleophila	KT876573
	Oncology Unit (S58)			H3-5	0.0140	Rhodotorula glutinis	KT876598
H4	Oncology Unit (S59)	0.0253	1.0856	H4-1	0.8884	Fusarium dimerum	KT876596
	Oncology Unit (S59)			H4-3	0.0004	Magnusiomyces capitatus	KT876612
H5	Oncology Unit (S60)	1.0856	1.0193	H5-1	1.1148	Fusarium dimerum	KT876593
	Oncology Unit (S60)			H5-3	0.005	Candida tropicalis	KT876574
H6	Oncology Unit (S61)	0.5256	1.1898	H6-1	1.1238	Fusarium dimerum	KT876594
H7	Oncology Unit (S62)	1.0789	1.1588	H7-1	1.1513	Fusarium oxysporum	KT876583
1.10	Oncology Unit (S62)	0.0052	0.0450	H7-3	0.0045	Candida tropicalis	K18/65/5
Πö	Oncology Unit (S63)	0.0953	0.0152	П0-1 Ц0-2	0.0063	Condido albicono	K18/0380
	Oncology Unit (S63)			H8-1	0.0120	Rhodotorula mucilaginosa	KT876500
ЦО	Oncology Unit (S64)	0 1026	0.0162	H0_1	0.0000	Exophiala dormatitidis	KT876581
113	Oncology Unit (S64)	0.1920	0.0102	H9-2	0.0049	Candida orthopsilosis	KT876576
	Oncology Unit (S64)			H9-3	0.0109	Pichia kudriavzevii	KT876579
H10	Oncology Unit (S65)	0.4961	1.1005	H10-1	0.9606	Fusarium dimerum	KT876589
	Oncology Unit (S65)			H10-4	0.0163	Trametes ochracea	KT876608
P1	Oncology Unit (W56)	0.0030	0.0247	P1-2	0.0082	Exophiala dermatitidis	KT876582
	Oncology Unit (W56)			P1-3	0.0024	Trametes versicolor	KT876603
P2	Oncology Unit (W57)	0.0061	1.0891	P2-1	0.8451	Fusarium dimerum	KT876587
	Oncology Unit (W57)			P2-2	0.9429	Fusarium dimerum	KT876597
Do	Oncology Unit (W57)	0.0040	0.0000	P2-3	0.8627	Fusarium dimerum	KT876588
P3	Oncology Unit (W58)	0.0016	0.0202	P3-1	0.0177	Trametes ochracea	K1876607
P4	Oncology Unit (W59)	0.0035	0.0125	P4-1	0.0164	Beauveria bassiana	K18/6586
DC		0.0005	4 4740	P4-2	0.0084		K18/0384
60	Oncology Unit (W60)	0.0025	1.1740	P5-1	0.0000 AA08 0	Fusarium dimerum	KT876502
	Oncology Unit (W60)			P5-3	0.0024	Piptoporus betulinus	KT876609
P7	Oncology Unit (W62)	0.0011	0.0417	P7-1	0.0097	Trametes versicolor	KT876605
P8	Oncology Unit (W63)	0.0044	0.0060	P8-1	0.0144	Trametes versicolor	KT876606
	Oncology Unit (W63)			P8-2	0.0106	Stereum gausapatum	KT876601

### 10 M. Al-Maqtoofi and C. R. Thornton

Table 1. cont.

	Location	Swab ELISA abs	Mixed culture ELISA abs	Isolate	Axenic culture ELISA abs	Identification based on ITS	GenBank accession
Sink ID	(Source) <sup>a</sup>	(450 nm) <sup>0</sup>	(450 nm) <sup>0</sup>	no.	(450 nm) <sup>0</sup>	sequencing <sup>c</sup>	no.
P9	Oncology Unit (W64)	0.0022	0.0163	P9-1	0.0101	Stereum gausapatum	KT876600
	Oncology Unit (W64)			P9-2	0.0068	Trametes versicolor	KT876604
	Oncology Unit (W64)			P9-3	0.0140	Stereum gausapatum	KT876602
P10	Oncology Unit (W65)	0.0051	0.0280	P10-1	0.0032	Phaeophlebiopsis peniophoroides	KT876610

a. S, sink; W, tap water from corresponding sink number; T, water sample from main tank.

b. Threshold absorbance value for detection in ELISA 0.100. Shading indicates earliest point in sampling process at which antigen was detectable in ELISA tests with ED7.

c. Fusarium strains in bold further characterized by TEF-1α PCR analysis (Table S3 and Supporting Information Data Set 1).

systems are potential reservoirs of human pathogenic strains in the FSSC, FOSC and FDSC groups (Short et al., 2011).

Accurate techniques that can be used to identify the fungus in environmental samples containing mixed populations of fungi are currently lacking and, while nucleic acid-based technologies have been developed for the differentiation of Fusarium from other human pathogenic species and to identify Fusarium species complexes, such techniques have typically been used in retrospective analysis of axenic cultures collected during human and environmental population studies (Bouchara et al., 2009; Steinmann et al., 2011; Lackner et al., 2012). Furthermore, these studies have often employed Fusarium-selective media that eliminate other fungi present in polymicrobial communities (Short et al., 2011). While monoclonal anti-bodies (mAbs) and antibody fragments have been developed for detecting and differentiating Fusarium species in vitro or in planta (Wong et al., 1988; Arie et al., 1991, 1995; Danks et al., 1996; Hayashi et al., 1998; Hu et al., 2012, 2013), no attempts have been made to use mAbs to track human pathogenic strains in environmental samples. Jensen et al. (2011) recently reported the development of Fusariumspecific mAbs for immunohistochemical diagnosis of fusariosis. The IgM mAbs, which recognize 51 and 63 kDa antigens, reacted strongly with fungal elements in both experimentally infected animals and biopsy samples from patients with fusariosis sepsis and dissemination to the skin.

In this prospective study, we set out to determine whether human pathogenic species of Fusarium could be identified in sink drains directly by using crude antigen extracts of biofilms and detection using а genus-specific immunoglobulin M (IgM) mAb, ED7, that binds to an extracellular approximately 200kDa carbohydrate antigen present on the surface of spores and hyphae. While the function of the antigen is currently unknown we were able, in Enzyme-Linked Immunosorbent Assay (ELISA) tests, to detect its presence in 52% of swab samples and, following biological amplification of biofilms on a non-selective mycological medium, were able to identify additional biofilm samples containing pathogenic strains of Fusarium. This is the first time, to our knowledge, that a mAb-based detec-tion method has been used to track Fusarium in environmental samples. The mAb was able to differentiate Fusarium from a wide spectrum of unrelated fungi, including the human pathogens Aspergillus (Thornton and Wills, 2015), Candida, Geotrichum, Rhodotorula and Trichosporon (Miceli et al., 2011; Davies and Thornton, 2014), Cyphellophora and Phialophora (Feng et al., 2014), Exophiala (Zeng et al., 2007), Trichoderma (Sandoval-Denis et al., 2014), Engyodontium (Macedo<sup>^</sup> et al., 2007; Thamke et al., 2015) and Mucor (Petrikkos et al., 2012), several of which have been reported previously to inhabit biofilms in water distribution systems (Dogget, 2000). The 100% accuracy of the ED7 ELISA, confirmed by using ITS sequencing and

TEF PCR analysis of recovered isolates, demonstrates its robustness in detecting potentially infec-tious *Fusarium* species in polymicrobial communities. Importantly, ED7 reacted with all of the species complex strains isolated including the most common clinical patho-types of *Fusarium*, FSSC 1-a, FOSC 33 and FDSC ET-gr (Schroers et al., 2009; Short et al., 2011).

While the ED7 ELISA was able to identify Fusarium to the level of genus only, the simplicity of the mAb-based approach to detection, even when combined with a standard mycological isolation procedure, means that a recognized environmental niche of this group of patho-genic fungi can be monitored readily. The widespread occurrence of human pathogenic Fusarium species in sinks of a tertiary care hospital and sinks of a heavily popu-lated university campus, show that indoor plumbing-associated biofilms and water sources are an unseen source of Fusarium infectious propagules for nosocomial and community-acquired infections of vulnerable individu-als, an observation consistent with previous studies (Annaisie et al., 2011; Short et al., 2011). While no cases of fusariosis were reported during the course of this study, the close proximity of the patients to hospital sinks colon-ized with both pathogenic fusaria and with other opportunistic fungal pathogens is a serious concern given the known vulnerability of immunocompromised individuals to invasive fungal infections.

### Experimental procedures

### Ethics statement

All animal work described in this study was conducted under a UK Home Office Project License, and was reviewed by the institution's Animal Welfare Ethical Review Board (AWERB) for approval. The work was carried out in accordance with The Animals (Scientific Procedures) Act 1986 Directive 2010/63/ EU, and followed all the Codes of Practice which reinforce this law, including all elements of housing, care, and euthanasia of the animals. Permission for sink sampling at the Royal Devon and Exeter Hospital was granted by the Director of Infection Prevention and Control.

### Fungal culture

Fungi (Supporting Information Table S1) were routinely cultured on Potato Dextrose Agar (PDA: 70139; Sigma), Sabouraud Dextrose Agar (SDA: Sabouraud Dextrose Broth (SDB: S3306; Sigma) containing 2% (w/v) agar), Malt Yeast extract Agar (MYA: Y3127; Sigma), or Oatmeal Agar (OA: O3506; Sigma), sterilized by autoclaving at 121°C for 15 minutes. Cultures were grown at 26°C under a 16 hours fluo-rescent light regime.

# Development of mAb, preparation of immunogen and immunization regime

BALB/c mice were immunized with soluble antigens prepared from lyophilized mycelium of a human pathogenic strain of

Fusarium solani species complex 1-a (CBS strain 224.34). Conidia were suspended in water after 10-day-old PDA slant cultures were flooded with 5 ml dH<sub>2</sub>O and gently agitated with an inoculation loop. Conidial suspensions were then filtered through Miracloth to remove mycelium and transferred to 1.5 ml micro-centrifuge tubes. The conidia were washed three times with dH<sub>2</sub>O by repeated vortexing and centrifugation at 14 462g for 5 min and finally suspended in dH<sub>2</sub>O to give a concentration of 10<sup>6</sup> conidia ml<sup>-1</sup> solution. Flasks containing 100 ml of sterilized Potato Dextrose Broth (PDB: P6685; Sigma) were inoculated with 200 µl of the conidial suspension and incubated with shaking (75 rpm) for 48 h at 26°C. Hyphal biomass was collected on Miracloth, snap frozen in liquid N2, and lyophilized. Culture filtrates were retained for gel electrophoresis and Western blotting studies and stored at 22°C until required. About 1 mg of lyophilized biomass was sus-pended in 1 ml phosphate buffered saline (PBS: 0.8% NaCl: 0.02% KCl: 0.115% Na2HPO4: 0.02% KH<sub>2</sub>PO<sub>4</sub>; pH7.2) and the resultant suspension centrifuged for 5 min at 14 462g. The supernatant, containing solubilized antigens, was used as the immunogen and as a source of antigens for hybridoma screening assays. For immunization, 6week-old BALB/c female white mice were given four intraperitoneal injections (300 µl per injection) of antigen extract containing 2.3 mg protein ml<sup>-1</sup> PBS at 2-week intervals and a single booster injection 5 days before fusion.

#### Production and screening of hybridomas and determination of antibody specificity

Hybridoma cells were produced by the method described elsewhere (Thornton, 2001) and the supernatants were screened by Enzyme-Linked Immunosorbent Assay (ELISA) against antigens immobilized to the wells of Maxisorp microtiter plates (442404; Nunc) (50 µl per well). For antibody specificity tests, fungi were grown on replicate agar slopes and surface washings containing water-soluble antigens prepared as described in Thornton (2001). Protein concentrations, determined spectrophotometrically at 280 nm (Nanodrop, Agilent Technologies Limited, Berkshire, UK), were adjusted to 60 µg ml<sup>-1</sup> buffer. Fifty µl volumes were then used to coat the wells of microtitre plates. After incubating overnight at 4°C, wells were washed four times with PBST (PBS containing Tween-20, 0.05% (v/v)), once each with PBS and dH<sub>2</sub>O and then air-dried at 238C in a laminar flow hood. The plates were stored in sealed plastic bags at 4°C in preparation for screening of hybridoma superna-tants by ELISA as described below.

### Enzyme-linked immunosorbent assay

Wells containing immobilized antigens were incubated successively with hybridoma tissue culture supernatant (TCS) for 1 hour, followed with goat anti-mouse polyvalent (immunoglobulin classes IgG, IgA and IgM) peroxidase conjugate (A-0412; Sigma Chemical Company, Poole, United Kingdom) diluted 1 in 1000 in PBST for a further hour. Bound antibody was visualized by incubating wells with tetramethyl benzidine (TMB: T-2885; Sigma) substrate solution (Thornton, 2001) for 30 minutes. The reactions were stopped by the addition of 3 M H<sub>2</sub>SO4 and absorbance values were determined at 450 nm with an MRX automated microplate reader (Dynex Technologies, Billingshurst, UK). Wells were given four 5-minute rinses with PBST between incubations and a final rinse with PBS before addition of the substrate solution. Working volumes were 50  $\mu$ l per well and control wells were incubated with tissue culture medium (TCM) containing 10% (v/v) fetal bovine serum. All incubation steps were performed at 238C in sealed plastic bags. The threshold for detection of the antigen in ELISA was determined from control means (23 TCM absorbance values) (Sutula et al., 1986). These values were consistently in the range 0.050–0.100. Consequently, absorbance values > 0.100 were considered as positive for the detection of antigen.

### Determination of Ig subclass and cloning procedure

The Ig class of mAbs was determined by using antigenmediated ELISA. Wells of microtitre plates coated with *F. solani* CBS224.34 water-soluble antigens from surface washings were incubated successively with ED7 TCS for 1 hour, followed with goat anti-mouse IgG<sub>1</sub>, IgG<sub>2a</sub>, IgG<sub>2b</sub>, IgG<sub>3</sub>, IgM or IgA-specific antiserum (ISO-2; Sigma) diluted 1 in 3000 in PBST for 30 minutes and rabbit anti-goat peroxidase conju-gate diluted 1 in 1000 (A-5420; Sigma) for a further 30 minutes. Bound antibody was visualized with TMB substrat as described above. Hybridoma cells lines were sub-cloned three times by limiting dilution. They were preserved by slowly freezing in fetal bovine serum/dimethyl sulfoxide (92:8 [v/v]), and stored in liquid nitrogen.

### Gel electrophoresis and Western blotting

For sodium-dodecyl-sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), culture filtrates from 2-days-old PDB shake cultures of F. solani CBS224.34 and F. oxysporum f.sp. lycopersici CBS167.30, prepared as described, were diluted in Laemmli buffer (Laemmli, 1970) and were denatured by heating at 958C for 10 min. Antigens were separated in 4%-20% (w/v) polyacrylamide gradient gels (161-1159; Bio-Rad) for 1.5 hours at 238C (165V) under denaturing conditions, and pre-stained broad range markers (161-0318; Bio-Rad) were used for molecular weight determinations. For Westerns, sep-arated antigens were transferred electrophoretically to a PVDF membrane (162-0175; Bio-Rad). The membranes were blocked for 16 hours at 4°C with PBS containing 1% (w/v) bovine serum albumin (BSA) and incubated with ED7 TCS diluted 1 in 2 with PBS containing 0.5% (w/v) BSA (PBSA) for 2 hours at 238C. After washing three times with PBS, mem-branes were incubated for 1 hour with goat anti-mouse IgM (1-chain specific) alkaline phosphatase conjugate (A-9688; Sigma), diluted 1 in 15 000 in PBSA. After the membranes were washed twice with PBS and once with PBST, the bound antibodies were visualized by incubation in BCIP/NBT sub-strate solution. Reactions were stopped by immersion in dH2O and air-dried between sheets of Whatman filter paper.

# Characterization of antigen by enzymatic and chemical modifications and by heating

Water-soluble antigens from surface washings of slopes of *F. solani* CBS224.34 were prepared as described. Heat stability studies were conducted by placing tubes of solubilized antigen in a boiling water bath. At 10 minutes intervals, samples were removed, centrifuged at 14 462g for 5 minutes, and antigens immobilized to the wells of microtitre plates for assay by ELISA

as described. For periodate oxidation, microtitre wells containing immobilized antigens from surface washings of the fungus were incubated with 50 ml of sodium meta-periodate solution (20 mM NalO<sub>4</sub> in 50 mM sodium acetate buffer (pH4.5)) or acetate buffer only (control) at 4°C in sealed plastic bags. Plates were given four 3-minute PBS washes before processing by ELISA as described. For protease digestions, microtitre wells containing immobilized antigen were incubated with 50 ml of pronase (protease XIV; 9 mg ml<sup>-1</sup> in PBS) or trypsin (1 mg ml<sup>-1</sup> in Milli-Q H<sub>2</sub>O) solution or Milli-Q H<sub>2</sub>O or PBS only controls respectively for 4 hours at 378C or 4°C. Plates were given four 3-minute rinses with PBS and then assayed by ELISA with ED7 TCS as described.

# Immunofluorescence and immunogold electron microscopy

For immunfluorescence (IF), sterilized slides were coated with a washed spore suspensions of F. solani CBS224.34 containing 1% (w/v) glucose solution and incubated at 26°C for 16 hours to allow spore germination and formation of germ tubes. After airdrying, the cells were fixed to the slides as described in Thornton (2001) and incubated with ED7 TCS or TCM only (negative control) for 1 hour, followed by three 5 minute PBS washes. Slides were then incubated with goat anti-mouse poly-valent fluorescein isothiocyanate (FITC) conjugate (diluted 1 in 40 in PBS) (F1010; Sigma) for 30 minutes. Slides were given three 5 minute washes with PBS and mounted in PBS-glycerol mounting medium (F4680; Sigma) before overlaying with cover-slips. All incubation steps were performed at 238C in a humid environment to prevent evaporation and slides were stored in the dark, at 4°C, prior to examination using an epifluorescence microscope (Olympus IX81) fitted with 495 nm (excitation) and 518 nm (emission) filters for FITC. For immunogold BSA (PBST-BSA) which had been sterile filtered through a 0.2 Im filter. The grids were washed three times (3 minutes each) in sterile filtered PBST and then incubated in ED7 TCS or TCM only (negative control) for 1 hour. Afterffour washes (3 minutes each) with sterile filtered PBST, the grids

were incubated for a further hour in PBST-BSA containing a 1:20 dilution of goat anti-mouse 20 nm gold conjugate (EM.GAF20; BBI Solutions). The grids were washed four times (3 minutes each) in electron microscopy (IEM) the method described in Thornton & Talbot (2006) was used. Spores and hyphae of *F. solani* were prepared by incubating washed conidia in 1% (w/v) glucose solution at 26°C for 16 hours to allow spore germination and for-mation of germ tubes. Cells were embedded in LR White resin (Agar Scientific Ltd.) and ultra thin sections prepared for immu-nolabeling. Sections immobilized to nickel grids were blocked by immersion in PBST containing 1% (w/v)

### Statistical analysis

Unless otherwise stated, numerical data were analysed using the statistical programme Minitab (Minitab 16, Minitab  $V^R$ , Coventry, UK). Analysis of variance (ANOVA) was used to compare means of more than two data sets and Post-hoc Tukey–Kramer analysis was then performed to distinguish which sets were significantly different from one another.

### Sampling from drains

A total of 65 sinks were swabbed, comprising 32 sinks across the ICU, ITU, hematology, oncology and ophthalmology units of the Royal Devon and Exeter tertiary care hospital (Exeter, Devon, UK) and 33 restroom sinks located around the University of Exeter campus (Exeter, Devon, UK). In addition, coldwater samples were collected from taps connected to the sinks in the hematology and oncology unit, and from the two main water tanks feeding the ophthalmology unit. To isolate fungi from sink biofilms, sterile cotton buds (Boots, UK) wetted with PBS were used to scour the inner surfaces of sink drain-pipes for approximately 10 seconds. Swabs with visible ditritus were immersed in 1.5-ml micro-centrifuge tubes containing 1 ml PBS to dislodge biofilm debris, and the sealed tubes transferred to the laboratory for processing by ELISA and mycological culture.

### Immunodetection of *Fusarium* species in sink swabs and identification of fungi by analysis of the ITS regions of the rRNA-encoding gene unit and Translation elongation factor-1α PCR

Biofilm debris was pelleted by centrifugation at 14 462g for 5 minutes and 50  $\mu$ l samples of supernatant transferred to the wells of microtitre plates for assay by ELISA (Table 1 and Supporting Information Table S2; Swab-ELISA) as described. The biofilm pellet was re-suspended in 1 ml dH<sub>2</sub>O, 200  $\mu$ l samples spread on the surface of PDA containing 1  $\mu$ g ml<sup>-1</sup> of the broad-spectrum antibiotic rifampicin, and the plates incubated for 2 days at 26°C under a 16 hours fluorescent light regime. Fungi in these mixed culture plates were separated on the basis of gross morphological characteristics and axenic slope cultures generated following sub-culture on PDA. Crude anti-gen extracts were prepared as surface washings from mixed cultures and from axenic cultures and assayed by ELISA (Table 1 and Supporting Information Table S2; Mixed culture-ELISA and Axenic culture-ELISA, respectively) as described.

Fungal DNA was extracted from axenic culture material by using the CTAB method (Chow & Kafer, 1993) and fungi were identified by sequencing of the ITS1-5.8S-ITS2 region of the rRNA-encoding gene unit (White et al., 1990) according to procedures described elsewhere (Thornton et al., 2002), using the primers ITS1ext (5-GTAACAAGGTTTCCGTAGGTG-3) and ITS4ext (5-TTCTTTCCTCCGCTTATTGATATGC-3). Species identity was predicted based on > 95% sequence identity (E-value 5 0.0) (Altschul et al. 1997) of the ITS1-5.8S-ITS2 region of recovered species to species recorded in Gen-Bank. Fusarium species were further identified to species complex level by using the forward primer ef-1 (5-ATGGG-TAAGGA(A/G)GACAAGAC-3) and reverse primer ef-2 (5 GGA(G/A)GTACCAGT (G/C)ATCATGTT-3 ), which amplify an approximately 700 bp region of Translation Elongation Factor 1alpha (TEF-1a), the single-locus identification tool in Fusar-ium (Geiser et al., 2004). PCR reactions were carried out in a total volume of 25 µl consisting of 1 µl DNA at a concentration of 30-75 ng µl<sup>-1</sup>, 12.5 µl of GoTaqV<sup>R</sup> Green Master Mix DNA polymerase (Promega, MF7112), 9.5 µl of nuclease free water (Promega) and 1 µl of each primer at 20 pmol. The following cycling parameters were used: an initial denaturation step at 958C for 8 minutes; 35 cycles of 15 seconds at 958C (denaturation); 20 seconds at 54°C (annealing), 1 minutes at 728C (extension) followed by a final 5 minutes extension step at 728C. Phylogenetic sub-groups of Fusarium species were determined by interrogation of the FUSARIUM-ID v. 1.0 database (http://isolate.fusariumdb.org) (O'Donnell et al., 2010), with

the newly acquired TEF-1 $\alpha$  sequences (Supporting Infor-mation Data Set 1).

#### Nucleotide sequence accession numbers

Newly determined ITS sequences were submitted to GenBank and the ITS accession numbers KT876496 to KT876723 were

obtained. Species designations of recovered fungi are shown in Table 1.

#### Acknowledgements

M. Al-Maqtoofi was funded by a Ministry of Higher Education and Scientific Research (MOHESR) of Iraq studentship (No. S634), to whom we are grateful. The authors would also like to thank the RD&E hospital for allowing us to sample patient sinks.

### **Conflicts of Interest**

We declare that none of the authors involved in writing this article have any conflicts of interest with respect to the con-tent of this article.

#### References

- Altschul, S.F., Madden, T.L., Schaffer, A.A., Zhang, Z., Miller, W., and Lipman, D.J. (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database programs. Nucleic Acids Res 25: 3389–3402.
- Anaissie, E.J., Penzak, S.R., and Dignani, M.C. (2002) The hospital water supply as a source of nosocomial infections: a plea for action. Arch Intern Med 162: 1483–1492.

Anaissie, E.J., Kuchar, R.T., Rex, J.H., Francesconi, A., Kasai, M., Muller, F.M., et al. (2011) Fusariosis associated with pathogenic *Fusarium* species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mould pathogens. Clin Infect Dis 33: 1871–1878.

- Arie, T., Hayashi, Y., Nagatani, A., Furuya, M., and Yamaguchi,
  I. (1991) Production and partial characterization of monoclonal antibodies against *Fusarium oxysporum* 860926a. Ann Phytopathol Soc Jpn 57: 696–701.
- Arie, T., Hayashi, Y., Yoneyama K, Nagatani, A., Furuya, M., and Yamaguchi, I. (1995) Detection of *Fusarium* spp. in plants with monoclonal antibody. Ann Phytopathol Soc Jpn 61: 311–317.
- Arrese, J.E., Pierard-Franchimont, C., and Pierard, G.E. (1996) Fatal hyalohyphomycosis following *Fusarium* onychomycosis in an immunocompromised patient. Am J Dermatopathol 18: 196–198.
- Bigley, V.H., Duarte, R.F., Gosling, R.D., Kibbler, C.C., Seaton, S., and Potter, M. (2004) *Fusarium dimerum* infection in a stem cell transplant recipient treated successfully with voriconazole. Bone Marrow Transplant 34: 815–817.
- Bouchara, J-P., Hsieh, H.Y., Croquefer, S., Barton, R., Marchais, V., Pihet, M., et al. (2009) Development of an oli-gonucleotide array for direct detection of fungi in sputum samples from patients with cystic fibrosis. J Clin Microbiol 47: 142–152.
- Boutati, E.I., and Anaissie, E.J. (1997) *Fusarium*, a significant emerging pathogen in patients with haematological malig-

nancies: ten years experience at a cancer centre and implications for management. Blood 90: 999–1008.

- Chang, D.C., Grant, G.B., O'Donnell, K., Wannemuehler, K.A., Noble-Wang, J., Rao, C.Y., et al. (2006) Multistate out-break of *Fusarium* keratitis associated with use of a contact lens solution. JAMA 296: 953–963.
- Chow, T.Y.K., and Kafer, € E. (1993) A rapid method for isolation of total nucleic acids from *Aspergillus nidulans*. Fungal Genet Newsl 40: 25–27.
- Danks, J.N., Rizvi, R.H., Barker, I., Turner, J.A., Rahman, S., and Northway, B.J. (1996) Specific monoclonal antibodies to *Fusarium* species and *Michrodochium nivale*. Food Agric Immunol 8: 249–268.
- Davies, G., and Thornton, C.R. (2014) Differentiation of the emerging human pathogens *Trichosporon asahii* and *Trichosporon asteroides* from other pathogenic yeasts and moulds by using species-specific monoclonal antibodies.

PLoS ONE 9: e84789.

- Dean, R., Van Kan, J.A.L., Pretorius, Z.A., Hammond-Kosack, K.E., Di Pietro, A., Spanu, P.D., et al. (2012) The top 10 fun-gal pathogens in molecular plant pathology. Mol Plant Pathol 13: 414–430.
- Dignani, M.C., and Anaissie, E. (2004) Human fusariosis. Clin Microbiol Infect 10: 67–75.
- Doggett, M.S. (2000) Characterisation of fungal biofilms within a municipal water distribution system. Appl Env Microbiol 66: 1249–1251.
- Dursun, D., Fernandez, V., and Miller, D. (2003) Advanced *Fusarium* keratitis progressing to endophthalmitis. Cornea 22: 300–303.
- Edelstein, S.L., Akduman, L., Durham, B.H., Fothergill, A.W., and Hsu, H.Y. (2012) Resistant *Fusarium* keratitis progressing to endophthalmitis. Ophthalmol Contact Lens 38: 331–335.
- Feng, P., Qiaoyun, L., Najafzadeh, M.J., Gerrits van den Ende, A.H.G., Sun, J., Li, R., et al. (2014) *Cyphellophora* and its relatives in *Phialophora*: biodiversity and possible role in human disease. Fungal Divers 65: 17–45.
- Geiser, D.M., del Mar Jimenez-Gasco, M., Kang, S., Makalowska, I., Veeraraghavan, N., Ward, T.D., et al. (2004) FUSARIUM-ID v.1.0: A DNA sequence database for identifying *Fusarium*. Eur J Plant Pathol 110: 473–479.
- Girmenia, C., Pagano, L., Corvatta, L., Mele, L., Del, A., Favero, P., et al. (2000) The epidemiology of fusarioses in patients with haematological diseases. Br J Haematol 111: 272–276.
- Gurusidappa, S.B., and Mamatha, H.S. (2011) Fusarial skin lesion in immunocompromised. Ind J Cancer 48: 116–117.
- Hayashi, Y., Arie, T., Yoneyama, K., and Yamaguchi, I. (1998) Characterisation of the antigenic determinant on *Fusarium oxysporum* recognized by a genus-specific monoclonal anti-body. J Gen Appl Microbiol 44: 43–47.
- Hu, Z-Q., Liu, J-L., Li, H-P., Xing, S., Xue, S., Zhang, J-B., et al. (2012) Generation of a highly reactive chicken-derived singlechain variable fragment against *Fusarium verticillioides* by phage display. Int J Mol Sci 13: 7038–7056.
- Hu, Z-Q., Li, H-P., Zhang, J-B., Huang, T., Liu, J-L., Xue, S., et al. (2013) A phage-displayed chicken single-chain antibody fused to alkaline phosphatase detects *Fusarium* pathogens and their presence in cereal grains. Anal Chim Acta 764: 84–92.

- Jensen, T.G., Gahrn-Hansen, B., Arendrup, M., and Bruun, B. (2004) *Fusarium* fungaemia in immunocompromised patients. Clin Microbiol Infect 10: 499–501.
- Jensen, H.M.E., Aalbæk, B., Jungersen, G., Hartvig, T., Moser, C., Rozell, B.L., et al. (2011) Immunohistochemical diagnosis of fusariosis with monoclonal antibodies. Myco-ses 54: s54–s55.
- Jurkunas, U., Behlau, I., and Colby, K. (2009) Fungal keratitis: changing pathogens and risk factors. Cornea 28: 638–643.
- Koehler, P., Tacke, D., and Cornely, O.A. (2014) Bone and joint infections by Mucorales, *Scedosporium, Fusarium* and even rarer fungi. Crit Rev Microbiol 9: 1–14.
- Lackner, M., Najafzadeh, M.J., Sun, J., Lu, Q., and de Hoog, G.S. (2012) Rapid identification of *Pseudallescheria* and *Scedosporium* strains by using rolling circle amplification. Appl Environ Microbiol 78: 126–133.
- Laemmli, U.K. (1970) Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 227: 680–695.
- Latenser, B.A. (2003) Fusarium infections in burn patients:
- a case report and review of the literature. J Burn Care Rehabil 24: 285–288.
- Macedo,<sup>^</sup> D.P.C., Neves, R.P., de Souza-Motta, C.M., and Magalhaes,<sup>~</sup> O.M.C. (2007) Engyodontium album fungaemia: the first reported case. Braz J Microbiol 38: 110–112.
- Mehl, H.L., and Epstein, L. (2008) Sewage and community shower drains are environmental reservoirs of *Fusarium* species complex group 1, a human and plant pathogen. Env Microbiol 10: 219–227.
- Miceli, M.H., Diaz, J.A., and Lee, S.A. (2011) Emerging opportunistic yeast infections. Lancet Infect Dis 11: 142–151.
- Muhammed, M., Carneiro, H., Coleman, J., and Mylonakis, E. (2011) The challenge of managing fusariosis. Virulence 2: 91–96.
- Musa, H.O., Al Eisa, A., Halim, M., Sahovic, E., Gyger, M., Chaudhri, N., et al. (2000) The spectrum of Fusarium in patients infection immunocompromised with haematological malignancies and nonin immunocompromised patients; institution А single experience over 10 years. Br J Haematol 108: 544-548.
- Nucci, M., and Anaissie, E. (2002) Cutaneous infection by *Fusarium* species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis 35: 909–920.
- Nucci, N., and Anaissie, E. (2007) *Fusarium* infections in immuncompromised patients. Clin Microbiol Rev 20: 695–704.
- O'Donnell, K., Sutton, D.A., Rinaldi, M.G., Sarver, B.A.J., Arunmozhi Balajee, S., Schroers, H.-J., et al. (2010) Internet-accessible DNA sequence database for identifying Fusaria from human and animal infections. J Clin Microbiol 48: 3708–3718.
- Petrikkos, G., Skiada, A., Lortholary, O., Roilides, E., Walsh, T.J., and Kontoyiannis, D.P. (2012) Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 54: S23–S24.
- Rougeron, A., Schuliar, G., Leto, J., Sitterle, E., Landry, D., Bougnoux, M.E., et al. (2014) Human-impacted areas of France are environmental reservoirs of the *Pseudallescheria boydii/Scedosporium apiospermum* species complex. Env Microbiol 17: 1039–1048.
- Sandoval-Denis, M., Sutton, D.A., Cano-Lira, J.F., Gene, J., Fothergill, A.W., Wiederhold, N.P., et al. (2014) Phylogeny

of the clinically relevant species of the emerging fungus *Trichoderma* and their antifungal susceptibilities. J Clin Micro-biol 52: 2112–2125.

- Schroers, H. J., O'Donnell, K., Lamprecht, S.C., Kammophthalmologyr, P.L., Johnson, S., Sutton, D.A., et al. (2009). Taxonomy and phylogeny of the *Fusarium dimerum* species group. Mycologia 101:44-70.
  - Short, D.P.G., O'Donnell, K., Zhang, N., Juba, J.H., and Geiser, D.M. (2011) Widespread occurrence of diverse human pathogenic types of the fungus *Fusarium* detected in plumbing drains. J Clin Microbiol 49: 4264–4272.
  - Steinmann, J., Schmidt, D., Buer, J., and Rath, P-M. (2011) Discrimination of *Scedosporium* prolificans against *Pseudallescheria boydii* and *Scedosporium apiospermum* by semiautomated repetitive sequence-based PCR. Med Mycol 49: 475–483.
  - Sutula, C.L., Gillett, J.M., Morrisey, S.M., and Ramsdell, D.C. (1986) Interpreting ELISA data and establishing the positive-negative threshold. Plant Dis 70: 722–726.
  - Thamke, D.C., Mediratta, D.K., Dhabarde, A., and Shukla, A.K. (2015) Mycotic keratitis due to Engyodontium album: first case report from India. Indian J Med Microbiol 33: 303–304.
  - Thornton, C.R. (2001) Immunological methods for fungi. In Molecular and Cellular Biology of Filamentous Fungi, A Practical Approach. Talbot, N.J. (ed.). Oxford, UK: University Press, pp. 227–257.
  - Thornton, C.R. (2008) Development of an immunochromatographic lateral flow device for rapid serodiagnosis of invasive aspergillosis. Clin Vacc Immunol 15: 1095–1105.
  - Thornton, C.R. (2009) Tracking the emerging human pathogen *Pseudallescheria boydii* by using highly specific monoclonal antibodies. Clin Vacc Immunol 16: 756–764.
  - Thornton, C.R. (2012) Serological techniques for diagnosis. In Fungal Plant Pathogens, Principles and Protocols. Lane, C., Beales, P., and Hughes, K. (eds.). Wallingford, UK: CABI, pp. 159–177.
  - Thornton, C.R., Pitt, D., Wakley, G.E., Talbot, N.J. (2002) Pro-duction of a monoclonal antibody specific to the genus *Trichoderma* and closely related fungi, and its use to detect Trichoderma spp. in naturally infested composts Microbiol-ogy 148: 1263–1279.
  - Thornton, C.R., and Wills, O.E. (2015) Immunodetection of fungal and oomycete pathogens: Established and emerging threats to human health, animal welfare, and global food security. Crit Rev Microbiol 41: 27–51.
  - Thornton, C.R., Ryder, L.S., Le Cocq, K., and Soanes, D.M. (2015) Identifying the emerging human pathogen *Scedosporium prolificans* by using a species-specific monoclonal antibody that binds to the melanin biosynthetic enzyme tet-
  - rahydroxynaphthalene reductase. Environ Microbiol 17: 1023–1048.
  - Thornton, C.R., Talbot, N.J. (2006) Immunofluorescence microscopy and immunogold EM for investigating fungal infections of plants. Nat Protocols 1: 2506–2511.
  - Torres, H.J., and Kontoyiannis, D. (2011) Hyalohyphomycosis (hyaline moulds). In Essentials of Clinical Mycology, Kauffman, C.A., Pappas, P.G., Sobel, J.D., and Dismukes, W.E. (eds.). New York: Springer Science1Business Media, pp. 281–304.
  - Walsh, T.J., and Groll, A.H. (1999) Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transplant Infect Dis 1: 247–261.

- White, T.J., Bruns, T., Lee, S., Taylor, J. (1990) Amplification and direct sequencing of fungal ribosomal RNA genes for phyloge-netics. In PCR Protocols: a Guide to Methods and Applica-tions. Innis, M.A., Gelfand, D.H., Sninsky, J.J., and White, T.J. (eds). San Diego, USA: Academic Press, pp. 315–322.
- Wong, W.C., White, M., and Wright, I.G. (1988) Production of monoclonal antibodies to *Fusarium oxysporum* f.sp. *cubense* race 4. Lett Appl Microbiol 6: 39–42.
- Zeng, J.S., Sutton, D.A., Fothergill, A.W., Rinaldi, M.G., Harrak, M.J., and de Hoog, G.S. (2007) Spectrum of clinically relevant *Exophiala* species in the Unites States. J Clin Microbiol 45: 3713–3720.
- Zhang, N., O'Donnell, K., Sutton, D.A., Nalim, F.A., Summerbell, R.C., Padhye, A.A., et al. (2006) Members of the *Fusarium solani* species complex that cause infections in both humans and plants are common in the environment.

J Clin Microbiol 44: 2186-2190.

#### Supporting information

Additional Supporting Information may be found in the online version of this article at the publisher's web-site:

Supporting Data Set 1. Translation elongation factor 1 alpha (tef) gene sequences of *Fusarium* species.

Table S1. Details of fungi used in ELISA specificity tests of ED7.

Table S2. Summary of ELISA tests and mycological culture of sink swabs.

Table S3. Summary of species complex identities following Translation Elongation Factor-1 $\alpha$  PCR analysis of *Fusarium* isolates recovered from sink.